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Type 2 diabetes is a progressive condition where beta cell function deteriorates over time. 
Insulin injection therapy is often required 5-10 years post-diagnosis, but many people who 
require insulin delay starting it. There are currently education groups available for people 
with type 2 diabetes starting insulin, but these have been designed to support safe insulin 
administration and do not consider psychological problems or barriers, such as fear of 
hypoglycaemia or weight gain. There is evidence to support the effectiveness of group 
education and psychological interventions for people with type 2 diabetes, but so far 
insulin group education has not been evaluated. Research is needed to develop 
psychologically informed insulin group education which incorporates elements of 
psychological interventions for people with type 2 diabetes, to understand how 
psychological factors such as depressive symptoms, diabetes distress and insulin beliefs 
affect initiation of insulin and to understand from people who have attended insulin 
education their views of it and how it could be improved. 
Methods: 
Study 1 is a systematic review and meta-analysis to assess the effectiveness of behaviour 
change techniques in psychological interventions to improve HbA1c for people with type 2 
diabetes. Study 2 used qualitative semi-structured interviews to determine the views of 
people with type 2 diabetes in south London who had attended insulin education, 
regarding barriers to insulin self-management, views on current insulin group education, 
and suggestions for additional support to aid insulin self-management. Study 3 is an 8-year 
medical records follow-up of an existing National Institute of Health Research funded south 
London Diabetes cohort (SOUL-D) of n=1735 people with type 2 diabetes. It examined 
whether psychological factors (depressive symptoms, diabetes distress and insulin beliefs) 
around diagnosis delay time to insulin initiation and insulin requiring status in people with 
type 2 diabetes. Finally, study 4 combined evidence from studies 1-3 to inform the manual 
development of a psychological intervention called Diabetes Insulin Management 
Education (DIME). The DIME intervention aimed to optimise insulin initiation in people with 
type 2 diabetes. Initial testing of DIME took place with groups of people with type 2 
diabetes who initiated insulin (from south London). Study 5 was a qualitative (one-to-on 
exit interviews) and quantitative (case study of interviewees) evaluation of the DIME pilot 






In study 1, the most commonly used behaviour change techniques in psychological 
interventions which were associated with improved HbA1c included ‘social support’, 
‘feedback and monitoring’, and ‘goal setting’. Study 2 revealed positive experiences of 
insulin group education for people with type 2 diabetes was linked to sharing experiences 
with other people starting insulin, reassurance from healthcare professionals, appropriate 
supportive materials, and skill of the facilitator to address insulin concerns and manage 
group dynamics.  In study 3, in a cox regression, depressive symptoms at type 2 diabetes 
diagnosis (HR=1.06, 95% CI=1.02-1.10, p=0.005) were the only psychological factor which 
predicted significantly shorter time insulin initiation, controlling for other baseline 
confounding variables. Following initial testing of DIME, positive feedback included: 
alleviation of fears and anxieties around insulin; positive communication style; finding 
common ground with people in the group; and group dynamics were managed well. 
 
Conclusions: 
Psychological interventions as well as behaviour change technique categories are beneficial 
to improving HbA1c. A group environment and facilitator skill play a key role in positive 
impact of insulin education. Appropriate psychological techniques to address depressive 
symptoms should be taken into consideration in development of insulin initiation 
education. Initial testing of a psychological intervention to optimise insulin initiation 
provides positive feedback and improvement in HbA1c and should be tested in a 
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Data collection of qualitative interviews 
Qualitative interviews in study 2 were conducted at the participants’ local general practice 
surgery. Qualitative interviews in study 5 were conducted immediately after the 3rd session 
of the pilot psychological intervention which took place at a local general practice surgery 
or community venue. For both studies these venues were chosen for convenience and to 
maximise recruitment. Interviewers were not the participants healthcare professionals; 
therefore, researchers hoped the participants would feel comfortable sharing their views 
within the healthcare setting.  
Before the interviews commenced in study 2 and 5, interviewers introduced themselves i.e. 
who they worked/studied for (King’s College London) and provided information regarding 
the research. Diabetes nurses who were involved with data collection did not interview any 
of their patients. It was emphasised the discussion was to gain views on their experience of 
the insulin education groups so future developments could be made. For study 2, I did not 
disclose that I had type 1 diabetes to the participants as I was more interested in their 
experience as opposed to comparing experiences. In study 5, I revealed I had type 1 
diabetes during the pilot sessions of the new psychological intervention (study 4), where 
participants described feeling reassured to hear from someone else with diabetes who was 
treated with insulin. Regardless of this disclosure, in study 5, interviewees openly discussed 
their feedback of the psychological intervention. During study 2, sometimes the 
participants did ask diabetes medical questions, they were politely asked to seek advice 
from their diabetes nurse or general practitioner as to not conflict with the aims of the 
research. In addition, for the interviews I conducted it was not appropriate for me to offer 
medical advice as I am not a medical professional. Though I felt none of the medical 
questions were of great concern and did not compromise the safety of the participant, I did 
report these concerns to members of the research team who were diabetes nurses (KW & 
MA) and responsible for their care.  
Even though I could empathise with some of the experiences of living with diabetes, I 
refrained from commenting on these as to not influence the interviewees responses to 
interview questions. It was only appropriate to reflect on my own personal experience 





Data analysis of qualitative research  
Field notes were made by all interviewers and were made immediately after interviews 
occurred. These were useful to refer to when analysing data and discussing themes 
between researchers for detailed interpretation of data. There were multiple interviewers 
for study 2 so each researcher listened to audiotapes of interviews conducted by the other 
2 researchers to identify any interviewer bias to be eliminated in subsequent interviews. 
Final themes were generated after discussions within the wider research team to reduce 
bias in interpretation of results.  
Reporting of qualitative research  
Qualitative research bias was reduced by reporting a range of perspectives, so the 
viewpoint of one group is not represented as the sole truth (known as ‘fair dealing’).  In 
study 2, people with type 2 diabetes were purposively sampled by sex, age (</45, 46-59, 
60+ years), and ethnicity (White, Black, south Asian/other) to obtain views from a range of 
people. This was not possible in study 5 as there were only 3 participants who attended all 
three sessions of the psychological intervention. The aim of qualitative analysis was to 
identify common themes that emerged across participants. In addition, quotes were 
reported relating to specific individual accounts with the aim of reporting views of 
individuals as well as the majority.  
Awareness of wider context from results of qualitative research  
In study 2, the concept of ‘transferability’ is discussed whereby the results of the qualitative 
analysis can be applied to another sociocultural setting. Study 2’s results can be applied to 
existing theoretical health models which were then used to develop the new psychological 
intervention in study 4.  
Improving reflexivity in the future 
This thesis took steps to reduce bias across all 5 studies. To reduce bias in the future, 
people with type 2 diabetes could be involved with further development of the 
psychological intervention to offer further perspectives of the work to assist application to 
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1.1. Definition of type 2 diabetes and epidemiology  
Type 2 diabetes is a progressive condition characterised by hyperglycaemia (high blood 
glucose levels). Hyperglycaemia in type 2 diabetes is caused by insulin resistance and beta 
cell dysfunction (DeFronzo, 2004). Type 2 diabetes develops as insulin resistance rises and 
then beta cells compensate by secreting more insulin to normalise blood glucose. Over 
time beta cell function deteriorates, less insulin is secreted, and blood glucose levels rise. 
At diagnosis people with type 2 diabetes have impaired glucose tolerance, impaired fasting 
glucose and hyperglycaemia (DeFronzo, 2004), figure 1.1. Development of type 2 diabetes 
is associated with diabetes complications (Stratton et al., 2000). Type 2 diabetes can be 
delayed by intervening at the stage of impaired glucose tolerance/impaired fasting glucose 
with lifestyle change and if type 2 diabetes is adequately managed from diagnosis diabetes 















Globally, it is estimated 510 million people may have type 2 diabetes by 2030 (Basu et al., 
2019). The increasing prevalence of type 2 diabetes is accounted for by an ageing 
population and rising numbers of people who are overweight and obese (González, 
-10 years pre 
diagnosis 
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Figure 1.1- The progression of type 2 diabetes 




Johansson, Wallander, & Rodríguez, 2009), and these are the main risk factors for type 2 
diabetes. More than 80% of people with type 2 diabetes at diagnosis are overweight and 
this increases insulin resistance (Stringhini et al., 2012). Other risk factors for type 2 
diabetes include modifiable risk factors such as sedentary lifestyle, smoking, previous 
impaired glucose tolerance or impaired fasting, elevated triglycerides, low levels of high-
density lipoprotein cholesterol, hypertension, inflammation. Non-modifiable risk factors 
include sex, ethnicity, family history of type 2 diabetes, history of gestational diabetes, 
polycystic ovary syndrome (Chen, Magliano, & Zimmet, 2012). In Asia, although the rate of 
obesity is lower than in Europe, type 2 diabetes is developed in individuals with a lower 
body mass index (Yoon et al., 2006). This can be accounted for by a higher fat percentage at 
each body mass index category than Europeans causing more insulin resistance and hence 
the onset of type 2 diabetes (Deurenberg, Deurenberg‐Yap, & Guricci, 2002).  
1.2. Long term complications in type 2 diabetes 
Type 2 diabetes is associated with both microvascular (damage to smaller blood vessels) 
and macrovascular (damage to larger blood vessels) complications, and these can impact 
quality of life, and risk of mortality (Deshpande, Harris-Hayes, & Schootman, 2008).  High 
blood glucose levels and low-density cholesterol lead to chronic inflammation 
(atherosclerosis) which narrows arteries and decreases blood flow (Grundy, 1993; Yan, 
Ramasamy, Naka, & Schmidt, 2003) resulting in a heart attack or stroke (macrovascular 
complications) (Deshpande et al., 2008). The high concentration of blood glucose molecules 
can also damage smaller blood vessels, destroying blood vessel cells, decreasing blood flow 
resulting in tissue death (Loomans et al., 2004). Microvascular complications include 
retinopathy (damage to the retina of the eyes), neuropathy (damage to nerves), and 
nephropathy (deterioration of kidney function).  Progression of diabetes complications can 
be delayed through appropriate type 2 diabetes treatment and achieving optimal glycaemic 
levels (Ohkubo et al., 1995). 
 
1.3. Clinical targets for people with type 2 diabetes 
The main targets set for people with type 2 diabetes are for blood pressure, cholesterol 
and glycaemia, achieving these targets reduces the risk of cardiovascular disease and 
diabetes complications (Gæde, Lund-Andersen, Parving, & Pedersen, 2008; Oellgaard et al., 
2018). The target blood pressure is ≤135/85 mmHg and for cholesterol ≤4.9 mmol/l 
(Oellgaard et al., 2018).  
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HbA1c (glycated haemoglobin) is the standard measure of glycaemia (also referred to as 
glycaemic levels), representing glucose concentration in the blood over ~3 months (Little & 
Sacks, 2009). A series of trials have influenced HbA1c targets for type 2 diabetes over the 
years including the UK Prospective Diabetes Study (UKPDS(UKPDS, 1998b)) published in 
1998; Diabetes Control and Complications Trial (DCCT(DCCT, 1993)); the Action in Diabetes 
and Vascular Disease Preterax and Diamicron MR Controlled Evaluation (ADVANCE(Patel & 
Group, 2007)) trial; and the Action to Control Cardiovascular Risk in Type 2 Diabetes 
(ACCORD(ACCORD, 2008)) trial. Study characteristics are summarised in table 1.1.  
 
Table 1.1- Summary of type 2 diabetes trials that influence HbA1c targets 
Trial Country  Study design Outcomes Sample 
size 








Randomised controlled trial (intensive 
HbA1c target versus standard HbA1c 
target) 




ACCORD USA and Canada  Randomised controlled trial (intensive 
HbA1c target versus standard HbA1c 
target) 
Rate of cardiovascular events 10, 251  
DCCT USA and Canada Randomised controlled trial (intensive 
therapy [3+ daily injections] versus 
standard treatment [1 or 2 daily 
injections]) 




The UKPDS (1998) demonstrated that a 1% reduction in HbA1c reduces the risk of 
microvascular disease by 25% (UKPDS, 1998b), this is similar to DCCT where 2% reduction 
in HbA1c led to 50% reduction in microvascular disease (DCCT, 1993). In addition, the 
UKPDS 1998 trial went on to find that tight HbA1c leads to a reduction in microvascular and 
macrovascular disease (Stratton et al., 2000). The ADVANCE trial expanded on UKPDS 
findings where intensive therapy (≤48 mmol/mol) had a 10% relative reduction in 
combined macrovascular and microvascular events compared with standard therapy. 
However, there was no difference between groups in rates of macrovascular events alone, 
and the combined result was accounted for by a significant reduction in nephropathy, 
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showing greater clinical benefits of intensive therapy for microvascular complications than 
macrovascular complications. The ADVANCE trial supports the glycaemic target of 48-
53mmol/mol (Heller & Group, 2009). The ACCORD trial examined whether intensive 
therapy could also have benefits for macrovascular complications e.g. cardiovascular 
events. People with type 2 diabetes with increased cardiovascular risk were recruited and 
assigned to intensive therapy (HbA1c target <42 mmol/mol) or standard therapy (HbA1c 
target 53-63 mmol/mol). In the intensive therapy condition, cardiovascular deaths 
increased by 35% and all-cause mortality by 22% compared with standard therapy 
(ACCORD, 2008). Initially, it was thought severe hypoglycaemia and weight gain 
contributed to increased mortality but a post hoc analysis revealed this was not the case 
(ACCORD, 2016) and the most likely reason was persistently higher HbA1c levels (Riddle et 
al., 2010). It was concluded that for people with type 2 diabetes at high risk for 
cardiovascular events, optimal HbA1c targets should be 58mmol/mol and further 
reductions could put them at risk of mortality (ACCORD, 2017). A retrospective cohort 
study supported these findings in addition to finding a U-shaped association where low (43-
49 mmol/mol) and high HbA1c (87-99 mmol/mol) were associated with all-cause mortality. 
The lowest risk of all-cause mortality was at around 58 mmol/mol (Currie et al., 2010).  
The National Institute for Health and Care Excellence (NICE) guidelines recommend a 
HbA1c target of 48 mmol/mol managed with lifestyle and monotherapy (not associated 
with hypoglycaemia) (NICE, 2015). If someone with type 2 diabetes is treated with any drug 
associated with hypoglycaemia then their recommended HbA1c target is 53 mmol/mol. If 
HbA1c rises to 58 mmol/mol on any treatment, then treatment should be intensified. NICE 
guidelines also advise setting individualised targets based on ‘personal preferences, 
comorbidities, risks from polypharmacy, and their ability to benefit from long‑term 
interventions because of reduced life expectancy’ (NICE, 2015). A consensus report of ADA 
and European Association for the Study of Diabetes (EASD) also promotes individualised 
treatment plans and glycaemic targets for type 2 diabetes called the ‘goals of care’ to 
prevent diabetes complications and maintain quality of life. The ‘goals of care’ are based on 
individual characteristics (lifestyle, comorbidities, age, HbA1c, weight, motivation, mental 
health), side effects of medications, the complexity of treatment, availability and cost of 
treatment, a treatment which will optimise adherence and persistence, shared-decision 
making plans and goals, and available ongoing support (Davies et al., 2018).  
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1.4. Treatment of type 2 diabetes  
Type 2 diabetes is a cardiovascular disease and the aims of treatment are 3-fold to 
normalise: blood pressure, cholesterol, and glycaemia. Blood pressure can be lowered 
through physical activity, low salt diet, smoking cessation, reduction in alcohol, weight loss, 
and antihypertensive medication (Rayner, Allender, Scarborough, & Group, 2009). 
Cholesterol can be normalised through a high-fibre diet, diet low in saturated fats, 
increased physical activity, and cholesterol-lowering medication such as statins (Zipes, 
Libby, Bonow, Mann, & Tomaselli, 2018).  
Type 2 diabetes treatment aims to reduce glycaemia and insulin resistance. Beta cell 
deterioration and increase in insulin resistance can be prevented with intensive weight-loss 
around diagnosis, though this is often not achieved (Dyson et al., 2011; Lean et al., 2018). 
The usual treatment pathway for people with type 2 diabetes is lifestyle modification 
(weight loss, reducing sedentary lifestyle), followed by oral antidiabetic medications 
(OADs). The most commonly prescribed OADs to reduce glycaemia are sulphonylureas (e.g. 
gliclazide) and most commonly used to reduce insulin resistance are biguanides (e.g. 
metformin) or Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g. sitagliptin). 
Insulin injection therapy also reduces glycaemia. Insulin treatment is often required around 
5-10 years from diagnosis (Khunti, Damci, et al., 2012; Turner, Cull, Frighi, Holman, & 
Group, 1999), when beta cell function has declined to 15 to 20% of normal function 
(Lebovitz, 1999). In the UK, NICE guidelines recommend insulin therapy as a second 
intensification of drug treatment, where someone with type 2 diabetes is on 2 OADs in 
addition to HbA1c being 58mmol/mol or above (NICE, 2015). An alternative recommended 
intensification at this point could also be 3 OADs or OADs in combination with injectable 
incretin mimetics (figure 1.2). Injectable incretin mimetics or glucagon-like peptide-1 
receptor agonists (GLP-1 RAs) help decrease insulin resistance and work by increasing the 
hormone incretin which is involved in producing insulin and reduce glucose produced by 
the liver (Nielsen, 2005). Other worldwide guidelines also recommend insulin as the second 
intensification of drug treatment (ADA, 2016; Aschner, 2017; CDA, 2018; Garber et al., 
2017; Mosenzon, Pollack, & Raz, 2016; NICE, 2015). American Diabetes Association (ADA) 
and Korean Diabetes Association (KDA) recommend insulin therapy combined with 1 OAD if 
HbA1c is 75mmol/mol or above (ADA, 2016; Lee et al., 2017). Canadian, International 
Diabetes Federation (IDF), and KDA guidelines recommend immediate use of insulin in 
people with metabolic decompensation or presence of hyperglycaemia with symptoms 
(Aschner, 2017; CDA, 2018; Lee et al., 2017).  
30 
 
Diabetes treatment can normalise glycaemia and limit hyperglycaemia and hypoglycaemia. 
Hyperglycaemia is defined as having a blood glucose of ≥11.1 mmol/L (WHO, 1999). 
Hypoglycaemia is defined as having a blood glucose reading of <3.5mmol/L, it can be 
caused by an excess of insulin, increased physical activity and lower carbohydrate intake. 
Warning symptoms that indicate hypoglycaemia can include but are not limited to: 
sweating, fatigue, dizziness, blurred vision, increased heart rate (Frier, 2009). There are 
several variables which can impact blood glucose, increase risk of hypoglycaemia or 
hyperglycaemia including diet (foods containing carbohydrate or protein); physical activity; 
dose, timing and frequency of diabetes treatment; side effects of medications; hormonal 
changes (stress, illness, menstrual cycle); and dehydration (Davies et al., 2018; Nathan et 
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1.5. Using insulin as a treatment for people with type 2 diabetes 
Though insulin therapy makes hypoglycaemia more likely, it is the most intensive treatment 
for diabetes in terms of lowering blood glucose and therefore is most likely to achieve 
HbA1c targets, (Davies et al., 2018; Nathan et al., 2009). Insulin therapy is associated with 
improved HbA1c (Al Mansari et al., 2018; Asche, LaFleur, & Conner, 2011; Ayyagari et al., 
2015; Caballero, 2009; Cramer & Pugh, 2005; Donnelly, Morris, Evans, & collaboration, 
2007; Hajós et al., 2011; Mashitani et al., 2013; Rajagopalan, Joyce, Ollendorf, & Murray, 
2003) and lower risk of diabetes complications (Caballero, 2009; Turner et al., 1999; 
UKPDS, 1998b). Qualitative research eliciting views of people with type 2 diabetes has 
identified positive benefits of insulin such as perceptions of relief after taking first insulin 
injection; more energy; and perceived risk reduction of long-term complications (Holmes-
Truscott, Browne, & Speight, 2016; Holmes‐Truscott, Skinner, Pouwer, & Speight, 2015).  
1.5.1. Insulin regime for people with type 2 diabetes  
Insulins are categorised into 3 different types depending on the duration of effect: long-
acting; intermediate-acting; and short-acting. In type 2 diabetes, NICE guidelines 
recommend starting with Neutral Protamine Hagedorn (NPH; intermediate-acting) as basal 
insulin in combination with Metformin (unless intolerance) (NICE, 2015). NPH plus short-
acting insulin is recommended separately or as a pre-mixed formula if HbA1c is 
≥75mmol/mol. Alternatively, insulin detemir or insulin glargine (long-acting analogue 
insulin) should be prescribed if the person with type 2 diabetes needs help from someone 
else to inject insulin (as this reduces insulin injection frequency); or they are experiencing 
recurrent hypoglycaemia because these formulations have a flatter profile of action. 
Premixed insulin that includes short-acting insulin is recommended if there is a preference 
for injecting before a meal, hypoglycaemia is frequent, or blood glucose rises after the 
main meal. There should be a switch from NPH to insulin detemir or insulin glargine if 
target HbA1c cannot be reached and frequent hypoglycaemia is experienced. For people on 
basal insulin (NPH insulin, insulin detemir or insulin glargine), if HbA1c targets are not being 
met and there is a rise in post-prandial blood glucose then short-acting insulin before meals 
is recommended, a basal-bolus regime.  
 
1.5.2. Cost-effectiveness of insulin treatment  
In the UK, type 2 diabetes costs the national health service (NHS) around £8.8 billion per 
year (Hex, Bartlett, Wright, Taylor, & Varley, 2012), 80% is spent on treating diabetes 
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complications (e.g. cardiovascular, inpatient days, renal disease, neuropathy, stroke, foot 
ulcers and amputations etc) and the remainder on type 2 diabetes treatment (e.g. primary 
care services, prescriptions, influenza immunisation, medical exemption, smoking cessation 
programmes, diabetes education programmes, retinopathy screening, and blood glucose 
monitoring). Some evidence suggests insulin might not be cost-effective, accounted for by 
increased prescription costs (insulin and increased blood glucose monitoring equipment) 
and increased healthcare utilisation (Bexelius, Lundberg, Wang, Berg, & Hjelm, 2013; 
Brismar et al., 2013; Brixner et al., 2019). These studies were conducted in Sweden and the 
USA where the cost to the person with diabetes might be higher owing to healthcare 
insurance plans as compared with government-funded health service available in the UK. 
However, a UK-based study also found insulin is not cost-effective long-term (Valentine et 
al., 2015). The authors suggest the reason for this finding could be explained by data from 
trials over real-world practice. Studies often sampled people with type 2 diabetes and 
suboptimal HbA1c and insulin intensification was late in the progression of type 2 diabetes, 
resulting in modest improvements in glycaemia and reduced cost-effectiveness. On the 
other hand, there is evidence which indicates insulin therapy for people with type 2 
diabetes is associated with reduced healthcare costs (Almbrand, Johannesson, Sjostrand, 
Malmberg, & Ryden, 2000; Aloumanis, Benroubi, Sourmeli, & Drossinos, 2013; Kleinman, 
Schaneman, & Lynch, 2008; Levin et al., 2011; Liebl, Khunti, Orozco-Beltran, & Yale, 2015; 
Rosenblum & Kane, 2003; Xie, Wei, Pan, & Baser, 2013). Lower healthcare costs with insulin 
therapy for type 2 diabetes is associated with early initiation (Liebl et al., 2015), low rates 
of and less severe hypoglycaemia (Bell et al., 2015; Heller, Frier, Herslov, Gundgaard, & 
Gough, 2016; Meneghini, Lee, Gupta, & Preblick, 2018; Parekh, Ashley, Chubb, Gillies, & 
Evans, 2015; Ridderstrale, Jensen, Gjesing, & Niskanen, 2013; Xie et al., 2013), and use of 
long-acting insulin such as insulin detemir (Borah et al., 2009; Ridderstrale et al., 2013) or 
insulin glargine (Dailey & Strange, 2008; Levin et al., 2011).  
 
1.6. Problems associated with insulin treatment in type 2 diabetes 
Potential problems with insulin treatment for people with type 2 diabetes include: delay in 
initiating insulin treatment, psychological aspects of insulin use, suboptimal HbA1c, 
adherence and persistence to insulin, and clinical inertia.  
1.6.1. Delay in initiating insulin treatment  
Even though insulin therapy is associated with improved diabetes outcomes and cost-
effectiveness, as described in the previous sections, the delay in initiating insulin therapy in 
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the UK is significant (Khunti, Damci, et al., 2012; Rubino, McQuay, Gough, Kvasz, & Tennis, 
2007). Studies report between 25-48% of people with type 2 diabetes refuse or are 
unwilling to initiate insulin therapy (Holmes-Truscott, Skinner, Pouwer, & Speight, 2016; 
Hosomura et al., 2017; Khan, Lasker, & Chowdhury, 2008; Larkin et al., 2007; Machinani, 
Bazargan-Hejazi, & Hsia, 2013; Polonsky, Fisher, Guzman, Villa-Caballero, & Edelman, 2005; 
UKPDS, 1998b). Insulin is likely to be started later than recommended by international 
guidelines (Costi, Dilla, Reviriego, Castell, & Goday, 2010), with some evidence suggesting 
insulin therapy in type 2 diabetes is only initiated when HbA1c is above 86 mmol/mol (10%) 
(Zografou, Strachan, & McKnight, 2014). Delay in initiating insulin therapy can be 
associated with the psychological aspects of insulin use (Hessler et al., 2018).  
1.6.2. Psychological aspects of insulin use 
There are many psychological aspects of insulin-taking for people with type 2 diabetes 
including needle phobia, hypoglycaemia, and psychological insulin resistance.  
1.6.5.1. Needle phobia 
In the general population, the prevalence of needle phobia has been reported at around 
22% (Wright, Yelland, Heathcote, Ng, & Wright, 2009), which is higher in females and 
people of younger age (McLenon & Rogers, 2019; Wright et al., 2009). Needle phobia is 
associated with anxiety, sweating, and difficulties breathing (McLenon & Rogers, 2019; 
Wright et al., 2009).  A review found the prevalence of needle phobia in people with 
diabetes ranges from 1.3-41.7%, however, this includes type 1 diabetes studies (McLenon 
& Rogers, 2019). Considering people with type 2 diabetes, needle phobia is often cited as a 
reason for preventing insulin initiation which has negative consequences on glycaemia (Fu, 
Wong, Chin, & Luk, 2015; Haque, Navsa, Emerson, Dennison, & Levitt, 2005; Karter et al., 
2010; Polonsky & Jackson, 2004). 
1.6.5.2. The psychological aspects of hypoglycaemia  
Hypoglycaemic events are associated with a delay in initiating insulin treatment, higher 
HbA1c prior to therapy intensification, and lack of healthcare professional support 
(Hosomura et al., 2017; Mauricio et al., 2017). There are particular psychological 
consequences of hypoglycaemia such as anxiety (Polonsky, Fisher, Hessler, & Edelman, 
2015; Snoek, Hajos, & Rondags, 2014), depressive symptoms (Barendse, Singh, Frier, & 
Speight, 2012), social isolation, embarrassment, stress (Snoek et al., 2014) and diabetes 
burnout (Polonsky, 1999). These are particularly relevant concerning insulin as this 
treatment has an increased risk of hypoglycaemic events compared with other type 2 
diabetes treatments (UKPDS, 1998b).  
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1.6.5.3. Psychological insulin resistance 
Psychological insulin resistance has been extensively researched and is defined as an 
opposition to initiating insulin treatment or ongoing therapy due to negative beliefs 
surrounding insulin (Petrak, Herpertz, Stridde, & Pfützner, 2013; Peyrot et al., 2005; 
Polonsky, Hajos, Dain, & Snoek, 2011). Psychological insulin resistance is detrimental to 
physical and mental health as it is associated with diabetes complications (Holmes-
Truscott, Skinner, et al., 2016), depressive symptoms (Larkin et al., 2007; Makine et al., 
2009; Woudenberg, Lucas, Latour, & Scholte op Reimer, 2012) and diabetes distress (Chen 
et al., 2011; Hermanns, Mahr, Kulzer, Skovlund, & Haak, 2010; Holmes-Truscott, Skinner, et 
al., 2016; Makine et al., 2009; Polonsky et al., 2011; Snoek, Skovlund, & Pouwer, 2007; 
Woudenberg et al., 2012). Psychological insulin resistance can be categorised into three 
categories: emotional; cognitive; and social (Gherman, Veresiu, et al., 2011), summarised in 
figure 1.3.  
Emotional psychological insulin resistance includes anxiety towards treatment for 
example: fear of injections, or blood (Berard et al., 2018; Bogatean & Hâncu, 2004b; Ellis, 
Mulnier, & Forbes, 2018; Fu et al., 2015; Goderis et al., 2009; Haque, Emerson, Dennison, 
Navsa, & Levitt, 2005; Hassali et al., 2014; Hayes, Fitzgerald, & Jacober, 2008; Hussein et al., 
2019; Jeavons, Hungin, & Cornford, 2006; Karter et al., 2010; Khan et al., 2008; Khunti, 
Davies, & Khunti, 2015; Lakkis, Maalouf, Mahmassani, & Hamadeh, 2013a; Lee, Lee, & Ng, 
2012; Nadasen & Naidoo, 2012; Nakar, Yitzhaki, Rosenberg, & Vinker, 2007; Phillips, 2007; 
Polinski et al., 2013; Ratanawongsa et al., 2012; Ross, 2013; Tan, Tan, & Yeo, 2003; Taylor 
et al., 2017); a sense of personal failure towards diabetes self-management (Bogatean & 
Hâncu, 2004b; Brod, Alolga, & Meneghini, 2014; Brod, Kongsø, Lessard, & Christensen, 
2009; Ellis et al., 2018; Jeavons et al., 2006; Karter et al., 2010; Khunti et al., 2015; Lee et 
al., 2012; Oliveria et al., 2007; Peyrot & Rubin, 2007; Peyrot et al., 2005; Polonsky & 
Jackson, 2004; Rebolledo & Arellano, 2016; Ross, 2013; Snoek et al., 2007; Tan et al., 2011; 
Tan et al., 2003; Taylor et al., 2017; Woudenberg et al., 2012); fear of side effects such as 
hypoglycaemia (Brod et al., 2009; DCCT, 1991; Ellis et al., 2018; Evans, Sharplin, et al., 
2010; Hassali et al., 2014; Jeavons et al., 2006; Karter et al., 2010; Khan et al., 2008; Khunti 
et al., 2018; Lakkis et al., 2013a; Mauricio et al., 2017; Nakar et al., 2007; Petrak et al., 
2013; Tan et al., 2011; Taylor et al., 2017) and weight gain (Berard et al., 2018; Brod et al., 
2009; Brod, Pohlman, & Kongsø, 2014; Evans, Sharplin, et al., 2010; Haque, Emerson, et al., 
2005; Khan et al., 2008; Khunti et al., 2015; Kostev, Dippel, & Rathmann, 2015; Lee et al., 
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2012; Peyrot, Skovlund, & Landgraf, 2009; Polonsky et al., 2015; Ross, 2013; Taylor et al., 

















A sense of personal failure stems from the idea the individual with type 2 diabetes believes 
it is their fault they have been unable to achieve optimal glycaemic levels target and 
therefore are to blame for requiring insulin therapy. Therefore, insulin is delayed as it is 
seen as a personal threat and confirmation of their ‘failure’ (Ng, Lai, Lee, Azmi, & Teo, 
2015). There is mixed evidence regarding insulin therapy and weight gain (DCCT, 1988; 
Hermansen & Mortensen, 2007; Pontiroli, Miele, & Morabito, 2011). Insulin is associated 
with weight gain because insulin causes excess glucose entering cells to be stored as fat, in 
addition, insulin therapy allows blood glucose to enter cells instead of being lost through 
urine, therefore water retention prevents loss of energy through urine (Hermansen & 
Mortensen, 2007; Strachan & Frier, 2013). Also, hypoglycaemia requires glucose 
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consumption to stabilise blood glucose, this increases calorie intake, therefore if insulin 
therapy increases hypoglycaemic events then this could be a reason for gaining weight 
(Hermansen & Mortensen, 2007; Strachan & Frier, 2013). Long-acting insulins  (Hartman, 
2008; Holman et al., 2009; Khunti, Srinivasan, Shutler, & Davies, 2010; Nathan et al., 2009; 
Pontiroli et al., 2011; Yale et al., 2013), lower frequency of doses (Pontiroli et al., 2011), and 
insulin in combination with GLP-1 RAs prevent weight gain (Fuechtenbusch, Aberle, 
Heitmann, Nicolay, & Jung, 2019; Vanderheiden et al., 2016).  
Cognitive psychological insulin resistance refers to misconceptions around insulin therapy 
for example: loss of independence, lifestyle restriction and/or concerns about 
independently administering insulin (Bogatean & Hâncu, 2004b; Brod et al., 2009; Escalada 
et al., 2016; Garnero et al., 2018; Hassali et al., 2014; Hayes et al., 2008; Hussein et al., 
2019; Karter et al., 2010; Khan et al., 2008; Nadasen & Naidoo, 2012; Phillips, 2007; Tan et 
al., 2011); viewing insulin therapy as a last resort (Ellis et al., 2018; Haque, Emerson, et al., 
2005; Hassali et al., 2014; Jeavons et al., 2006; Karter et al., 2010; Khan et al., 2008; Lakkis 
et al., 2013a; Mosnier-Pudar et al., 2009; Phillips, 2007; Ratanawongsa et al., 2012; Tan et 
al., 2011; Tan et al., 2003); uncertainty around efficacy of insulin (Hassali et al., 2014; Khan 
et al., 2008; Lakkis et al., 2013a; Lee et al., 2012; Peyrot et al., 2005); being asymptomatic 
or perceiving diabetes as less severe (Bogatean & Hâncu, 2004b; Garnero et al., 2018; 
Phillips, 2007); and lack of knowledge about diabetes or insulin (Goderis et al., 2009; 
Haque, Emerson, et al., 2005; Karter et al., 2010; Patel, Stone, Chauhan, Davies, & Khunti, 
2012). Cognitive psychological insulin resistance can be linked to the necessity-concerns 
framework whereby an individual makes a treatment decision based on risk-analysis i.e. 
perceived risks versus benefits (Horne et al., 2013). Qualitative research finds that people 
with type 2 diabetes value the importance of addressing concerns around insulin therapy 
as well as learning about the necessity of insulin (Patel, Stone, McDonough, et al., 2015). 
However, this can be problematic in type 2 diabetes as people with suboptimal glycaemic 
levels can feel asymptomatic. If someone with type 2 diabetes does not experience 
hyperglycaemic symptoms then they could assume there are no problems, or that current 
treatment is adequate. Therefore, they may view that insulin treatment is not necessary 
especially if the risks of persistent high blood glucose levels are not communicated well.  
Social psychological insulin resistance includes social stigma e.g. idea of injecting in public, 
and/or lack of social support (Bogatean & Hâncu, 2004b; Brod, Alolga, et al., 2014; Brod et 
al., 2009; Fisher et al., 2019; Hassan et al., 2013; Hussein et al., 2019; Janes, Titchener, 
Pere, Pere, & Senior, 2013; Khan et al., 2008; Lee et al., 2012; Mehmet, Hussey, & Ibrahim, 
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2015; Nadasen & Naidoo, 2012; Ong, Chua, & Ng, 2014; Patel et al., 2012; Phillips, 2007; 
Tan et al., 2011; Taylor et al., 2017). Social-psychological considerations are particularly 
relevant in insulin-taking behaviour as injectable therapies are perceived as more 
demanding than OADs and have a greater social impact (Peyrot, Harshaw, Shillington, Xu, & 
Rubin, 2012). 
1.6.3. Sub-optimal HbA1c and insulin treatment  
Even though research indicates, once insulin has been initiated, people are less negative 
towards insulin therapy (Cosson et al., 2019; Gherman & Alionescu, 2015; Hermanns et al., 
2010; Holmes-Truscott, Furler, Blackberry, O'Neal, & Speight, 2017; Odawara, Ishii, Tajima, 
& Iwamoto, 2016; Perez-Nieves et al., 2016), have higher treatment satisfaction (Polonsky, 
Traylor, et al., 2014) and have improved quality of life (Hajós et al., 2011, 2012; Pouwer & 
Hermanns, 2009), many people with type 2 diabetes on insulin therapy have suboptimal 
glycaemic levels (Harris, Kapor, Lank, Willan, & Houston, 2010; Khunti et al., 2016; Tong, 
Vethakkan, & Ng, 2015). There could be several reasons which could account for this. 
Firstly, the progression and deterioration of beta cells, in general, make type 2 diabetes 
more difficult to manage, especially at the point where insulin therapy is required (UKPDS, 
1998b). Secondly, in the UK, since the introduction of Quality and Outcomes Framework 
and the need for people with type 2 diabetes to meet HbA1c targets, it is now more 
common for practice nurses and general practitioners to treat people with type 2 diabetes 
on insulin in primary care rather than in secondary care by diabetes specialists (Burden & 
Burden, 2007; Chadder, 2013).  In this case, the lack of specialist knowledge and 
familiarisation of insulin for people with type 2 diabetes on insulin could account for 
suboptimal HbA1c (Kunt & Snoek, 2009). On a patient-level, there are issues with 
adherence to insulin therapy (administering correct dose and frequency) and persistence 
(continuation of treatment) (Cramer et al., 2008; Garnero et al., 2018). Someone could be 
persistent i.e. continues with insulin over time, but nonadherent i.e. omits some doses. Or 
vice versa, a person could be adherent and take prescribed dose and frequency of insulin, 
but nonpersistent and discontinue insulin therapy. Both non-adherence and non-
persistence negatively impacts glycaemic levels, increases the risk of mortality (Currie et al., 
2012), and increases healthcare costs (Kennedy-Martin, Boye, & Peng, 2017).  
1.6.4. Adherence to insulin treatment  
The word ‘adherence’ is considered as stigmatising and has potentially detrimental effects 
on health outcomes when this type of language is used in clinical practice (NHSE, 2018). 
‘Adherence’ is only used in this thesis owing to the term being a keyword/ Medical Subject 
38 
 
Headings (MeSh) term from previous research. In this context, adherence refers to optimal 
medication-taking behaviour, whereas non-adherence refers to suboptimal medication-
taking behaviour.  
There are varied reports of rates of adherence (30-85%) to insulin therapy in type 2 
diabetes (Guerci, Chanan, Kaur, Jasso-Mosqueda, & Lew, 2019), these vary between studies 
based on the measure of adherence, type of insulin and population (Barag, 2011; Brod, 
Rana, & Barnett, 2012; Cooke, Lee, Tong, & Haines, 2010; Cramer et al., 2008; Davies et al., 
2018; Donnelly et al., 2007; Farsaei, Radfar, Heydari, Abbasi, & Qorbani, 2014; Guerci et al., 
2019; He, Chen, Wang, Wu, & Wu, 2017; Peyrot et al., 2017). Other variability can be 
accounted for there being no validated threshold for adherence to insulin therapy and the 
complexity of data collection which makes measuring adherence to insulin unreliable 
(Stolpe, Kroes, Webb, & Wisniewski, 2016).  
Treatment demand and complexity of treatment including consideration of self-monitoring 
blood glucose, administering insulin, interaction with daily life and lifestyle such as diet 
(Davies et al., 2013),  higher insulin dose and more frequent injections (Donnelly et al., 
2007; Peyrot, Rubin, Kruger, & Travis, 2010) makes insulin adherence more difficult.  
Around 20% people with type 2 diabetes report non-adherence via insulin omission e.g. 
skipping doses (Osborn & Gonzalez; Peyrot, Barnett, Meneghini, & Schumm‐Draeger, 2012; 
Peyrot, Rubin, Kruger, et al., 2010; Rubin, Peyrot, Kruger, & Travis, 2009) or not injecting 
correct doses (Trief, Cibula, Rodriguez, Akel, & Weinstock, 2016). A self-report internet 
survey found people with type 2 diabetes are less adherent to insulin therapy than people 
with type 1 diabetes, perhaps due to people with type 2 diabetes having a ‘residual insulin 
response’ and therefore not having an immediate negative consequence of insulin 
omission that people with T1D experience (Peyrot, Rubin, Kruger, et al., 2010). Polonsky et 
al.’s evaluation of the literature proposes that the two key causes of treatment 
nonadherence in type 2 diabetes are: treatment burden (e.g. complexity of treatment, side 
effects, the cost to the patient) and beliefs around treatment (e.g. perceived efficacy, 
negative beliefs, healthcare professional relationship) (Polonsky & Henry, 2016).  
Some reasons for insulin omission are proposed as unintentional, for example, 
forgetfulness due to distraction, busy schedules or memory deficits (Brod, Pfeiffer, & 
Harald Kongsø, 2014; Brod, Pohlman, et al., 2014; Ellis et al., 2018; Holmes-Truscott, 
Browne, et al., 2016). Forgetting could be explained by the complexity of some insulin 
regimes (Bermeo-Cabrera, Almeda-Valdes, Riofrios-Palacios, Aguilar-Salinas, & Mehta, 
39 
 
2018b; García-Pérez, Álvarez, Dilla, Gil-Guillén, & Orozco-Beltrán, 2013) . On the other 
hand, the complexity of insulin regime could account for nonadherence to insulin therapy 
such as difficulty self-titrating, which is not related to forgetting (Brod, Pohlman, et al., 
2014; Brod et al., 2012; Cefalu et al., 2008; Ellis et al., 2018; Hortensius et al., 2012; Jenkins, 
Hallowell, Farmer, Holman, & Lawton, 2011; Leiter, Boras, & Woo, 2015; Ong et al., 2014; 
Vinter-Repalust, Petricek, & Katic, 2004).  
Poor adherence is related to low socio-economic status (Bermeo-Cabrera, Almeda-Valdes, 
Riofrios-Palacios, Aguilar-Salinas, & Mehta, 2018a; Donnelly et al., 2007); lower-income 
(Peyrot, Rubin, Kruger, et al., 2010); higher education (Peyrot, Rubin, Kruger, et al., 2010); 
younger age (Donnelly et al., 2007; Fisher et al., 2019; Peyrot, Rubin, Kruger, et al., 2010), 
higher body mass index (Donnelly et al., 2007; Fisher et al., 2019); prior injectable use 
(Fisher et al., 2019); more than one event of severe hypoglycaemia (Fisher et al., 2019); 
negative perception of prior use of insulin of family/friends (Fisher et al., 2019); and ethnic 
minority (Cramer & Pugh, 2005). These factors should be taken into consideration when 
targeting people with type 2 diabetes to improve insulin adherence.  
1.6.5. Persistence to insulin treatment  
Non-persistence is also a problem in type 2 diabetes, after one year, 20-40% of people with 
type 2 diabetes discontinue insulin (Hadjiyianni et al., 2017; Miao, Wei, Lin, Xie, & Baser, 
2014; Perez-Nieves et al., 2016; Roussel et al., 2016). Those who do not persist with insulin 
after 90 days of initiation are highly likely to restart it (Ascher-Svanum et al., 2014), owing 
to deteriorating blood glucose control. Other studies also find people with type 2 diabetes 
re-uptake insulin owing to suboptimal HbA1c, in addition, to supporting from healthcare 
professionals or friends/family (Idris et al., 2019). Persistence to insulin therapy is higher 
for long-acting insulin than intermediate-acting insulin which could be explained by 
reduced hypoglycaemia (Anderten, Dippel, & Kostev, 2015; Pscherer, Chou, Dippel, 
Rathmann, & Kostev, 2015), and lower insulin-injection frequency (Baser, Tangirala, Wei, & 
Xie, 2013; Donnelly et al., 2007; Guerci et al., 2019). For those who experience 
hypoglycaemia with insulin in the first 6 months, they are more likely to discontinue insulin 
within 12 months of initiation (Dalal, Kazemi, Ye, & Xie, 2017), though once the reason for 
hypoglycaemia has been resolved, re-uptake of insulin is more likely (Peyrot et al., 2017).  
1.6.6.  Clinical inertia  
Healthcare professionals experience clinical inertia when a problem is recognised but they 
fail to act upon it (Phillips et al., 2001). A 2012 observational study of 10 countries (Canada, 
China, Germany, Israel, Italy, Poland, Portugal, Spain, Turkey, UK) revealed for all countries 
40 
 
(except Germany) most people with type 2 diabetes were on 2 OADs before initiating 
insulin (Khunti, Damci, et al., 2012). This could suggest insulin is being prescribed according 
to international guidelines as a second intensification of drug treatment. However, pre-
insulin HbA1c was above target (>58 mmol/mol according to NICE guidelines) for all 
countries. Studies worldwide find insulin is prescribed when HbA1c is above target (Calvert, 
McManus, & Freemantle, 2007; Harris et al., 2010; Hosomura et al., 2017; Khunti, Damci, et 
al., 2012; Khunti et al., 2018; Khunti et al., 2016; Khunti, Wolden, Thorsted, Andersen, & 
Davies, 2014; Khunti et al., 2015; Lovshin & Zinman, 2013; Nichols, Koo, & Shah, 2007; 
Pantalone et al., 2019; Phillips et al., 2001). Even when HbA1c is above target, an audit in 
Canada found only 56% of healthcare professionals planned to intensify treatment, 5% 
planned to keep treatment the same, and the remaining healthcare professionals planned 
to communicate the importance of lifestyle modifications (Harris, Ekoe, Zdanowicz, & 
Webster-Bogaert, 2005). These studies provide evidence for a delay and clinical inertia 
towards initiating insulin therapy.  
Phillips and colleagues suggested clinical inertia occurs for the following reasons: 
healthcare professionals overestimate their adherence to relevant guidelines; healthcare 
professionals believing their patient with type 2 diabetes is improving; and lack of 
healthcare professional training to achieve HbA1c targets (Phillips et al., 2001). Specialist 
knowledge could be a contributing factor with diabetes specialists being more likely to 
intensify treatment than non-specialists (Ellis et al., 2018; Peyrot et al., 2005; Reach, Le 
Pautremat, & Gupta, 2013; Shah, Hux, Laupacis, Zinman, & Van Walraven, 2005; Sterzi, 
Auziere, Jensen, & Lopes, 2017). In addition, clinical inertia can occur when healthcare 
professionals lack knowledge such as being unaware of HbA1c targets (Grant et al., 2007; 
Haque, Emerson, et al., 2005; Kunt & Snoek, 2009; Nakar et al., 2007; Zafar, Stone, Davies, 
& Khunti, 2015), therefore it is important for healthcare professionals to take 
accountability and obtain correct information regarding targets (Zafar et al., 2015). 
However, this could be difficult as there is mixed research evidence for the advantages of 
having tight blood glucose control in type 2 diabetes. For example, mixed results of clinical 
trials in improving complication status via intensive glycaemic targets such as ADVANCE 
(ADVANCE, 2008), ACCORD (ACCORD, 2008), and UKPDS (UKPDS, 1998a) trials. These mixed 
findings could lead to clinical inertia and delay of insulin treatment, as the clear benefits of 
intensive HbA1c via insulin therapy have not been clearly communicated (Bloomgarden, 
2008; Khunti et al., 2016).  
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Clinical inertia is multifactorial and is associated with practical barriers such as time 
constraints (Grant et al., 2007; Kunt & Snoek, 2009; Tan et al., 2011), and perceived 
patient-barriers for example, fear of hypoglycaemia (Ellis et al., 2018; Grant et al., 2007; 
Haque, Emerson, et al., 2005; Sterzi et al., 2017), feelings of personal failure and potential 
impact on quality of life (Ellis et al., 2018; Lakkis et al., 2013a; Nakar et al., 2007; 
Ratanawongsa et al., 2012).   
1.7. Strategies to overcome problems with insulin treatment 
Researchers have made several suggestions around addressing problems associated with 
insulin use in type 2 diabetes. These are important on a patient and healthcare professional 
level when educating people with type 2 diabetes about the benefits of uptake and 
continued self-management of insulin treatment. Strategies are summarised in relation to 
avoiding clinical inertia, the importance of healthcare professional communication, and 
behavioural and psychological insulin interventions.  
1.7.1. Strategies to avoid clinical inertia  
Strategies have been proposed by (Shaefer, 2006), to avoid clinical inertia by healthcare 
professionals and include: establishing a set HbA1c goal (in accordance with relevant 
guidelines); defining a timeframe for this goal; and finally displaying the progress of the 
goal to oneself and people with type 2 diabetes (e.g. having results visible to both parties 
during follow-up). In support of these strategies, other research has found HbA1c can be 
improved by displaying progress and providing feedback on performance to health 
professionals (Parchman, Pugh, Romero, & Bowers, 2007) and people with type 2 diabetes 
(Ziemer et al., 2006). Insulin education for healthcare professionals should be created in 
multiple ways to increase insulin uptake for example, written, web-based, seminars or 
workshops (Peyrot, Rubin, & Khunti, 2010). However, clinical inertia is complex and 
addressing healthcare professional barriers in isolation may not resolve the problem, hence 
healthcare professional, patient, and system barriers should be considered all together to 
fully address the issue (Zafar et al., 2015).  
1.7.2. Healthcare professional communication  
Healthcare professional communication with people with type 2 diabetes is essential when 
addressing insulin treatment problems, and effective healthcare professional 
communication can positively influence insulin uptake, and insulin adherence and 
persistence (Ciechanowski, Katon, Russo, & Walker, 2001; Ellis et al., 2018; García-Pérez et 
al., 2013; Gherman, Schnur, et al., 2011; Tiv et al., 2012). On the contrary, poor healthcare 
professional communication regarding insulin can have a negative impact on people with 
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type 2 diabetes such as emotional response (fear and shock), lack of involvement in a 
decision regarding treatment, and gaps in knowledge regarding the importance and need 
for insulin (Given, McCay, Hill, O'Kane, & Coates, 2015).   
Positive healthcare professional communication strategies in relation to insulin treatment 
include shared decision making (Peyrot, Barnett, et al., 2012; Polonsky & Henry, 2016) goal 
setting (Phillips, 2007),  displaying adequate knowledge around insulin therapy (Bogatean & 
Hâncu, 2004a; Furler, Spitzer, Young, & Best, 2011; Goderis et al., 2009; Peyrot et al., 2005), 
using a blame-free approach (Garnero et al., 2018), and making time to answer questions 
and address concerns around insulin therapy (Stuckey et al., 2018; Tang et al., 2018). Good 
healthcare professional communication is related to lower diabetes distress and better 
diabetes self-care at any point of type 2 diabetes treatment intensification (Edelman et al., 
2019). 
The ‘diabetes and emotional health guide for healthcare professionals’ supporting adults 
with diabetes recommend steps for communicating with people with type 2 diabetes about 
psychological insulin resistance  (Hendrieckx, Halliday, Beeney, & Speight, 2019). This guide 
uses a 7 A’s mode: be Aware that people with type 2 diabetes experience psychological 
insulin resistance; Ask the person with type 2 diabetes about psychological insulin 
resistance e.g. “What are the benefits of insulin for you?”; Assess psychological insulin 
resistance using a questionnaire (for example the Insulin Treatment Appraisal Scale; ITAS 
(Snoek et al., 2007)); Assign to another healthcare professional e.g. diabetes specialist, 
mental health professional, or structured education group if needed; Advise about 
psychological insulin resistance e.g. by normalising concerns, educate around diabetes 
progression and need for insulin; Assist by creating an action plan; Arrange follow-up 
appointments to monitor progress. The 7 A’s model is similar in approach to encouraging 
effective healthcare professional communication and are a guide for discussing insulin 
therapy with people with type 2 diabetes. However, this approach has not been empirically 
tested relating to addressing problems around insulin treatment.   
1.7.3. Psychological and behavioural interventions 
1.7.3.1. Psychological interventions which improve type 2 diabetes outcomes 
Motivational interviewing is a common counselling technique which is non-judgemental 
and patient-centred aiming to resolve ambivalence (Rollnick & Miller, 1995). Ambivalence 
is highly relevant in the case of insulin therapy interventions as many uncertainties and 
concerns arise for people with type 2 diabetes (Ng et al., 2015). Motivational interviewing 
based interventions have been found to be effective in for people with type 2 diabetes in 
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improving blood glucose (A & Byron-Daniel, 2014; Chen, Creedy, Lin, & Wollin, 2012; 
Mulimba & Byron-Daniel, 2014; Song, Xu, & Sun, 2014; Winkley et al., 2019), and weight 
loss in type 2 diabetes (Ekong & Kavookjian, 2016; Mulimba & Byron-Daniel, 2014). People 
with type 2 diabetes are receptive to this therapy owing to feeling empowered; non-
judgemental approach; being listened to; and preparing action plans and setting goals 
(Dellasega, Añel-Tiangco, & Gabbay, 2012). There is limited research around motivational 
interviewing and insulin use. Whilst motivational interviewing was encouraged in the 
‘Stepping Up’ intervention (Furler et al., 2017), there was not an assessment of whether it 
was implemented. Therefore, there is a gap in research which examines whether 
motivational interviewing techniques are successful in improving problems associated with 
insulin use.  
Cognitive behaviour therapy is another type of talking therapy which has been empirically 
tested in type 2 diabetes research. Cognitive behavioural therapy focuses on how 
cognitions (i.e. thoughts, attitudes or beliefs) affect behaviour and helps develop skills for 
dealing with problems. Cognitive behavioural therapy was initially developed to treat 
depression (Beck & Alford, 2009), because of how cognitions (thoughts, attitudes) can 
influence behaviour. Common unhelpful thinking styles (not limited to people with 
depression) include personalising (negatively attributing outcomes to oneself); 
catastrophising (thinking the ‘worst-case scenario’); and all or nothing (holding high 
standards, might not engage in behaviour change unless success is certain). In systematic 
reviews of cognitive behavioural therapy or psychological interventions for people with 
type 2 diabetes, cognitive behavioural therapy is associated with improvements in 
depressive symptoms (Li et al., 2017; Uchendu & Blake, 2017; Wang, Tsai, Chou, & Chen, 
2008), fasting glucose, quality of life, anxiety (Li et al., 2017), and HbA1c (Ismail, Winkley, & 
Rabe-Hesketh, 2004). Again, no individual studies specifically examine whether cognitive 
behavioural therapy is effective for resolving problems around insulin use.    
1.7.3.2. Advantages of self-monitoring blood glucose in relation to insulin therapy 
Psychological receptiveness to insulin therapy is associated to experiences of successful 
intensification of previous diabetes treatment in line with deteriorating blood glucose, in 
addition to accepting type 2 diabetes as a progressive condition (Jenkins, Hallowell, Farmer, 
Holman, & Lawton, 2010). Therefore, self-monitoring blood glucose is a behavioural 
technique recommended to emphasise type 2 diabetes progression and when 
intensification is required. However, there are potential barriers to self-monitoring blood 
glucose that need to be addressed including psychological issues (anxiety of testing and/or 
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result of the test, depression, self-esteem, self-efficacy, fear of needles, burden, avoidance) 
(Ciechanowski, Katon, & Russo, 2000; Egede & Osborn, 2010; Fisher, 2007; Hortensius et 
al., 2012; O'Neil et al., 2014; Ong et al., 2014; Polonsky, Fisher, Hessler, & Edelman, 2014; 
Schabert, Browne, Mosely, & Speight, 2013; Vincze, Barner, & Lopez, 2004; Weinger, 
Butler, Welch, & La Greca, 2005), inconvenience (Fisher, 2007; Kirk, Graves, Bell, 
Hildebrandt, & Narayan, 2007; Ong et al., 2014; Renard, 2005; Vincze et al., 2004), social 
stigma (Ong et al., 2014; Schabert et al., 2013; Tak‐Ying Shiu, Kwan, & Wong, 2003), and 
not understanding the benefits (Polonsky, Fisher, et al., 2014). However, group type 2 
diabetes education has been found to increase acceptance to self-monitoring blood glucose 
(Bruce, Davis, Cull, & Davis, 2003).   
1.7.3.3. Current insulin education intervention research   
A systematic review of factors affecting adherence to insulin therapy found diabetes 
education improves insulin adherence (Davies et al., 2013). In addition, higher treatment 
satisfaction for people with type 2 diabetes on insulin therapy was related to receiving 
diabetes education (Boels et al., 2017), however, for both these studies the type of 
diabetes education was not reported.  Researchers have recommended 
psychological/behavioural educational strategies to overcome problems with insulin 
treatment including: demonstration of insulin injections with healthcare professional 
supervision (Allen, Zagarins, Feinberg, & Welch, 2017; Furler et al., 2011; Gherman, Schnur, 
et al., 2011; Jenkins et al., 2010; Phillips, 2007; Polonsky et al., 2019; Stuckey et al., 2018; 
Tan et al., 2011), insulin ‘trial period’, and (Gherman, Schnur, et al., 2011), and sharing of 
success stories of other people with type 2 diabetes on insulin (Allen et al., 2017). These 
strategies have not been empirically tested.  
There is limited empirical evidence which specifically relates to interventions targeting the 
psychological aspects of insulin treatment.  A DVD intervention for UK-based south Asian 
people with type 2 diabetes was designed to address misconceptions of insulin, which was 
then discussed with an healthcare professional (Patel, Stone, Hadjiconstantinou, et al., 
2015). Misconceptions portrayed in the DVD included: severity of diabetes, fear of 
hypoglycaemia, sense of personal failure, link between insulin and complications, the pain 
of injections, administration difficulties, social stigma, source of insulin, and driving licence 
issues. Positive changes were seen in attitudes and insulin knowledge. The healthcare 
professionals delivering this intervention found the DVD time consuming, indicating this 
intervention not being feasible in real-world practice. A less time-intensive intervention 
could be printed materials such as an insulin tool called ‘Questions about Starting Insulin: 
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Information on the Myths, Misconceptions and Clinical Realities about Insulin’. This again 
aimed to address concerns around insulin therapy as well as aid healthcare professional 
communication (Brod, Alolga, et al., 2014). Ten questions relating to insulin uptake barriers 
were generated from 13 focus groups of people with type 2 diabetes conducted across 
Germany, Sweden, The Netherlands, UK, and USA. Then, an interview with 4 clinical experts 
were responsible for producing answers to these questions.  The questions related to 
barriers and misconceptions of insulin including difference between insulin and OADs, fear 
of side effects, link between insulin and complications, necessity, sense of personal failure, 
insulin dependence, insulin titration, lifestyle restrictions, and pain of injections. The 
limitation of this intervention, like Patel et al, is it only considered barriers to insulin 
initiation and not adherence or persistence issues, however some of the pre-initiation 
concerns might translate to self-management concerns e.g. concerns about weight gain 
(Holmes‐Truscott et al., 2015). The advantage of this resource is it can be used to support 
different modes of type 2 diabetes education e.g. one-to-one, and group. A full evaluation 
of these two interventions is yet to be tested in a randomised controlled trial. Mathers et al 
did test their intervention in a randomised controlled trial (Mathers et al., 2012). This 
intervention involved healthcare professionals using a decision aid tool in a single 
consultation with insulin naïve people with type 2 diabetes to support shared decision-
making around diabetes treatment choice. Though not limited to insulin therapy only, the 
intervention did result in improved knowledge, perception of consequences (for example, 
hypoglycaemia, weight gain and complications), and independent decision-making. Though 
this intervention does find advantages around shared decision making in type 2 diabetes 
education, the intervention did not improve HbA1c over the control group, nor measure 
psychological aspects of insulin use (e.g. psychological insulin resistance) as an outcome. A 
Romanian randomised controlled trial found individual sessions of structured education to 
initiate insulin in type 2 diabetes were effective in improving HbA1c 6 months later 
compared with less intensive education, however, there were no differences between 
groups in improving body weight or the number of hypoglycaemic episodes (Bala, Rusu, 
Moise, & Roman, 2019). Again, this study did not consider the psychological aspects of 
insulin use. None of these studies (Bala et al., 2019; Brod, Alolga, et al., 2014; Mathers et 
al., 2012; Patel, Stone, Hadjiconstantinou, et al., 2015) examine group insulin education.  
1.7.4. Group diabetes education  
The core rationale for group-based insulin education is social support from others in the 
same situation. Social support for people with type 2 diabetes is associated with reduced 
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HbA1c (Stopford, Winkley, & Ismail, 2013; Strom & Egede, 2012). Social factors also have 
an important role in insulin initiation, for example, family or peer support (Bogatean & 
Hâncu, 2004a; Burden & Burden, 2007; Farsaei et al., 2014; Nadasen & Naidoo, 2012; Patel 
et al., 2012; Phillips, 2007) and knowing others who take insulin (Bogatean & Hâncu, 2004a; 
Tan et al., 2011).   
There is evidence of the efficacy of a group-based diabetes education programme people 
with type 2 diabetes called Diabetes Education and Self-Management for Ongoing and 
Newly Diagnosed (DESMOND) in weight loss, and positive illness beliefs (Davies et al., 2008; 
Khunti, Gray, et al., 2012a). No significant differences were found in HbA1c 12 months later 
between intervention and control however this could be accounted for by intervention 
baseline HbA1c values being higher. A real-world evaluation of DESMOND found a 
significant reduction in HbA1c (Chatterjee, Davies, Stribling, Farooqi, & Khunti, 2018). 
Systematic reviews and meta-analysis of studies worldwide find group-based type 2 
diabetes education shows benefits in HbA1c, diabetes knowledge self-management skills, 
self-efficacy, weight, and treatment satisfaction compared with control conditions (Norris, 
Lau, Smith, Schmid, & Engelgau, 2002; Odgers‐Jewell et al., 2017; Steinsbekk, Rygg, Lisulo, 
Rise, & Fretheim, 2012). Some of the studies criteria included people with type 2 diabetes 
on insulin therapy, though no studies related specifically to group-based insulin education.   
There are existing group education programmes such as X-PERT Insulin (X-PERT Health) and 
the Injectable Therapies Toolkit (The DESMOND Collaborative), however, they do not 
specifically address psychological aspects of insulin use. A review of type 2 diabetes models 
of injectable therapy initiation found successful models included nurse-led group sessions 
(Appannah, Rice, & Ogrin, 2017). 
1.8. Chapter summary  
Insulin injection therapy is an inevitable treatment for many people with type 2 diabetes 
when beta cells have deteriorated to a point where other therapies cannot help them 
achieve optimal glycaemic levels. Insulin has been found to be effective in normalising 
blood glucose levels and this significantly reduces the risk of long-term complications. 
There is however a significant delay in initiating insulin therapy, accounted for largely by 
clinical inertia and psychological aspects of insulin use for people with type 2 diabetes. 
There are also problems with insulin use such as suboptimal HbA1c, adherence, and 
persistence to insulin treatment. Healthcare professional communication with people with 
type 2 diabetes and the delivery of insulin specific education is essential in resolving these 
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problems. Existing group insulin education needs to incorporate psychological aspects of 
insulin use before initiating insulin treatment with the aim of providing a strong foundation 
for supporting future adherence and persistence to insulin to improve type 2 diabetes 
outcomes. The overall aim of this thesis was to develop a group psychological intervention 
to optimise insulin initiation for people with type 2 diabetes. This was addressed through 4 
studies whose aims, and objectives are outlined below. 
1.10. Aims and objectives of the thesis  
Study 1:  
Aim: To examine the relationship between behaviour change technique categories and 
HbA1c in type 2 diabetes.  
Objective 1: To extract which behaviour changes techniques underpin psychological 
interventions from a meta-analysis of 67 randomised controlled trials comparing 
psychological interventions to control to improve HbA1c in type 2 diabetes. 
Objective 2: To conduct a meta-regression to determine the relationship between HbA1c 
and behaviour change technique category. 
Objective 3: To conduct a meta-regression to determine the relationship between HbA1c 
and frequency of behaviour change techniques. 
Study 2:  
Aim: To examine the experiences of attending nurse-led group-based insulin start group 
education for people with type 2 diabetes. 
Objective: To conduct a qualitative evaluation via one-to-one semi-structured interviews of 
the experiences of people with type 2 diabetes who have attended an insulin start group in 
south London.  
Study 3 
Aim: To examine the association between i) depressive symptoms, ii) diabetes distress iii) 
negative insulin beliefs on a) time to insulin-requiring status and b) time to insulin 
initiation.  
Objective 1: To extract date of insulin-requiring status and insulin initiation from primary 
care medical records of the SOUth London Diabetes (SOUL-D) cohort. 
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Objective 2: To conduct a survival analysis to determine time to insulin-requiring status 
from type 2 diabetes diagnosis of the SOUL-D cohort. 
Objective 3: To conduct a survival analysis to determine time to insulin initiation from type 
2 diabetes diagnosis of the SOUL-D cohort. 
Objective 4: To conduct a survival analysis to determine time to insulin initiation from 
insulin-requiring status of the SOUL-D cohort. 
Objective 5: To compare survival distributions between baseline psychological variable 
categorical groups (depressive symptoms, diabetes distress and negative insulin beliefs). 
Objective 6: To conduct Cox regression analysis to determine the association between 
baseline psychological variable categorical groups (depressive symptoms, diabetes distress 
and negative insulin beliefs) and time to insulin-requiring status controlling for confounding 
variables.  
Objective 7: To conduct Cox regression analysis to determine the association between 
baseline psychological variable categorical groups (depressive symptoms, diabetes distress 
and negative insulin beliefs) and time to insulin initiation controlling for confounding 
variables.  
Study 4 
Aim: To develop a nurse-led group psychological intervention to optimise insulin initiation 
for people with type 2 diabetes. The intervention is called Diabetes Insulin Management 
Education (DIME).  
Objective 1:  To use effective behaviour change techniques from study 1 to underpin the 
DIME intervention.  
Objective 2: To integrate views and suggestions from study 2 into DIME development. 
Objective 3: To consider which psychological variables in study 3 impact insulin initiation in 
the development of DIME. 
Objective 4: To use findings from studies 1-3 to inform the behaviour change wheel to 
identify relevant behaviour change techniques to underpin the DIME intervention.  
Objective 5: To integrate psychological techniques used in previous diabetes education 
manuals to develop the DIME intervention. 
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Objective 6: To pilot test the DIME intervention on two groups of people with type 2 
diabetes initiating insulin. 
Study 5 
Aim: To determine the acceptability of the pilot DIME intervention. 
Objective 1: To qualitatively evaluate the experiences of people who attended the DIME 
pilot sessions. 
Objective 2: To extract clinical data of the DIME exit interviewees to form case studies pre 






Chapter 2 : A meta-analysis to 
determine the effectiveness of 
behaviour change techniques in 
psychological interventions to improve 

























2.1. Chapter scope 
This chapter describes study 1 of this thesis. This study extracts behaviour change 
techniques from the psychological intervention descriptions of trials from an existing 
systematic review and meta-analysis of psychological interventions to improve HbA1c in 
type 2 diabetes (Winkley et al., 2019), appendix 2.1. Study 1 of this thesis repeats a meta-
analysis of HbA1c outcomes from the studies included in the existing review but with 
English language studies only (67 out of 70 studies). In addition, study 1 of this thesis 
conducts an additional analysis of the existing review to determine whether there is an 
association between behaviour change techniques and improvement in HbA1c.  
2.2. Introduction  
The behaviour change wheel is a model to explain behaviour that was created for the 
purpose of designing and evaluating behaviour change interventions (Michie, Atkins, & 
West, 2014). At the core of the behaviour change wheel is the COM-B behavioural model, 
COM-B refers to how capability, opportunity, and motivation interact to influence 
behaviour. The capability component includes the physical (e.g. skill) and psychological 
(e.g. knowledge) ability to carry out a behaviour. The motivation component refers to the 
cognitive processes which allow someone to perform the behaviour, including automatic 
(e.g. emotional) and reflective (e.g. making plans) processes. The opportunity component is 
concerned with the social (e.g. norms) and physical (e.g. location) factors that make the 
behaviour possible to achieve (Michie, van Stralen, & West, 2011), figure 2.1.  
The use of the behaviour change wheel has revolutionised the way science standardises, 
develops, evaluates, and reports complex behavioural interventions. A program of research 
that has stemmed from the behaviour change wheel is a standardised taxonomy that aims 
to describe specific active ingredients within interventions. This has been termed the 
Behaviour Change Technique Taxonomy version 1 (BCTTv1) (Michie et al., 2015). Behaviour 
change techniques can be defined as small, observable and replicable components of an 
intervention which can lead to a change in behaviour in an individual or group of people. 
The BCTTv1 comprises of 93 behaviour change techniques which are classified into 16 
























The use of these behaviour change techniques allows for a standardised language amongst 
health researchers and healthcare professionals when designing interventions and 
reporting findings. This ensures that the interventions can be replicated, therefore 
improving the fidelity of delivery and facilitating replicability, and evaluation (Dugdale et 
al., 2016).  
There is some literature on behaviour change techniques and interventions to improve 
outcomes in type 2 diabetes. Studies found a higher frequency of behaviour change 
techniques used in behavioural interventions targeting physical activity and weight loss in 
type 2 diabetes was associated with better improvement in glycaemic levels (Avery, Flynn, 
1. Goals and planning 
2. Feedback and monitoring 
3. Social support 
4. Shaping knowledge 
5. Natural consequences 
6. Comparison of behaviour 
7. Associations 
8. Repetition and substitution  
9. Comparison of outcomes 
10. Reward and threat 
11. Regulation 
12. Antecedents 
13. Identity  
14. Scheduled consequences 
15. Self-belief 
16. Covert learning  
Figure 2.2- Behaviour change techniques categories 
Opportunity 
(Physical and social) 
Capability 
(Physical and psychological) 
Motivation 
(Reflective and automatic) 
Behaviour 
Figure 2.1-The COM-B model 
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Van Wersch, Sniehotta, & Trenell, 2012) and weight loss (Hankonen et al., 2014). Behaviour 
change techniques in dietary focused interventions that are associated with improved 
glycaemic levels include: ‘instruction on how to perform a behaviour’ (shaping knowledge), 
‘behavioural practice/rehearsal’ (repetition and substitution), ‘demonstration of the 
behaviour’ (comparison of behaviour), and ‘action planning’ (goals and planning) (Cradock 
et al., 2017). Behaviour change techniques associated with reduced fat intake in type 2 
diabetes were associated with ‘goals and planning’, including ‘goal setting’ and ‘review of 
behaviour/outcome goals’ (Hankonen et al., 2014). A web-based intervention for people 
with type 2 diabetes which used the following behaviour change techniques were 
associated with improvements in behaviour change, well-being or clinical parameters:  
‘feedback on behaviour’(feedback and monitoring), ‘information about health 
consequences’(natural consequences), ‘problem-solving’(goals and planning), and ‘self-
monitoring of behaviour’(feedback and monitoring) (van Vugt, de Wit, Cleijne, & Snoek, 
2013). A qualitative analysis extracting behaviour change techniques from implementation 
interventions (Presseau et al., 2015) based on studies identified in a systematic review 
(Tricco et al., 2012) found the most frequent behaviour change technique categories 
included: associations, natural consequences, shaping knowledge, antecedents, social 
support and goals and planning. 
Psychological interventions such as cognitive behavioural therapy and counselling (e.g. 
motivational interviewing) are associated with an improvement in glycaemic levels for 
people with type 2 diabetes (Alam, Sturt, Lall, & Winkley, 2009; Ismail et al., 2004; Schmidt, 
van Loon, Vergouwen, Snoek, & Honig, 2018; Winkley et al., 2019). However, there is 
limited understanding of which behaviour change techniques underpin these psychological 
interventions aiming to improve glycaemic levels for people with type 2 diabetes. Coding 
interventions using specific behaviour change techniques ensures that future intervention 
design can develop more effective interventions owing to certainty around which 
techniques are the active ingredients of the intervention. This is opposed to counselling or 
cognitive behavioural therapy which are potentially broad in definition.  
Study 1 of this thesis coded behaviour change techniques from psychological interventions 
descriptions from a recent existing systematic review of psychological interventions to 
improve HbA1c in type 2 diabetes (Winkley et al., 2019). The aim of this study was to 
examine the relationship between behaviour change technique categories and HbA1c in 




Winkley et al, 2019 reports a systematic review, aggregate meta-analysis, and network 
meta-analysis of psychological interventions to improve HbA1c in type 2 diabetes (Winkley 
et al., 2019). Study 1 of this thesis performs an aggregate meta-analysis of the English-
language studies included in Winkley et al (Winkley et al., 2019). Here, the main methods 
of the Winkley et al are reported according to Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) checklist, appendix 2.2. This section also reports 
which studies and data were analysed for additional analysis in this thesis chapter (i.e. not 
included in Winkley et al, 2019).  
2.3.1. Protocol and registration 
A study protocol was registered with Prospective Register of Systematic Reviews 
(PROSPERO; CRD42016033619) detailing methods and analysis plan for the Winkley et al, 
systematic review and meta-analysis (Winkley et al., 2019). Additional analyses reported in 
this chapter were not detailed in the protocol.   
2.3.2. Eligibility criteria 
2.3.2.1. Types of studies 
Randomised controlled trials of psychological interventions for people with type 2 diabetes 
were included (published and unpublished). Study designs which included no control group 
were excluded (e.g. pre-post observational and N-of-1 studies). Information could be 
extracted from multiple publications where relevant i.e. long-term follow-ups or protocols. 
English-language studies only were included in this thesis chapter (study 1). Three non-
English language studies from the existing review (Winkley et al., 2019) were not included 
owing to difficulties finding BCTTv1 trained native translators. 
2.3.2.2. Participants 
Adults (≥18 years) diagnosed with type 2 diabetes were included. People with type 1 
diabetes, pre-diabetes, impaired glucose tolerance, gestational diabetes, or other medical 
conditions were excluded. If studies included multiple conditions including type 2 diabetes, 
the study was included if separate analysis for people with type 2 diabetes was provided by 
trial authors.  
2.3.2.3. Interventions 
Inclusion of intervention was based on all the following criteria for a psychological 
intervention: 
1) relied on a therapeutic reliance (based on communication between person[s] with type 
2 diabetes and psychological intervention facilitator);  
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2) facilitated by psychology professionals (e.g. psychologist, therapist accredited or in 
training); or facilitators were trained in a psychological intervention by a psychology 
professional; or facilitators were supervised by a psychology professional; 
3) underpinned by a psychological model;  
4) aimed to improve emotional, cognitive or behavioural functioning.  
Where a decision on inclusion could not be made based on reported intervention 
description, trial authors were contacted for more detail. Self-help interventions were 
excluded unless guided by a facilitator.  
Control groups included: usual care (including enhanced usual care), waiting list control, 
and attention control (matching frequency and duration of sessions as psychological 
intervention) and diabetes education.   
2.3.2.4. Outcomes  
The primary outcome was change in glycaemic levels, HbA1c measured in % or mmol/mol.  
2.3.3. Information sources 
Studies were identified through electronic database searching, reviewing reference lists of 
included studies, and searching conference abstracts. The search was applied from January 
2003 to July 2018 for MEDLINE (Ovid) Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), The Cochrane Library, PsycINFO, EMBASE (Ovid), Cochrane Controlled 
Trials Register and Web of Science. The following conference abstracts were screened from 
2012 to July 2018 to determine any unpublished work: Diabetes UK, the ADA, EASD, and 
the IDF. If work was unpublished, authors were contacted for full-text papers.  
2.3.4. Search 
The following key search terms were adapted for each database: ‘psychological therapies’, 
‘mood disorders’, ‘diabetes mellitus’ and ‘clinical trials’. A full search strategy for MEDLINE 
is provided in appendix 2.3.  
2.3.5. Study selection 
Two researchers (RU and KW) independently searched the electronic databases and 
screened abstracts followed by full-text papers. A third researcher (KI) resolved any 
discrepancies over the decision of full-text article inclusion. Any ambiguity at abstract 
screening meant papers were included for full-text screening. There was high inter-
reliability between researchers at full-text inclusion stage (Cohen’s kappa=0·95). 
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2.3.6. Data collection process 
A data extraction form was developed in Microsoft Excel (based on a Centre for Reviews 
and Dissemination template) and was pilot tested on 10 randomly selected included 
studies, and refined. One researcher (RU) extracted data from all studies which was 
checked by a second researcher (KW), any disagreements were resolved by a statistician 
(DS) or psychiatrist (KI). If there were 3 or more study arms, the least and most intensive 
(according to frequency, duration and/or mode of interventions) were included for meta-
analysis.  
2.3.6.1. The additional data collection process  
Two researchers (RU & DO) performed additional data collection to extract behaviour 
change techniques from psychological intervention descriptions of English-language studies 
included in the aggregate meta-analysis of the Winkley et al paper (Winkley et al., 2019). A 
second data extraction table was prepared in Microsoft Excel. These two researchers (RU & 
DO) were post-graduate health psychology researchers and were trained via online BCTTv1 
training (BCTTv1, 2019). Behaviour change technique extraction was pilot tested on 10 
studies independently and initial ratings were compared amongst researchers (RU & DO) to 
agree on interpretations and prevent future discrepancies. These studies were re-rated, 
and the remaining studies were independently coded before overall ratings were 
compared. A third researcher (KW) resolved any disagreements regarding behaviour 
change technique coding. Inter-rater reliability between the two researchers’ coders was 
calculated to determine agreeability and was high (Cohen’s kappa=0.96). 
The psychological intervention description was examined in detail from sources available: 
published papers, supplementary materials, or study protocols. From intervention 
descriptions, relevant behaviour change technique descriptions were copied into the data 
extraction table. The BCTTv1 was reviewed several times to identify correct behaviour 
change techniques to match the language used in the intervention description. In some 
cases, it was relevant to code more than one behaviour change technique to an 
intervention excerpt. Also, multiple examples from an intervention excerpt could be 
applied to one behaviour change technique. The behaviour change technique must have 
been related to the intervention target behaviour or outcome hence behaviour change 
techniques were not coded with reference to research activity e.g. material reward for 
taking part in research (as opposed to material reward for engaging in the specific target 
behaviour such as physical activity). Behaviour change techniques could be extracted from 
tables outlining interventions, in these cases full phrases or sentences were not extracted 
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e.g. ‘action-planning’ but table text was required to match behaviour change technique 
taxonomy codes to be included (no inferences were made).   
 2.3.7. Data items 
Information was extracted from each randomised controlled trial on: 
1) Participants characteristics: mean age (years), type 2 diabetes duration (years), 
inclusion/exclusion criteria. 
2) Psychological intervention and control group (as applicable) characteristics: name of 
intervention, frequency of sessions, duration of intervention, duration of each session, 
interventionist, mode of delivery (face-to-face; telephone), the format of delivery (one-
to-one; group), fidelity assessment. 
3) Outcomes characteristics: mean baseline and follow-up HbA1c (% or mmol/mol), the 
standard deviation of baseline HbA1c, timepoint of follow-up.  
4) Publication characteristics: year of publication, country of data collection. 
Information was extracted from descriptions of psychological interventions for the 
additional analysis of this thesis chapter which included: behaviour change techniques 
(multiple rows per study if multiple behaviour change techniques were coded), an example 
of the behaviour change technique from study transcript, and location of the behaviour 
change technique in the transcript.   
2.3.8. Risk of bias in individual studies 
Risk of bias was assessed using the Cochrane Handbook Tool for Risk of Bias (Higgins et al., 
2011). The risk of bias assessment was determined independently by two researchers (RU 
& KW) and any discrepancies resolved by a third researcher (KI). 
2.3.9. Summary measure and synthesis of results 
Statistical analysis was conducted in STATA 15 (StataCorp, College Station, TX, USA). Effect 
sizes (Cohen’s d) were pooled in a random-effects meta-analysis of the standardised mean 
difference in HbA1c between baseline and follow-up (12 months or closest) between 
psychological intervention and control group for each trial (and overall effect size for all 
trials).  
2.3.10. Risk of bias across studies 
Publication bias was used to assess the risk of bias across studies. This was assessed using 
Egger’s publication bias (Egger, Smith, Schneider, & Minder, 1997), and the trim and fill 
method (Duval & Tweedie, 2000) to determine missing studies. 
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2.3.11. Additional analyses  
Meta-regressions were performed to determine the association between study 
characteristics (psychological intervention category, behaviour change technique category, 
frequency of behaviour change technique per study, year of publication, and treatment 
fidelity) and treatment effect (HbA1c) (Sutton & Higgins, 2008). Five or more studies were 
necessary to conduct meta-regression (Borenstein, Hedges, Higgins, & Rothstein, 2011), 
therefore behaviour change techniques were categorised into 16 groups domains based on 
their mode of action to ensure enough studies per group to perform this analysis (Michie et 
al., 2014) (figure 2.2).  
2.4. Results 
2.4.1. Study selection  
Thirty-one thousand and sixty-nine records were identified through electronic database 
searching (figure 2.3). After duplicates were removed 23080 records were screened and 67 
English-language full-text papers were eligible for inclusion where HbA1c data was 
available for meta-analysis. Reasons for exclusion are reported in figure 2.3.  
2.4.2. Study characteristics 
Study characteristics are summarised in table 2.1. In this thesis chapter 67 out of the 70 
previously reported studies were synthesised (Winkley et al., 2019). Three excluded studies 
were excluded as they were non-English language, these studies were in Spanish (n=1) 
(Muñoz-Flórez & Cortés, 2017) and Iranian (Farsi; n=2) (Davazdah Emamy, Roshan, 
Mehrabi, & Attari, 2009; Hamid, 2011).  
2.4.2.1. Participant characteristics  
All studies (n=67) included adults with type 2 diabetes. A case definition of people with 
type 2 diabetes included in the trials are presented in table 2.2 (mean age, type 2 diabetes 
duration, and inclusion/exclusion criteria). 
2.4.2.2. Psychological intervention and control group characteristics  
The psychological interventions described in trials were categorised into three groups: 
cognitive behavioural therapy (n=22), counselling (n=44), and interpersonal psychotherapy 
(n=1). Through extracting additional information on behaviour change techniques, it was 
found cognitive behavioural therapy and counselling studies shared similar behaviour 
change techniques (table 2.3) including ‘goals and planning’ and ‘social support’. Zero 
behaviour change techniques were coded for the interpersonal psychotherapy study (Gois 
et al., 2014).  
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Psychological interventions were mainly delivered face-to-face (n=52), others were 
delivered via telephone (n=8), or face-to-face and telephone (n=7). The format of delivery 
was one-to-one (n=40), group (n=24) or family (n=3). The mean number of sessions was 
7.39 (SD=4.81), mean duration of each session was 1.25 hours (SD=0.67), and the mean 
overall duration of intervention was 25.34 weeks (SD=26.95).  
Psychological intervention facilitators included diabetes specialists (n=30, i.e. diabetes 
nurses [n=24], diabetologists [n=4], diabetes researchers [n=1], dieticians [n=1]), 
psychology professionals (n=23, i.e. counsellors [n=5], clinical psychologists [n=12], 
psychiatrist [n=2], IAPT practitioner [n=1], health psychologist [n=1], depression clinical 
specialist [n=1], psychology assistant [n=1]), and other (n=13, i.e. lifestyle facilitator [n=1], 
psychology researcher [n=5], peers [n=1], community health worker [n=3], medical 
assistant [n=1], music therapist [n=1], occupational therapist [n=1]).  
Fidelity assessment of the psychological intervention treatment was present in 20 out of 
the 67 studies (table 2.1) via expert observation or assessment of audio-tape recordings of 
psychological interventions.  
The frequency of studies per behaviour change technique category is presented in table 
2.4. ‘Covert learning’ was the least common behaviour change technique and was not 
extracted from any of the included studies. Examples of the most frequently coded 
behaviour change technique included: 
‘Social support’ (n=52 studies) e.g. “Group motivational interviewing was the 
intervention used in the experimental group.”(Momtazi, Salimi, Zenouzian, 
Shourani, & Urquhart, 2018) 
‘Goals and planning’ (n=51 studies) e.g. “…devising a specific action plan to 
implement the solution.” (Rees et al., 2017) 
‘Feedback and monitoring’ (n=28 studies) e.g.  “…given an accelerometer to wear 
for 1 week at baseline and again at 3-month follow up to measure physical 
activity.”(Chlebowy et al., 2015) 
Most psychological interventions described 1, 3, or 4 behaviour change techniques (figure 
2.4). One study reported using  12 behaviour change techniques (De Greef, Deforche, 
Tudor-Locke, & De Bourdeaudhuij, 2010). One study did not have sufficient text to describe 
the intervention in detail and therefore no behaviour change techniques were extracted 
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(Gois et al., 2014). The mean frequency of behaviour change techniques per psychological 
intervention was 3.63 (SD=2.28).  
Control groups were categorised into the following: usual care (n=45), attention control 
(n=17), waiting list control (n=4), and diabetes education (n=1). 
2.4.2.3. Outcome characteristics  
Trials reported HbA1c in % or mmol/mol. Mean HbA1c per study is reported in table 2.2. 
The mean follow-up time was 7.49 months (SD=4.19).  
2.4.2.4. Publication characteristics   
Included trials were published between 2004 and 2018. Trials were published in Europe 
(n=26), North America (n=23), Asia (n=12), Australia (n=4), and South America (n=2).  
2.4.3. Risk of bias within studies 
Most studies were rated unclear (n=35) and low (n=29) risk of bias, few were rated high risk 
of bias (n=3), table 2.1 (figure 2.5). 
2.4.4. Results of individual studies and synthesis of results   
A random-effects meta-analysis for all included trials (N=67) found HbA1c was significantly 
lower for people with type 2 diabetes receiving the psychological intervention condition 
compared with the control condition (SMD= -0.17, 95% CI= -0.24, -0.11, p<0.001), figure 
2.6. Heterogeneity was moderate (I2=64.6%, p<0.001).  
2.4.4.1. Sub-analysis of HbA1c by psychological intervention category 
A sub-group random-effects meta-analysis of HbA1c by psychological intervention category 
found there was significantly lower HbA1c for people with type 2 diabetes receiving both 
counselling (SMD=-0.18, 95% CI= -0.26, -0.11, p<0.001) and cognitive behavioural therapy 
(SMD= -0.16, 95% CI= -0.29, -0.04, p=0.009) compared with the control. A meta-regression 
found no difference in HbA1c effect size between counselling and cognitive behavioural 
therapy conditions (b=-0.17, 95% CI= -0.18, 0,15, p=0.84). There was moderate to high 
heterogeneity for both counselling (I2=69.8%, p<0.001) and cognitive behavioural therapy 



















2.4.5. Risk of bias across studies 
For all studies (N=67), according to Egger’s test there was evidence of publication bias 
(p<0.001) but the trim and fill method identified no missing studies.  
2.4.6. Additional analysis: Meta regression of behaviour change techniques  
A meta-regression found no association between behaviour change technique category and 
HbA1c (b=-0.16 [95% CI= -0.25, -0.06], p=0.91). Though there were no significant 
differences in effect size between behaviour change technique categories,  a sub-group 
meta-analysis found 6 behaviour change technique categories led to a significant reduction 
in HbA1c: ‘goals and planning’ (n=51, SMD=-0.15, p<0.001), ‘feedback and monitoring’ (n= 
28, SMD=-0.24, p<0.001), ‘social support’ (n=52, SMD=-0.17, p<0.001), ‘shaping knowledge’ 
(n=17, SMD=-0.26, p=0.001), ‘regulation’ (n=20, SMD=-0.2, p<0.001), and ‘identity’ (n=13, 
SMD=-0.27, p=0.02), table 2.5.  
A meta-regression found no association between presence of fidelity assessment and 
HbA1c (b=0.11 [95% CI=-0.04, 0.27], p=0.15). Meta-regressions found no association 
between frequency of behaviour change techniques per psychological intervention (b=-
0.02 [95% CI=-0.05, 0.02], p=0.29), or year of publication (b=-0.01 [95% CI=-0.45, 0.42], 


















Table 2.1-Study characteristics of English language studies included in the meta-analysis of psychological interventions to improve HbA1c in type 2 diabetes 
Reference Intervention name Type of Psychological 
Intervention 
Control group Fidelity 
assessment 
Risk of bias 
(Akturan, Kaya, Ünalan, & 
Akman, 2017) 
BATHE therapeutic interview technique Counselling Usual care NR High 
 
(Balducci et al., 2017) Physical activity counselling  Counselling Usual care NR Low 
(Browning et al., 2016) Motivational interviewing Counselling Usual care NR Low 
(Carrasquillo et al., 2017) Community health worker intervention Counselling Enhanced usual 
care  
Reported  Low 
 
(Chee et al., 2017) Structured lifestyle intervention Counselling Usual care NR Unclear 
(Chen, Creedy, et al., 2012) Motivational interviewing  Counselling Diabetes education NR Unclear 
(Chew, Vos, Stellato, Ismail, & 
Rutten, 2018) 
Structured, value-based, emotion-focused educational programme 
(VEMOFIT) 
Counselling Attention control  NR Low 
 
(Chiu et al., 2016) Minimal psychological intervention (MPI) Counselling Usual care NR Unclear 
(Chlebowy et al., 2015) Motivational interviewing Counselling Usual care Reported Unclear 
(Chwastiak et al., 2017) Community mental health care (CMHC)-based collaborative care model Counselling  Usual care NR Unclear 
 
(Dale, Caramlau, Sturt, Friede, & 
Walker, 2009) 
Telephone peer-delivered intervention Counselling Usual care NR Unclear 
 
(De Greef et al., 2010) Cognitive-Behavioural Pedometer-based group intervention CBT Usual care NR Low 
(De Greef, Deforche, Tudor-
Locke, & De Bourdeaudhuij, 
2011) 
Pedometer-based physical activity intervention Counselling Usual care NR Low 
 
(Döbler et al., 2018) Post discharge telephone-delivered follow-up intervention Counselling Usual care Reported  Low 
(Eakin et al., 2014) Telephone-delivered weight loss intervention Counselling Usual care Reported  Unclear 
(Egede, Williams, Voronca, 
Gebregziabher, & Lynch, 2017) 
Behavioural activation treatment CBT Same-room 
treatment 
Reported  Unclear 
 




(Evans, Lewin, Bowen, & Lowe, 
2010) 
Dealing with Anxiety CBT program CBT Waiting list control NR Low 
 
(Fan et al., 2016) Individualised diabetes education program Counselling Group education NR High 
(Farmer et al., 2012) Nurse-led consultation-based intervention Counselling Usual care Reported Unclear 
(Furler et al., 2017) The Stepping Up Model of care Counselling  Usual care NR Low 
(Garcia-Huidobro, Bittner, 
Brahm, & Puschel, 2011) 
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Reference Intervention name Type of Psychological 
Intervention 
Control group Fidelity 
assessment 
Risk of bias 




(Gomes et al., 2017) Family social support in an education program Counselling Education NR Unclear 
(Gregg, Callaghan, Hayes, & 
Glenn-Lawson, 2007) 
Limited acceptance intervention CBT Education alone NR Low 
 




(Hartmann et al., 2012) Mindfulness-Based Stress-Reduction Intervention Counselling Usual care NR Unclear 
(Hawkins, 2010) Videophone motivational interviewing diabetes self-management 
education 
Counselling Attentional control  Reported Unclear 
 
(Hermanns et al., 2015b) Diabetes-Specific Cognitive Behavioural Treatment Program CBT Diabetes education NR Low 
(Hermanns et al., 2017) MEDIAS 2 BSC Counselling Diabetes education NR Low 
(Huang et al., 2016) Motivation enhancement therapy (MET) plus CBT CBT Usual care NR Unclear 
(Ismail et al., 2018) Diabetes-6 (D6) intervention Counselling Usual care Reported Unclear 
(Jansink et al., 2013) Comprehensive diabetes programme Counselling Usual care NR Low 
(Jiang, Fan, Wu, Geng, & Hu, 
2017) 
Care intervention Counselling Usual care NR High 
 
(Juul, Maindal, Zoffmann, 
Frydenberg, & Sandbaek, 2014a) 
Training course for practice nurses Counselling Usual care NR Unclear 
 
(Juul, Andersen, Arnoldsen, & 
Maindal, 2016) 
Brief diabetes risk reduction intervention Counselling  Usual care NR Unclear 
 
(Kasteleyn, Vos, Rijken, 
Schellevis, & Rutten, 2016) 




Panpakdee, & Vorapongsathorn, 
2006) 




(Keogh et al., 2011) Psychological family-based intervention Counselling Usual care NR Unclear 
(Kim et al., 2015a) Community-Based Multi Modal Behavioural Self-Help Intervention 
(SHIP-DM) 
Counselling Education only Reported  Unclear 
 
(Lamers, Jonkers, Bosma, 
Knottnerus, & van Eijk, 2011) 
Nurse-administered minimal psychological intervention (MPI) CBT Usual care Reported  Low 
 
(Li, Li, Shi, & Gao, 2014) Motivational Interviewing (MI) Counselling Diabetes education  NR Low 
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Reference Intervention name Type of Psychological 
Intervention 
Control group Fidelity 
assessment 
Risk of bias 
(Mandel, Davis, & Secic, 2013) Music Therapy (MT) and Music-Assisted Relaxation and Imagery (MARI) CBT Diabetes education Reported  Low 
 
(D'Eramo Melkus et al., 2010) Diabetes education, Coping skills training, Care intervention CBT Usual care Reported  Unclear 
(Momtazi et al., 2018) Group motivational interviewing Counselling Wait-list control NR Unclear 
(Osborn et al., 2010b) Brief culturally tailored diabetes intervention Counselling  Usual care NR Unclear 
(Penckofer et al., 2012) The Study of Women's Emotions and Evaluation of a Psychoeducational 
(SWEEP) Program 
CBT Usual care Reported Unclear 
 
(Petrak, 2015) CBT vs. Sertraline CBT Sertraline 









(Piette et al., 2011) Telephone-delivered CBT program CBT Enhanced usual 
care  
Reported  Unclear 
 
(Pladevall, Divine, Wells, 
Resnicow, & Williams, 2015) 
The Multi-Arm Intervention Diabetes Adherence Study Counselling  Usual care Reported  Low 
 




(Rees et al., 2017) Problem-Solving Therapy for Primary Care (PST-PC) CBT Usual care  NR Unclear 
(Sacco, 2009) Brief, regular, telephone-delivered lifestyle modification program Counselling  Usual care NR Unclear 
 





Aguilar-Vafaie, Amiri, & Besharat, 
2016) 
Group based acceptance and commitment therapy (ACT) CBT Education with 
routine treatment  
NR Unclear 
 
(Siebolds, Gaedeke, & Schwedes, 
2006) 




(Steed, Barnard, Hurel, Jenkins, & 
Newman, 2014) 
University College London-Diabetes Self-management Programme (UCL-
DSMP) 
Counselling Usual care NR Unclear 
 
(van Son, Nyklicek, et al., 2014) Mindfulness-based cognitive therapy (MBCT) CBT Usual care NR Low 
(Wagner et al., 2016) Stress management intervention Counselling  Diabetes 
education;  
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Reference Intervention name Type of Psychological 
Intervention 
Control group Fidelity 
assessment 
Risk of bias 
(Welch, Zagarins, Feinberg, & 
Garb, 2011) 
Brief diabetes self-management education intervention (DSME) Counselling  Diabetes self-
management 
education 
Reported  Unclear 
 
 
(Welschen et al., 2013) CBT CBT Usual care Reported  Low 
(West, DiLillo, Bursac, Gore, & 
Greene, 2007) 
Behavioural obesity treatment program with motivational interviewing Counselling  Attention control Reported  Low 
 
(Whittemore, Melkus, Sullivan, & 
Grey, 2004) 
Multifaceted nurse-coaching intervention Counselling  Usual care NR Low 
 
(Williams et al., 2004) The Improving Mood–Promoting Access to Collaborative Treatment 
(IMPACT) 
CBT Usual care NR Low 
 
(Wolever et al., 2010) Integrative health (IH) coaching Counselling  Usual care NR Low 
(Wroe, Rennie, Sollesse, 
Chapman, & Hassy, 2018) 





Table 2.2- Case definition of participants included in a meta-analysis of psychological interventions to improve HbA1c in type 2 diabetes 























































(Akturan et al., 2017) 2017, Turkey 57·51 (7.0) 
 










(Browning et al., 2016) 2016, China 63·7 (7·6) 
 
64.0 (9.0) 10.0 (6·5) 
  





(Carrasquillo et al., 2017) 2017, USA 55·3 (7·1) 
 
55·2 (6·1) 11·7 (8·2) 
 




8% or more 
 
(Chee et al., 2017) 2017, Malaysia NR 
 
NR NR NR I1: 7.7% (1.1) 
I2: 7.7% (1.4) 






(Chen, Creedy, et al., 
2012) 
2012, Taiwan 59·19 (10·24)  58·67 (10·23) 7·98 (7·57) 
 









8% or more 
 
(Chiu et al., 2016) 2016, Taiwan 64·78 (0·3) 64·59 (0·4) 10.0 (0·6) 
 





(Chlebowy et al., 2015) 2015, USA 55·8 (2·1) 
  









8% or more 
(Dale et al., 2009) 2009, UK NR NR NR  NR 1) 8.9% (1.5) 
2) 8.4% (1.1) 





(De Greef et al., 2010) 2010, Belgium NR NR NR NR 7.5% (1.1) 
 





(De Greef et al., 2011) 2011, Belgium I1: 70 (6·3) 
I2: 66·6 (9·5)  
66 (11·1) NR  NR I1: 7.23% (0.71) 
I2: 7.12% (1.35) 






(Döbler et al., 2018) 2018, Germany 51·6 (5·7) 52·2 (5·4) 8·7 (6·6) 9·6 (5·9) 7.8% (1.7) 7.6% (1.4) 18-70 None None 
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(Eakin et al., 2014) 2014, Australia 57·7 (8·1) 
  
58·3 (9·0) NR NR Median: 
7.6% (6.3, 8.5) 
Median: 






(Egede et al., 2017) 2017, USA 62·7 (3·4) 
  










(Evans, Lewin, et al., 
2010) 




All: 14·3(1-45) All: 14·3(1-
45) 





(Fan et al., 2016) 2016, China 62·94 (10·72) 64·89 (10·14) 11·4 (4·8) 11·6 (5·0) 9.61% (1.92) 9.80% (1.98) None None None 
(Farmer et al., 2012) 2012, UK 62·5 (11.0) 64·1 (10·3) 6·7 (4·8) 6·9 (5·3) 8.37% (1.25) 8.28% (1.22) ≥18  ≥3 7.5% or more 
 
(Furler et al., 2017) 2017, Australia 61·7 (9·7) 62·0 (10·6) NR  NR 8.7% (8.1-9.7) 8.5% (8-9.6) <80  None 7.5% or more 
(Garcia-Huidobro et al., 
2011) 
2011, Chile 53·4 (8·1) 53·5 (9·8) NR NR 10.3% (2.0) 9.5% (2.2) 18-70 None 7% or more 
(Gois et al., 2014) 2014, Portugal 56·82 (4·25) 53·81 (7·04) 13·12 (4·85) 11·63 (6·68) 9.36% (2.38) 8.76% (1.94) 18-65 >6  None 
(Gomes et al., 2017) 2017, Brazil NR NR NR NR 9.47% (2.01) 9.40% (2.00) ≥40 None None 
(Gregg et al., 2007) 2007, USA 49·8 49.8 5·3 6·6 8.17% (1.86) 8.21% (1.91) ≥18  None None 
(Griffin et al., 2014) 2014, UK 59·5 (7·5) 59·8 (7·5) NR NR 7.23% (1.62) 7.01% (1.23) 40-69  < 36 None 
(Hartmann et al., 2012) 2012, Germany 58·7 (7·4) 59·3 (7·8) 11.0 (7·5) 12·2 (7·6) 7.26% (1.08) 7.27% (1.06) 30-70  <36 None 
(Hawkins, 2010) 2010, USA 64 65·8 (10·4) NR NR 9.0% (2.3) 8.9% (3.1) ≥60  None 7% or more 
(Hermanns et al., 2015b) 2015, Germany 34·2 (14·9) 43·4 (13·8) 14·2 (10·3) 14·2 (10·7) 8.9% (1.8) 8.9% (1.8) 18-70 None None 
(Hermanns et al., 2017) 2017, Germany NR NR NR NR 8.0% (1.3) 7.9% (1.2) 18-75 None None 









(Ismail et al., 2018) 2018, UK 59 (11·1) 
 
58·9 (11·4) 10.0 (7-13) 
 








8% or more 




63·9 (9·8) 7·5 (6·0) 
 
7·8 (5·8) 7.8% (0.9) 7.7% (0.7) <80  None 7% or more 
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(Jiang et al., 2017) 2017, China 56·3 (5·3) 57·1 (5·5) 1·24 (0·38) 1·27 (0·36) 7.7% (0.9) 8.3% (1.1) 18-70 None None 
(Juul et al., 2014a) 2014, Denmark 60·2 (8·2) 
 
60·7 (8·6) 8 (4-14) 
 





(Juul et al., 2016) 2016, Denmark Median: 
58 (50, 63) 
Median: 
60 (51, 64) 
NR NR 40.7 mmol/mol 
(3.5) 








(Kasteleyn et al., 2016) 2016, 
Netherlands 
66.0 (9·3) 65·6 (9·4) 7.0 (2·8-16) 8·5 (5-15) 7.2% (3.5) 6.8% (3.1)  >35  >12 
 
None 
(Keeratiyutawong et al., 
2006) 
2006, Thailand NR NR NR NR 8.93% (2.4) 7.89% (1.8) 21-60  <120  None 
(Keogh et al., 2011) 2011, Ireland 59·96 (11·67) 
 
57·29 (11·34) 9·17(7·1) 
 






>12 8% or more 




8.9% (2.05) 8.8% (3.06) ≥35 
 
None 7% or more 
(Lamers et al., 2011) 2011, 
Netherlands 
70·7 (6·6) 69·7 (6·6) 8·2 (8·8) 9·8 (9·1) 7.5% (1.1) 7.2% (1.4) ≥60 None None 
(Li et al., 2014) 2014, China 58·5 (5.0) 59·2 (5·2) 1·3 (0·5) 1·2 (0·4) 10.1% (2.7) 9.7% (3.5) 40-70  12-24 9% or more 
(Mandel et al., 2013) 2013, USA 58 (11·29) C1: 57·1 (9·67) 
C2: 58·9 
(10·76) 




7.7% (1.81) C1: 7.4% (1.56) 








(D'Eramo Melkus et al., 
2010) 
2010, USA 47.0 (9.0) 
 





(Momtazi et al., 2018) 2018, Iran NR NR NR NR 8.23% (1.10) 7.98% (0.80) 30-60  None 7% or more 
(Osborn et al., 2010b) 
 
 
2010, USA 56·9 (11·3) 58·4 (10·1) 13·2 (12) 12·3 (9·4) 7.8% (1.4) 7.3% (1.6) ≥18  ≥12 None 
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(Penckofer et al., 2012) 2012, USA 54·8 (8·8) 54 (8·4) 10·5 (8·2) 10 (6·5) 7.8% (1.8) 7.9% (2.0) ≥18  ≥6 None 
(Petrak, 2015) 2015, Germany 49 (10·6) 47·9 (12·8) 15·7 (10·4) 15·0 (10·6) 9.30% (1.49) 9.20% (1.44) 21-69 None 7.5% or more 
(Pibernik-Okanović, 
2015) 
2015, Croatia 57·7 (6·2) 58·2 (5·6) 11·4 (9·1) 10·5 (6·9) 7.4% (1.2) 7.2% (1.1) 18-65  ≥12 None 
(Piette et al., 2011) 2011, USA 55·1 (9·4)  56 (10·9) NR  NR 7.5% (1.7) 7.7% (1.7) ≥21 None None 
 
(Pladevall et al., 2015) 2015, USA 64·5 (10·5) 
 
C1: 64·9 (11·5) 
C2: 63·3 (10·9) 
NR  NR 8.0% (1.3) C1: 8.2% (1.4) 
C2: 8.0% (1.4) 
≥18  
 
None 7% or more 
(Plotnikoff et al., 2013) 2013, Canada 62·3 (11·1) 
 
C1: 61.0 (11·7) 
C2: 61·4 (12·6) 




7.08% (1.3) C1: 7.06% (1.9) 






(Rees et al., 2017) 2017, Australia 60·1 (7.0) 58·6 (8·8) 17·5 (10) 23.0 (15.0) 8.2% (1.57) 8.1% (1.2) None None None 
(Sacco, 2009) 2009, USA All: 52(8·6) All: 52(8·6) All: 9·5 (7·2) All: 9·5 (7·2) 8.4% (1.37) 8.5% (2.01) 18-65 None None 
(Safren et al., 2014) 2014, USA 55·44 (8·72)  58·31 (7·41) NR NR 8.81% (1.78) 8.74% (1.41) 18-70  None 7% or more 
(Shayeghian et al., 2016) 2016, Iran 55·18 (8·26) 55·70 (8·98) 4·9 (1·40) 4·54 (1·54) 7.46% (1.66) 7.61% (1.38) 40-60 12-120 None 





8.47% (0.86) 8.35% (0.75) ≥18  None None 
(Steed et al., 2014) 2014, UK 59·2 (8·8) 60·3 (8·6) 10·7 (7·5)  10·9 (7·9) 8.2% (1.3) 8.6% (1.8) < 75  None None 




56.0 (13.0)  57.0 (13.0) NR NR 7.5% (1.2) 7.6% (1.2) 18-80  None None 
(Wagner et al., 2016) 2016, USA 60.0 (11·2) 60·8 (12·1) NR NR 8.5% (1.4) 8.6% (1.9) ≥18 ≥6 7% or more 
(Welch et al., 2011) 2011, USA I1: 56·1 (10·4) 
I2: 54·9 (9·3) 
C1: 57·2 (10·9) 
C2: 54·4 (10·3) 
I1: 9·8 (8) 
I2: 9 (7·3) 
C1: 7 (6·5) 
C2: 7·1 (5·8) 
I1: 9.1 (1.5) 
I2: 8.8 (1.0) 
C1: 8.8 (1.3) 
C2: 8.9 (1.2) 








(Welschen et al., 2013) 2013, 
Netherlands 
60·5 (9·4) 61·2 (8·8) 7·6 (5) 7·8 (6·1) 6.8% (1.0) 6.7% (1.0) 18-75  None 7% or more 
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(West et al., 2007) 2007, USA 54.0 (10.0) 52.0 (10.0) 5·8 (6·5) 4·9 (5.0) 7.54% (1.4) 7.62% (1.4) ≥18  None None 
(Whittemore et al., 
2004) 




7% or more 





(Wolever et al., 2010) 2010, USA 53·1 (8·29) 52·8(7·64) 11·8 (8·5) 
 





(Wroe et al., 2018) 2018, UK 63·48 (11·04) 63·63 (10·71) NR  NR  67.12 
mmol/mol 
(21.02) 





















Table 2.3- Number of counselling and cognitive behavioural therapy studies which included each behaviour 
change technique category 
Behaviour change technique 
category  
Number of counselling studies 
which included each behaviour 
change technique category  
Number of cognitive 
behavioural therapy studies 
which included each behaviour 
change technique category 
1. Goals and planning 31 15 
2. Feedback and monitoring 20 7 
3. Social support 36 14 
4. Shaping knowledge 13 4 
5. Natural consequences 2 2 
6. Comparison of behaviour 7 4 
7. Associations 1 2 
8. Repetition and substitution 9 2 
9. Comparison of outcomes 7 3 
10. Reward and threat 5 2 
11. Regulation 7 11 
12. Antecedents 5 3 
13. Identity 8 6 
14. Scheduled consequences 1 1 
15. Self-belief 2 0 
16. Covert learning 0 0 
Table 2.4- Frequency of studies per behaviour change technique category 
Behaviour change technique category  Number of studies behaviour change techniques 
are present 
1. Goals and planning 51 
2. Feedback and monitoring 28 
3. Social support 52 
4. Shaping knowledge 17 
5. Natural consequences 4 
6. Comparison of behaviour 11 
7. Associations 3 
8. Repetition and substitution 11 
9. Comparison of outcomes 10 
10. Reward and threat 8 
11. Regulation 20 
12. Antecedents 8 
13. Identity 13 
14. Scheduled consequences 2 
15. Self-belief 2 
16. Covert learning 0 
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Table 2.5- Standardised mean difference in HbA1c per behaviour change technique category 








1. Goals & planning -0.15 <0.001*** -0.23, -0.08 
2. Feedback & monitoring -0.24 <0.001*** -0.36, -0.12 
3. Social support -0.17 <0.001*** -0.23, -0.12 
4. Shaping knowledge -0.26 0.001** -0.43, -0.11 
6. Comparison of behaviour -0.26 0.05 -0.50, 0.004 
8. Repetition and substitution -0.15 0.18 -0.38, 0.07 
9. Comparison of outcomes -0.19 0.05 -0.38, -0.004 
10. Reward and threat -0.05 0.61 -0.23, 0.14 
11. Regulation -0.2 <0.001*** -0.32, -0.08 
12. Antecedents -0.29 0.1 -0.63, 0.05 
13. Identity -0.27 0.02* -0.50, -0.05 


























































































































































































































































































































































































































































































1. Goals and planning                                  
2. Feedback and 
monitoring 
          
                       
3. Social support                                  
4. Shaping knowledge                                  
5. Natural 
consequences 
          
                       
6. Comparison of 
behaviour 
          
                       
7. Associations                                  
8. Repetition and 
substitution 
          
                       
9. Comparison of 
outcomes 
          
                       
10. Reward and threat                                  
11. Regulation                                  
12. Antecedents                                  
13. Identity                                  
14. Scheduled 
consequences 
          
                       
15. Self-belief                                  
16. Covert learning                                  
Frequency of behaviour 
change techniques per 
study 
7 2 1 3 6 6 3 5 8 3 
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Figure 2.5-Risk of bias assessment per study in a meta-analysis of psychological interventions to 
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2.5.1. Summary of evidence 
The overall meta-analysis found a significant improvement in HbA1c for people with type 2 
diabetes who received a psychological intervention versus the control group. Behaviour 
change techniques which were most commonly reported in the psychological interventions 
descriptions of trials included ‘social support’, ‘goals and planning’ and feedback and 
monitoring’. Behaviour change techniques which most commonly underpinned cognitive 
behavioural therapy and counselling psychological interventions included ‘goals and 
planning’ and ‘social support’. This may account for why no differences in HbA1c 
improvement were found between cognitive behavioural therapy and counselling 
interventions. 
Study 1 of this thesis found no significant differences in effect sizes between behaviour 
change technique categories and HbA1c. Therefore, it cannot be determined from this 
analysis which behaviour change technique categories are significantly better at improving 
HbA1c in type 2 diabetes. Even though there were no significant differences between 
them, behaviour change technique categories which were associated with a significant 
reduction in HbA1c included ‘goals and planning’, ‘feedback and monitoring’, ‘social 
support’, ‘shaping knowledge’, ‘regulation’, and ‘identity’. This relates to other research 
into type 2 diabetes and effectiveness of behaviour change techniques which have similarly 
found improved outcomes using ‘goals and planning’ (Cradock et al., 2017; Hankonen et al., 
2014; van Vugt et al., 2013), ‘feedback and monitoring’ (van Vugt et al., 2013), ‘social 
support’ (Presseau et al., 2015), and ‘shaping knowledge’ (Cradock et al., 2017). However, 
these studies did not investigate the association between psychological interventions and 
HbA1c, hence making these findings novel.  
This study identified the mean number of behaviour change techniques per psychological 
intervention as 3.63. There was no association between frequency of behaviour change 
techniques per psychological intervention and HbA1c, therefore the optimal number of 
behaviour change techniques which improve HbA1c cannot be determined. This is a similar 
finding to a meta-regression in a study of behavioural interventions for obese adults where 
more behaviour change techniques were not associated with better outcomes 
(Dombrowski et al., 2012). On the contrary, findings from another type 2 diabetes study 
reported that the more behaviour change techniques used, the better the outcomes  
(Avery et al., 2012; Hankonen et al., 2014). In the analysis of this thesis, the trial which 
reported the highest number of behaviour change techniques did not have the largest 
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effect size in improving HbA1c (De Greef et al., 2010). In addition, the trial which reported 
the least behaviour change techniques did not have the smallest effect size in improving 
HbA1c (Gois et al., 2014). Again, supporting no association between frequency of behaviour 
change techniques and HbA1c. 
Since the Behaviour Change Wheel and BCTTv1 were introduced almost 10 and 5 years ago, 
respectively, the reporting of specific techniques underpinning interventions should have 
improved (Michie et al., 2011; Michie et al., 2015). However, during data extraction of 
study 1 of this thesis, psychological intervention descriptions were unclear. It is possible 
that not all relevant behaviour change techniques were extracted due to lack of reporting. 
In addition, less than a third of studies reported fidelity assessment and therefore are 
unable to determine whether intervention facilitators were competent at delivering 
behaviour change techniques or whether behaviour change techniques were delivered as 
intended. Other systematic reviews also report poor reporting of fidelity assessment 
(Ekong & Kavookjian, 2016; Walton, Spector, Tombor, & Michie, 2017).  For one nurse-led 
diabetes study which did assess fidelity (Ismail et al., 2018), it was found that some 
psychological techniques were delivered in the control condition (Magill et al., 2018), 
indicating contamination of skills can be an issue with randomised controlled trial results 
and subsequent interpretation. This also highlights the importance of fidelity assessment, 
so it is known which skills were delivered in the study conditions.  
2.5.2. Strengths and limitations 
A strength of this thesis chapter is, by identifying which smaller components of 
psychological interventions (behaviour change techniques) improve HbA1c, this ensures 
the future development of psychological interventions for people with type 2 diabetes is 
more likely to be successful in improving HbA1c.  Another strength is at least two 
researchers were involved across the research process with high levels inter-reliability 
indicating consistency in screening full-text papers and coding behaviour change 
techniques. Therefore, there is confidence that other researchers could replicate these 
methods and obtain similar results.  
Non-English language studies were excluded for this analysis owing to difficulties recruiting 
and training translators in BCTTv1, however, the overall effect size for HbA1c did not differ 
between this sample (n=67) and the overall sample (n=70). This analysis did not code which 
behaviour change techniques underpinned the control groups in the randomised controlled 
trials. Most studies reported usual care as the control condition with a limited description 
of what this entailed; therefore, behaviour change technique coding would not have been 
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possible in most cases. This study focused on HbA1c as an outcome, analysis of 
psychological (depression, diabetes distress) or self-management (dietary, medication 
adherence etc.) outcomes may have yielded different results.  
Multiple factors could account for significant improvements in HbA1c for people with type 
2 diabetes who have received a psychological intervention. Randomised controlled trials 
did not test behaviour change techniques or other active ingredients in isolation and 
pooling these studies for meta-analysis does not control for confounders. In addition, the 
analysis of this thesis chapter only reports the impact of individual behaviour change 
techniques on glycaemic levels. Therefore, without controlling for confounders or 
evaluating key combinations of behaviour change techniques, it is uncertain which specific 
combination of active ingredients lead to improvements in glycaemic levels. Improved 
reporting of active ingredients and the development of more sophisticated meta-analytic 
methods may help identify which intervention components are truly associated with 
specific outcomes (Dombrowski et al., 2012).   
2.5.3. Conclusions  
This analysis was the first to determine which behaviour change techniques underpin 
psychological interventions targeting HbA1c for people with type 2 diabetes. It was not 
possible to identify the most effective behaviour change techniques nor the optimal 
number of behaviour change techniques to improve HbA1c. However, the most frequently 
used behaviour change techniques which were associated with statistically significant 
improvements in HbA1c included: ‘social support’, ‘goals and planning’, and ‘feedback and 
monitoring.’ Future research to develop psychological interventions for people with type 2 
diabetes should define behaviour change techniques in the psychological intervention 
design process, conduct fidelity assessment of interventionists, process evaluation of 
behaviour change techniques, and ensure consistent reporting of behaviour change 
techniques.  These steps would help to identify the specific active ingredients of a 
successful psychological intervention to improve HbA1c for people with type 2 diabetes.  
2.6. Chapter summary  
Study 1 described in this chapter provides a foundation for which behaviour change 
techniques are most useful for DIME development. After extracting data from 67 studies, 
this study highlights the importance of reporting specific behaviour change techniques and 
other active ingredients in DIME development and reporting. This is also useful for 
subsequent DIME testing, fidelity assessment and dissemination.  Chapter 3 and 4 moves 
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away from behaviour change techniques for now, but chapter 5 examines behaviour 



























Chapter 3 : Experiences of attending 
group education to support insulin 




























3.1. Chapter scope 
This chapter outlines study 2 of this thesis which has been peer-reviewed and accepted for 
publication in the Diabetes Therapy journal (Upsher et al., 2019). This chapter is an 
unformatted version of the publication with extra methodological detail. This chapter is a 
qualitative evaluation of an existing insulin start group currently run in south London. 
Views of people with type 2 diabetes who attended the insulin start group provide valuable 
insight into the development of the DIME intervention in terms of content and delivery.  
3.2. Introduction  
There are an estimated 422 million people with type 2 diabetes living with diabetes 
worldwide (WHO, 2016), costing world healthcare services over 827 billion US dollars (NCD, 
2016; Seuring, Archangelidi, & Suhrcke, 2015). Type 2 diabetes is a progressive condition if 
not managed intensively with weight-loss strategies from diagnosis (Lean et al., 2018), and 
which are not achievable for many people. And even with optimal HbA1c and appropriate 
medication regimes, beta cell function deteriorates over time (Barag, 2011). Therefore, a 
large proportion of people with type 2 diabetes require insulin injections around 5-10 years 
from diagnosis, a treatment which is associated with improved HbA1c (Donnelly et al., 
2007) and reduced risk of diabetes complications (Turner et al., 1999). With the growing 
population of type 2 diabetes, there has been a shift from initiating and managing insulin in 
secondary care to primary care (NHS, 2014). However, a recent United Kingdom survey 
found a shortage of diabetes specialists nurses/educators, fewer qualified nurses recruited 
into diabetes specialist roles, and an estimated 57% of diabetes specialist nurses due to 
retire within 10 years (DUK, 2016). Additionally, primary care nurses who are trained to 
support people with insulin education are also a limited resource. There’s a similar picture 
in North America (Rizza et al., 2003). Therefore, there are fewer diabetes specialist nurses 
available with specialist skills to initiate insulin. A solution, requiring fewer specialists, is to 
provide insulin education in groups. Diabetes group education is cost-effective compared 
with individual support (Yki-Järvinen et al., 2007).   
In the south London borough of Lambeth (United Kingdom), there is an existing ‘insulin 
start group’ for people with type 2 diabetes newly prescribed insulin therapy. The group is 
comprised of 2 sessions (2 hours each) 1 week apart to provide key educational and safety 
information around initiating and self-managing with insulin. The curriculum includes type 
2 diabetes progression; safe insulin administration; insulin storage; dose titration; 
hypoglycaemia; driving with insulin; blood glucose readings review; sick day rules; travelling 
with insulin; and interpreting results of annual reviews. There are up to 6 people per group 
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and are facilitated by diabetes specialist nurses/educators. Referral to these insulin start 
groups is made by general practitioners in primary care. There is evidence that group 
education for people with type 2 diabetes can improve diabetes self-management and 
HbA1c (Chatterjee, Davies, Heller, et al., 2018; Deakin, Cade, Williams, & Greenwood, 2006; 
Loveman, Frampton, & Clegg, 2008; Scain, Friedman, & Gross, 2009; Trento et al., 2010), 
and is viewed favourably by healthcare professionals (Winkley et al., 2018). However, the 
evidence is for diabetes self-management education in general, less is known about type 2 
diabetes insulin education groups.  
People with type 2 diabetes have reported many negative beliefs around insulin therapy 
(Chatterjee, Davies, Heller, et al., 2018; Ellis et al., 2018; Ng et al., 2015), termed as 
psychological insulin resistance (Petrak et al., 2013; Peyrot et al., 2005; Polonsky et al., 
2011) as outlined in the introduction of this thesis. However, there is currently no national 
or international guidance on how to address insulin concerns for people with type 2 
diabetes (RCN, 2012) which could be incorporated into education groups to provide 
optimal support.  
In summary, insulin education groups are useful to reduce the cost burden for health 
services; and maximise the expertise of diabetes specialist nurses as the number of people 
with type 2 diabetes continue to rise. Therefore, it is important to gauge the views of 
people with type 2 diabetes who have attended insulin education groups to identify views 
on the barriers to insulin self-management, and suggestions for additional support to 
maximise the potential of aiding insulin self-management in type 2 diabetes. The aim of 
this study was to examine the perspectives of people with type 2 diabetes who have 
attended nurse-led group-based insulin start group education.  
3.3. Methods 
This study employed a qualitative design using semi-structured one-to-one interviews of 
people with type 2 diabetes from south London. This qualitative research was reported 
according to the ‘consolidated criteria for reporting Qualitative research checklist’ 
(COREQ), appendix 3.1. Ethical approval was obtained by King’s College Hospital (ref: 
17/LO/0363). Information sheets and consent forms for study 2 can be found in appendix 
3.2 and 3.3 respectively.  
3.3.1. Recruitment and sample  
English-speaking adults (≥18 years) with type 2 diabetes were invited to participate in the 
study if they had attended an insulin start group in south London and commenced insulin. 
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All participants received the same type of education facilitated by diabetes specialist 
nurses/educators at community venues in south London after receiving their first insulin 
prescription. People attending the insulin start groups started on once-daily basal insulin, 
with a starting dose of 10 units which they were taught how to titrate within the group. 
People with type 2 diabetes were purposively sampled by sex, age (</45, 46-59, 60+ years), 
and ethnicity (White, Black, South Asian/other).  
3.3.2. Development of interview schedule 
An initial interview topic guide was designed by 3 researchers (RU, KW, MA) based on 
current literature (table 3.1). The interview schedule was assessed for face validity through 
discussion with healthcare professionals and piloting the interview on 2 people with type 2 
diabetes who had attended an insulin start group, topics guides were then revised. For 
subsequent interviews, each researcher listened to audiotapes of interviews conducted by 
the other 2 researchers for fidelity purposes, allowing reflection and discussion of interview 
technique, and to identify any interviewer bias to be eliminated in subsequent interviews. 
Topic guides were revised as required to account for individual interviewing styles and for 
rigorous data collection.  
Table 3.1- Topic guide for study 2 interview schedule 
• Reasons for referral to the diabetes specialist team  
• Need for insulin, barriers to uptake and adherence 
o Benefits of insulin 
o Disadvantages of insulin 
o Delay in insulin? 
o Concerns/worries before insulin initiation  
• Views on insulin self-management support 
o Views on group insulin education  
o Positive views on insulin self-management support 
o Less positive/helpful aspects of on insulin self-management support 
o Readiness to initiate insulin 
o Follow-up support 
o Recommendations for future insulin education support  
 
3.3.3. Data collection 
Interviews were conducted by one of the 3 female researchers (RU, KW, MA) who had 
experience with conducting qualitative research and were based at King’s College London, 
2 researchers were also diabetes specialist nurses (MA, KW). Diabetes specialist nurses did 
not interview any person with diabetes for whom they had personally educated. Eligible 
participants were identified on Egton Medical Information Systems (medical record system) 
by diabetes specialist nurses on the research team who were then contacted via telephone 
and, if willing, arranged a date and time for the interview. Interviewees were given the 
choice of interview location to maximise recruitment: King’s College London research 
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facility; or the participants’ local general practice surgery. A family member or friend was 
invited to be present at the interview, if the interviewee desired.  
Participants were informed the study was funded by the National Institute for Health 
Research and the specific purpose of the project was to determine views on the barriers to 
insulin self-management, views on diabetes education courses, and suggestions for 
additional support to aid insulin self-management in type 2 diabetes. Each participant was 
interviewed once. To ascertain adequate sample size, after every 3 interviews, the 
transcripts were assessed (by RU and KW) for information power based on study aim (views 
of insulin education received); sample specificity (people who attended an insulin start 
group and sample based on age, gender and ethnicity); quality of dialogue (assessed by the 
knowledge base of researchers as well as rapport between researcher and participants); 
and analysis strategy (outlined below) (Malterud, Siersma, & Guassora, 2016).  
3.3.4. Data analysis  
Interviews were transcribed and anonymised data from transcripts were managed in 
NVivo12 (qualitative computer software). Inductive thematic analysis identified themes 
within the data via 6 stages (Braun & Clarke, 2006): 1) familiarisation of data by reading of 
transcripts and listening to audiotapes, making field notes of initial impressions; 2) 
generation of initial codes (RU & MA; reviewed by KW); 3) Searching for themes by 
collating codes that depict the data; 4) Reviewing themes and making sure the themes 
apply accurately to all coded data; 5) Defining and naming each theme to describe which 
aspects of the data the theme represents; 6) Producing a final report. The data was 
examined to distinguish common perceptions across participants and differences by age 
and ethnicity.  
3.4. Results 
A total of 15 people with type 2 diabetes were recruited. The mean age was 61.40 
(SD=10.58), the majority were female (53.3%), 60 years or over (53.3%), and Black African 
or Caribbean ethnicity (60%), (table 3.2, table 3.3). The mean diabetes duration was 11.33 
years (SD=7.18). The mean HbA1c level was 73.53 mmol/mol (SD= 21.49). Diabetes 
treatment is reported in table 3.2. The most common insulin treatment was Humulin I 
(73.3%), and most common oral antidiabetic medication combination was Metformin, 
Gliclazide and Sitagliptin (33.3%). Three people were prescribed Glucagon-like peptide-1 
treatment. No one dropped out of the study, 1 person declined to participate (lack of time), 
and there were 3 people who were eligible but did not respond to the research team. The 
mean duration of interviews was 28.10 minutes (SD=9.82).  
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The analysis generated three key themes: 1) creating a supportive environment; 2) 
facilitator skills; 3) effectiveness of group. There were further sub-themes within each 
theme (figure 3.1).  
1.Creating a supportive environment  
An environment which best provided insulin self-management support consisted of three 
components including group members (peers), group facilitators, and supportive resources 
(printed materials).   
a. Peer support 
Many conveyed that being in a group was a positive supportive experience, for example, to 
hear different people’s perspective, to share one’s own experience, and being with other 
people with diabetes:  
“…you can come in and then share your experience and also gain from other 
people’s experience…” (13M) 
“You feel more comfortable, you are not the only one [with diabetes]…I was happy 
as well because I’m going to see other people as well.” (08F) 
Another highlighted a sense of personal failure in relation to having to take insulin for their 
diabetes but feel comforted by a range of people in the group being in the same situation 
as themselves: 
“… so thinking, "What have I done wrong?", but when you sit around, you see 
young ones, old ones, and everybody's been on it[insulin], it's kind of an 
inspiration.”(12M) 
b. Providing reassurance  
Reassurance was provided by the insulin group facilitator who would deliver important 
educational information such as frequency of injections:  
“Well reassurance from them that it wasn’t going to be a big task to take the 
injections every night and it was only one.” (04M) 
The type of information was not the only important factor in providing reassurance but the 
way in which the information was communicated lead to feelings of empowerment: 
“I was empowered, you know, the nurse explained a lot of things to us.” (01F) 
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c.  Printed materials  
For some, printed materials which were given to the group to take home were an 
informative resource to support the educational content and reinforce knowledge learnt:  
“Yes, they are informative, you know, they have a lot of information that you need 
to know about diabetes and insulin, you know.” (06M) 
 “The leaflets were just a form of reinforcement, that’s what they were.” (15M) 
Others reported negatively on these resources which led to them being unread or thrown 
away, one explanation was this was due to being given too many leaflets: 
“if you had a lot of papers, you know, some of it might go missing…but few I read 
honestly” (01F) 
“I probably binned them, but they were, they were useful at the time.” (10F) 
Other interviewees suggested the printed materials were not suitable for all audiences 
such as those where English is not their first language: 
“lots of information papers but they are too much to read, especially because 
English is not my language that’s why maybe.” (02F) 
2.Facilitator skills 
It was important for facilitators to have the appropriate skills to manage concerns around 
insulin therapy within the groups. Managing group dynamics could be positively or 
negatively attributed to the skill of the facilitator.  
a. Addressing negative insulin beliefs 
One approach group facilitators used to address the fear of injections were practical 
demonstrations and practice of injecting which eliminated concerns for some: 







However, facilitators did not address fears for all, one interviewee described feelings of 
anxiety which prevented retention of information: 
“… of course being human beings we sometimes shut down from things that we 
fear… So we don't necessarily take onboard as much as we could do were we not 
human beings that have fears and anxieties and personalities…” (03F) 
In addition, there was one account indicating the diabetes specialist nurse facilitator lacked 
skills to support fears around insulin:  
“there was one lady who was really frightened…I noticed that the nurse wasn’t 






Figure 3.1- Summary of themes and subthemes in study 2  
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Table 3.2- Overall demographics of interviewees with type 2 diabetes in study 2 
Characteristics  N % Mean (SD) 
Age   61.40 (10.58) 
</45 2 13.3  
  46-59 5 33.3  
  60+ 8 53.3  
Ethnicity     
  Black African/Caribbean 9 60.0  
  Caucasian  5 33.3  
  Asian/other 1 6.7  
Gender    
  Female 8 53.3  
  Male 7 46.7  
Diabetes Duration   11.33 (7.18) 
HbA1c   73.53 (21.49) 
Insulin type    
Humulin I 11 73.3  
Novomix 30 2 13.3  
Lantus 1 6.7  
Abasaglar 1 6.7  
Oral antidiabetic 
medications 
   
Zero 2 13.3  
Gliclazide 
Only 
2 13.3  
Metformin only 2 13.3  
Metformin and Gliclazide 2 13.3  
Metformin, Gliclazide, 
Sitagliptin 
5 33.3  
Metformin, Gliclazide and 
Linagliptin 
2 13.3  
Glucagon-like peptide-1    
Zero 12 80  
Dulaglutide 2 13.3  
Liraglutide 1 6.7  
 
 
b. Managing group dynamics  
An interviewee described the importance of the diabetes specialist nurse facilitator 
allowing time for everyone’s questions and managing different people within the group to 
check their understanding: 
“Because they take a small number of people and the nurses … gives yourself time 
to talk to people individually and then, you know, some people… take time to digest 
information but then the nurse has got time to listen to those people and then 




There were however reports of frustration around listening to other group members 
experiences indicating group dynamics were not well managed in some cases: 
“…listening to other people’s experience, plenty of time was given so people could 
go on and on and on, that may be something to manage, yeah, because people can 
go into their lifetime stories and many of them moved away from the point being 
discussed.” (13M) 
 In related accounts, a preference for one-to-one education was expressed so questions 
could be answered unlike their experience within a group: 
“You know, we're in a group, you can't keep on asking questions when other people 
have their hands up…if it's like one-to-one thing you've been apportioned a time, 
like fifty minutes I’m going to be with you, ask all the question...” (12M) 
There was an indication that people in the group were at different ‘levels’ including insulin 
experience (i.e. previously on injection therapy) and age, these factors were not controlled 
within the group setting: 
“I'm more experienced than they are… I've been injecting myself [previously], so it, 
it was a bit pedestrian for, really it was a bit pedestrian…it wasn't the same for me 
as it was for these people trying to learn how to inject themselves.” (10F) 
“…the kind of only daunting thing for me was that when you’re seeing a lot of 
people much, much older around you [in the group]…” (07M) 
 
Table 3.3-Demographics of each interviewees with type 2 diabetes in study 2 
Participant 
number  
Age group Sex Ethnic group 
1 46-59 Female Black African/Caribbean  
2 60+ Female Asian/other 
3 60+ Female White 
4 60+ Male White 
5 46-59 Female Black African/Caribbean 
6 60+ Male Black African/Caribbean 
7 </45 Male Black African/Caribbean 
8 46-59 Female White 
9 60+ Female White 
10 60+ Female White 
11 60+ Female Black African/Caribbean 
12 46-59 Male Black African/Caribbean 
13 60+ Male Black African/Caribbean 
14 46-59 Male Black African/Caribbean 




3.Effectiveness of group 
By gauging knowledge and beliefs of people who had attended insulin group education, 
inferences could be made about the effectiveness of the group. Subthemes which were 
indicators of effectiveness of the insulin group include: ongoing management success, need 
for more peer support, and insulin concerns post-group.  
a. Ongoing self-management success 
Success of insulin self-management post-insulin group was highlighted by improvement in 
blood glucose levels: 
“…my sugar levels are down. I’m a happy person.” (01F) 
However, not all diabetes self-management feedback post-insulin group was positive. For 
example, groups did not appear to take into consideration cultural differences in diet and 
lifestyle, with one report of need for education around Afro-Caribbean diets and diabetes: 
 “… with the greatest respect there is the marked difference between a Western diet 
and Afro-Caribbean and even an Asian diet, there’s a marked difference. So...with 
the best of intentions making a suggestion to somebody from another culture 
without understanding their own diet, the advice might sound alien…” (15M) 
Other self-management techniques which required more attention in insulin groups 
included injection technique, and describing the different types of insulin: 
“I find the actual injection thing, I find it very hard to press it, because you’re 
holding your... you know, and then you have to put it in, I find that very hard…” 
(09F) 
“I thought they should have explained to us why some people, they call it active, 
instant reacting insulin, why are some people on that and some people on the other 
one?” (12M) 
There was also lack of knowledge around knowing how to react to pseudo hypoglycaemia. 
This is an event of hypoglycaemia symptoms that can occur when blood glucose levels are 
>3.9 mmol/L(70mg/dl) (i.e. not hypoglycaemic levels) resulting from previous exposure to 
long term hyperglycaemia: 
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“I woke up this morning feeling a bit, I don't know, I haven’t felt like this for a long 
time, I feel dizzy. In fact, I took my, when I was not feeling well, I took my blood to 
test it. It wasn’t even on hypo level, so I don’t know why I was feeling like that...” 
(11F) 
b. Need for more peer support 
Need for further peer support beyond the insulin education groups was indicated by 
wanting more social activities and meeting up with group member living close by: 
“But then they can always encourage that little group that's local to each other. I 
don't know whether you realise it but like there's six of you in this room at the 
moment that are all within a mile of each other.” (03F) 
Also, some expressed a desire for follow-up group or ‘booster’ sessions to refresh content 
learnt in groups: 
“how to put that into refresh my mind for that to come up, plus I used to forget 
something, very soon I will forget everything, yeah.” (14M) 
However, others were content with the original 2 sessions: 
“The two groups were just right.” (13M) 
Not only face-to-face support was mentioned, but one participant shared their positive 
experience of peer support via a web support group to ask questions about diabetes and 
insulin: 
 “I'm able to contact other people and if I have questions I'm able to post it and 
have somebody who’s had that experience so it’s a continuous thing.” (13M) 
c. Insulin concerns post-group 
There were some positive accounts of insulin therapy such as confidence in insulin efficacy 
and taking insulin, and improved well-being: 
 “I felt confident to start it and since then I’ve been doing it.” (06M) 
“It’s made me, you know, feel myself again.” (01F) 
However, interviewees did recount a range concerns which remained post-insulin group 
such as injecting for life, hypoglycaemia, where to inject, and weight gain. This suggests the 
insulin groups were not effective in eliminating all concerns around insulin therapy:  
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 “Just think about injecting myself for the rest of my life, I think that’s one of the 
biggest disadvantage for me you know” (07M) 
“The hypo quite a lot…I feel quite dizzy.” (11F) 
 “I’m having a problem with the injection, you know, that is locating areas in my 
tummy where to inject” (06M) 
“I noticed that I put on weight with insulin.” (12M) 
Another concern from one interviewee was travelling with insulin, which now prevented 
him from seeing friends as he did not want to take insulin with him:  
“Even I go and stay with a friend of mine down in Crawley and since I’ve been on 
insulin I haven’t been down to see him because I don’t want to be taking medication 
down with me.” (04M) 
3.4.1. Common perceptions across participants and difference by ethnicity and age 
Irrespective of ethnicity or age, there were common perceptions across participant groups, 
for example, positive interactions meeting others with type 2 diabetes, sense of 
reassurance from nurse facilitator, mixed feelings towards printed materials, desire for 
psychological support, mixed sense of how facilitator managed group dynamics, 
improvement in blood glucose post insulin initiation yet challenges with injection 
technique, desire for more peer support or content with existing level of education, and 
post-group concerns (where to inject, insulin a lifelong treatment, travelling with insulin, 
hypoglycaemia).  Common perceptions and differences by ethnicity and age are 
summarised in table 3.4. Mostly, there were no distinguishable differences between 
ethnicity or age groups. The 60+ age group seemed to express the need for psychological 
support more than the other age groups, this age group also reported desire for more 
social activities within the insulin education groups and seeking further peer support 
online. Black African/Caribbean participants were the only ethnic group to highlight the 
lack of consideration for cultural differences in diet and lifestyle, in addition to having 






Table 3.4- Commonalities and differences in ethnicity and groups for people with type 2 diabetes who attended an insulin 
start group 
Theme Common perceptions across 
groups 
Differences by ethnicity  Differences by age 
1a. Peer 
Support 
Feelings of encouragement 
from meeting and attending a 
group with other people with 
type 2 diabetes starting insulin. 
No distinguishable differences. No distinguishable differences. 
1b. Providing 
reassurance 
The nurse facilitator provided 
reassurance and 
empowerment, who explained 
things well and was friendly.  
The Asian/other participant did 
not provide comment regarding 
reassurance from the nurse 
facilitator. There were no 
distinguishable differences 
between Black African/Caribbean 
and Caucasian ethnicity.    
No distinguishable differences. 
1c. Printed 
materials  
Too many printed materials 
provided. 
For some printed materials 
provided useful information 
and were kept so they could 
refer to them in future. 
Others did not keep printed 
materials. 
Black African/Caribbean and 
Asian/other (but not Caucasian) 
participants discussed language 
barriers in reading printed 
materials and that too many 
printed materials were provided.  
 
Some Black African/Caribbean 
and Caucasian (but not 
Asian/other) participants felt 
printed materials contained 
useful information and kept them 
for future reference, others 
discarded them.  
Both 46-59 and 60+ age groups 
(</45 age group did not 
comment) remarked on 
language barriers, too many 
printed materials provided, or 
printed materials were kept for 




Some concerns around insulin 
were addressed, desire for 
psychological support. 
Black African/Caribbean 
participants found practical 
demonstration on insulin 
injections useful (Caucasian and 
Asian/other participants did not 
comment on this).  
 
Both 46-59 and 60+ age groups 
found practical demonstration 
on insulin injections useful and 
some felt concerns around 
insulin were addressed.  
 
The 60+ age ground desired 
psychological support.  
2b. Managing 
group dynamics 
Nurse facilitator allowing time 
for everyone’s questions, 
frustration of listening to other 
group members experiences, 
preference for one-to-one 
No distinguishable differences. No distinguishable differences. 
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education, people with 
different ‘levels’ in group (e.g. 





Improvements in blood glucose 
post insulin group, some issues 
with injection technique and 
challenges with diet.  
Some Caucasian and Asian/other 
participants found it easy to 
inject. Other Caucasian and some 
Black African/Caribbean 
participants desired more 
education on injection technique 
post-group.  
Black African/Caribbean 
participants highlighted the lack 
of consideration for cultural 
differences in diet and lifestyle, 
and confusion around pseudo-
hypoglycaemia. 
</45 age group highlighted the 
lack of consideration for 
cultural differences in diet and 
lifestyle.  
60+ age group had confusion 
around pseudo-hypoglycaemia. 
3b. Need for 
peer support 
Some desired more follow-up 
sessions, others were content 
with existing level of insulin 
education.  
Caucasian participants wanted 
more social activities. Black 
African/Caribbean participants 
sought more peer support via 
online forums.  
60+ age group showed interest 
in more social activities and 






Concerns around where to 
inject, insulin being a lifelong 
treatment, travelling with 
insulin and hypoglycaemia.  
Black African/Caribbean 
participants had concerns over 
insulin and weight gain. 
The 46-59 ae group had 
concerns over insulin and 
weight gain. 
 
3.5. Discussion  
The aim of this qualitative interview study was to identify perceptions of group insulin 
education for people with type 2 diabetes. Interviews of people with type 2 diabetes who 
had attended group insulin education in south London revealed three main themes: 
creating a supportive environment, facilitator skills, and effectiveness of group. 
3.5.1. Creating a supportive environment  
Social support including peer support is important for improving outcomes in type 2 
diabetes (Stopford et al., 2013; Strom & Egede, 2012). In study 2 of this thesis, peer support 
in insulin group education was found to be associated with positive experiences as well as 
reducing personal failure related to starting insulin by being around other people in the 
same situation.  
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Previous research indicates acceptance of insulin therapy is associated with healthcare 
professional support (Hassan et al., 2013). Diabetes nurses/educators providing 
reassurance was found to be beneficial in the analysis of thesis study 2. Reassurance was 
also achieved by providing important educational information as well as the way in which 
information was communicated to empower the group.  
Printed materials were given to group members to support learning. These generated 
mixed reviews, some finding them informative and others criticising the volume of 
paperwork. These materials were also difficult for those whose first language was not 
English. Further consideration is required to make resources equitable for all.  
3.5.2. Facilitator skills 
Previous research has indicated starting insulin can decrease negative insulin beliefs such 
as fears of hypoglycaemia (Hajós et al., 2011). However, it is unknown whether this is 
related to receiving certain types of insulin education or the skill of the diabetes 
nurse/educator. Study 2 of this thesis found fears of injecting were addressed in group 
insulin education through practical demonstrations and practicing injecting in the group. 
This is supported by the wider literature where there is evidence that receipt of practical 
advice such as, insulin injection demonstrations, help people with type 2 diabetes avoid 
delays in initiating insulin (Polonsky et al., 2019).  
However, not all interviewees in study 2 of this thesis study were satisfied and 
communicated the facilitator lacked skills to support or address their fears and anxiety 
around insulin therapy. In addition, in some circumstances facilitators did not manage 
group dynamics well and some participants expressed concerns as some of the diabetes 
nurses did not answer everyone’s questions, and were not effective at managing people at 
different life stages for example level of insulin knowledge and experience or age group. 
Whilst some diabetes specialist nurses delivering insulin start groups in south London might 
have had some group education training for other diabetes education groups, for example, 
DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed), 
they are often expected to run insulin start groups without formal training. There is no 
current accredited group insulin education training in the UK which may account for 
inconsistences in facilitator skill.  Meta-analyses have demonstrated that psychological 
interventions using cognitive behavioural therapy and counselling can help support people 
with type 2 diabetes to self-manage and improve HbA1c (Alam et al., 2009; Ismail et al., 
2004; Winkley et al., 2019). Whilst, some of the included studies were delivered to groups 
of people, they were not specifically related to insulin initiation. However, facilitators 
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trained in these psychological skills might be better equipped to addressed insulin concerns 
in a group setting.  
3.5.3. Effectiveness of group 
Previous research related to group type 2 diabetes education has demonstrated 
improvements in HbA1c (Chatterjee, Davies, Heller, et al., 2018; Deakin et al., 2006; 
Loveman et al., 2008; Scain et al., 2009; Trento et al., 2010). Findings of study 2 of this 
thesis provide further support for group type 2 diabetes education with interviewees 
providing accounts of improved blood glucose readings post insulin education group. There 
were also negative reports including lack of consideration for cultural differences in 
relation to dietary content. It is important to consider these differences as culturally 
appropriate education for people with type 2 diabetes is associated with improvement in 
HbA1c and knowledge compared with untailored group education (Hawthorne, Robles, 
Cannings‐John, & Edwards, 2010).  
The insulin start group education delivered to participants in this study are not equivalent 
to structured education (with a manualised evidence-based curriculum), hence this may 
account for descriptions of missing elements of insulin education such as injection 
technique, types of insulin and hypoglycaemia awareness in some groups. An insulin 
education group which is defined as structured education according to UK guidelines (NICE, 
2011; SIGN, 2017), could eliminate inconsistency in curriculum between groups.  
The need for more peer support which was indicated by desire for social activities, group 
booster sessions and web support might suggest that the insulin group was not entirely 
successful in terms of providing support necessary to independently self-manage. 
Nevertheless, additional peer support may help support self-management in the longer 
term where group diabetes education has previously found to be unsuccessful (Khunti, 
Gray, et al., 2012b; Rankin, Cooke, Elliott, Heller, & Lawton, 2012).  
3.5.4. Strengths and limitations of current research 
A strength of the findings of this thesis study is the transferability of the results. Ultimately 
determining the transferability of the results is down to the reader who decides whether 
they can be applied to another sociocultural setting (Kuper, Lingard, & Levinson, 2008) and 
this can be aided by applying study results to existing theoretical health models. This study 
can be applied to the COM-B ('capability', 'opportunity', 'motivation' and 'behaviour') 
health behaviour model (Michie et al., 2011). For example, ‘Ongoing self-management 
success’ (theme 3.1) relates to the capability of self-managing with insulin in terms of 
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knowledge and skill. The theme ‘Insulin concerns post-group’ (theme 3.3) relates to the 
motivation to use insulin therapy (e.g. confidence to inject and plans to do so). Finally, 
‘Need for more peer support’ (theme 3.2) relates to the opportunity to self-manage with 
insulin in terms of physical opportunity (e.g. travelling with insulin) or having social 
support. Furthermore, this supports using the COM-B model to re-design future insulin 
education interventions.  
Although, the sample was limited to south London, this area is diverse in terms of ethnicity 
and socio-economic status and the sampling strategy took this into consideration. 
Therefore, what is learnt from this population is likely to be transferable to other areas of 
the UK and western Europe. Recruitment of majority Black African or Caribbean ethnic 
group was considered an advantage due to the large population of people from non-white 
European ethnicity in south London. Even though the minority of the sample was of south 
Asian ethnicity, difficulty in recruiting this demographic was anticipated owing to previous 
research of people with type 2 diabetes from south London (Winkley et al., 2015; Winkley 
et al., 2018). This group has a low prevalence compared with other ethnic groups therefore 
there was a smaller pool of people from this ethnic group to sample who had attended an 
insulin start group. Another limitation is current medications were not assessed so are 
unable to distinguish whether perceptions of group insulin education vary for those on 
differing treatments. Although, audiotapes were accurately transcribed and there was 
consistency between the data presented and findings, a potential limitation is transcripts 
were not returned to participants for comment or correction, and participants did not 
provide feedback on findings.  In future research these additional measures could be taken 
to determine whether participants provide further insight post-interview.   
3.5.5. Conclusions  
This study highlights the importance of peer support and facilitator skill in creating a 
positive supportive environment in group insulin education. However, diabetes specialist 
nurses delivering group insulin education may need to develop psychological skills to 
enhance patient-communication, better manage group dynamics, and to address concerns 
around insulin therapy. In addition, insulin group content and supporting printed materials 
need to be further developed to be equitable to all regarding language and cultural 
differences.  Follow-up peer support could be useful in optimising ongoing insulin self-
management. This study provides a foundation for developing structured insulin education 




3.6. Chapter summary  
The findings of this study 2 indicate that people with type 2 diabetes starting insulin often 
positively benefit from being educated in a group. Healthcare professional reassurance as 
well as practical injection demonstrations are important aspect to emphasise in DIME 
intervention to empower the group. Psychologically trained healthcare professionals who 
can manage group dynamics and address concerns could also be a beneficial aspect to 
DIME over current insulin start groups. This study provides further rationale for 
development of DIME and creating a new psychological education group for people with 
type 2 diabetes starting insulin. The next chapter examines the association between 
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4.1. Chapter scope 
This chapter describes study 3 of this thesis. For people with type 2 diabetes, delay in initiating 
insulin in the UK is a significant problem. While the reasons are complex and multifactorial, 
psychological factors are understudied. This chapter examines the prospective relationship 
between psychological factors (depressive symptoms, diabetes distress and negative insulin 
beliefs) measured at type 2 diabetes diagnosis and a) time to insulin-requiring status, and b) 
time to insulin initiation.  
4.2. Introduction  
4.2.1. Psychological factors and insulin-related outcomes   
There are two key insulin-related outcomes. The first is at the point after diagnosis a person 
with type 2 diabetes medically needs insulin treatment termed in this thesis as ‘insulin-
requiring status.’ This thesis chapter defines ‘insulin-requiring status’ according to NICE 
guidelines i.e. NICE recommend insulin initiation when dual OAD therapy does not result in 
optimal HbA1c (<58mmol/mol) (NICE, 2017). The second insulin-related outcome is the point 
after diagnosis a person with type 2 diabetes is first prescribed insulin termed in this thesis as 
‘insulin initiation’. This distinction is important as there can be a delay from requiring to 
receiving insulin therapy.   
4.2.1.1 Depression and insulin-related outcomes  
For people with type 2 diabetes, depressive symptoms are twice as common than the general 
population (Ali, Stone, Peters, Davies, & Khunti, 2006; Anderson, Freedland, Clouse, & 
Lustman, 2001; Krishna, 2018; Moulton, Hopkins, Ismail, & Stahl, 2018). Not only is depression 
associated with increased risk of type 2 diabetes (Kan et al., 2013; Knol et al., 2006; Mezuk et 
al., 2013; Nouwen et al., 2010; Rotella & Mannucci, 2013; Yu, Zhang, Lu, & Fang, 2015), but 
diabetes is a risk factor for depression (Chireh, Li, & D'Arcy, 2019).  
In type 2 diabetes, depression is associated with poor diabetes self-care (Nanayakkara et al., 
2018) including poor diet (Gonzalez, Safren, et al., 2008; Park, Hong, Lee, Ha, & Sung, 2004), 
less physical activity (Gonzalez, Safren, et al., 2008), poor treatment adherence (DiMatteo, 
Lepper, & Croghan, 2000; Gonzalez, Peyrot, et al., 2008), social isolation (Feng & Astell-Burt, 
2017), poor attendance to diabetes education programmes (Park et al., 2004; Schwennesen, 
Henriksen, & Willaing, 2016; Winkley et al., 2015) and more hypoglycaemia (Biggers et al., 
2019). Depression and reduced diabetes self-care are associated with increased glycaemic 
levels (Katon et al., 2010; Lustman et al., 2000; Richardson, Egede, Mueller, Echols, & 
Gebregziabher, 2008), long-term complications (Lin et al., 2010; Pouwer, Nefs, & Nouwen, 
2013) and mortality (Ismail, Winkley, Stahl, Chalder, & Edmonds, 2007; Lin et al., 2009). In 
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relation to insulin therapy, depressive symptoms are also associated with negative insulin 
beliefs (Gherman & Alionescu, 2015) and spending more time to adjust to insulin therapy e.g. 
more time training to inject (Dzida et al., 2015). To date, there are no studies which examine 
the prospective relationship between depressive symptoms and time to insulin-requiring 
status. Previous evidence finds depressive symptoms do not appear to be associated with time 
to insulin initiation (Iversen et al., 2015; Nefs, Pop, Denollet, & Pouwer, 2013). However, these 
studies recruited insulin naïve people with established type 2 diabetes but from time of type 2 
diabetes diagnosis which is a potential residual confounder.  
4.2.1.2. Diabetes distress and insulin-related outcomes 
Diabetes distress in type 2 diabetes is an umbrella term (Robinson et al., 2018) for a number of 
potentially overlapping psychological constructs including:  
1) emotional burden 
2) diabetes self-management 
3) social relationships 
4) healthcare professional relationship  
Even though the prevalence of diabetes distress is higher in people with depressive symptoms 
and type 2 diabetes (Fisher et al., 2009; Perrin, Davies, Robertson, Snoek, & Khunti, 2017), 
factor analysis have found that depressive symptoms and diabetes distress are two separate 
constructs (Schmitt et al., 2014). To support this, some researchers have observed that 
diabetes distress, but not depression, is associated with higher glycaemic levels (Fisher et al., 
2010; Tsujii, Hayashino, Ishii, Distress, & Group, 2012) and other studies find people with type 
2 diabetes might have high diabetes distress but not depressive symptoms (Snoek et al., 2012). 
This suggests the importance of examining diabetes distress and depressive symptoms as 
separate factors in examining the relationship to insulin-related outcomes. 
Diabetes distress is associated with poor treatment adherence (Gonzalez, Kane, Binko, Shapira, 
& Hoogendoorn, 2016), worsening glycaemic levels (Aikens, 2012; Gonzalez, Shreck, Psaros, & 
Safren, 2015; Hayashino et al., 2012; Tsujii et al., 2012; Winchester, Williams, Wolfman, & 
Egede, 2016), and a higher risk of mortality (Dalsgaard et al., 2014). Makine et al demonstrated 
that for people with type 2 diabetes, higher scores for depressive symptoms and diabetes 
distress was associated with higher negative insulin beliefs (Makine et al., 2009). In addition, 
there is evidence that diabetes distress mediates the relationship between depression and 
glycaemic levels (Van Bastelaar et al., 2010). These studies were cross-sectional and did not 
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examine the direction of association i.e. whether depression comes first and leads to distress 
which leads to reduced self-care and therefore worsens glycaemic levels. Or whether reduced 
self-care comes first and leads to diabetes distress. There are no studies which examine 
whether diabetes distress is associated with earlier onset of becoming insulin requiring or 
earlier onset of insulin initiation. 
4.2.1.3. Negative insulin beliefs and insulin-related outcomes 
Insulin initiation necessitates a ‘willingness’ to use insulin as well as minimal negative insulin 
appraisals (Holmes-Truscott et al., 2017), suggesting negative insulin beliefs could delay insulin 
initiation. Negative insulin beliefs pre-insulin initiation were associated with a delay in insulin 
initiation, specifically four factors on the modified Insulin Treatment Appraisal Scale (mITAS): 
‘concerns about injections’, ‘failed diabetes management’, ‘increased disease severity’, and 
‘concerns about side effects’ (Hessler et al., 2018). These studies were cross-sectional and the 
longitudinal association between negative insulin beliefs and earlier onset of becoming insulin-
requiring or initiating insulin has not been studied. 
4.2.2. Other factors associated with insulin initiation   
Socio-demographic factors that are associated with delayed insulin initiation include older age 
(Hassali et al., 2014), higher body mass index (Lakkis, Maalouf, Mahmassani, & Hamadeh, 
2013b; Nefs et al., 2013), ethnic minorities e.g. black African and south Asian (Bellary et al., 
2008; Millett et al., 2007), higher glycaemic levels (Holmes-Truscott et al., 2017) and higher 
cardiovascular risk (Khan et al., 2008).  
Another socio-environmental factor is the law. People with diabetes in the UK must inform the 
driving licence authority when they initiate insulin therapy, and licence renewal is required 
every 3 years (GOV.UK, 2019). Fear of hypoglycaemia can be associated with driving 
occupation (Barendse et al., 2012). In the UK, people with type 2 diabetes who drive for their 
occupation and require a group 2 licence (for example, bus or lorry drivers) are requested to 
submit 3 months of blood glucose meter readings after starting insulin. Hypoglycaemia can 
prevent them from obtaining a licence (DUK, 2019). The threat of not being able to work could 
be enough to deter someone from wanting to initiate insulin therapy, and hence this barrier 
should be taken into consideration when studying time to insulin initiation.   
4.2.3. Factors associated with psychological factors 
There are socio-demographic and clinical factors associated with depressive symptoms, 
diabetes distress and negative insulin beliefs. For example, in people with type 2 diabetes, 
there is an association between the presence of depressive symptoms and a number of factors 
including higher glycaemic levels (Katon et al., 2010), presence of macrovascular complications 
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(Ismail et al., 2017), and female sex (Ali et al., 2006; Alonso-Morán, Satylganova, Orueta, & 
Nuño-Solinis, 2014). Factors associated with type 2 diabetes distress are younger age, being 
female, ethnic minority, higher body mass index, higher glycaemic levels, and more diabetes 
complications (Peyrot, Rubin, & Polonsky, 2008; Pintaudi et al., 2015; Stoop et al., 2014; 
Wardian & Sun, 2014). Negative insulin beliefs are associated with ethnic minorities and 
female sex (Nam, Chesla, Stotts, Kroon, & Janson, 2010) in people with type 2 diabetes. It is 
important to examine these socio-demographic factors as potential confounders in the 
relationship between psychological factors and insulin-related outcomes. 
4.2.4. The south London diabetes cohort 
In the original SOUth London Diabetes (SOUL-D) study (baseline), newly diagnosed (within 6 
months) people with type 2 diabetes were recruited between 2008 and 2012 from primary 
care in the boroughs of Lambeth, Southwark, Lewisham and Bromley in south London (Winkley 
et al., 2013). One hundred and thirty-eight general practices were invited to participate, 96 
consented to participate and 1735 people with type 2 diabetes were consented and seen. The 
original SOUL-D cohort has been followed-up at 1-years and 2-years. Study 3 of this thesis 
follows up the original SOUL-D cohort 8-years later, i.e. the 8-year follow-up SOUL-D study. In 
the primary analysis, depressive symptoms at diagnosis of type 2 diabetes were not associated 
with worsening HbA1c over 2-year follow-up. Despite this, depressive symptoms at baseline 
were associated with a greater incidence rate of macrovascular complications at 2-year SOUL-
D follow-up (Ismail et al., 2017). The 8-year follow-up SOUL-D study aims to examine 
depressive symptoms at baseline as well as other psychological factors (diabetes distress and 
negative insulin beliefs), and time to insulin-related outcomes.  
4.2.5. Current study aims and hypotheses  
The aim of study 3 of this thesis, the 8-year follow-up SOUL-D study, was to examine the 
association between i) depressive symptoms, ii) diabetes distress iii) negative insulin beliefs on 
a) time to insulin-requiring status and b) time to insulin initiation.  
The 8-year follow-up SOUL-D study tested the hypotheses that:  
1) Higher depressive symptoms in newly diagnosed people with type 2 diabetes were 
associated with a shorter time to a) insulin-requiring status, and b) insulin initiation. 
2) Higher diabetes distress in newly diagnosed people with type 2 diabetes was associated 
with a shorter time to a) insulin-requiring status, and b) insulin initiation. 
3) Lower negative insulin beliefs in newly diagnosed people with type 2 diabetes were 




4.3.1. Design and setting  
This was an 8-year follow up of people with type 2 diabetes from the original SOUL-D 
prospective cohort study who consented to medical record follow-up.  
4.3.2. Ethical considerations 
Ethics for the original SOUL-D study was approved by King’s College Hospital Research Ethics 
Committee (reference 08/H0808/1) and by Lambeth, Southwark, and Lewisham Primary Care 
Trusts (reference RDLSLB 410). In addition, ethics was requested for the follow-up study by 
King’s College Hospital (reference 17/EE/0272) and Dulwich research ethics committee 
(reference 08/H0808/1). The medical records of participants in the original SOUL-D study who 
consented to 20 years follow-up were screened for the 8-year follow-up SOUL-D study. It was 
not necessary to re-consent participants to screen medical records for follow-up, however, 
participants were sent a letter to inform them that their data was to be used in line with the 
health research authority standardised General Data Protection Regulation outline (HRA, 2018) 
(see appendix 4.1).  
All personal data were kept confidential in line with NHS Code of Confidentiality. Once a 
participant in the original SOUL-D study provided informed consent, they were assigned a 
participant ID (identification) number for the study. The ID number was recorded on all study 
documents in the original and 8-year follow-up SOUL-D studies, including original study 
questionnaires and 8-year follow-up medical records data collection schedule. The 
participant’s name was not recorded on any study documents other than the informed 
consent form and Participant ID log.  
Contact details (email, telephone numbers, and/or addresses) of participants were kept in a 
file, in a locked filing cabinet in a locked office at a King’s College London campus. The original 
SOUL-D study questionnaire assessments and lab data were also kept in a separate file in a 
locked room at a King’s College London campus. Follow-up medical records data collection was 
entered electronically only and was stored on a University password-protected computer in a 
locked office at the University. Only the research team had access to computers which 
contained data for this research, in addition to locked filing cabinets/rooms.  
4.3.3. Participants and inclusion/exclusion criteria   
People with type 2 diabetes were recruited in the original SOUL-D study within 6 months of 
type 2 diabetes diagnosis. Type 2 diabetes diagnosis was made in accordance with the World 
Health Organization criteria (WHO, 1999) and validated by a review of participant medical 
records. World Health Organisation criteria recommend the following combination and 
107 
 
repetition of tests to diagnose type 2 diabetes: fasting plasma glucose (> 7.0 mmol/L); random 
plasma glucose (≥11.1 mmol/L); 2-hour post 75g oral glucose tolerance test (≥11.1 mmol/L); 
HbA1c tests (≥ 48 mmol/mol).   
The inclusion criteria for the original SOUL-D study were adults with type 2 diabetes (18-75 
years). The exclusion criteria were: >6 months type 2 diabetes duration; other diabetes types 
(type 1 diabetes or gestational diabetes); not fluent in English; residing outside of south 
London; current severe mental health condition e.g. dementia, personality disorder, bipolar 
disorder, substance dependence; advanced or terminal condition; and advanced diabetes 
complications (registered blind, dialysis, above knee amputation).  
4.3.4. Measures/materials  
Table 4.1 summarises the exposure and outcome factors and how they were measured. The 
original SOUL-D study factors are referred to as baseline factors. Medical records for the 8-year 
follow-up SOUL-D data collection were accessed via Egton Medical Information Systems (EMIS) 
web (EMIS, 2016) at the participants’ general practice surgeries and entered into a 
standardised Microsoft Excel data collection schedule.  
4.3.4.1. 8-year follow-up SOUL-D descriptive data 
Follow-up time. The time from the original SOUL-D data collection to the 8-year follow-up 
SOUL-D was calculated in months.  
Active status. EMIS indicated whether the participant was active, deceased or inactive. ‘Active’ 
refers to the participant currently accessing healthcare at the surgery. ‘Inactive’ refers to the 
participant previously accessing healthcare at the surgery but have since moved to another 
surgery. A blue band at the top of the EMIS screen indicated the participant was active, a red 
band for deceased, and a grey band for inactive. A deceased variable was coded as yes 
(deceased), no (active and not deceased) or inactive (inactive). Reason for death was also 
recorded via the ‘problems’ or ‘documents’ tab in EMIS.  
HbA1c. A history of HbA1c measurements was recorded via the ‘investigations’ tab in EMIS, 
every HbA1c measurement was recorded since type 2 diabetes diagnosis. HbA1c was recorded 
in mmol/mol, if reported in % HbA1c in EMIS it was transformed into mmol/mol via an online 
HbA1c converter. Date of HbA1c measurement was also extracted.  
OADs. A history of types of OADs were recorded via the past and current ‘medication’ tab in 
EMIS. Start and stop date was recorded for previous OADs and start date for current OADs.  
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Other injectables. Injectables, not including insulin treatment, were recorded via the past and 
current ‘medications’ tab in EMIS. Types of other injectables included: exenatide, liraglutide, 
dulaglutide, and insulin degludec plus liraglutide. Start and stop date was recorded for 
previous other injectables and start date for current other injectables. 
Insulin treatment. Insulin treatment was identified via the past and current ‘medication’ tab in 
EMIS. Type of insulin was recorded including fast-acting insulin (insulin lispro, insulin aspart, 
insulin glulisine, soluble insulin); long-acting insulin (insulin glargine, insulin determir, Toujeo, 
humulin M3, insulatard); intermediate-acting insulin (NPH); pre-mixed insulin (Humalog Mix 
50, Novo mix 30). 
4.3.4.2. Exposure baseline psychological factors  
Depressive symptoms: Patient health questionnaire (PHQ-9). This 9-item, self-report 
questionnaire was used to assess depressive symptoms over the last 2 weeks (Kroenke, 
Spitzer, & Williams, 2001). Responses were based on a 4-point Likert scale ranging from ‘not at 
all (score=0)’ to ‘nearly every day (score=3)’. For example, ‘how often have you been (how 
much have you been) bothered by…little interest for pleasure in doing things?’ Overall 
questionnaire scores ranged from 0-27, with higher scores indicating more depressive 
symptoms. This factor can be used as continuous or categorical. For PHQ-9 categorical, a ≥10 
score was the cut-off indicating the caseness for probably depressive disorder. The tool has 
been validated in the SOUL-D sample using a two-stage survey design comparing the PHQ-9 
against a gold standard diagnostic interview (Twist et al., 2013).  This tool is often used in 
primary care as it is free and easy to administer with little training. In addition, the PHQ-9 has 
good internal consistency (Cronbach’s α=0.85), meaning the questionnaire often detects 
depression when depression is present (Kroenke et al., 2001).  
Diabetes distress: Problem areas in diabetes (PAID) questionnaire. This 20-item self-report 
questionnaire assesses current diabetes distress and emotions experienced when coping with 
diabetes (Polonsky et al., 1995). Items are measured on a 5-point Likert scale from ‘not a 
problem (score=0)’ to ‘serious problem (score=4).’ For example, ‘Not having clear and concrete 
goals for your diabetes care?’ Responses for all items are summed and multiplied by 1.25 to 
derive generate an overall score between 0-100. Scores can be continuous or categorical. PAID 
was used as a categorical factor for the follow-up study where ≥40 scores represented a high 
diabetes distress/emotional. This scale has high internal consistency  (Cronbach’s α=0.95) 
(Welch, Jacobson, & Polonsky, 1997). The PAID scale has concurrent validity as it was highly 
correlated with previously established scales measuring similar constructs including four 
coping subscales (diabetes integration coping, avoidance coping, passive resignation coping, 
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tackling spirit coping), Health Belief Model scale and the Diabetes Social Support Measure 
(Welch et al., 1997). In addition discriminant validity was found by detecting differences in 
PAID scores between type 1 diabetes and type 2 diabetes groups (Welch et al., 1997). 
Negative insulin beliefs: Barriers to insulin treatment (BIT) questionnaire. This 14-item self-
report questionnaire assesses beliefs around insulin injection therapy in response to various 
statements (Petrak et al., 2007). People with type 2 diabetes on any or no treatment can 
answer this questionnaire as it assesses beliefs towards insulin regardless of current diabetes 
treatment.  BIT items comprise of a 10-point scale ranging from ‘totally disagree (score=1)’ to 
‘totally agree (score=10),’ with a score of 5-6 indicating an unsure response to the statement. 
An example statement is: ‘I am afraid of the pain when injecting insulin’. This questionnaire 
comprises of 5 subscales: fears of injections & self-testing (subscale 1, items 1-3); expectations 
regarding positive insulin-related outcomes (subscale 2, items 4-6); expected hardship from 
insulin therapy (subscale 3, items 7-9); stigmatisation by insulin injections (subscale 4, items 
10-12); fear of hypoglycaemia (subscale 5, items 13-14). Subscale 2 was reversed scored as 
higher scores on these items indicate low negative insulin beliefs, whereas higher scores on 
the other subscales indicate high negative insulin beliefs. To calculate the overall BIT scores, 
scores for all items were summed and mean scores ≥5.57 indicate high negative insulin beliefs 
(Boughdady, Winkley, Ismail, & Amiel, 2014). This tool is reliable, finding high internal 
consistency between subscales (Cronbach’s α= 0.78) and has predictive validity in two cross-
sectional studies of people with type 2 diabetes who have never been on insulin treatment 
(d=0.76) (Petrak et al., 2007).  
4.3.4.3. Insulin-related outcomes: 8-year follow-up SOUL-D data collection 
Insulin-requiring status. Participants were identified as requiring insulin according to NICE 
guidelines which stated: despite being on 2 OADs, the person with type 2 diabetes has 
suboptimal HbA1c (≥58 mmols/mol) (NICE, 2009). The date at which a participant started a 
second OAD was compared to HbA1c lab test data. One month after a second (or more) OAD 
was prescribed, and if the HbA1c was ≥58mmol/mol, this was coded as insulin-requiring and 
the date at which this first occurred was recorded. One-month (or more depending on 
available data) was selected as the duration post prescription of the second OAD because it 
allowed time for this medication to take effect, as opposed to coding as becoming insulin-
requiring in the month the person started the second OAD.  
Insulin initiation. Insulin initiation was defined as the date of first insulin prescription. This was 
derived from the ‘medication’ tab in EMIS, assessing both current and past medications, and 
from the drug history to obtain the first insulin prescription date.  
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4.3.4.4. Confounding baseline factors  
Owing to the multiple factors that can influence diabetes progression, treatment and 
outcomes, it was important to take into account the effects of confounding factors for which 
the regression method was used. A confounder is a risk factor or exposure that is associated 
with the primary risk factor of interest (the independent variable e.g. depressive symptoms, 
diabetes distress, negative insulin beliefs) and the primary outcome of interest (the dependent 
variable e.g. insulin-requiring status, insulin initiation), figure 4.1. Controlling for confounding 
factors increases the validity of the results (Field, 2013). Failure to control for confounding 
factors can lead to over or underestimation of an association between the exposure and 
outcome. This section describes the confounding factors identified from the original SOUL-D 














Sociodemographic factors. Age, sex, and ethnicity were obtained through self-report 
questionnaires, based on the 2001 UK Census (ONS, 2001).  
Body mass index. Height and weight measurements were used to calculate body mass index 
(weight (kg)/height(m)2).  
Glycaemic levels. Glycaemic levels were measured in % by a HbA1c serum blood sample using 
high performance liquid chromatography (HPLC) (Premier 9210 analyser, Menarini, Italy). 
Exposure e.g. 
depressive symptoms, 
diabetes distress or 
negative insulin beliefs 
Outcome e.g. insulin 
initiation or insulin 
requiring status 
Confounding factors e.g. age, 
sex, ethnicity, body mass 
index, HbA1c, microvascular 
complications, macrovascular 
complications, driving licence 
status 
Figure 4.1-Potential confounding factors in the SOUL-D study 
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Macrovascular complications. Macrovascular complications were identified by self-report and 
validated by medical records and included a history of myocardial infarction; coronary artery 
bypass graft; cerebrovascular accident; and carotid or limb re-vascularisation. Macrovascular 
complications were coded as present or absent.  
Microvascular complications. Microvascular complications included neuropathy, retinopathy, 
or nephropathy. A neurothesiometer (Scientific Laboratory Supplies, Wilford, Nottingham) was 
used to measure neuropathy by measuring the vibration perception threshold (VPT) on the 
first toe of both feet and asking when the person with diabetes could feel the vibration. This 
was repeated 3 times and the lowest voltage was recorded. A >25 voltage indicated significant 
sensory neuropathy and at risk of diabetic foot ulcers (Edmonds & Foster, 2014). Urinary ACR 
was used as a measure of nephropathy, ratios of ≥3 indicated positive for microalbuminuria. 
Retinopathy was assessed through local hospital Diabetes Eye Complication Screening service 
using two-field photography (NHS, 2007) and coded using English Retinopathy Minimum 
grading system (ENSPDR, 2019). Microvascular complications were coded as present or absent.  
Driving licence status. Driving licence status was identified through self-report and coded as 
yes or no for categories of the status.  
Table 4.1-8-year follow-up SOUL-D exposure and outcome factors 
Factors How measured Cut off points for categorical data 
Depressive 
symptoms 
PHQ-9 questionnaire  ≥10 score= depressive symptoms 
Diabetes distress PAID questionnaire  ≥40 score= high diabetes distress 
Insulin beliefs  BIT questionnaire  ≥5.57 score = high negative insulin beliefs 
Age Self-report n/a  
Sex Self-report Male/Female 
Ethnicity  Self-report White/non-white 
Body mass index Height/weight measurements n/a 
HbA1c Serum blood sample n/a  
Macrovascular 
complications 





Present/absent for neuropathy, retinopathy or 
nephropathy  
    Neuropathy Neurothesiometer >25 VPT voltage= sensory neuropathy 
    Retinopathy DECS: two-field photography Present/absent 
    Nephropathy Urinary ACR Ratio ≥3 =positive for microalbuminuria= 
Present 





Medical records (information 







4.3.5. Procedure  
Potential participants for the original SOUL-D study were identified by general practice staff or 
the clinical diabetes team by medical record search strategy using diagnosis and medication 
prescription codes. The search strategy was tested extensively before being implemented in 
every surgery in EMIS. People with type 2 diabetes who consented to be contacted by the 
clinical team were invited by a research assistant for the original SOUL-D study assessment. 
Before an 8-year follow-up SOUL-D medical record data collection commenced, the original 
SOUL-D study consent forms were reviewed to identify those participants who had given 
written consent for a 20-year medical record follow-up. General practice managers in primary 
care were contacted via email to invite them to participate in the 8-year follow-up SOUL-D 
study. If there was no response by email, the research team contacted practice managers on 
the telephone. The first general practice surgeries who were contacted were those who were 
recruited first to original SOUL-D study to maximise follow-up time. The research team had 
NHS research passports to allow access to surgeries in south London.   
Once general practices agreed to take part in the 8-year follow-up SOUL-D study, room 
bookings were made at the surgery to use a computer and gain access to EMIS for medical 
record screening. Some surgeries allowed the research team to use surgery computers in 
admin rooms or reception. Medical records for the SOUL-D participants were accessed via 
EMIS. Unique EMIS logins for the study were generated at each individual surgery. An initial 
EMIS screening determined whether the participants were active, deceased, or inactive. If 
participants were active, all relevant information to determine insulin initiation and insulin-
requiring status could be obtained, and data was entered into the Microsoft excel data 
collection schedule. If participants were deceased, medical record data were obtained up to 
date of death, EMIS would only indicate the participant had deceased if they had died whilst 
being a patient at that surgery (i.e. were active at the surgery at the date of death).  If the 
participant was inactive, then as much information was obtained as possible up to the date the 
participant left the surgery. This was sometimes enough to obtain data for insulin-related 
outcomes. For inactive participants, a private company called Capita who runs Primary Care 
Support England (PCSE) were contacted and could trace participants’ current general practice 
addresses who resided in England. This data could only be exchanged on receipt of NHS 
numbers, full name, date of birth, previous general practice address, and proof of consent. 
Once inactive participants could be traced to their current surgery, participants’ medical 
records could be viewed at that surgery they moved to if accessible to the research team (i.e. 
in south London at this stage).  
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4.3.6. Statistical analysis  
4.3.6.1. Data management 
All data was entered into the Microsoft Excel data collection schedule before being converted 
into STATA 15 (StataCorp, 2017) for analysis.  
4.3.6.2. Original SOUL-D versus 8-year follow-up SOUL-D characteristics  
SOUL-D study baseline characteristics (age, sex, ethnicity, body mass index, HbA1c, presence of 
complications, driving license status, depressive symptoms, diabetes distress, and insulin 
beliefs) were reported for the original SOUL-D sample (n=1735) and the sample of the 8-year 
follow-up SOUL-D study. Mean and standard deviations were reported for continuous 
variables (age, body mass index, HbA1c), and the number of participants and percentages 
were reported for categorical variables (sex, ethnicity, presence of complications, driving 
license status, depressive symptoms, diabetes distress, and insulin beliefs). T-tests (for 
continuous data) and Pearson chi-square tests (for categorical data) were used to compare 
whether the 8-year follow-up SOUL-D sample significantly differed in these baseline 
characteristics to the original SOUL-D cohort.  
4.3.6.3. Original SOUL-D characteristics stratified by psychological factors 
SOUL-D baseline characteristics were stratified by each categorical psychological baseline 
variable (PHQ-9, PAID, BIT), to determine any significant relationships.  
4.3.6.4. Eight-year SOUL-D follow-up characteristics  
For the 8-year follow-up SOUL-D characteristics, the average time to follow-up was described. 
Median data was presented instead of the mean where data was skewed. The number and 
percentage of the following were calculated for the deceased in addition to the cause of death. 
Mean (SD) HbA1c at follow-up was reported with the number and percentage of people who 
had optimal HbA1c (<58 mmol/mol) and suboptimal HbA1c (≥58 mmol/mol).  
4.3.6.5. Type 2 diabetes treatment progression of 8-year follow-up SOUL-D participants  
Type 2 diabetes treatment progression of the 8-year follow-up SOUL-D participants was 
described by reporting frequency (n and %) of people on lifestyle modifications only since type 
2 diabetes diagnosis (i.e. had not been prescribed any diabetes drug treatment); the number 
of people prescribed 1, 2, 3, or 4 OADs only; people prescribed other injectables during the 
follow-up period; people who had been insulin-requiring during the follow-up period; and 
people who had initiated insulin (i.e. prescribed insulin treatment) during the follow-up period. 
The types of other injectables and insulin was reported with frequencies. The mean average 
number of OADs prescribed before the first insulin prescription was reported. Finally, the 
mean (SD) HbA1c measurement closest to pre-first insulin prescription was reported.  
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4.3.6.6. Survival analysis  
The purpose of using survival analysis is to analyse the time to an event i.e. survival time. This 
thesis chapter uses survival analyses to determine: 1) time to insulin-requiring status, and 2) 
time to insulin initiation. Censoring in survival analysis refers to when information about 
survival time is incomplete or missing (the event did not occur for a participant) (Altman & 
Bland, 1998). Censored data is not the same a missing data, censored cases are not excluded 
from the analysis, their data still contributes to the time at risk (‘risk of experiencing event’) up 
to the last interval during which they were known to be alive. Censored data is not considered 
in other analyses such as regression or odds ratios (Ferreira & Patino, 2016). The Kaplan-Meier 
method of survival analysis is useful to estimate survival overtime even when data is censored 
or different participants are followed-up for different lengths of time  (Jager, Van Dijk, Zoccali, 
& Dekker, 2008). The Kaplan-Meier methods shows the probability of an event at certain time 
intervals and helps compare two groups. In this thesis study, the Kaplan-Meier method plots 
survival curves for i) the presence of depressive symptoms versus no presence of depressive 
symptoms; ii) high diabetes distress versus low diabetes distress; iii) high negative insulin 
beliefs versus low negative insulin beliefs for time to insulin-related outcomes. Non-parametric 
log-rank tests (Bland & Altman, 2004) compared survival distributions between the original 
SOUL-D study psychological variable categorical groups (PHQ-9, PAID, BIT). 
Mean or median survival times were reported. The median survival time is a better measure of 
central location than the mean due to survival times often being skewed. Outliers can have a 
substantial impact on the mean which distorts the mean from the center. Skewed data has a 
smaller effect on the median as it is not dependent on all the values of the data meaning 
outliers do not impact the median as much as the mean. However, the median survival time 
can only be plotted where the cumulative survival drops below 50 percent, where this did not 
happen mean survival times were reported. The survival time started from original SOUL-D 
study data collection (i.e. type 2 diabetes diagnosis) to time of the event (insulin-requiring and 
insulin initiation) (Jager et al., 2008). A sub-analysis was performed on participants who were 
insulin requiring using the Kaplan-Meier method to chart time from when they became insulin-
requiring when they initiated insulin. If the event occurred before or at baseline (i.e. original 
SOUL-D study data collection), then this observation was excluded from the analysis. For 
censored cases, time was calculated from the original SOUL-D study data collection to date of 
follow-up data collection. For those who had deceased by follow-up, time from the original 
SOUL-D study data collection to date of death was only recorded in absence of event (i.e. 
censored), otherwise, time to event was recorded.  
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The Kaplan-Meier technique is an exploratory unadjusted analysis i.e. this analysis does not 
allow for adjustment of confounder variables and only examined the association between 
independent variables (psychological factors) and time to dependent variables (insulin-
requiring status and insulin initiation).   
4.3.6.7. Cox regression  
The Cox regression method allows for further validation of the association between exposure 
and time to the event by adjusting for confounders. Cox regression analyses estimated hazard 
ratios (HR) of time to insulin-requiring status and insulin initiation with 95% confidence 
intervals (CI). The estimated hazard ratio for each variable considers the other variables in the 
model. A hazard ratio is a test statistic of the effect of an independent variable on an outcome 
(dependent variable) over time. 
If all assumptions were met (see the section below), a Cox regression model included the 
following variables: age, sex, ethnicity, body mass index, HbA1c, microvascular complications, 
macrovascular complications, driving license status, depressive symptoms, diabetes distress, 
insulin beliefs. The Cox regression model used a maximum of 10 events per variable e.g. if 
there were 100 insulin initiation events then the Cox regression model included 10 variables. 
Previous research has determined 10 events per variable was associated with estimates closest 
to the true value (Peduzzi, Concato, Feinstein, & Holford, 1995; Peduzzi, Concato, Kemper, 
Holford, & Feinstein, 1996).   
4.3.6.8. Testing assumptions for Kaplan-Meier and Cox regression  
The following assumptions relate to the Kaplan-Meier test and were addressed in study design: 
1) Event status is mutually exclusive. The event status was a mutually exclusive outcome 
from the censored. In addition, at least one of these states must have occurred.  
2) Time to event measured precisely. The time to event or censorship was measured at a 
precise time point as opposed to an interval period. This was measured in months. 
3) Left censoring avoided. The exact point of the original SOUL-D study (i.e. baseline) 
measurement could be identified.  
The remaining assumptions relate to Cox regression which was tested using statistical tests as 
described below:  
4) Proportional hazards assumptions. This refers to a ratio of the hazards for two individuals 
being constant over time. The Harrell & Lee test (Schoenfeld residuals, (Lee, Harrell Jr, 
Tolley, & Rosati, 1983)) were also used to test this assumption, where the time-dependent 
covariate should be greater than 0.05. A plot of Schoenfeld residuals was also plot, where 
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a horizontal line in graph indicated no violation of assumption. Further, a log-log plot to 
test proportionality reveals no violation of the assumption if lines in the plot are parallel. If 
a variable violated the proportional hazards assumption, then this variable was excluded 
from the Cox model. If there was a continuous alternative to a categorical variable that did 
not violate the assumption, e.g. depressive symptoms, then this could be included in the 
Cox model.  
5) Deviance of residuals. Deviance of residuals was calculated to assess for outliers (more 
than 3 or less than -3), this was evaluated using a two-way scatter plot.  
6) Multicollinearity. This is where there are high intercorrelations between explanatory 
variables, which if used in combination in a regression model can disturb the data, and 
hence may not be reliable (Grewal, Cote, & Baumgartner, 2004). This assumption was 
tested through correlations between the 3 psychological variables (PHQ-9, PAID, BIT) were 
checked to see whether they were smaller than 0.8 before including them as potential 
confounders in Cox regression analysis. 
4.3.6.9. Sample size estimation   
A sample size estimation was calculated in STATA 15 based on the survival Cox regression 
model.  The following parameters were inputted into the calculation: alpha level=0.05, 
power=80 percent, hazard ratio= 0.4. The variability (SD) was calculated by the difference in 
standard deviations of the mean in depressive symptoms between those who were on insulin 
versus those not on insulin at a 5-year follow-up (Keij, 2015). The power calculation was 
adjusted for censoring, the probability of the event was set at 0.06 as the 5-year follow-up 
observed around 6% were prescribed insulin injection therapy. The estimated number of 
events (insulin initiation) was n=38, and the estimated sample size was 624.  
4.3.6.10. Missing data 
Case mean substitution was used to impute missing values for the psychological measure 
(PHQ-9, PAID, and BIT) scores only. Case mean substitution was used at the individual 
participant level where there was 20% or fewer missing data per participant. For example, for 
the PHQ-9 there are 9 items in the questionnaire so 20% or fewer missing equates to 1 or 2 
items for the individual participant missing. So, if a participant is missing 2 questions on the 
PHQ-9 and has a total of 14 on the remaining 7 questions, the average would be 2 for each 
item. This average of 2 would then be added for the remaining 2 missing items bringing the 
total to 18. This method imputes the missing scores based on mean scores available for that 
participant and assumes that the missing value is related to available data points (Raymond, 
1986). An advantage of case mean substitution is it uses data provided by the same participant 
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to estimate own missing data, as opposed to using data from other cases in the sample. Case 
mean substitution is a robust method when imputing 20% missing data in random or 
systematic patterns (Roth, Switzer III, & Switzer, 1999).  
4.4. Results 
4.4.1. SOUL-D participant characteristics 
4.4.1.1. Flow of participants  
Figure 4.2 shows the study flowchart. The 8-year follow-up SOUL-D data collection took place 
between September 2017-January 2019. One thousand seven-hundred and thirty-five were 
screened at the original SOUL-D study and 1699 people provided consent for medical record 
data to be screened for 20 years. The number of records that were screened for the 8-year 
follow-up SOUL-D study was 1298 (from 56 surgeries) of which 1003 (out of 1699, 59.0%) 
records were obtained and 295 were inactive (participants had moved to a different surgery 
and record not yet obtained), 456 records are yet to be screened. Of the 1003 records 
obtained, 31 records were inactive, but enough data could be extracted for insulin-requiring 
status/insulin initiation (from previous active surgery).  
4.4.1.2. Original SOUL-D versus 8-year follow-up SOUL-D characteristics  
The baseline characteristics of the participants in this 8-year follow-up  SOUL-D study (n=1003) 
did not statistically significantly differ from the original SOUL-D cohort (N=1735), according to 
age, sex, ethnicity, body mass index, HbA1c, microvascular complications, macrovascular 
complications, driving license status, depressive symptoms, diabetes distress and negative 
insulin beliefs (table 4.2). Therefore, this sample is representative of the whole cohort based 
on these characteristics. 
4.4.1.3. Original SOUL-D study characteristics stratified by psychological factors 
The original SOUL-D study characteristics were stratified by baseline categorical psychological 
factors (table 4.3). The presence of depressive symptoms was associated with younger age, 
females, higher body mass index, and presence of macrovascular symptoms. High diabetes 
distress was associated with to younger age, females, and non-White ethnicity. High negative 
insulin beliefs were associated with younger age, females, non-White ethnicity, presence of 
macrovascular symptoms, and driving license status.   
4.4.1.4. Eight- year follow-up SOUL-D characteristics 
For the 8-year follow-up SOUL-D study (n=1003), the median follow-up time was 92 months 
(7.67 years, IQR=80-103 months). By follow-up, 53 people had died. Reasons for death include: 
bowl obstruction (n=1), cancer (n=18), heart attack (n=3), liver failure (n=3), pneumonia (n=2), 
stroke (n=1), tumour (n=1), and information unknown from primary care records (n=24). The 
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mean HbA1c at follow-up was 57.29 mmol/mol (SD=17.90), with more people with optimal 

















 8-year follow-up 
SOUL-D study (n=1003) 





mean (SD)   
963 56.63 (10.85) 1735 56.12 (11.01) 0.289 
Sex, n (%) 1093  1735  0.780 
   Male  547 (54.5)  949 (54.7)  
   Female  456 (45.5)  786 (45.3)  
Ethnicity, n (%) 963  1733  0.663 
   White   489 (48.8)  863 (49.8)  
   Non-White  474 (47.3)  870 (50.2)  
Body mass index, 
mean (SD)   
962 31.96 (6.43) 1732 32.00 (6.51) 0.828 
Hba1c (%), mean 
(SD)   
909 6.97 (1.39) 1620 7.01 (1.45) 0.539 
Presence of 
microvascular 
symptoms, n (%) 
804  1430  0.943 
   Yes  266 (26.5)  471 (32.9)  
   No  538 (53.6)  959 (67.1)  
Presence of 
macrovascular 
symptoms, n (%) 
954  1711  0.404 
   Yes  80 (8.4)  160 (9.4)  
   No  874 (91.6)  1551 (90.6)  
Driving licence, n 
(%) 
991  1709  0.420 
   Yes  551 (55.6)  985 (57.6)  




9), n (%) 
995  1714  0.944 
   Yes  144 (14.5)  252 (14.7)  
   No  851 (85.5)  1462 (85.3)  
Diabetes Distress 
(PAID), n (%) 
962  1560  0.480 
   High  58 (6.0)  99 (6.3)  
   Low  904 (90.1)  1461 (93.7)  
Negative insulin 
beliefs (BIT), n 
(%) 
920  1582  0.526 
   High  227 (22.6)  408 (25.8)  
   Low  693 (69.1)  1174 (74.2)  
a There are missing data for some variables in the 8-year follow-up SOUL-D sample resulting in different 
percentages; the total number of individuals for each variable is therefore given.  
b There are missing data for some variables in the original SOUL-D sample resulting in different percentages; the 
total number of individuals for each variable is therefore given.  
























Age   p<0.001*   p<0.001*   p=0.002* 
   N 1462 252  1460 98  1173 407  
   M(SD) 56.72 (11.07) 53.08 (10.30)  56.76 (10.90) 49.78 (11.01)  56.73 (11.06) 54.74 (11.05)  
Sex, n(%)   p=0.01*   p=0.001   p<0.001* 
   Male 819 (56.0) 119 (47.2)  823 (56.4) 39 (39.8)  694 (59.2) 187 (45.9)  
   Female 643 (44.0) 133 (52.8)  637 (43.6) 59 (60.2)  479 (40.8) 220 (54.1)  
Ethnicity, n(%)   p=0.65   p<0.001*   p<0.001* 
   White 736 (50.4) 123 (48.8)  770 (52.7) 32 (32.7)  692 (59.0) 113 (27.8)  
   Non-White 725 (49.6) 129 (51.2)  690 (47.3) 66 (67.3)  481 (41.0) 294 (72.2)  
Body mass index   p<0.001*   p=0.40   p=0.99 
   N 1459 252  1457 98  1171 406  
   M(SD) 31.78 (6.34) 33.34 (7.26)  31.95 (6.55) 32.52 (5.84)  32.01 (6.47) 32.00 (6.48)  
HbA1c   p=0.13   p=0.89   p=0.71  
   N 1370 236  1371 92  1108 373  
   M(SD) 6.98 (1.46) 7.14 (1.44)  6.95 (1.37) 7.26 (1.67)  6.97 (1.44) 7.13 (1.57)  
Presence of microvascular 
complications, n(%) 
  p=0.33   p=0.69   p=0.48 
   Yes 390 (32.3) 74 (35.7)  405 (33.4) 24 (31.2)  321 (33.3) 110 (31.3)  
   No 818 (67.7) 133 (54.3)  807 (66.6) 53 (68.8)  643 (66.7) 242 (68.8)  
Presence of macrovascular 
complications, n(%) 
  p=0.01*   p=0.56   p=0.02* 
   Yes 125 (8.7) 34 (13.7)  129 (9.0) 7 (7.2)  120 (10.4) 26 (6.5)  
   No 1317 (91.3) 214 (86.3)  1310 (91.0) 90 (92.8)  1039 (89.6) 374 (93.5)  
Driving licence status, 
n(%) 
  p=0.14   p=0.26   p<0.001* 
  Yes 840 (58.4) 133 (53.4)  845 (58.6) 50 (52.6)  724 (62.6) 186 (46.2)  





4.4.1.5. Type 2 diabetes treatment progression of 8-year follow-up SOUL-D participants 
Nearly fifteen percent of the 8-year follow-up SOUL-D study participants were on lifestyle 
modifications only since type 2 diabetes diagnosis (n=147) and were not prescribed any 
diabetes drug treatment. Within the 8-tear follow-up period, most people were prescribed 
1 OAD only (n=391), n=205 were prescribed 2 OADs only, n=91 were prescribed 3 OADs 
only, and n=9 were prescribed 4 OADs only.  
Forty-eight people (4.8%) were treated with other injectables (GLP-1 RAs) at some point 
during the follow-up period including exenatide (n=4), liraglutide (n=27), dulaglutide 
(n=16), and insulin degludec plus liraglutide (n=1).  
Three-hundred and forty-one people (34.0%) were insulin-requiring during the follow-up 
period i.e. were on 2 or more OADs despite suboptimal HbA1c (>58 mmol/mol).  
Ninety-six people (9.6%) initiated insulin within the follow-up period, most starting on one 
type of insulin (n=92), n=4 on 2 types of insulin, table 4.4. The most common starting 
insulin was intermediate-acting insulin (NPH; n=47, 49.0%). The most common number of 
OADs prescribed before the first insulin prescription was 2 (Mean=1.75, SD=0.88). The 
HbA1c measurement closest to pre-first insulin prescription was on average suboptimal 
(Mean=85.41, SD=26.27). 
4.4.2. Insulin requiring status   
Forty-one observations were excluded from analysis owing to insulin-requiring occurring on 
or before the original SOUL-D study data collection (baseline), hence 962 observations 
remained. More people had not been insulin-requiring during the follow-up period (n=620) 
than those who had been insulin-requiring (n=341). The overall median time to insulin-
requiring status was 80 months (range 1-125), around 6.67 years.  
A Kaplan-Meier survival estimate curve (figure 4.3) shows a steady increase in insulin-
requiring events up to 110 months where the number of events then remains static.  
4.4.2.1. Survival distribution for insulin-requiring status by depressive symptoms: non-
parametric comparison 
On average, those who had depressive symptoms at baseline required insulin earlier 
(n=140, Mean=68.81 months, SD=32.30) than those who did not have depressive 
symptoms (n=814, Mean=75.09 months, SD=28.28) by about 7 months, figure 4.4. A log-
rank test revealed a statistically significant difference in survival distribution between the 





















4.4.2.2. Survival distribution for insulin-requiring status by diabetes distress: non-parametric 
comparison 
On average, those who had high diabetes distress at baseline required insulin earlier (n=55, 
Mean=67.02 months, SD=32.77) than those with low diabetes distress (n=866, Mean=74.52 
months, SD=28.41) by about 7 months, figure 4.5. A log-rank test revealed there was no 
statistically significant difference in survival distribution between the two groups, χ2(1) = 
1.11, p=0.29.   
4.4.2.3. Survival distribution for insulin-requiring status by negative insulin beliefs: non-
parametric comparison 
On average, those who had high negative insulin beliefs at baseline required insulin earlier 
(n=216, Mean=72.59 months, SD=29.98) than those with low negative insulin beliefs 
(n=663, Mean=74.96 months, SD=28.72) by about 2 months, figure 4.6. A log-rank test 
revealed there was no statistically significant difference in survival distribution between the 
two groups, χ2(1) = 2.23, p=0.14. 
 
Table 4.4- Frequency of starting insulins of SOUL-D participants (n=96) 
Starting insulin treatment 
n (%) 
Intermediate acting insulin 
NPH 47 (49.0) 
Long acting  
Insulin glargine 14 (14.6) 
Insulin determir 4 (4.2) 
Humulin M3 1 (1.0) 
Toujeo 1 (1.0) 
Fast-acting insulin 
Insulin aspart 4 (4.2) 
Soluble insulin 1 (1.0) 
Pre-mixed insulin  
Humalog Mix 50  1 (1.0) 
NovoMx 30 18 (18.8) 
Insulatard 1 (1.0) 
Combination of starting insulin 
Insulin aspart and NovoMx 30 1 (1.0) 
Insulin aspart and NPH 1 (1.0) 
Insulin aspart and insulin glargine 1 (1.0) 
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Figure 4.5- Kaplan-Meier survival distribution for diabetes distress groups for time to insulin requiring 
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Figure 4.6- Kaplan-Meier survival distribution for negative insulin beliefs groups for time to insulin requiring 
status in the SOUL-D cohort 
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4.4.2.4. Testing assumptions for Cox regression  
There was 341 insulin-requiring events, 11 variables were included in the Cox regression 
model: age, sex, ethnicity, depressive symptoms, diabetes distress, insulin beliefs, body 
mass index, macrovascular complication status, microvascular complication status, HbA1c, 
and driving licence status.  
On testing the proportional hazards assumption, microvascular complications (categorical 
variable) was statistically significant (p=0.01) and therefore violates the assumption. All 
other variables were not statistically significant. However, a plot of Schoenfeld residuals 
reveals a nearly horizontal line in the graph indicating there is no violation of the 
proportional hazard’s assumption, figure 4.7. In addition, a log-log plot to test 
proportionality shows the lines in the plot are parallel which indicates this variable does 
not violate the assumption (figure 4.8). Therefore, the microvascular complications variable 
was included in the Cox regression model.  
The deviance residuals were calculated to assess for outliers (more than 3 or less than -3). 
A two-way scatter plot shows there are no outliers, figure 4.9.  
There was no evidence of multicollinearity between baseline psychological variables. Even 
though these variables were all statistically significantly associated with one another (table 
4.5), the regression coefficients were less than 0.80. Therefore, all three psychological 
factors could be included as independent variables in the Cox regression analyses.  
 
Table 4.5-Intercorrelations for the original SOUL-D explanatory psychological variables 
Baseline psychological 
variables 
PHQ-9 PAID BIT 
PHQ-9 1 0.30** 0.06* 
PAID 0.30** 1 0.14** 
BIT 0.06* 0.14** 1 
**. Correlation is significant at the 0.01 level (2-tailed). 









































Test of PH Assumption
Figure 4.8- Log-log plot to test proportional hazards for insulin requiring status  in the SOUL-D cohort 

















4.4.2.5. Cox regression: insulin-requiring status  
Two independent variables made a unique statistically significant contribution to the model 
(age and HbA1c), controlling for all other variables, table 4.6. People with higher HbA1c 
(HR=1.38, 95% CI=1.29-1.47, p<0.001) and younger age (HR=0.97, 95% CI=0.96-0.98, 
p<0.001) at baseline were more likely to be insulin-requiring within the follow-up period.  
4.4.3. Insulin initiation  
Thirty-six observations were excluded from the analysis owing to insulin initiation 
commencing before baseline, hence 967 observations remained. More people had not 
been prescribed insulin during the follow-up period (n=871) than those who had been 
prescribed insulin (n=96). The overall median time to insulin initiation was 89 months 
(IQR=75-103 months), around 7.17 years. 
A Kaplan-Meier survival estimate curve (figure 4.10) shows that after 95 months (7.92 
years) there was a more rapid increase in insulin initiation events, and after around 110 






















-3 -2 -1 0
Linear prediction
Figure 4.9- Deviance residuals plot to assess outliers in Cox regression for insulin requiring status in the SOUL-D cohort 
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Table 4.6- Cox regression for insulin requiring status in SOUL-D cohort 
Baseline  Hazard ratio 
Standard 
error Sig. 
95.0% CI  
Lower Upper 
Age at baseline 0.97 0.01 <0.001 0.96 0.98 
Sex (female) 1.02 0.15 0.87 0.77 1.36 
Ethnicity (non-white) 0.89 0.13 0.44 0.66 1.20 
Depressive symptoms 
(Depressive symptoms) 
1.34 0.24 0.10 0.95 1.91 
Diabetes distress (High) 0.74 0.23 0.33 0.40 1.36 
Negative insulin beliefs (High) 1.17 0.18 0.30 0.87 1.59 
Body mass index 1.00 0.01 0.69 0.98 1.02 
Macrovascular complication 
(present) 
1.00 0.28 0.99 0.59 1.72 
Microvascular complications 
(present) 
1.41 1.16 0.35 0.87 1.50 
HbA1c  1.38 0.04 <0.001 1.29 1.47 
Driving licence (yes) 1.15 0.16 0.30 0.88 1.52 
 
4.4.3.1. Survival distribution for insulin initiation by depressive symptoms: non-parametric 
comparison 
On average, those who had depressive symptoms at baseline initiated insulin earlier 
(n=140, Mean= 83.27 months, SD=23.98) than those who did not have depressive 
symptoms (n=817, Mean=86.34 months, SD=20.88) by about 3 months, figure 4.11. A log-
rank test revealed a statistically significant difference in survival distribution between the 
two groups, χ2(1) = 17.81, p < 0.001.   
4.4.3.2. Survival distribution for insulin initiation by diabetes distress: non-parametric 
comparison 
On average, those who had high diabetes distress at baseline initiated insulin earlier (n=59, 
Mean=77.42 months, SD=26.08) than those with low diabetes distress (n=866, Mean=86.27 
months, SD=20.64) by about 9 months, figure 4.12. A log-rank test revealed a statistically 
significant difference in survival distribution between the two groups, χ2(1) = 8.54, 
p=0.003.   
4.4.3.3. Survival distribution for insulin initiation by negative insulin beliefs: non-parametric 
comparison 
On average, those who had high negative insulin beliefs at baseline initiated insulin earlier 
(n=222, Mean=85.41 months, SD=20.53) than those with low negative insulin beliefs 
(n=659, Mean=86.46 months, SD=21.59) by about 1 month, figure 4.13. A log-rank test 
129 
 
revealed there was no statistically significant difference in survival distribution between the 
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Figure 4.10- A Kaplan-Meier survival estimate curve for time to insulin initiation in the SOUL-D cohort 
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Figure 4.13- Kaplan-Meier survival distribution for negative insulin belief groups for time to insulin 
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4.4.3.4. Testing assumptions for Cox regression 
There were 96 insulin initiation events, hence a maximum of 10 variables were included in 
the Cox regression model: age, sex, ethnicity, depressive symptoms, diabetes distress, 
insulin beliefs, body mass index, macrovascular complication status, microvascular 
complication status, and HbA1c. On testing the proportional hazards assumption, 
depressive symptoms as a categorical variable was statistically significant (p=0.02) and 
violated the proportional hazards assumption, however, depressive symptoms as a 
continuous variable was not statistically significant (p=0.15), hence not violating the 
proportional hazards assumption. Therefore, depressive symptoms as a continuous 
variable does not violate the proportional hazards assumption and was included in the Cox 
regression model. All other variables were not statistically significant and therefore do not 
violate this assumption. Further, a plot of Schoenfeld residuals reveals a nearly horizontal 
line in the graph indicating there is no violation of the proportional hazard’s assumption, 
figure 4.14.   
The deviance residuals were calculated to assess for outliers (> 3 or < -3). A two-way scatter 
plot shows there are no outliers, figure 4.15.  
There was no evidence of multicollinearity between baseline psychological variables. Even 
though these variables were all statistically significantly associated with one another (table 
4.5), the regression coefficients were less than 0.80. Therefore, all three psychological 
variables could be included as independent variables in Cox regression analyses. 
4.4.3.5. Cox regression: insulin initiation 
Four independent variables made a unique statistically significant contribution to the 
model (age, depressive symptoms macrovascular complications, and HbA1c), controlling 
for all other variables, table 4.7. People who had a macrovascular complication at baseline 
were 2.4 times more likely to initiate insulin within the follow-up period (HR=2.40, 95% 
CI=1.13-5.08, p=0.02) than those without macrovascular complications. People with higher 
depressive symptom scores (HR=1.06, 95% CI=1.02-1.10, p=0.005), higher HbA1c (HR=1.26, 
95% CI=1.11-1.42, p<0.001) and younger age (HR=0.96, 95% CI=0.93-0.98, p<0.001) at 
baseline were more likely to initiate insulin within the follow-up period.  
4.4.4. Time from insulin-requiring to insulin initiation  
The mean time from being insulin-requiring to starting insulin (n=55) was 31.22 months 






































































Test of PH Assumption


























Table 4.7- Cox regression for insulin initiation in the SOUL-D cohort 
Baseline variables Hazard ratio 
Standard 
error Sig. 
95.0% CI  
Lower Upper 
Age at baseline 0.96 0.01 <0.001 0.93 0.98 
Sex (female) 1.25 0.33 0.40 0.75 2.11 
Ethnicity (non-white) 0.71 0.19 0.21 0.42 1.21 
Depressive symptoms 
(continuous)  
1.061 0.56 0.005 1.02 1.10 
Diabetes distress (High) 1.23 0.54 0.64 0.52 2.90 
Negative insulin beliefs (High) 1.35 0.38 0.28 0.78 2.34 
Body mass index 0.96 0.02 0.06 0.92 1.00 
Macrovascular complication 
(present) 
2.40 0.92 0.02 1.13 5.08 
Microvascular complications 
(present) 
1.00 0.26 0.99 0.61 1.66 
HbA1c  1.26 0.08 <0.001 1.11 1.42 
 
4.5. Discussion 
This was a prospective cohort study of an 8-year follow-up of an incident cohort of people 
with type 2 diabetes (n=1735), the SOUL-D cohort. For this study n=1003 were followed up 
from September 2017-January 2019 in terms of accessing their medical records. Three 
hundred and forty-one (34.0%) people with type 2 diabetes became insulin-requiring 
during the follow-up period. Ninety-six people (9.6%) were prescribed insulin within the 
follow-up period. 
4.5.1. Summary of findings: time to insulin-requiring status 
The median time to insulin-requiring status in this cohort was around 6.5 years from type 2 
diabetes diagnosis. Psychological factors (depressive symptoms, diabetes distress or insulin 
beliefs) measured at type 2 diabetes diagnosis were not associated with time to insulin-
requiring status after adjusting for confounding variables (age, sex, ethnicity, body mass 
index, HbA1c, microvascular complications, macrovascular complications, driving license 
status). Factors associated with shorter time to insulin-requiring status (after adjusting for 
confounding) were higher HbA1c and younger age.  
4.5.2. Summary of findings: time to insulin initiation  
The median time to starting insulin therapy from type 2 diabetes diagnosis was around 7 
years. This research was novel in exploring an 8-year prospective relationship between 
psychological factors (depressive symptoms, diabetes distress, and insulin beliefs) and time 
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to insulin initiation. People with higher depressive symptom scores at type 2 diabetes 
diagnosis had a statistically significantly shorter time to insulin initiation than those with 
lower depressive symptoms, this association remained after adjusting for confounding 
variables  (age, sex, ethnicity, body mass index, HbA1c, microvascular complications, 
macrovascular complications, driving license status). Diabetes distress and negative insulin 
beliefs at type 2 diabetes diagnosis were not associated with time to insulin initiation after 
adjusting for other confounding variables. Other factors that were associated with shorter 
time to insulin initiation (after adjusting for confounding) included: the presence of 
macrovascular complications, higher HbA1c, and younger age.  
4.5.3. Comparison to the literature 
4.5.3.1. Insulin delay 
Previous research has reported a delay of up to 5 years in starting insulin (Khunti, Damci, et 
al., 2012) which is longer than this 8-year follow-up SOUL-D study reporting 2.5 years 
between insulin-requiring status and insulin initiation.  
4.5.3.2. Depressive symptoms  
In an adjusted analysis, depressive symptoms were not associated with insulin-requiring 
status. However, in an unadjusted analysis, depressive symptoms were associated with 
insulin-requiring status. An explanation for this could be the baseline age or HbA1c 
mediates this relationship. Therefore, there is not a direct relationship between depressive 
symptoms at type 2 diabetes diagnosis and time to insulin-requiring status, more that 
depressive symptoms are associated with younger age or higher HbA1c which is associated 
with insulin-requiring status. Mediation analyses were not conducted in this thesis chapter.  
The 8-year follow-up SOUL-D findings of an association between depressive symptoms and 
time to insulin initiation are contrary to previous evidence from two studies that found 
depressive symptoms were not associated with time to insulin initiation (Iversen et al., 
2015; Nefs et al., 2013). Findings of this thesis study are based on PHQ-9 depressive 
symptom scores, however, Iversen et al., 2015 measured depressive symptoms via the 
Hospital Anxiety and Depression Scale (HADS; (Spinhoven et al., 1997)) and Nefs et al., 2013 
used the Edinburgh Depression Scale (EDS; (Cox, Holden, & Sagovsky, 1987)). Previous 
research has indicated both HADs and PHQ-9 are both reliable and valid measures of 
depressive symptoms, however, the PHQ-9 identifies significantly more people with 
moderate or severe depression than the HADs scale (Cameron, Crawford, Lawton, & Reid, 
2008). This may have contributed to the finding of an association between depressive 
symptoms and time to insulin initiation in this thesis study. The PHQ-9 is sensitive to 
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determining depressive symptoms as it has previously been validated against diagnostic 
interviews within the SOUL-D cohort (Twist et al., 2013).  However, in this cohort, baseline 
depressive symptoms were associated with baseline and 2-year follow-up macrovascular 
complications (Ismail et al., 2017) which indicates the need to initiate insulin sooner. This is 
further supported by this 8-year follow-up SOUL-D analysis which found macrovascular 
complications were associated with shorter time to insulin initiation.  
4.5.3.3. Diabetes distress 
In this study, there was no association between diabetes distress and time to insulin-
requiring status or insulin initiation. This is contrary to what would be expected as previous 
longitudinal and cross-sectional research links diabetes distress to suboptimal glycemic 
levels (Aikens, 2012; Gonzalez et al., 2015; Hayashino et al., 2012; Tsujii et al., 2012; 
Winchester et al., 2016). However, as depressive symptoms were associated with insulin 
initiation and diabetes distress was not associated with insulin initiation in the SOUL-D 
cohort, this supports previous evidence which found diabetes distress and depressive 
symptoms are separate constructs (Fisher et al., 2007; Gonzalez, Delahanty, Safren, Meigs, 
& Grant, 2008; Schmitt et al., 2014).  
4.5.3.4. Negative insulin beliefs 
There was no association between negative insulin beliefs at baseline and insulin-requiring 
status or insulin initiation. The BIT questionnaire is a validated measure of insulin beliefs 
(Petrak et al., 2007). However, other measures of insulin beliefs have been used in this 
field, for example, the Insulin Treatment Appraisal Scale (ITAS) (Snoek et al., 2007). 
Previous research has found that fewer negative insulin appraisals (measured using ITAS) 
were associated with willingness to start insulin therapy (Holmes-Truscott, Blackberry, 
O’Neal, Furler, & Speight, 2016), however, this was a cross-sectional study and measured 
behavioral attitudes as opposed to behavior (initiating insulin). Other research found an 
association between negative insulin beliefs and delay to insulin initiation, again this study 
used ITAS (Hessler et al., 2018), which could account for different findings in this thesis 
chapter.  
4.5.3.5. Age  
Elderly people with type 2 diabetes are often given higher glycemic targets due to the 
increased risk of hypoglycemia which can be associated with cognitive impairment, 
accidents, and hospital admissions (Sinclair, Abdelhafiz, Forbes, & Munshi, 2019; Sinclair et 
al., 2012). In addition, some elderly people may have a functional limitation which means 
they are unable to self-administer insulin (Yakaryılmaz & Öztürk, 2017). These factors 
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contribute to elderly people with type 2 diabetes being less likely to be prescribed insulin 
therapy, which is consistent with findings of younger age being associated with shorter 
time to insulin initiation in this thesis chapter. In addition, it was found younger age was 
associated with insulin-requiring status. This falls in line with previous research that people 
diagnosed in older age have better glycemic levels than those diagnosed at a younger age 
(Benoit, Fleming, Philis-Tsimikas, & Ji, 2005; Huang, 2016), therefore if younger people 
have higher glycemic levels then they could require insulin sooner.  
4.5.3.6. HbA1c 
NICE guidelines recommend starting insulin when despite dual OAD therapy, HbA1c is 
above 58mmol/mol (NICE, 2009), to prevent long-term diabetes complications. The 
findings of this thesis chapter appear to suggest that NICE guidance is followed as those 
with higher HbA1c at type 2 diabetes diagnosis initiated insulin sooner. However, in In this 
cohort the average pre-insulin initiation HbA1c was above 58 mmol/mol (Mean=85.41, 
SD=26.27), which falls in line with other research which found despite clinical need people 
delay insulin initiation (Khunti, Damci, et al., 2012; Rubino et al., 2007; Zografou et al., 
2014).  
4.5.4. Strengths and limitations 
A limitation of cohort design is the observational nature, therefore causation cannot be 
inferred, only association, as it is not possible to control for all factors that relate to the 
outcome. However, observational research can inform future clinical trials where causation 
can be determined. The strength of a prospective cohort design is that it allows for an 
estimation of time to an event eliminating the risk of recall bias, and it is possible to 
estimate the population at risk of an outcome. 
It is important to follow up as many participants as possible from baseline to reduce the 
risk of biased results, as the reason for the loss of participants might be related to the 
exposure or outcome. Not all participants from the original SOUL-D cohort were followed-
up in this 8-year follow-up SOUL-D study, and bias may have been introduced in the 
selection of participants followed up from certain surgeries or only following up those who 
still reside in south London. There were no statistically significant differences in baseline 
characteristics between the original SOUL-D sample (n=1735) and the 8-year follow-up 
SOUL-D sample (n=1003) analysed in this report indicting bias was minimised. In addition, 
this 8-year follow-up SOUL-D sample was powered, the sample size estimation was n=624 
(80% power, 0.05 alpha level), this study followed-up up n=1003.  
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The point at which a person was insulin-requiring might not be the exact point as it was 
based on the available HbA1c values from the participants’ medical record. For example, 
for some, it could have been 6 months since the last HbA1c test and therefore they could 
have been requiring at any point over that time. This means the true time to insulin-
requiring status could not be determined. The definition of insulin-requiring for this 
analysis was according to NICE guidelines (2 OADs plus HbA1c >58mmol/mol), however, 
NICE guidelines also recommend setting individualised targets based on other factors such 
as comorbidities, personal preferences etc. This might account for why a proportion of 
people were coded as ‘insulin-requiring’ (according to this definition) but did not initiate 
insulin.  
In this 8-year follow-up SOUL-D study, the date of insulin initiation was defined as the date 
of first insulin prescription, however, this might not be the true point of insulin initiation. 
For example, insulin might not have been initiated exactly on that date of the first insulin 
prescription or initiated at all. Additional information from the participant could confirm 
whether this was true i.e. asking the participants whether they did start insulin on that date 
or at all, however, this would rely on retrospective memory which may be inaccurate (i.e. 
recall bias). Therefore, the date of first insulin prescription was the best prospective 
measure of insulin initiation. 
This thesis chapter analysis did not examine adherence or persistence to insulin therapy, 
without data on adherence, it cannot be determined whether participants prescribed 
insulin went on to administer insulin. Previous research on OAD adherence suggests that 
more than 50% of people do not take their medication (Donnan, MacDonald, & Morris, 
2002). Therefore, when glycaemic targets are not being met (because of this poor 
treatment adherence) health care professionals might unnecessarily intensify their 
treatment (Rozenfeld, Hunt, Plauschinat, & Wong, 2008). If this translates to intensifying to 
insulin therapy, then this could lead to problems with adhering to this therapy.  Future 
research with type 2 diabetes cohorts could compare prescription databases with medical 
records to help identify adherence issues with insulin therapy. Future research on this 
cohort could also ascertain whether people with type 2 diabetes and comorbid depressive 
symptoms are more likely to discontinue insulin therapy. Previous research found that 
people with type 2 diabetes and depressive symptoms are more likely to discontinue 
insulin within 90 days of initiation (Ascher-Svanum et al., 2014), the SOUL-D cohort has the 
potential to analyse discontinuation beyond 90 days. 
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In this thesis chapter analysis, baseline depressive symptoms are only considered and there 
is no measurement of depressive symptoms at the point of insulin-requiring status or 
insulin initiation. However, research indicates depressive symptoms are persistent over 
time in people with type 2 diabetes (De Groot et al., 2010). Therefore, people with 
depressive symptoms at type 2 diagnosis are likely to have depressive symptoms upon 
insulin initiation as a result depressive symptoms should be considered when supporting 
people with type 2 diabetes initiating insulin.   
4.5.5. Implications and future research   
Depressive symptoms were the only psychological factor that was associated with shorter 
time to insulin initiation. Younger age and higher HbA1c predicted shorter time to insulin-
requiring status and insulin initiation. These, therefore, are 2 good reasons to intervene 
early with insulin to prevent unnecessary damage from hyperglycemia especially for 
younger people who will live with type 2 diabetes for a long-time, increasing the risk of 
diabetes complications within their lifetime.  
This thesis study, an 8-year follow-up of the SOUL-D cohort, may help to inform future 
research looking into whether psychological interventions that target depressive symptoms 
are effective in improving insulin self-management and glycemic control. Other research 
should consider whether those who started insulin continued with the therapy, to 
determine persistence and discontinuation. For people who discontinue insulin therapy, it 
would be interesting to examine the reasons why, for example, had their glycemic control 
improved or worsening psychological functioning. Participants from the SOUL-D cohort 
could be seen for further data collection to determine whether depressive symptoms, 
diabetes distress, or negative insulin beliefs reduce after insulin initiation by re-
administering these psychological measures.  
4.6. Chapter summary  
This chapter reports on study 3 of this thesis which demonstrated that depressive 
symptoms were associated with insulin initiation. Depressive symptoms are potentially 
modifiable using treatments such as psychological interventions. The next 2 chapters, 
chapter 5 and chapter 6 report on the development of the DIME intervention. Based on 
findings from this chapter, the DIME intervention incorporates techniques to support 
people with depressive symptoms who may have difficulties managing their thoughts and 
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5.1. Chapter scope 
This chapter describes part of study 4 of this thesis in developing the DIME intervention. In 
this chapter, previous research (chapter 1) and thesis studies 1-3 (chapters 2-4), outlined in 
table 5.1, inform the behaviour change wheel to identify relevant behaviour change 
techniques for the DIME intervention. The DIME intervention was designed to build on the 
content from an existing insulin start group in south London (described in chapter 3).  
Table 5.1- Relevance of previous thesis chapters in the development of DIME 
Thesis chapter Relevance to DIME development 
Chapter 1: Thesis introduction.  Outlines problems associated with insulin treatment in type 2 
diabetes. 
Chapter 2: A systematic review and meta-
analysis of psychological interventions to 
improve HbA1c in type 2 diabetes. 
Outlines the types of psychological techniques and behaviour change 
technique categories which are effective in improving HbA1c in type 
2 diabetes.  
Chapter 3: Perspectives of group insulin 
education for people with type 2 diabetes. 
Outlines the want and need for group insulin self-management 
education for those initiating insulin, in addition, the need for 
psychological support to address fears and concerns around insulin. 
Chapter 4: Prospective study of the 
association between psychological status 
at type 2 diabetes diagnosis and insulin 
initiation.  
Found an association between depressive symptoms and insulin 
initiation, demonstrating a need to provide additional support for 
people with depressive symptoms starting insulin therapy.  
 
5.2. Introduction   
The Behaviour Change Wheel is an integrated framework of 19 behaviour change 
frameworks (figure 5.1). The COM-B model (described in chapter 2) is the centre of the 
Behaviour Change Wheel and suggests that capability, opportunity, and motivation can 
influence behaviour (Michie et al., 2011).  The middle and outer rings of the Behaviour 
Change Wheel represent intervention functions and policy categories respectively (figure 
5.1) which link to the COM-B model. There are 9 intervention functions: training, 
education, environmental restructuring, enablement, modelling, persuasion, 
incentivisation, coercion, and restriction. Definitions of the intervention functions are 
provided in appendix 5.1. There are 7 policy categories which are defined in appendix 5.2: 
communication/marketing, guidelines, fiscal measures, regulation, legislation, 
environmental/social planning, service provision.  
Identifying the components of the Behaviour Change Wheel in the context of a target 
behaviour(s), results in an intervention strategy outlining specific behaviour change 
techniques through which an intervention can be implemented. Behaviour change 
techniques can form the foundation of intervention design. The behaviour change wheel 
has been used in type 2 diabetes research to design interventions. For example, a self-
management intervention for UK African and Caribbean communities with type 2 diabetes 
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(Moore, Rivas, Stanton-Fay, Harding, & Goff, 2019), and a complex intervention to improve 
medication intensification in type 2 diabetes for general practitioners (Murphy et al., 2017). 
One of these studies has planned feasibility work (Moore et al., 2019), the other study has 
a published protocol of proposed feasibility testing (Murphy et al., 2018). Another study 
used the behaviour change wheel to design a group intervention to prevent an infectious 
disease (melioidosis) in people with type 2 diabetes (Suntornsut et al., 2016). This study 
was tested for feasibility on 70 people with type 2 diabetes (non-randomised) (Suntornsut 
et al., 2018). Follow-up observations, questionnaires and one-to-one interviews found the 
behaviour to prevent the infection improved, in addition, the intervention was acceptable 
to participants.   
The behaviour change wheel has not yet been utilised to design a psychological 
intervention to optimise insulin initiation in type 2 diabetes. The aim of study 4 of this 
thesis was to develop a nurse-led group psychological intervention (DIME) to optimise 
insulin initiation for people with type 2 diabetes.  
5.3. Behaviour Change Wheel in DIME development  
The three stages of the Behaviour Change Wheel to designing interventions are: 1) 
understanding the target behaviour; 2) identifying intervention functions; and 3) identifying 
content and implementation options. Each stage is built on several steps, figure 5.2. These 
stages are outlined in the remainder of this chapter.  
5.3.1 Stage 1: Understand the behaviour 
Stage 1 involved understanding the behaviour which was to be intervened. This was 
achieved through 4 steps: define the problem in behavioural terms; select target 
behaviour; specify the target behaviour; and identify what needs to change.  
5.3.1.1. Define the problem in behavioural terms 
The first step of intervention design was to define the problem in behavioural terms which 
involved specifying the precise population and behaviour of interest.  
The target behaviour for the DIME intervention group was ‘improving insulin self-
management’ for people with type 2 diabetes. This behaviour generally occurs within 
primary care, general practitioners and community diabetes specialist nurses are usually 













Figure 5.1- The behaviour change wheel (Michie, van Stralen, & West, 2011) 
Stage 1: Understanding the 
target behaviour
• Define the problem in 
behavioural terms
• Select target behaviour
• Specify the target 
behaviour
• Identify what needs to 
change
Stage 2: Identifying 
intervention functions
• Identify intervention 
functions
• Identify policy categories 
Stage 3: Identifying content 
and implementation options
• Identify behaviour change 
techniques
• Identify mode of delivery
Figure 5.2- Stages of the Behaviour Change Wheel 
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5.3.1.2. Select target behaviour 
Improving insulin self-management encompasses several behaviours. To help select a more 
specific target behaviour, a list of potential behaviours was generated:  
• Injecting insulin  
• Treatment of hypoglycaemia  
• Insulin dose titration  
• Storing and travelling with insulin  
• Blood glucose checking  
• Physical activity  
• Carbohydrate awareness  
The next step in this stage of the Behaviour Change Wheel was to prioritise the behaviours 
and evaluate them based on how promising they were in the following domains: impact of 
behaviour change; the likelihood of changing the behaviour; the likelihood of the behaviour 
impacting other behaviours (spill over effect); and how easy it is to measure the behaviour.  
‘Less is more’ is often relevant in intervention design, to concentrate on a few behaviours 
in-depth rather than spend less time intervening several behaviours. However, it is 
important to consider that target behaviours are often surrounded by multiple other 
behaviours (Presseau, Tait, Johnston, Francis, & Sniehotta, 2013). Owing to the nature of 
insulin education, it is essential to intervene towards all the above listed behaviours to 
ensure the safe delivery of insulin therapy to best avoid hypoglycaemia and 
hyperglycaemia. Behaviours which are not addressed in current insulin start group in south 
London include physical activity and diet (i.e. carbohydrate awareness) relating to insulin 
self-management. These were expressed as important to insulin education by participants 
who took part in interviews in chapter 3 (study 2). ‘Improving insulin self-management’ was 
agreed as a target behaviour, as previously stated, which encompasses all the above 
behaviours.  
5.3.1.3. Specify the target behaviour 
The focus now was to specify the target behaviour (table 5.2). Similarly, David French and 
colleagues suggest the initial mechanisms of an intervention can be defined by outlining: 
“who needs to do what differently, when, where, how?” (French et al., 2012).  
In the previous step, the target behaviour was identified: improving insulin self-
management. Diabetes specialist nurses need to deliver the intervention owing to their 
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specialist knowledge in diabetes and insulin, diabetes specialist nurses also currently 
deliver the current insulin start groups in south London (who). The DIME intervention  
Table 5.2-Specifying the target behaviour for DIME intervention 
Describe the target behaviour according to who needs to do what, when, how often and with whom 
Target behaviour:  Improving insulin self-management   
Who needs to perform the behaviour? Diabetes specialist nurses  
What do they need to do differently to 
achieve the desired change? 
Group insulin education underpinned by psychological 
techniques 
When do they need to do it? Within 1 month of insulin prescription  
Where do they need to do it? Local venue (general practice, hospital, community venue) 
How often do they need to do it? 3 sessions  
With whom do they need to do it? people with type 2 diabetes   
 
needs to differ from the current insulin start group in south London by offering additional 
psychological support to address concerns around insulin therapy (what). The behaviour 
needs to be targeted within 1 month of insulin prescription (when). Interviews from 
chapter 3 revealed some people with type 2 diabetes were negatively affected by the 
varying knowledge base of the group in relation to insulin, if people enter the group around 
the same time i.e. all new to insulin, then this aims to reduce this negative view. However, 
psychological training to best manage group dynamics should also address this problem. 
The intervention should be delivered at a convenient location for the people with type 2 
diabetes to access, this should be their local general practice, hospital, or local community 
venue within the borough (where).  The current insulin start group is 2 sessions, and DIME 
was designed with 3 sessions to allow the addition of relevant educational content and 
adopting psychological delivery techniques (how often). The intervention is for people with 
type 2 diabetes new to insulin injection therapy (with whom).  
5.3.1.4. Identify what needs to change  
Evidence from chapters 1-4 informed what needed to change, and which COM-B 
components were relevant, outlined in table 5.3.  Chapter 1 (introduction chapter) relayed 
the psychological problems associated with insulin initiation and continued self-
management including psychological insulin resistance, and how treatment beliefs or 
treatment burden are associated with insulin adherence or persistence. Aspects of the 
COM-B model could change to address these psychological problems. For example, 
increasing knowledge and skill (psychological and physical capability) around administering 
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insulin and its regimen, insulin efficacy, and side effects including hypoglycaemia (how to 
prevent and treat) and weight gain, could help alleviate emotional (e.g. fears) and cognitive 
(e.g. misconceptions) psychological insulin resistance as well as reduce treatment burden 
or negative insulin beliefs to promote insulin adherence and persistence. The opportunity 
for social interaction (social opportunity) in a group setting would allow for shared social 
norms and could help address social psychological insulin resistance. Chapter 1 also 
provided evidence from previous literature supporting the need for knowing how to inject 
(capability) (Polonsky et al., 2019), overcoming psychological insulin resistance (capability) 
(Ng et al., 2015), remembering to inject (capability) (Brod, Pohlman, et al., 2014), self-
monitoring blood glucose (capability) (Jenkins et al., 2010), action plans (capability) 
(Dellasega et al., 2012), social support (opportunity) (Bogatean & Hâncu, 2004a), and 
HbA1c related to reducing complications (motivation) (Jenkins et al., 2010). Chapter 2 
(study 1) found the most frequently used behaviour change categories associated with 
improvement in glycaemic control were ‘social support’(opportunity), ‘goals and planning’ 
(capability; motivation), and ‘feedback and monitoring’ (capability). In chapter 3 (study 2) 
themes generated in the qualitative analysis were linked to COM-B components, for 
example, ‘Ongoing self-management success (theme 3.1) links to capability; ‘Need for more 
peer support’ (theme 3.2) links to opportunity, and ‘insulin concerns post-group’ (theme 
3.3) links to motivation. Chapter 4 (study 3) provided evidence that depressive symptoms 
are associated with insulin initiation (motivation).  On review of all this evidence, all COM-B 
domains were identified as needing to change (capability, opportunity, and motivation) for 
insulin self-management to improve.  
5.3.2. Stage 2: Identify intervention functions 
A ‘behavioural diagnosis’ at stage 1 identified what needs to change (all COM-B domains) 
to improve insulin self-management. Stage 2 of the Behaviour Change Wheel involved 
linking the behavioural diagnosis with intervention functions, in addition to identifying 
which policy categories the intervention can be implemented through.  
5.3.2.1. Identify intervention functions  
The COM-B components link to the intervention functions shown in table 5.4 (Michie et al., 
2014) and figure 5.1. Intervention functions are defined in appendix 5.1.  
The next step was to determine which intervention functions were appropriate for 
intervention development as evaluated by the APEASE (Affordability, Practicability, 
Effectiveness and cost-effectiveness, Acceptability, Side effects and safety, Equity) criteria. 
Full definitions of the APEASE criteria are provided in appendix 5.3. The intervention 
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functions which met all APEASE criteria (table 5.5) and were identified for DIME 
development were: education (e.g. educating people with type 2 diabetes about diabetes 
and insulin self-management), persuasion (e.g. persuading people with type 2 diabetes that 
insulin therapy is the best treatment to improve HbA1c and prevent long term 
complications), training (e.g. training people with type 2 diabetes on how to inject insulin 
and to check blood glucose), environmental restructuring (e.g. relating to access to 
education group, for example, location and time of sessions), modelling (e.g. demonstrate 
how to use a needle), and enablement (e.g. goal setting and reviewing goals). 
The three intervention functions which did not meet APEASE criteria were: incentivisation, 
coercion, and restriction. It was evaluated as not affordable to incentivise people to 
manage with insulin therapy, it was not acceptable to coerce people into using insulin 











Table 5.3- Identifying what needs to change according to COM-B for DIME intervention 
COM-B 
component 




Know how to inject insulin. Chapter 1, 3 
Psychological 
capability 
Know more about insulin and why it is important. Chapter 1& 3 
Overcome mental obstacles e.g. reduce unwanted feelings towards insulin such 
as fear of injections. 
Chapter 1& 3 
Remembering to inject. Chapter 1&3 
Self-monitoring blood glucose.  
Action plans for improving management with insulin.  
Chapter 1, 2 &3 
Physical 
opportunity  
Insulin education accessibility.  
Have more time for injections. 
Making sure insulin is available when needed e.g. transporting insulin.  




Social support from healthcare professionals, family, friends, and other people 
with diabetes to manage with insulin.  
Have more people around them injecting insulin.  
Chapter 1, 2& 3 
Reflective 
motivation  
Explore cultural beliefs towards diabetes.  Chapter 3 
Having confidence to inject.  Chapter 3 
Believe that insulin will improve HbA1c/symptoms or prevent complications.  Chapter 1& 3 
Believe that insulin with reduce blood glucose and prevent complications. Chapter 1& 3 
Explore intentions in continuing to self-manage with insulin therapy.  Chapter 3 
Goal setting in relation to managing with insulin therapy. Chapter 2& 3 
Automatic 
motivation 
Understanding the benefits in continuing insulin therapy.  Chapter 3 
Reduce fears and negative emotions towards insulin therapy. 
Reduce depressive symptoms which may impact insulin self-management.   






Table 5.4- How intervention functions link to COM-B 
COM-B Intervention functions  
Physical capability Training 
Psychological capability Education, Environmental, Restructuring, Enablement, Training, 
Modelling 
Physical opportunity Training, Restriction, Environmental restructuring, Enablement 
Social opportunity Restriction, Environmental restructuring, Modelling, Enablement 
Reflective motivation  Education, Persuasion, Modelling, Enablement, Incentivisation, 
Coercion  
Automatic motivation  Training, Incentivisation, Coercion, Environmental restructuring  





Table 5.5- APEASE assessment of intervention functions for DIME 
Intervention functions Does the intervention function meet the APEASE criteria in the context of 
improving uptake of continuing insulin therapy? 
Education Yes 
Persuasion Yes 
Incentivisation  No (Not affordable) 
Coercion No (Not acceptable) 
Training Yes 














5.3.2.2. Identify policy categories  
The intervention functions, as described in the previous step, link to policy categories (table 
5.6). The idea of the DIME intervention was to replace an existing insulin start group in 
south London, hence DIME lends itself towards the following policy categories: service 
provision; communication and marketing; environmental and social planning. The 
intervention is a service provision as it is delivering a service within primary care. The 
communication and marketing category refer to printed materials for people with type 2 
diabetes to take home following the insulin group. The environmental and social planning 
category refers to the location the group is held for ease of access. This is important as 
evidence suggests the inconvenient location is a barrier to attending group-based type 2 
diabetes education (Coates, Slevin, Carey, Slater, & Davies, 2018; Horigan, Davies, Findlay‐
White, Chaney, & Coates, 2017; McSharry, McGowan, Farmer, & French, 2016; Winkley et 
al., 2015; Winkley et al., 2018). According to APEASE criteria assessment, the other policy 
categories were either not practical, acceptable or affordable (table 5.6). Guidelines for 
what to include in insulin education for people starting insulin treatment already exist 
(NICE, 2017).  
5.3.3. Stage 3: Identify content and implementation options  
Stage 3 of the Behaviour Change Wheel involved identifying content and implementation 
options. This was achieved with 2 steps outlined below: identify behaviour change 
techniques; and identify the mode of delivery.  
5.3.3.1. Identify behaviour change techniques  
At this stage intervention functions and associated COM-B components were linked to 
most commonly used behaviour change techniques (Michie et al., 2014), table 5.7. These 
behaviour change techniques were evaluated using the APEASE criteria. Any additional 
relevant behaviour change techniques were also listed in table 5.7. Specific behaviour 
change technique examples relating to DIME are provided in the draft intervention strategy 
in table 5.9. Behaviour change techniques categories which were identified in the meta-
analysis from chapter 2 of this thesis (study 1), ‘social support’, ‘goals and planning’ and 
‘feedback and monitoring’, were also included in the additional relevant behaviour change 
technique column of table 5.7 if not already stated. The behaviour change technique ‘Social 
support (unspecified)’ includes both motivational interviewing and cognitive behavioural 
therapy, of which both techniques were also used in the development of DIME (see chapter 
6 for more information). Examples of additional relevant behaviour change techniques 
which correspond with the ‘feedback and monitoring’ category include: ‘biofeedback’ and 
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‘self-monitoring of outcome of behaviour’. There were no additional relevant behaviour 
change techniques which correspond with the ‘goals and planning’ category as these were 
already included in the ‘most commonly used behaviour change techniques’ column 
including: ‘goal setting (behaviour)’, ‘goal setting (outcome)’, ‘problem-solving’, ‘action 
planning’, ‘review behaviour goals’, and ‘review outcome goals’. 
 
Table 5.6- Identifying policy categories for DIME 
Intervention 
function  
Policy categories  Does the policy category meet the APEASE criteria?  
Education Communication/marketing Yes 
Guidelines Guidelines already exist for initiating insulin therapy 
Regulation Not practical  
Legislation  Not acceptable  
Service provision Yes 
Persuasion Communication/marketing Yes 
Guidelines Guidelines already exist for initiating insulin therapy 
Regulation Not practical 
Legislation  Not acceptable 
Service provision Yes 
Training Guidelines  Guidelines already exist for initiating insulin therapy 
Fiscal measures Not affordable 
Regulation Not practical 
Legislation  Not acceptable 
Service provision Yes 
Restructuring Guidelines  Guidelines already exist for initiating insulin therapy 
Fiscal measures  Not affordable  
Regulation  Not practical 
Legislation  Not acceptable 
Environmental/social 
planning 
Yes (in context of accessibility to education) 
Modelling Communication/marketing  Yes 
Service provision Yes 
Enablement Guidelines Guidelines already exist for initiating insulin therapy 
Fiscal measures  Not affordable 
Regulation  Not practical 




Service provision Yes 











Most commonly used behaviour change techniques   Does the behaviour change 
technique meet the APEASE 
criteria? 
Additional relevant behaviour change techniques  






Information about social and environmental consequences  Not relevant in this context • Biofeedback 
• Self-monitoring of outcome of behaviour 
• Information about emotional consequences 
• Information about others’ approval  
 
Information about health consequences Yes 
Feedback on behaviour Yes  
Feedback on outcome(s) of the behaviour Yes 
Prompts/cues Yes 
Self-monitoring of behaviour  Yes 






Credible source Yes  • Biofeedback 
• Focus on past success 
• Verbal persuasion about capability  
• Information about emotional consequences 
• Information about others’ approval 
• Social comparison 
Information about social and environmental consequences Not relevant in this context 
Information about health consequences Yes 
Feedback on behaviour Yes 







Demonstration of the behaviour Yes • Biofeedback 
• Self-monitoring of outcomes of behaviour 
• Habit formation 
 
Instruction on how to perform a behaviour Yes 
Feedback on the behaviour Yes 
Feedback on the outcome(s) of the behaviour Yes 
Self-monitoring of behaviour Yes 






Restructuring  Physical 
opportunity 
 
Adding objects to environment Not relevant in this context  
Prompts/cues Yes  









Demonstration of the behaviour Yes  








Social support (unspecified) Yes  
Social support (practical) Yes 
Goal setting (behaviour) Yes 
Goal setting (outcome) Yes  
Adding objects to the environment  Not relevant in this context 
Problem solving Yes 
Action planning Yes 
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 Self-monitoring of the behaviour Yes 
Restructuring the physical environment  Not relevant in this context 
Review behaviour goals Yes 




5.3.3.2. Identify mode of delivery 
There are two main modes of delivery: face-to-face, and distance which are categorised 
further in table 5.8. The three modes of delivery which met APEASE criteria were: face-to-
face (group), print media (leaflet), and phone (phone helpline). At least 3 telephone follow-
up calls would be delivered over DIME duration to check on progress as this is the current 
level of care for people with type 2 diabetes starting insulin. Individual face-to-face was 
rated as not cost-effective. Modes of delivery which were rated as not affordable were 
broadcast media, outdoor media, newspaper, digital media, and individually accessed 
computer programme. Mobile phone text was rated as not practical and not safe. 
Telephone calls were evaluated as more appropriate to check in on people with type 2 
diabetes starting insulin and answer any queries or concerns. Individually accessed 
computer programmes were rated as not practical.  
5.4. Behaviour Change Wheel draft DIME intervention strategy 
Table 5.9 outlines a draft DIME intervention strategy based on all the components of the 
Behaviour Change Wheel (relevant intervention functions, policy categories, COM-B 
components). Twenty-seven behaviour change techniques were identified to deliver the 
















Table 5.8- Identifying mode of delivery for DIME 
Mode of delivery Does mode of delivery meet the APEASE 
criteria? 
Face-to-face Individual Not cost-effective 
Group Yes 
Distance Population-level Broadcast 
media 
TV Not affordable 
Radio Not affordable 
Outdoor 
media 
Billboard Not affordable 
Poster Not affordable 








Individual level Phone Phone helpline Yes  
Mobile phone 
text 
Not practical, potential safety concerns 
Individually accessed 
computer programme  







Table 5.9- Draft DIME intervention strategy based on behaviour change wheel 
Policy categories Intervention function COM-B  Behaviour change techniques 
[BCTTv1 code] 
Intervention strategy – examples within context 
Communication/marketing 
• Educational materials 
to support group.  
Service provision 
• Service to be provided 
in primary care. 
Environmental/social planning 
• Accessibility to 
education. 
Education 





• Persuading that 
insulin injections 
lead to positive 
consequences. 
Training 
• On injecting insulin 
and self-monitoring 
of blood glucose.  
Restructuring 
• Time and location of 
group for easy 
access 
Modelling 
• Modelling insulin 
injection behaviour 
Enablement  




• Know more about insulin and why 
it is important  
• Overcome mental obstacles e.g. 
reduce unwanted feelings 
towards insulin such as fear of 
injections 
Physical capability  
• Know more about how to deliver 
insulin 
Physical opportunity 
• Access to insulin education  
Social opportunity 
• Have more people around them 
doing it  
• Have social support from others 
Reflective motivation 
• Believe it would be a good thing 
to do  
• Develop better plans for doing it 
• Develop routines and habit of 
doing it 
Automatic motivation 
• Feel you want to do it enough  
• Feel you need to do it enough 
1. Goal setting (behaviour) [1.1] 
2. Problem solving [1.2] 
 
 
3. Goal setting (outcome) [1.3] 
4. Action planning [1.4] 
 
 
5. Review of behaviour goal(s) 
[1.5] 




7. Feedback on the behaviour [2.2] 
8. Self-monitoring of behaviour 
[2.3] 
9. Self-monitoring of outcome of 
behaviour [2.4] 
10. Biofeedback [2.6]  
 




1. Set goal of checking blood glucose every morning and 
taking insulin every day. 
2. Prompt group to identify barriers to insulin treatment 
and discuss strategies for overcoming them.  
3. Set morning blood glucose goal as an outcome for 
titrating insulin to correct dose.  
4. Encourage a plan to carry hypo treatment when going 
out. Encourage a plan to inject insulin in same context 
every day.  
5. Review behaviour goals of previous sessions and 
address any issues, adjust accordingly.  
6. Examine how much morning blood glucose readings 
have reduced and encourage titration of insulin dose 
accordingly (e.g. need more or less insulin to achieve 
outcome).  
7. Provide feedback on performance of injecting insulin. 
8. Ask group to record daily insulin doses.  
 
9. Ask group to record their daily morning blood glucose 
readings.  
 
10. Inform the person of their HbA1c reading to improve 
adoption of insulin injections.  
11. Inform the person of their reduction in blood glucose 
readings following starting insulin therapy. 
12. Motivational interviewing and cognitive behavioural 
therapy.  
13. If group brings someone along with them to group, ask 
them to help remind people with type 2 diabetes to 






12. Social support (unspecified) 
[3.1] 
13. Social support (practical) [3.2] 
 
14. Instruction on how to perform a 
behaviour [4.1] 
15. Information about health 
consequences [5.1] 
 
16. Salience of consequences [5.2] 
17. Information about emotional 
consequences [5.6] 
18. Demonstration of the behaviour 
[6.1] 
 
19. Social comparison [6.2] 
 
20. Information about others’ 
approval [6.3] 
 
21. Prompts/cues [7.1]  
 
 
22. Behavioural practice/ rehearsal 
[8.1] 
 




24. Credible source [9.1]  
 
 
14. Advise the group how to inject insulin or check blood 
glucose correctly. 
15. Explain how injecting insulin can improve HbA1c and 
prevent diabetes complications. 
16. Produce pictures of a fatty liver to highlight dangers of 
being overweight/obese.  
17. Explain that injecting insulin to reduce blood glucose 
can improve wellbeing.  
 
18. Diabetes specialist nurses and other group members 
demonstrates taking insulin injection and blood 
glucose checking.  
19. Compare confidence or importance of taking insulin 
amongst group. 
20. Discuss with group how family/friends will approve of 
insulin injections to improve health. 
21. Introduce to group prompts/cues for remembering to 
take insulin e.g. phone alarm.  
22. Prompt group to practice insulin injection technique 
using water pen and sponge in session.  
23. Prompt group to take their insulin in the same context 
(e.g. room/time) everyday (if possible). Discuss and 
compare personal strategies (e.g. after brushing teeth) 
24. The group is delivered by a diabetes specialist nurse 
who will emphasise the importance of insulin injection 
therapy. 
25. Arrange location and time of the group so it is 
accessible to people attending. 
26. Tell the group they can successfully reduce HbA1c 
using insulin despite recent unwanted glucose 
readings/hba1c OR they can successfully inject insulin 




25. Restructuring physical 
environment [12.1]  
26. Verbal persuasion about 
capability [15.1] 
27. Focus on past success [15.3] 
27. Advise to describe successes in injecting insulin and 
checking blood glucose. 
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5.5. Discussion  
Here, the behaviour change wheel has been applied to designing the DIME intervention, a 
psychological intervention to support insulin initiation for people with type 2 diabetes. 
Stage 1 of the behaviour change wheel provided a behavioural diagnosis, i.e. ‘improving 
insulin self-management’, where specific target behaviours included: injecting insulin, 
treating hypoglycaemia, insulin dose titration, storing and travelling with insulin, blood 
glucose checking, physical activity, and carbohydrate awareness. DIME is a psychologically 
informed diabetes specialist nurse-led group 3-session intervention for people with type 2 
diabetes within one month of insulin prescription at a local health or community location. 
Evidence from previous studies of this thesis (1-3) identified all domains of the COM-B 
model (capability, opportunity, and motivation) were required to improve insulin self-
management. Stage 2 of the behaviour change wheel identified intervention functions and 
policy categories relevant to the COM-B components which were evaluated using the 
APEASE criteria. The intervention functions relevant to DIME included; education, 
persuasion, training, environmental restructuring, modelling and enablement. The policy 
categories evaluated as relevant to DIME included service provision; communication and 
marketing; environmental and social planning. Stage 3 identified the mode of delivery for 
DIME, 3 of which met APEASE criteria: face-to-face (group), print media (leaflet), and phone 
(phone helpline). Stage 3 also identified specific behaviour change techniques linked to 
previously outlined intervention functions and associated COM-B domains. Twenty-seven 
behaviour change techniques were evaluated as relevant to DIME. This encompassed the 
following behaviour change technique categories: ‘goals and planning’, ‘feedback and 
monitoring’, ‘social support’, ‘shaping knowledge’, ‘natural consequences’, ‘comparison of 
behaviour’, ‘associations’, ‘repetition and substitution’, ‘comparison of outcomes’, 
‘antecedents’, and ‘self-belief’.   
5.5.1. Behaviour change wheel limitations 
A potential limitation is there are too many target behaviours which surround ‘improving 
insulin self-management’, this makes it difficult to disentangle which elements of the 
intervention might be effective i.e. ‘the active ingredients’. Several behaviours must be 
targeted to ensure safe delivery of insulin, in addition to providing a rounded education 
which people with type 2 diabetes desire.   
A limitation of the intervention design at this stage is the assessment of APEASE criteria. 
The criteria were discussed only between two researchers (RU & KW). To make a valid 
‘acceptability’ assessment, judgement from patient public involvement (PPI) may have 
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been beneficial. However, the best judgements were made based on research (RU & KW) 
and clinical (KW) experience. Following pilot (chapter 7) and feasibility testing (beyond PhD 
thesis), further funding could incorporate PPI to strengthen intervention design.  
5.6. Chapter summary 
Through using a current integrated framework, the Behaviour Change Wheel, 27 behaviour 
change techniques were identified as the basis for the DIME educational content, 
materials, and activities. The following chapter (chapter 6) provides an in-depth description 























































6.1. Chapter scope 
This chapter describes study 4 of this thesis and provides the core information regarding 
the DIME intervention. It is reported according to the items of the Template for 
Intervention Description and Replication (TIDieR) checklist (appendix 6.1), namely the 
‘why’, ‘what’, ‘who’, ‘how’, ‘where’ and ‘when’ of the intervention.  Chapter 5 used the 
Behaviour Change Wheel to identify relevant behaviour change techniques for DIME. 
However, the behaviour change wheel does not detail how to develop specific content for 
sessions, psychological techniques, or intervention materials. Therefore, this chapter 
discusses the additional rationale and theory underpinning DIME.  
6.2. Intervention brief name 
The intervention is called DIabetes self-Management Education (DIME). 
6.3. Why? Rationale and theory 
6.3.1. Diabetes education guidelines  
In the UK, diabetes self-management education can be categorised into three levels: level 
one (information and one-to-one support); level two (informal learning such as peer 
support); and level three (structured education). For diabetes education to be defined as 
level 3 structured education, it must meet national criteria including being evidence-based, 
theory-driven, involving supporting materials, curriculum written-down, delivered by 
appropriately trained educators, quality assured and is audited (NICE, 2011; SIGN, 2017). 
The current insulin start group in south London is not a structured education programme. 
In addition, feedback from people with type 2 diabetes who have attended the insulin start 
group (chapter 3, study 2) suggests the current level of education is not supportive enough 
to address fears and concerns around insulin therapy. A 2018 consensus report by ADA and 
EASD for management of hyperglycaemia in type 2 diabetes expands on these UK 
definitions and recommends standards for key components of diabetes self-management 
education and support (DSMES). These guidelines similarly outline the need for evidence-
based theory-driven curriculum, delivered by trained quality-assured professionals, that is 
quality audited (Davies et al., 2018).  In addition, the ADA/EASD standards suggest DSMES 
is individualised to meet needs of the person(s) (e.g. language and culture), delivered to 
group or individual, includes content on psychological issues and concerns, available at 
critical times (e.g. when transitions in treatment occur), monitors progress in health status 
and quality of life. The DIME intervention aims to become a structured education 
programme and meet these NICE/SIGN and ADA/EASD standards. In the scope of this 
thesis, DIME development aims to incorporate evidence-based theory-driven curriculum 
delivered by a trained (in motivational interviewing) diabetes specialist nurse, delivered to 
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a group, includes content on psychological issues and concerns, available at insulin 
initiation (i.e. a critical time), and monitors progress, for example, insulin dosage and blood 
glucose readings.  
NICE guidelines recommend a structured education programme when starting insulin 
therapy with the following curriculum (NICE, 2015): 
• Injection technique  
• Injection sites 
• Telephone support 
• Self-monitoring  
• Insulin dose titration  
• Dietary awareness 
• Driving guidance (i.e. DVLA regulations) 
• Hypoglycaemia  
• Support from trained healthcare professional 
The DIME curriculum includes all these NCIE guideline recommendations for insulin 
education.  
6.3.2. Psychological techniques  
The theory of planned behaviour (Ajzen, 1991) is a health psychology model comprised of 
three components (subjective norms; attitudes; and perceived behavioural control) which 
all predict intention to perform a behaviour. Intentions to perform a behaviour predict 
engaging in a behaviour. Motivational interviewing techniques can influence and explore 
attitudes (e.g. towards insulin injections), perceived behavioural control (e.g. self-efficacy 
towards carrying out insulin injections) and intentions (e.g. towards delivering insulin 
therapy) as well as encouraging maintenance of the behaviours. A major criticism of the 
theory of planned behaviour is there is a gap between intentions and performing a 
behaviour known as the intention-behaviour gap (Sheeran, 2002). However, cognitive 
behavioural therapy techniques can be used to bridge this gap (Hobbis & Sutton, 2005), 
with specific examples provided in section 6.4.1.2. of this chapter. Therefore, motivational 
interviewing and cognitive behavioural therapy techniques were relevant to DIME 
intervention development. In support of this, a meta-analysis of psychological interventions 
for people with type 2 diabetes (study 1, chapter 2) revealed counselling (mainly 
motivational interviewing) and cognitive behavioural therapy techniques were effective in 
reducing HbA1c. No studies included in the meta-analysis used motivational interviewing or 
cognitive behavioural therapy techniques in the context of group insulin education for 
insulin initiation or insulin self-management for people with type 2 diabetes. Hence, DIME 
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is novel in exploring these techniques in relation to insulin treatment for people with type 2 
diabetes.  
Social cognitive theory (Bandura, 1991) is a theoretical concept which relates to the 
‘subjective norms’ component of the theory of planned behaviour referring to the 
importance of social support in influencing behaviour. A systematic review revealed 
increased social support increases positive outcomes in type 2 diabetes (Strom & Egede, 
2012), which is relevant to the DIME intervention being group-based. The aim of DIME 
being a group intervention is to provide social support to reduce social psychological insulin 
resistance i.e. social stigma and lack of social support.  In addition, social support was one 
of the most frequently used behaviour change technique categories in chapter 2 (study 1) 
meta-analysis. The behaviour change technique ‘social support (unspecified)’ encompasses 
motivational interviewing and cognitive behavioural therapy techniques. Therefore, 
strengthening the evidence for underpinning DIME with motivational interviewing and 
cognitive behavioural therapy techniques.  
6.3.2.1. Motivational interviewing  
A description of motivational interviewing is provided in chapter 1 of this thesis. There are 
four cornerstones, four processes and four foundational practice skills of motivational 
interviewing.  
The cornerstones of motivational interviewing are partnership; acceptance; compassion; 
and evocation. Partnership refers to the collaboration between a healthcare professional 
and patient, for example, the person with type 2 diabetes is seen as the diabetes expert 
and should be involved with decision making. Acceptance is where the healthcare 
professional accepts the person as they are e.g. the person with type 2 diabetes should 
have autonomy and be affirmed for their attempts to change health behaviours (not 
criticised for what they have not done). Compassion relates to having a person’s best 
interest at the forefront. Evocation acts on calling on the motivation that already exists 
rather than installing it.  
The processes of motivational interviewing include engaging (e.g. understanding the point 
of view of the person with type 2 diabetes); focusing (making a clear goal for health 
behaviour change); evoking (e.g. evokes the person’s own motivation and knowledge 
about change); planning (e.g. collaboration between a healthcare professional and the 
person with type 2 diabetes to identify next steps to take). The righting reflex refers to a 
healthcare professional correcting a patient or telling a patient what they should be doing, 
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this must be avoided in motivational interviewing to allow evoking of a person’s own 
motivation which best serves behaviour change.  
The foundational practise skills of motivational interviewing (OARS) to be conducted by a 
healthcare professional include: open questions (as opposed to closed questions which 
elicit one-word answers); affirmations (positively commenting on successes and efforts to 
change or work towards a goal); reflections (statements which aim to mirror what the 
person with type 2 diabetes has said to check understanding and perspective); and 
summarising (combines several reflections to give the person with type 2 diabetes an 
overview of what has been said).  
The DIME intervention uses group motivational interviewing which draws on the same 
cornerstones, processes and foundational practice skills as individual motivational 
interviewing. In addition, motivational interviewing in groups should promote positive 
interactions among group members, balance group dynamics, and include two or more 
group members with one or more group facilitators who meet face-to-face (Wagner & 
Ingersoll, 2012).  
6.3.2.2. Cognitive behavioural therapy  
Cognitive behavioural therapy is defined in chapter 1 of this thesis. Cognitive behavioural 
therapy was initially developed to treat depression (Beck & Alford, 2009), because of how 
cognitions (thoughts, attitudes) can influence behaviour. Cognitive behavioural therapy 
assumes that if someone has depressive symptoms, they may have unrealistic thought 
patterns which can negatively influence engaging in positive health behaviours (Beck, 
1970). As previously outlined common maladaptive cognitions (not limited to people with 
depression) which aim to be addressed in cognitive behavioural therapy include: 
• Personalising (negatively attributing outcomes to oneself) 
• Catastrophising (thinking the ‘worst-case scenario’) 
• All or nothing (holding high standards, might not engage in behaviour change 
unless success is certain).  
Relating to type 2 diabetes and insulin, people with type 2 diabetes may intend to check 
their blood glucose, however, they may attribute negative blood glucose readings to be 
their fault (personalising) which could disengage them from the behaviour. Cognitive 
behavioural therapy techniques would be useful here to challenge these types of unhelpful 
thinking styles to help people with type 2 diabetes understand that there are factors which 
fall outside an individual’s control contributing to changes in blood glucose. This would help 
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people with type 2 diabetes engage in the behaviour of blood glucose checking with a more 
positive perspective. 
The findings of study 3 in chapter 4 found that depressive symptoms are associated with 
shorter time to insulin requirement and initiation. Therefore, cognitive behavioural therapy 
techniques are highly relevant to incorporate in the development of DIME to address 
depressive symptoms. 
6.3.2.3. Psychological techniques and diabetes education  
The MOtiVational interviewing InTervention (MOVE-IT) is an education manual which 
integrates motivational interviewing and cognitive behavioural therapy techniques to 
encourage weight loss and physical activity to reduce the cardiovascular risk for those at 
high risk (Bayley et al., 2015). Another intervention is known as the Diabetes-6 (D-6) study, 
trained nurses in 6 skills taken from motivational interviewing and cognitive behavioural 
therapy to help improve HbA1c for people with type 2 diabetes (Ismail et al., 2018). The six 
skills included: active listening, managing resistance, directing change, supporting self-
efficacy, addressing health beliefs, and shaping behaviours. Both MOVE-IT and D-6 manuals 
were useful in the development of DIME owing to the in-depth description of psychological 
techniques and how to deliver them. In addition, activities were adapted to be relevant 
towards insulin (discussed in section 6.4.1. of this chapter).  
6.3.2.4. The stages of change 
The transtheoretical model was initially developed by Prochaska & colleagues (Prochaska & 
Velicer, 1997) to identify stages of change required to successfully quit smoking.  The 
transtheoretical model has more recently been studied on a range of applications including 
depression (Acton, Prochaska, Kaplan, Small, & Hall, 2001) and other health behaviours 
such as medication adherence (Willey et al., 2000), increasing physical activity (Titze, 
Martin, Seiler, Stronegger, & Marti, 2001) and weight loss (Mastellos, Gunn, Felix, Car, & 
Majeed, 2014). The transtheoretical model has not been specifically applied to insulin self-
management. The stages of change include pre-contemplation (do not feel there is a 
problem and do not feel the need to make changes, even if other people do), 
contemplation (ready to change and can see the benefits of engaging in a new behaviour), 
preparation (planning to engage in a new habit), action (engaging in the new behaviour), 
maintenance (the new behaviour is becoming a habit), and relapse (the new behaviour has 
stopped or there are periods of stopping and re-starting). There is evidence for integrating 
motivational interviewing with the stages of change whereby motivational interviewing 
techniques give the group a chance to reflect on reasons for change and personal values 
167 
 
(Wagner & Ingersoll, 2012). The stages of change were applied to insulin injections and 
included in the DIME (see 6.4.1.3 for more detail). The aim of using this theory is to not 
only recognise the current state of mind i.e. readiness to initiate insulin within the DIME 
intervention but in future insulin self-management to help overcome periods of 
psychological insulin resistance which lead to nonadherence or non-persistence (i.e. 
overcoming relapse).  
6.3.3.5. The behaviour change wheel 
The theory of planned behaviour on its own does not consider behaviour maintenance, 
habit, or emotional processing (West & Brown, 2013). The behaviour change wheel is a 
more recent behaviour change framework which takes in consideration internal 
(psychological and physical) and external (environmental) changes (Michie et al., 2011) to 
aid the design of behavioural interventions. DIME was developed using the behaviour 
change wheel which results in appropriate and relevant behaviour change techniques 
described in detail in chapter 5 and section 6.4.2.2 of this chapter.  
6.3.3. Dietary content 
The dietary content in DIME shares principles common to other insulin education 
programmes such as CLIMB  (Carbohydrate Lifestyle Insulin Management and Beyond; 
CLIMB) (Addington & Holcombe, 2017) and X-PERT (Deakin, 2015). All include sessions on 
carbohydrate awareness (i.e. what carbohydrates are and foods containing them), 
carbohydrate counting (how many carbohydrates are in certain foods), glycaemic index, 
and weight and insulin. Dietary content which is not included in these programmes that is 
incorporated into DIME is ‘time-restricted eating’. Time-restricted eating refers to eating all 
foods in the day but in a shorter time frame e.g. within 6-12 hours instead of the normal 
12-15. There is evidence for this leading to weight loss which reduces insulin resistance and 
hence improves HbA1c (Cho et al., 2019). ‘Carbs & Cals’ (Carbs&Cals, 2018) is an 
organisation who have developed resources for healthcare professionals to educate people 
with diabetes on carbohydrates in different food sources and is used widely in the UK and 
in other diabetes education programmes (Addington & Holcombe, 2017; Deakin et al., 
2006; Khunti, Gray, et al., 2012b). DIME use ‘carbs & cals’ activities to facilitate dietary 
content.   
6.4. What?  
Table 6.1 outlines the content of each session in the current insulin start group and DIME.  
There are some activities from the current insulin start group in south London which are 
replicated in DIME: ‘dose titration’ (session 1) and ‘quiz of last session’ (session 2). 
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Additional activities included in DIME were underpinned by psychological techniques and 
adapted from previous diabetes education programmes, which are outlined later in this 
chapter (section 6.4.1.2). Psychological and behavioural strategies which were included in 
DIME but are not in the current insulin start group include: exploring perspectives (session 
1; motivational interviewing technique); techniques for remembering insulin (session 1; 
behaviour change technique); review of progress since last time (session 2 and 3; behaviour 
change technique); relapses (session 2; cognitive behavioural therapy technique); and 
feedback on blood glucose reading and goal setting (session 2 and 3; behaviour change 
technique). Educational content which was identified from study 2 (chapter 3) which is 
included in DIME but not the current insulin start group includes diabetes complications 
(session 2); diabetes technology (session 2); weight and insulin (session 3); diet and 
carbohydrates (session 3); and exercise (session 3).  
6.4.1. Materials 
There were four different types of materials involved in DIME development including 
facilitator notes, workbooks, supporting materials, and printed materials.  
6.4.1.1. DIME facilitator notes 
A full version of the DIME facilitator notes can be found in appendix 6.2. The facilitator 
notes contain an ‘introduction to the manual and instructions for use’ detailing how the 
notes are to be used and guidance on booking venues which are convenient to the group 
members to maximise attendance.  
In the DIME facilitator notes, text highlighted in green emphasises psychological skills (e.g. 
motivational interviewing, cognitive behavioural therapy), text highlighted in yellow shows 
group activities and text highlighted in purple shows homework tasks. 
Subheadings display different topics within each session and subheadings are coded in 
different colours for each session to distinguish between them. At the beginning of each 
session, the DIME facilitator notes begin with ‘You will need’ with a list of materials needed 
in that session, ‘introductions’ to welcome the group and a session overview which 
describes the content to be covered in that session.  
Key learning points are displayed in a box for each new educational content to ensure the 
facilitator consistently covers the same material. The key learning point covers all essential 










Table 6.1-Session content of current insulin start group and DIME 
Session Current insulin start group content DIME content  
Session 1  • Introductions  
• Ground rules 
• Initial questions   
• Diabetes & the need for insulin                            
• Safe insulin administration  
• Insulin storage  
• Self-injecting first dose 
• Insulin dose titration 
• Activity 1: Dose titration  
• Diabetes medications  
• Hypoglycaemia 
• Driving with insulin and 
employment 
• Blood glucose meter technique 
review 
• Introductions  
• Ground rules 
• Exploring perspectives  
• Injection technique and checking 
blood glucose  
• Activity 1: Decisional balancing tool 
•  Diabetes medication choice 
• What is diabetes and the need for 
insulin? 
• Activity 2: What’s in it for you? 
• Hypoglycaemia  
• Dose titration 
• Activity 3: Dose titration  
• Driving and insulin 
• Techniques for remembering 
diabetes medication  
• Activity 4: Goal setting  
Session 2 • Reflections & titration issues 
• Activity 1: Quiz of last session  
• Problems encountered 
• Sick Day rules 
• Travel 
• Annual Review & interpreting 
results 
• Next steps 
• Burning issues 
• Introductions 
• Review of progress since last time 
• Activity 1: wheel of change 
• Relapses 
• Feedback on blood glucose reading 
and goal setting  
• Activity 2: Quiz of last session 
• Complications 
• HbA1c targets 
• Activity 3: Changes in blood glucose 
• Activity 4: Exploring importance of 
insulin  
• Sick day rules 
• Diabetes technology  
• Activity 5: Maintenance plan  
Session 3 N/A • Introductions 
• Review of progress since last time 
• Feedback on blood glucose readings 
and goal setting  
• What are carbohydrates? 
• Activity 1: Carb counting knowledge 
quiz 
• Weight, insulin & diabetes 
• Exercise and diabetes 
• How many carbs? 
• Types of carbs and glycaemic index 
• Ways to improve blood glucose  
• Activity 2: Thinking about carbs in 
our diet 
• Time restricted eating 
• Benefits of weight loss 
• Insulin on holiday 
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Some activities were outlined in the DIME facilitator notes and were not included in the 
workbooks as they were facilitator-led and designed to be completed by the whole group 
(other tasks outlined in next section were mostly completed individually or in pairs). For 
example, a cognitive behavioural therapy technique employed in the D-6 intervention 
which was included in DIME facilitator notes only is called ‘changes in blood glucose’ 
(session 2, activity 3). This activity involved working with unhelpful thinking styles, which is 
particularly helpful for people with depression. The activity addressed unhelpful thinking 
styles by identifying which factors relating to change in blood glucose and thinking about 
which of these factors are within or outside an individual’s control. This helps address 
people who personalise or attribute negative outcomes to themselves (especially relevant 
for people with depressive symptoms). Another activity outlined in DIME facilitator notes 
only was ‘exploring the importance of insulin’ (session 2, activity 4). This activity helps 
facilitators judge the groups’ readiness to change by using the ‘readiness to change ruler’ (a 
motivational interviewing technique). These are open questions and in this activity the 
group were asked where they might place themselves on a scale of 0 to 10 in response to 
the following questions: 
• “How important is it to you to take insulin injections?” 
• “How important is it to you to reduce blood glucose?” 
• “How confident are you in reducing your blood glucose?” 
Following these questions, the facilitator could ask a follow-up question: “Why do you 
place yourself at ___and, not 0?” to evoke change talk.  
At the end of each session, the DIME facilitator notes encourage ‘question and answer’ 
time for the group to ask any questions, a description of next sessions content, and an 
outline of any homework tasks.  
6.4.1.2. DIME workbooks and activities  
DIME is supported by workbooks for people with type 2 diabetes in the group which outline 
activities in each session (appendix 6.3).  
There were activities from MOVE-IT (Bayley et al., 2015) which were adapted for  DIME 
which encompasses psychological techniques (table 6.2). For example, ‘What’s in it for 
you?’ (session 1, activity 2) was an activity from MOVE-IT built on three questions to elicit 
change talk (motivational interviewing). The MOVE-IT intervention was based on 
cardiovascular risk, but was adapted for the DIME group to focus on starting insulin: 
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• Write down the top 3 reasons for starting insulin. 
• What might happen if you don’t take insulin? 
• What changes would you see if you continued with insulin (now and in the future)? 
 
Table 6.2-Psychological techniques underpinning session activities   
Session Activity Diabetes education 
manual adapted 
from 
Psychological techniques underpinning  
Session 1 1: Decisional balancing 
tool 
D-6 CBT* 
2: What’s in it for you? MOVE-IT MI** 
3: Dose titration Current insulin start 
group manual 
 
4: Goal setting MOVE-IT MI**, CBT*, SCT***, operant conditioning  
Session 2 1: Wheel of change New Transtheoretical model 
2: Quiz of last session Current insulin start 
group 
 
3: Changes in blood 
glucose 
D-6 CBT* 
4: Exploring the 
importance of insulin 
New MI** 
5: Maintenance plan MOVE-IT MI**, CBT*, SCT***, implementation 
intentions  
Session 3 1: Carb counting 
knowledge quiz 
Carbs & cals  
2: Thinking about 
carbs in our diet 
New  MI** 
*Cognitive behavioural therapy; **Motivational interviewing; ***Social cognitive theory  
 
The MOVE-IT manual outlined 2 planning activities which were adapted for DIME. These 
were ‘goal setting’ (session 1, activity 4), and maintenance plan (session 2, activity 5). 
Planning is a motivational interviewing process to clearly identify next steps the group can 
take based on personal motivations e.g. ‘Before the next session, my goal will be to….’. 
These planning activities also involved elements of cognitive behavioural therapy, for 
example problem-solving e.g. ‘What might get in the way of achieving this goal?’ and ‘How 
can I get around this?’. Other psychological techniques underpinning the planning activities 
are social cognitive theory (social support) e.g. ‘who can support me with this plan’, and 
operant conditioning (positive reinforcement) e.g. ‘if I achieve my goal, I will reward myself 
by…’. The facilitator is instructed to ensure rewards are realistic and would support 
behaviour change i.e. not just ‘self-motivation’, a list of potential rewards is listed at the 
end of the activity to help the group plan for these. Rewards may also be important for 
people with depressive symptoms. People with depressive symptoms may not reward 
themselves as they believe they are not worthy of them (Rehm, 1977), but rewards (e.g. 
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positive reinforcement an example of operant conditioning) can lead to successful 
behaviour change (Bandura, 1977). 
Relapse prevention (cognitive behavioural therapy) is a component of the maintenance 
planning activity e.g. ‘what situations might get in the way of achieving my goals’ and ‘if the 
above situations happen then what will I do to address these barriers to help me still 
achieve my goals?’. The latter question is structured as an ‘if-then’ statement (i.e. if this 
situation happens then…I will do this). This is known as an implementation intention 
(Gollwitzer, 1999) which helps transform intention into behaviour. One of the MOVE-IT 
activities included in the DIME session 1, goal setting activity 4 was ‘readiness to change 
ruler’ questions, a motivational interviewing technique to evoke change talk. The questions 
were: 
• ‘If I achieve this goal it will be…’ (from not very awarding to extremely rewarding). 
• ‘How confident am I that I will achieve this goal?’ (from not at all confident to 
extremely confident). 
There were also activities adapted from the D-6 manual (Ismail et al., 2018). The ‘climbing 
the mountain worksheet’ used in the D-6 intervention uses a cognitive behavioural therapy 
technique known as ‘graded hierarchy’ to aid goal setting. This involves breaking down a 
goal into small steps and is thought to be useful for people who might find tasks 
overwhelming. This was included in DIME as part of a goal-setting activity in session 1. Also, 
people with depressive symptoms may find small tasks overwhelming, therefore this 
activity is good for breaking-down tasks into more manageable smaller steps.  
The ‘decisional balancing tool’ is another D-6 activity which incorporates problem-solving 
(cognitive behavioural therapy) to firstly think of the pros of current diabetes treatment 
(without insulin), then the cons of current treatment, then think of the pros of insulin 
treatment to address the cons of current treatment (this is the core problem-solving 
component), and finally outline the cons of insulin treatment. The facilitator can then begin 
to address group concerns around insulin (another problem-solving element of the 
activity).  
One activity selected from the ‘Carbs and cals’ (Carbs&Cals, 2018) range was the ‘Carb 
counting knowledge quiz’ (Carbs&Cals, 2019). This activity was useful to incorporate 
dietary content which was outlined as missing from current insulin start groups in south 
London (chapter 3, study 2).  
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A new activity designed for DIME was the second activity in session 3 called ‘Thinking about 
carbs in our diet’. The group was encouraged to plan how they might swap carbohydrates 
for lower glycaemic index carbohydrates to prevent blood glucose spikes, as well as 
reducing the quantity of carbohydrates to help improve blood glucose control. The activity 
worked on the motivational interviewing principle that individuals could make a choice 
about what they would be happy to change in relation to diet, working upon their own 
motivations. In addition, the ‘readiness to change ruler’ questions (motivational 
interviewing) were asked so the facilitator could evoke change talk, for example ‘rate how 
confident you would be to make these changes’. This was followed by comparing strategies 
amongst the group which might aid this behaviour change e.g. planning meals and snack 
ahead of time.  
Activities which were adapted from the current insulin start group in south London were 
‘dose titration’ (session 1, activity 3) and ‘quiz of last session’ (session 2, activity 2). The 
‘dose titration’ activity was designed to check the groups understanding of how to adjust 
insulin doses based on morning blood glucose readings. It is important to encourage self-
titration as this is associated with empowerment (Khunti, Davies, & Kalra, 2013) and 
improving insulin persistence (Misra et al., 2019). The ‘quiz of last session’ was useful to 
check the groups’ memory of last sessions content and provide any missing information.  
At the end of the workbooks for session 1 and 2, homework tasks are set out which include 
a blood glucose chart to record blood glucose readings every morning. This helps with 
adjustments in insulin dose.  
6.4.1.3. DIME supporting materials 
For all DIME sessions a board, A3 paper, pens and sticky notes were required to assist 
facilitators in explaining key educational content as well as addressing psychological 
concerns. For example, one cognitive behavioural therapy technique, which was adapted 
from the D-6 manual aids shaping behaviour and is known as ‘keeping perspective’ (session 
2). This figure (figure 6.1) is drawn on the board and aims to normalise relapsing and 
prevent permanent relapse of engaging in a new health behaviour. This demonstrates the 
journey to success is built on improving and points of relapsing, however overall the person 
is improving despite periods of relapse. This technique encourages the group to think about 












Session 1 requires the following materials to demonstrate an insulin injection: water pen 
and sponge. Recent research has found that if insulin injections have been demonstrated 
by a healthcare professional, the person with type 2 diabetes is less likely to delay insulin 
treatment (Polonsky et al., 2019). It is recommended the facilitator also takes a blood 
glucose meter to this session to demonstrate taking blood glucose.  
Session 2 requires the following supporting materials: ‘wheel of change’, ‘A3 outline of the 
body’, and ‘HbA1c meter drawing’. The ‘wheel of change’ involves taking the group through 
the stages of change from the transtheoretical model: pre-contemplation, contemplation, 
preparation, action, maintenance, and relapse (figure 6.2). The group are then asked at 
what stage they think they are at in terms of adopting insulin injections and blood glucose 
checking as part of their daily routine. This activity also supports the ‘keeping perspective’ 
demonstration (described above) in terms of thinking about relapse prevention. The ‘A3 
outline of the body’ is used to elicit knowledge from the group regarding diabetes 
complications, the group are asked where on the body complications can occur and a sticky 
note is put there. Analysis of people who attended insulin start groups in study 2 (chapter 
3) of this thesis found they would have liked more education around complications. 
Research has found providing personalised information about risk of diabetes 
complications is associated with improvement in HbA1c and diabetes distress. (Skinner, 
Barrett, Greenfield, & Speight, 2014). The ‘HbA1c meter drawing’ (appendix 6.2) illustrates 
where on the meter each group member is with their most recent HbA1c reading. Green on 
the meter equates to optimal HbA1c (30-58 mmol/mol), yellow means above target (58-78 
mmol/mol) and red means suboptimal HbA1c (>78 mmol/mol). The meter is also a visual 
Figure 6.1-Keeping perspective graph 
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representation of what their average blood glucose reading is based on their HbA1c 
reading. For people with type 2 diabetes, self-knowledge HbA1c is significantly associated 
with lower HbA1c than people with type 2 diabetes who do not know their HbA1c (Trivedi 





For session 3 of DIME the following supporting materials are required: plastic food and 
plate, government eat well guide, and DIRECT liver scan. The plastic food and plate is used 
to help the group visualise how many carbohydrates they eat at mealtimes, the group then 
assesses whether they currently eat a ‘high carbohydrate diet’ (half plate contains 
carbohydrates), ‘moderate carbohydrate diet’ (25-40% of the plate contains 
carbohydrates), ‘low carbohydrate diet’ (25% or less of the plate contains carbohydrates), 
or a ‘very low carbohydrate diet’ (5-10% of the plate contains carbohydrates). This is 
compared against the governments eat well guide (Buttriss, 2016) which recommends a 








Figure 6.2-The wheel of change  
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the benefits of a low-carbohydrate diet e.g. promoting weight loss and improving HbA1c in 
type 2 diabetes (Bolla, Caretto, Laurenzi, Scavini, & Piemonti, 2019; Gannon & Nuttall, 
2004; McArdle et al., 2019; Unwin & Unwin, 2014; Westman, Yancy, Mavropoulos, 
Marquart, & McDuffie, 2008). There are concerns over long term adherence to low 
carbohydrate diets (Bolla et al., 2019), therefore DIME uses motivational interviewing 
techniques to draw on individuals own motivation to change towards diet to increase 
adherence and promote overall healthy eating. The group are asked to discuss the benefits 
of weight loss, this is followed by a picture of the DIRECT liver scan to illustrate how weight 
loss can reduce fat around the liver (Lean et al., 2018).  
6.4.1.4. DIME printed materials  
The DIME intervention is supported by printed materials (appendix 6.4) for the group to 
take away from the sessions which outline all session content in a condensed easy-to-read 
file. The only printed material content which is not in the DIME sessions is a question and 
answer sheet on the myths around insulin injection therapy, several resources were 
reviewed and merged, in addition to discussion with thesis supervisors to create this 
resource (ADA, 2007; Brod, Alolga, et al., 2014).  
6.4.2. Procedures  
In the borough of Lambeth in south London people with type 2 diabetes who required 
insulin were identified in primary care and were referred to an insulin start group. To pilot 
test the newly developed DIME intervention, in the months of November 2018-January 
2019 DIME replaced the current insulin start group. People with type 2 diabetes were 
referred as usual and the Lambeth Diabetes Team informed them via an information sheet 
(appendix 6.5) on the purpose of DIME, participants then consented (appendix 6.6) to take 
part in the pilot phase of DIME and were informed of the opportunity to be interviewed 
following the attendance of all three sessions. More information on the pilot testing of 
DIME is given in chapter 7 of this thesis.   
6.4.2.1 DIME processes: Psychological skills 
Key psychological techniques are highlighted in green in the facilitator notes. Here, a 
summary of the techniques with examples is provided.  
Offering information and advice draws on the ‘partnership’ cornerstone of motivational 
interviewing.  Previous research indicates people might already know up to 90% of health 
information of which researchers planned to tell them (Handmaker, Miller, & Manicke, 
1999). Therefore, it is important to only offer the necessary information and not repeat 
what the group already knows in order to maintain group engagement. This can be 
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achieved through the ‘elicit-provide-elicit’ (E-P-E) technique. The facilitator ‘elicits’ what 
the group already knows about a topic, before ‘providing’ any unknown information or 
correcting misunderstandings. The final ‘elicit’ refers to checking the understanding of the 
information provided. This technique is also useful to ‘chunk’ information into manageable 
pieces which can aid memory (Ackermann et al., 2017). Impaired memory (Rose & Ebmeier, 
2006) and concentration can be a bi-product of depression (Rock, Roiser, Riedel, & 
Blackwell, 2014; Rose & Ebmeier, 2006) therefore this technique could also be beneficial 
for people with depressive symptoms.  The first example of the E-P-E technique in the 
facilitator notes is in session 1 when providing information around types of diabetes and 
the progression of type 2 diabetes, this technique is suggested for giving all educational 
information throughout the DIME facilitator notes. Another example of aiding group 
member memory in DIME was ‘techniques for remembering insulin’ whereby the facilitator 
encouraged a discussion of ideas for remembering to insulin and how this behaviour can 
become a habit i.e. taking insulin at a particular time in the same place every day. There is 
evidence for reminders being useful for people with type 2 diabetes to take insulin (Borah 
et al., 2009; Brod et al., 2012).   
Another technique useful to offering information involves asking permission to talk about a 
topic, this is also encouraged throughout the DIME facilitator notes. This falls in line with 
the ‘partnership’ cornerstone of motivational interviewing as it initiates a collaborative 
style, and demonstrates respect (Steinberg & Miller, 2015).  
Foundational practice skills (OARS) of motivational interviewing were encouraged by the 
DIME facilitator. Open questions provide an opportunity to explore the perspectives of the 
group, for example, asking “What is the one thing that drives you crazy about your 
diabetes?” (session 1). Open questions can also aid broadening perspectives of the group, 
such as in session 1 where group members explore the importance of insulin therapy, in 
addition to the facilitator exploring personal values to suggest why taking insulin could be 
important. For example, a personal value might be spending time with family, taking insulin 
helps feel less fatigued and improves wellbeing, allowing someone to be better able to 
spend time with family.  
Affirmations are important when the group are describing and practicing techniques learnt 
in the group, for example, affirming correct insulin injection technique when practicing this 
behaviour in session 1.  In session 2 and 3, when the group reflect on their progress since 
last session, this is an opportunity for the facilitator to provide reflections and summary 
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statements to check their understanding of something a group member has said as well as 
piecing together important information. Chapter 4 identified the need to consider people 
with type 2 diabetes and depressive symptoms, as they are more likely to initiate insulin 
sooner than people without depressive symptoms. People with depression are more likely 
to focus on negative aspects of themselves or the environment (Beck, 1967) and are more 
susceptible to repetitive negative thinking (i.e. interpretation bias) (Krahé, Whyte, Bridge, 
Loizou, & Hirsch, 2019). Affirmations are therefore important for people with depressive 
symptoms (and without) to highlight strengths and help increase self-efficacy. To increase 
confidence, DIME facilitator notes encourages the facilitator to use affirmations (including 
small changes) the people with type 2 diabetes have made between sessions, for example 
attempting to inject insulin or checking blood glucose.  
Eliciting and activating change talk are part of the ‘evoking’ process of motivational 
interviewing which works on the principle that people are ambivalent about behaviour 
change. Motivation to change is known as ‘change talk’ and motivational interviewing helps 
people explore this. Motivational interviewing questions that help elicit change talk are 
known as DARN questions (Desire, Ability, Reasons, Need) and questions that activate 
change talk are known as CAT questions (Commitment, Activation, Taking steps). Examples 
of DARN-CAT questions which were adapted from D-6 for DIME are shown in table 6.3. 
DARN-CAT questions are in in all 3 sessions of DIME, after goal setting in session 1 and 2 to 
reflect on motivation towards personal goals, and after a ‘walking’ break in session 3 to 
reflect on motivation to exercise.  
Cognitive behavioural techniques were also employed in DIME. As these cognitive 
behavioural therapy techniques are embedded within activities adapted from other 
diabetes education manuals, they are described in section 6.4.1.2. of this chapter.  
 
Table 6.3- Motivational interviewing techniques: DARN-CAT questions 
DARN (Desire, ability, reasons, need) CAT (commitment, activation, taking steps) 
D: What do you hope for your own health in 
the future?  
C: So, what do you think you will do? 
A: What one step might you be able to take to 
achieve this goal? 
A: What might you be willing to do as a next 
step? 
R: What would you say are three good reasons 
to achieve this goal? 
T: What have you already done to attempt this 
goal? 







6.4.2.2 DIME processes: Behaviour change techniques  
Behaviour change techniques (derived from behaviour change wheel in chapter 5) were 
incorporated into all sessions of DIME. Table 6.4 outlines the behaviour change technique 
examples from each session and where it can be found in the DIME facilitator notes. 
Session 1 uses 38 behaviour change techniques, session 2 uses 21 behaviour change 
techniques, and session 3 uses 15 (table 6.5). The most frequently used behaviour change 
techniques overall are social support (unspecified) (n=20), goal setting (behaviour) (n=4), 
review behaviour goal(s) (n=4), instruction on how to perform the behaviour (n=4), and 
demonstration of the behaviour (n=4) (table 6.5). Social support (unspecified) was present 
in all sessions through motivational interviewing and counselling techniques.  
6.5. Who provided? 
The DIME intervention was designed to be delivered by diabetes specialist nurses who are 
the existing facilitators for the insulin start group in south London. They are appropriate to 
deliver the intervention owing to their knowledge and expertise in diabetes and insulin 
administration. Diabetes nurses would require additional psychological skills training 
(mainly motivational interviewing) to deliver the DIME intervention.  
6.6. How? 
The mode of delivery of the DIME intervention is face-to-face with supporting printed 
materials, and telephone follow-up calls (see chapter 5 ‘identify mode of delivery’ for more 
information). 
The number of people per DIME group is designed to be flexible. The group is designed for 
people within 1 month of insulin prescription to make sure people entering the group are 
at the same level in terms of familiarity with insulin therapy (see chapter 5 section 5.3.3.). 
Therefore, group sizes could vary depending on which people with type 2 diabetes have 
been prescribed insulin at the time of the group. The DIME facilitator notes accommodate 
for varying group sizes. For example, some activities benefit people working alone to 
complete worksheets to vary from group work, but if there is only a small group (e.g. 1-3 
people) then these activities could benefit from the facilitator talking through questions 
and writing answers with the group.  
6.7. Where? 
The DIME intervention is to be delivered at a convenient location for the group of people 
with type 2 diabetes attending, for example, local general practice surgery, hospital or 




Table 6.4- Behaviour change techniques used in each ‘new to insulin group’ session 
Session  Behaviour change 
technique (BCTTv1 
code) 
Behaviour change technique example from 
DIME 









delivered by a diabetes specialist nurse to 
emphasise the importance of insulin injection 
therapy to improve health (diabetes 




motivational interviewing, cognitive 





arrange the group in a location and at a time 
which is easily accessible to those attending 
Introduction  
Session 1  Social comparison 
(6.2)  
What have you heard from other people with 
diabetes who use insulin? 




Discuss how family/friends will approve of 





Encourage they can bring someone to next 
group session if they wish. 
Exploring perspectives 
Pros and cons (9.2) Decisional balance tool: list pros and cons for 
current treatment (without insulin) and 
treatment with insulin.  




Discuss barriers to insulin treatment. Discuss 
points to counteract barriers. 





Insulin helps…improve well-being. Key learning points 1.1: Barriers to 
insulin treatment 
Instruction on how 
to perform a 
behaviour (4.1) 
Advise the group on steps for injecting insulin Injection techniques & checking 
blood glucose  
Prompts/cues (7.1) Suggest group use these steps (outlined in 
booklet to take home) so they can refer to 
whilst still learning.  
Injection techniques & checking 
blood glucose  
Demonstration of 
the behaviour (6.1) 
Demonstrate how to inject insulin using an 
insulin pen filled with water and sponge to 
inject into. 
Injection techniques & checking 




Prompt group to practice insulin injection 
technique with water pen and sponge. 
Injection techniques & checking 
blood glucose  
Feedback on 
behaviour (2.2) 
Provide feedback on injection technique 
performance.   




Instruction on how 
to perform a 
behaviour (4.1) 
Advise group on how to check blood glucose 
with their meter.  
Injection techniques & checking 
blood glucose 
Demonstration of 
the behaviour (6.1) 





Prompt group to practice checking blood 
glucose in group. 




Provide necessary feedback on [blood glucose 
checking] technique. 





Explain that might experience hypo symptoms 
when blood glucose is dropping from high 




Encourage a plan to carry a hypo treatment 




Set group goal of checking blood glucose 
every morning.  




Advise that it is better to inject the same time 
every day to prevent blood glucose spikes or 
hypos. 
Dose titration 
Instruction on how 
to perform the 
behaviour (4.1) 
Advise group on how to titrate insulin doses. Dose titration 
Demonstration of 
the behaviour (6.1)  




Dose titration activity Activity 3: Dose titration 
Self-monitoring of 
behaviour (2.3) 
Ask group to record daily, their morning blood 
glucose readings 
Activity 3: Dose titration 
Prompts and cues 
(7.1) 
Discuss ideas for prompts/reminders for 
taking insulin.  
Techniques for remembering 





Prompt planning tasking insulin at a particular 
time every day in the same place. 




If a group member has brought someone 
along with them to the group (family 
member/friend) then ask them to help 
remind to take insulin. 
Techniques for remembering 
diabetes medication 
Graded tasks (8.7) Climb mountain sheet Activity 4: Goal setting 
Goal setting 
(behaviour) (1.1) 
Get everyone to think of ONE goal they would 
like to work on before next session 





Check they have set appropriate goals, 
challenge how they will remember to do this 
(qu3), and rewards.  
Activity 4: Goal setting 
Social support 
(emotional) (3.3) 
Suggest group could exchange contact details 
to provide support to each other if they want 
to. 
End of session 
Session 2 Focus on past 
success (15.3) 
Discuss…1 thing you have achieved since last 
time (e.g. successes in injecting insulin or 
checking blood glucose in past week) 
Review of progress since last time 
Review of behaviour 
goal(s) (1.5) 
Review how well people are getting on with 
daily injecting insulin and checking blood 
glucose, address concerns, and modify goals if 
necessary. 
Review of progress since last time 
Problem-solving 
(1.2) 




Tell group they can successfully reduce HbA1c 




outcome(s) of the 
behaviour (2.7) 
Ask group whether think titration needs to 
happen based on readings 
Feedback on blood glucose 
readings and goal setting  
  
Review of behaviour 
goals (1.5) 
Modify insulin dose target (if needed).  
Review of outcome 
goal(s) (1.7) 
Modify goal for desired blood glucose 
morning readings if not yet achieving. 
Feedback on blood glucose 
readings and goal setting  
Review of behaviour 
goals (1.5) 
Review goal setting from session 1 task- 
examine how well group have performed in 
working on goals set in last session, modify 
future goal accordingly. 
Feedback on blood glucose 




Talk about how complications are caused and 
how they can be prevented by managing 




Discuss HbA1c targets. HbA1c targets  
Biofeedback (2.6)  Inform each group member of their HbA1c 
reading and address how insulin injections 
might improve their reading. 
HbA1c targets  
Salience of 
consequences (5.2) 
Refer to HbA1c meter sheets- see if group 
knows where they are on the meter 
corresponding to blood glucose readings to 
highlight dangers of having high blood glucose 
readings. 
HbA1c targets  
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Re-attribution (4.3) “Which of these factors [affecting blood 
glucose] are within your control and which 
are less easy to control or outside of your 
control?” 




Ask more than one person in group (maintain 
group engagement) 
Activity 4: Exploring importance of 
insulin  
Instruction on how 




the behaviour (6.1) 
Check confidence with checking blood glucose 








behaviour (2.3 and 
2.4) 
Homework task: Blood glucose readings chart End of session   
Session 3 Feedback on 
outcome(s) of the 
behaviour (2.7) 
Ask group whether think titration needs to 
happen based on readings.  
Feedback on blood glucose 
readings and goal setting  
  
Review of behaviour 
goals (1.5) 
Modify insulin dose target (if needed). Feedback on blood glucose 
readings and goal setting  
Review of outcome 
goal(s) (1.7) 
Modify goal for desired blood glucose 
morning readings if not yet achieving. 
Feedback on blood glucose 
readings and goal setting  
Review of behaviour 
goals (1.5) 
Review goal setting from session 2 task- 
examine how well group have performed in 
working on goals set in last session, modify 
future goal accordingly. 
Feedback on blood glucose 
readings and goal setting  
Salience of 
consequences (5.2) 
Use plastic food and plates to get group to 
represent how many carbs they are eating. 
How many carbs?   
Goal setting 
(behaviour) (1.1) 
Ask group to work individually on activity 2: 
“Thinking about carbs in our diet” 




List these changes they would be happy to 
make on board (e.g. might include swapping 
sugar/starch carbs to fibrous carbs, reduce 
quantity of carbs) to share ideas amongst 
group 




Produce DIRECT study liver fat picture (1 
handout to pass around & on next page also) 
to highlight dangers of being overweight. 





Table 6.5- Frequency of behaviour change techniques within and between sessions 





















techniques in all 
sessions 
Goal setting (behaviour) 1.1 3  1 4 
Problem solving 1.2 1 1  2 
Action planning 1.4 2   2 
Review behaviour goal(s) 1.5  2 2 4 
Review outcome goal(s) 1.7   1 1 
Feedback on behaviour 2.2 2   2 
Self-monitoring of behaviour 
2.3 
1 1  
2 
Self-monitoring of outcome(s) 
of behaviour 2.4 
 1  
1 
Biofeedback 2.6  1  1 
Feedback on outcome(s) of 
behaviour 2.7 
 1 1 
2 
Social support (unspecified) 3.1 7 6 7 20 
Social support (practical) 3.2 1   1 
Social support (emotional) 3.3 1   1 
Instruction on how to perform 
the behaviour 4.1 
3 1  
4 
Re-attribution 4.3  1  1 
Information about health 
consequences 5.1 
2 1  
3 
Salience of consequences 5.2  1 2 3 
Information about emotional 
consequences 5.6 
1   
1 
Demonstration of the 
behaviour 6.1 
3 1  
4 
Social comparison 6.2 1 1 1 3 
Information about others’ 
approval 6.3 
1   
1 
Prompts/cues 7.1 2   2 
Behaviour practice/rehearsal 
8.1 
3   
3 
Habit formation 8.3 1   1 
Graded tasks 8.7 1   1 
Pros and cons 9.2 1   1 
Non-specific reward 10.3 1   1 
Verbal persuasion about 
capability 15.1 
 1  
1 
Focus on past success 15.3  1  1 
Total number of behaviour 
change techniques per session 








6.8. When and how much? 
The current insulin start group in south London consists of 2 sessions 1 week apart. Session 
one focuses on key safety aspects of insulin administration, and session 2 reflects on any 
problems encountered as well as ‘sick day rules’ and travelling with insulin. Each session is 
around 2 hours.  
Motivational interviewing sessions are designed to be 1-3 sessions (Rollnick & Miller, 1995). 
The DIME intervention was designed as 3 sessions to incorporate new content as well as 
allowing time for psychological techniques (such as motivational interviewing) to address 
fears and concerns around insulin and reduce ambivalence. The DIME intervention was 
designed to be offered within 1 month of insulin initiation (see chapter 6 ‘specify target 
behaviour’ for more information). For DIME session 1 and 2 are 1-2 weeks apart and 
session 3 is 4-8 weeks later to allow time to adjust to insulin therapy and consider potential 
problems which can be addressed in the final session. Each session is 2 hours long.  
6.9. Tailoring and modifications  
The DIME intervention is a group intervention and therefore is not entirely personalised, 
however there are certain aspects which can be personalised for example discussing the 
action of insulin types can be applied to which insulin the group members were prescribed. 
The DIME intervention was piloted on 2 groups of people with type 2 diabetes newly 
prescribed insulin therapy (see chapter 7 for more information). Following each session, 
DIME could be adapted and modified based on how well the session went and feedback 
from the facilitator (KW) and observer (RU). These modifications could be made at any time 
during the pilot phase and after each session. Exit interviews of a sample of people who 
received DIME could also determine relevant modifications (chapter 7). All these 
modifications were made in advance of a feasibility randomised controlled trial (beyond 
the scope of this PhD thesis).  
The following modifications were made following the pilot of session 1: 
• Layout of DIME facilitator notes to aid ease of navigation for facilitator: 
o Fewer words per page 
o New topic on new page 
o Colour coding (activities, psychological techniques) 
o Boxes for key learning outcomes 
o Incorporate facilitator tools into handbook 
• Consideration if only 1-3 people attended the group. Amend activities in this case e.g. 
can do as whole group out loud instead of in pairs or individually. 
• Added in ‘types of insulin’ into this session.  
• Added in driving (originally in session 3, needed for safety so moved to session 1).  
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• Added in Insulin Treatment Appraisal Scale to exploring perspectives if conversation 
stilted 
• Added in Decisional balancing tool 
The following modifications were made following the pilot of session 2: 
• Swapped order of HbA1c and complications content to review complications first 
• Add in spider diagram of blood glucose activity  
The following modifications were made following the pilot of session 3: 
• Added in use of plastic food and plates to represent how many carbohydrates group 
members are eating  
• Added DIRECT study liver scan 
More details on the modifications following exit interviews are provided in chapter 7. 
6.10. How well? 
Planned fidelity is to be examined in a feasibility randomised controlled trial (beyond the 
scope of this PhD). Audiotaping of DIME intervention sessions will be used to conduct 
fidelity assessment to a) demonstrate the facilitator is using behaviour change techniques 
and psychological techniques as intended (adherence), and b) whether these techniques 
were delivered at an adequate level (competence).   
6.11. Chapter summary 
The current insulin start group in south London and NICE guidelines for insulin education 
provided a starting point for the core educational content and safety information for the 
DIME intervention. The DIME intervention was underpinned by psychological theory and 
models including theory of planned behaviour, social cognitive theory, motivational 
interviewing, cognitive behavioural therapy, transtheoretical model, and the behaviour 
change wheel. Additional DIME content was included based on chapter 3 (study 2) 
interview responses on what people with type 2 diabetes desired in insulin education 
including information on: diabetes complications, diabetes technology, weight and insulin, 
diet and carbohydrates, and physical activity. Behaviour change techniques identified in 
chapter 2 (study 1) and chapter 5 (study 4) were incorporated into each session of DIME as 
appropriate to maximise behaviour change and aid insulin self-management. Chapter 4 
(study 3) highlighted the importance of being aware of depressive symptoms in relation to 
insulin initiation and therefore DIME incorporates techniques which support people with 
depressive symptoms. The next chapter describes the pilot testing and evaluation of the 





Chapter 7 : An evaluation of the pilot 




























7.1. Chapter scope 
This chapter describes study 5 of this thesis which is a qualitative evaluation of views of 
people who attended the DIME pilot sessions and a quantitative case study report to assess 
potential improvement in biomedical outcomes following the DIME intervention (and 
initiation of insulin). This chapter also outlines modifications made to the DIME manual 
following exit interviews. The aim of this study was to determine the acceptability of the 
pilot DIME intervention. 
7.2. DIME pilot 
Three sessions of DIME were piloted on two different groups of people with type 2 
diabetes who had recently initiated insulin (within 1 month of first insulin prescription) or 
were unsure about initiating insulin therapy but wanted to learn more. One person only 
attended the first round of DIME (all three sessions). Four people attended the second 
round of DIME, where 2 people attended all three sessions, 1 person did not attend the last 
session (reason unknown, difficult to reach), and the fourth person did not attend the 3rd 
session as they did not want to start insulin due to occupational reasons (bus driver). 
Modifications following each round of DIME are described in detail in chapter 5. The 
sessions were carried out at local general practice surgeries and a community venue within 
south London, a motivational interviewing trained diabetes specialist nurse (KW) facilitated 
the sessions and the sessions were observed by a PhD student (RU).  
7.3. Methods  
Interviews were one-off, semi-structured, and one-to-one of people who had attended all 
sessions of the DIME intervention. Ethical approval was obtained by King’s College Hospital 
(ref: 17/LO/0363). This research was reported according to the consolidated criteria for 
reporting qualitative research checklist (COREQ) (appendix 7.1).  
7.3.1. Recruitment and sample 
During the first session of DIME, the group was asked if they were willing to be interviewed 
regarding their experience of DIME following attending all three sessions. People were 
purposively sampled if they had attended all three sessions so they could give feedback on 
content across the intervention.  
7.3.2. Data collection  
The topic guide was designed by 2 researchers (RU & KW) (appendix 7.2). Interviews were 
conducted by a female PhD student researcher (RU) who had observed the DIME 
intervention sessions and has had experience of conducting qualitative research. The 
interview was not piloted. Owing to the semi-structured nature of the interviews, the 
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interviewer provided prompts and additional questions which were not in the topic guide. 
Eligible participants were given an information sheet (appendix 6.5) and consent form 
(appendix 6.6) to consider, and if willing they were contacted via telephone by the 
researcher (RU) to arrange a convenient date and time. At the convenience of the 
interviewee, the interview location was offered at a King’s College London research facility; 
or the participants’ local general practice surgery.  Friends or family of the interviewee 
were welcome to observe. Interviews were audiotaped and field notes were made 
immediately after the interview.  
Interviewees were informed the study was funded by the National Institute for Health 
Research and the specific purpose of the project was to test a newly developed group 
intervention to help people with type 2 diabetes start insulin.  
Interviewees consented to clinical data being obtained from their medical records 
regarding their diabetes treatment and biomedical outcomes pre and post DIME. Data built 
case studies for each interviewee including age, sex, ethnicity, diabetes treatment pre-
insulin, insulin type (dose and frequency), HbA1c, blood pressure, estimated glomerular 
filtration rate (eGFR) and total cholesterol.  
7.3.3. Data analysis  
Inductive thematic analysis identified relevant themes within the anonymised data and was 
managed in NVivo12. The 6 stages of analysis were: 1) familiarisation of data (reading 
transcripts and making initial impression notes); 2) generation of initial codes (RU & ASM; 
reviewed by KW); 3) Collating codes to search for themes; 4) Review of themes and 
applying to coded data; 5) Defining and naming each theme; 6) Production of this PhD 
thesis chapter (chapter 7).  
Case study data was qualitatively summarised. Independent sample t-tests were used to 
determine differences in biomedical outcomes (HbA1c, systolic blood pressure, diastolic 
blood pressure, eGFR, total cholesterol) pre and post DIME.  
7.4. Results 
7.4.1. Case study findings 
Three people attended all three sessions of DIME and were all willing to be interviewed. 
The demographic and clinical information of the interviewees is outlined in table 7.1. The 
mean age was 60.33 (SD=4.04). All three interviewees were white males who attended 
their first session of DIME within 1 month of first insulin prescription and all were 
previously on 3 OADs before initiating insulin (including metformin and gliclazide). 
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Interviewee 01 and 03 started on intermediate-acting insulin (Humulin I) taken once per 
day before bed, which is recommended by NICE guidelines (NICE, 2015). Interviewee 02 
started on premixed insulin (Novomix 30) taken before breakfast due to a post-prandial 
increase in blood glucose after breakfast. Interviewee 01 and 02 remained on their initial 
insulin type at 6-8 months follow-up (titrating dose up as required). Interviewee 03 
changed insulin from intermediate-acting (Humulin I) to long-acting (Abasaglar) 8 months 
later due to HbA1c targets not being reached (79 mmol/mol), however, HbA1c increased 
since starting the long-acting insulin (85 mmol/mol), perhaps due to optimal titration not 
yet being reached. Interviewee 02 obtained optimal HbA1c target (<58 mmol/mol) at 4 
months post-insulin initiation follow-up (48 mmol/mol) which was maintained at 9 months 
post-initiation (50 mmol/mol). Interviewee 01 remains above HbA1c target (94 mmol/mol) 
11 months post insulin initiation, but overall HbA1c has reduced by 15mmol/mol since pre-
DIME/insulin HbA1c test (109 mmol/mol).  
Overall, there were no significant changes pre to post DIME in systolic blood pressure 
(p=0.34), diastolic blood pressure (p=0.84), eGFR (p=0.95), and total cholesterol (p=0.93). 
All were in target range for blood pressure (<140/90mmHg) pre and post DIME (NICE, 
2019). Interviewee 01 and 02 had target eGFR (>90) pre and post DIME (NKF, 2013). 
Interviewee 03 presented eGFR of 60 pre and post DIME, so even though not in target 
there was no deterioration following DIME. Interviewee 03 had elevated total cholesterol 
pre-DIME (5.1) but this reduced post-DIME (4.2). For interviewee 01 and 02 total 
cholesterol remained in target (<5) pre and post DIME (NHS, 2019).  
7.4.2. Exit interview findings 
The average duration of interviews was 16.01 minutes. Inductive thematic analysis 
revealed three themes with further subthemes displayed below: self-management needs, 












Table 7.1- Case study data of DIME interviewees 
 Interviewee 01 Interviewee 02 Interviewee 03 
Date of first DIME 
session 
November 2018 December 2018 December 2018 
Age (on starting insulin)  58 65 58 
Sex Male Male Male 




Metformin* (Jun 10) 
Gliclazide** (Oct 11) 
Sitagliptin*** (Aug 18) 
Gliclazide** (Oct 15) 
Metformin* (Oct 15) 
Dapagliflozin**** (Dec 
15)  
Metformin* (Dec 12) 
Sitagliptin*** (Feb 13) 
Gliclazide** (Apr 18) 
Starting insulin type 
(starting month/year), 
dose, frequency 
Humulin I (Nov 18), 10 
units, once per day 
(before bed)  
Novomix 30 (Nov 18), 6 
units, once per day 
(before breakfast) 
Humulin I (Nov 2018), 12 
units, once per day (before 
bed) 




Humulin I (June 19), 18 
units, once per day 
(before bed) 
Novomix 30 (Aug 19), 10 
units, once per day 
(before breakfast) 
 
Abasaglar (Jul 19), 74 units, 
once per day (before bed) 
HbA1c (month/year) 
Pre-DIME  109 (Aug 18) 64 (Nov 18) 99 (Nov 18) 
Post-DIME  114 (Jul 19) 
94 (Oct 19) 
48 (Mar 19) 
50 (Aug 19)  
72 (Mar 19) 
79 (Jul 19) 
85 (Sep 19) 
Blood pressure (month/year) 













Pre-DIME  106 (Dec 18) 102 (Jul 18) 60 (Jul 18) 
Post-DIME   94 (Apr 19) 110 (Aug 19) 60 (Jul 19) 
Total cholesterol (month/year) 
Pre-DIME  2.9 (Dec 18) 3.4 (Jul 18)  5.1 (Nov 18) 
Post-DIME 3.6 (Apr 19) 3.4 (Aug 19)  4.2 (Jul 19) 



































1. Self-management needs 
The DIME intervention covered both practical demonstrations and practice relevant to 
insulin self-management as well as addressing psychological concerns of this treatment. 
a. Practical skills 
Interviewees valued learning practical insulin self-management skills such as learning how 
to inject: 
“I was going on insulin just the practical side of it you know how to do it and things 
to bear in mind to do with the insulin.” (02) 
They also described the challenges of initially self-administering insulin therapy but feeling 
better after practice: 
Figure 7.1- Summary of themes and subthemes in study 5 
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“I was a bit nervous at first and I scrambled a bit doing it myself, then I sort of got 
the hang of it because I don’t think I was doing it entirely correctly but after a while, 
a bit of trial and error.” (02) 
Other valued practical skills included self-monitoring blood glucose to direct insulin self-
management in relation to adjusting doses: 
“Keeping a record of my insulin and my blood sugar levels has led me to work out 
what it is that I'm doing wrong and that kind of thing.” (03)   
There was a preference for experience learning, for example, a walking activity to 
demonstrate the positive effects of exercise on blood glucose: 
“I didn't feel that I was under any kind of pressure but I was surprised by how much 
my sugar levels have gone down. And if someone had told me to do that I ever 
thought yeah, of course, but yeah. Actually having done it and actually had it 
proved to me. I was I was amazed and that's really useful to know.” (03) 
One DIME attendee did not enjoy the walking activity but did appreciate the value of doing 
so: 
“But I didn’t think much of the walk [laughs]… you know its something to think 
about you know.” (01)  
A session that one interviewee anticipated not being useful was the third session which had 
content on diet as they had been to previous diabetes education sessions on this topic. 
However, once they attended this session, they realised it was useful and more applied to 
insulin self-management: 
“Strangely enough the one I thought would be least useful and I wasn’t particular 
for was the last one which was mainly on food. Because I’ve had those sessions with 
various people before but in fact it was quite you know a good practical guide I 
thought.” (02) 
There were some practical skills which were not covered in the pilot DIME intervention 
such as handling insulin on long term trips: 
“…you know how do you keep it [insulin] and you know it’s ok if you are only going 





b. Psychological and emotional needs 
Two people described the benefits of starting insulin such as the alleviation of fears, feeling 
better, and feeling in control of self-management: 
“I was a bit scared about going on to the insulin of course but once on it, it seems 
quite routine.” (02) 
“think I'm beginning to feel some of the benefits of having my blood sugar levels 
under control that that I wasn't aware. I didn't realize there would be. Quite so 
much of a change in how I felt.” (03)    
“You know simple things like being in control of the amount that I give myself was 
something that took a little time to get used to but at the same time was quite 
liberating knowing that I could alter the amount if I needed to.” (03) 
This was supported by the DIME facilitator who appeared to alleviate concerns around 
insulin initiation as well as provide reassurance that insulin can prevent long-term 
complications:  
“There were questions obviously and concerns that I thought were addressed.”  
(01) 
“… it has given me reassurance, type of thing, that if I did control my diabetes, I can 
lead a moderately, err, the worst, the effects of diabetes would be greatly reduced, 
so it’s given me that reassurance. I am grateful for that.” (01) 
Another interviewee described the positive communication style between the DIME 
facilitator and the group which did not rely on ‘scare tactics’:   
“I didn’t want a situation where you say if I didn’t take the medicines…the 
consequences are….that way giving you a scary system or anything else I’ve learnt… 
I thought [the facilitator] came across as understanding and appreciated my 
problems.” (01)  
There was evidence for the need for ongoing psychological support following the DIME 
intervention, for example, reassurance with administering correct insulin dose:  
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“I did need a bit of encouragement about that because I put it up originally from 6 
to 8 [units] then to 10 but being still new at the game so to speak, I was a bit 
worried if I was doing the right thing” (02) 
For one DIME attendee there seemed to be a burden of diabetes treatment and managing 
medications as well as insulin, which was not covered in the DIME intervention: 
“…with the amount of drugs, I’m having, the tablets, it is, you know to me, it is a bit 
confusing…” (01) 
2. Group dynamics 
The format of DIME was a group; therefore, it was important to determine whether group 
dynamics were successful.  
a. Common ground  
There were reports of common ground amongst group attendees and interest in sharing 
experiences: 
“It was quite interesting to talk to the other people as well, as well as to get 
guidance on what to do. To compare, even though they might be on a different type 
of insulin, it’s interesting to see the common ground” (02) 
“I did find the talking with the other people who were in the group interesting. And 
helpful as well because that you were able to share experiences.” (03) 
However, it was noted (though not a problem in their group) group harmony may depend 
on the personalities within the group: 
“I thought, well it depends who you're on it with but the people I was on with I think 
it went very well.” (02) 
 
b. Preference for group education  
One interviewee described initially wanting one-to-one education but through attending 
DIME realised the usefulness of a group to provide a broader perspective: 
“I wanted one-to-one with a nurse strangely, you know, it needs quite useful to get 
another opinion or somebody might want to point something out you hadn't 
thought of and indeed the nurse might not have considered” (02) 
196 
 
Another found groups encouraging and would be interested in other exercise-based group 
education sessions:  
“I like the idea of the encouragement you get from being in a group and if there 
was a similar kind of group that had more perhaps physical exercise or something 
like that built into as well. I would enjoy that.” (03)   
One group attendee preferred one-to-one education but was happy to attend a group 
situation if required: 
“…my preference is on a one to one basis. I am not a team person that way, but if 
circumstances meant that I had to be in a group situation I was prepared to along 
with that.” (01) 
One-to-one was preferred to address sensitive issues: 
 “So, there are probably things that are pertinent to me particular that didn't get 
covered but then I wouldn't have expected them to within a group situation. “ (03) 
c. Group size  
The group sizes of the DIME pilot were small as commented by interviewees: 
“I think the first session there was supposed to be somebody else come along but 
that person did not attend.” (01) 
One preferred a smaller group to give everyone a chance to contribute: 
“I think that was the other point and a very small group. Yeah, if you get more than 
that [4 people in the group] you always risk the thing about it being somebody 
might dominate it or something and whereas, you know, there's there was good 
sort of, everyone was saying and equally contributing.” (02) 
On the contrary, another preferred a larger group to have the opportunity to share more 
experiences and get a more ‘rounded’ viewpoint: 
“I think if the group was bigger, it would be possible to perhaps get a more 
rounded, you know, there was two or three of us in that group and we were all 
doing different kinds of insulin at different times. And so, the experiences that we 
could share with were slightly limited.” (03) 
3. Delivery preferences 
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DIME was delivered in 3 sessions lasting 2 hours each, one group at a community setting, 
and the other group at a local general practice surgery.  
a. Amount and length of sessions  
The length of the sessions seemed to be acceptable: 
“I think the length of the sessions was about right.” (03) 
However, one felt they could be half an hour shorter: 
“They perhaps a little stretched out. I think perhaps an hour and a half rather than 
two hours.” (02)   
Another commented positively on having a larger gap between the second and third DIME 
session to implement what has been learned: 
“I think it’s right to have break it in so you can think about what has been discussed. 
If it’s all in one day, it’s very difficult to handle the thing.” (01) 
One urged for providing contact details of someone who could answer questions following 
the DIME intervention: 
“What I'd like to think that if something occurred to me that I was unsure about 
that there would be someone that I could phone to ask.” (03) 
b. Convenience of sessions  
The DIME location was convenient for two attendees and timing even though they both 
needed to book time off work: 
“the last two sessions I was able to get the time off work in order to do so. So that, 
that wasn’t an issue… it’s not too difficult for me to get here… there wasn’t any 
issues about barriers or anything else or that.” (01) 
“I have work but an hour and the location for me, it was very convenient. So I didn't 
have to come far at all. So that wasn't a problem. “ (02)  
Even though they attended all sessions, the location was not ideal for one interviewee: 
“I've got to say that the only gripe I had really with the sessions was where they 
were at and for me… even though it's not that far a distance is actually incredibly 




7.5. Discussion  
7.5.1. Summary of results 
Analysis of exit interviews revealed mostly positive feedback towards the DIME 
intervention in relation to practical skills learned, psychological support received, finding 
common ground amongst DIME attendees, and acceptability of DIME delivery including 
amount and length of sessions, and convenience of sessions. In summary, all 3 interviewees 
have remained on insulin therapy 9 (or more) months post-initiation. Case study data 
revealed, even though 2 out of 3 interviewees remain above HbA1c target (>58 mmol/mol) 
post-DIME and insulin initiation, all improved HbA1c from pre-DIME test to most recent 
HbA1c follow-up (9-11 months insulin initiation). In addition, overall there was 
maintenance of other biomedical targets post-DIME (blood pressure, eGFR, total 
cholesterol).  
 
7.5.2. Comparison to thesis study 2 findings  
Chapter 3 (study 2) describes a qualitative evaluation of an existing insulin start group run 
in south London. There are some similarities themes drawn from chapter 3 and the current 
chapter 7 qualitative analysis. For example, chapter 3 found that peer support from the 
insulin start group was important to create a supportive environment. Likewise, in DIME, 
attendees found common ground and enjoyed sharing their experiences of managing 
diabetes. Chapter 3 refers to interviewees being keen for more peer support such as social 
activities. One interviewee in chapter 7 also comments on the desire for more peer support 
in the form of exercise sessions. Peer support is an important aspect of group education 
where previous research has demonstrated it is beneficial knowing other people with type 
2 diabetes who are on insulin therapy (Bogatean & Hâncu, 2004a; Tan et al., 2011). The 
interviewees’ desire for exercise-based sessions follows the ‘walking activity’ in session 3 of 
DIME which is a type of experience-based learning. This relates to Kolb's Experiential 
Learning Theory (Kolb, 1984) which suggests knowledge is created through experience. The 
walking activity was designed to demonstrate exercise can reduce blood glucose, which 
was successful in 2 out of the 3 DIME interviewees. Healthcare professional reassurance 
and taking time to address concerns is important for insulin adherence (Stuckey et al., 
2018; Tang et al., 2018). The findings of this thesis chapter support the value of reassurance 
where the facilitator provided reassurance around injection technique (chapter 3) and that 
insulin prevents long term complications (chapter 7).  
Chapter 3 indicated group dynamics were not managed well in some insulin start groups, 
and some expressed a preference for one-to-one education so questions could be 
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answered. One interviewee in chapter 7 felt that a small group would give a better 
opportunity for everyone to contribute, but on the contrary, another preferred a larger 
group to encourage the sharing of broader experiences. Hence, views of optimal group size 
appear to be mixed. Optimal group size for diabetes education is unknown and further 
research is required (Rickheim, Weaver, Flader, & Kendall, 2002) and group size depends 
on the type of people within the group, the type of diabetes education, the method of 
delivery, and facilitator preference (Mensing & Norris, 2003). Though on a whole, 
interviewees were positive about DIME, one interviewee in DIME suggested more sensitive 
issues should be addressed one-to-one indicating group education cannot address all 
concerns.   
Even though there were similar themes between chapters 3 and 7, different conclusions 
were drawn in some cases. For example, chapter 3 found that not all insulin start group 
facilitators had the skills to address concerns around insulin, however, this did not seem an 
issue following DIME where communication style and alleviation of fears were positively 
commented on. One interviewee in DIME appreciated the facilitator not using ‘scare 
tactics’, for example, threatening with the risk of long-term diabetes complications. 
Research has long known that that health threat messages can cause defensive processing 
where people wish to protect their self-integrity, and therefore the threatening message is 
disregarded (Steele, 1988). Motivational interviewing, which is the psychological technique 
used in DIME, helps to reduce message defensive and increase message acceptance (Ehret, 
LaBrie, Santerre, & Sherman, 2015). Research has not evaluated whether this translates to 
behaviour in terms of persisting with insulin therapy in type 2 diabetes. Data from the case 
study of interviewees reveal they remained on insulin therapy at 9-11 months follow-up, 
which could be explained by motivational interviewing techniques increasing message 
acceptance promoting persistence to insulin therapy. Larger, powered studies are required 
to determine the reliability of these results.  
Following either an insulin start group or DIME, there still appeared to be concerns around 
diabetes self-management. For example, following the insulin start group (chapter 3) there 
were still concerns around hypoglycaemia, injecting, the longevity of insulin, weight, and 
insulin, and social stigma. These concerns following the insulin start group were not 
reported post-DIME which could indicate this new intervention resolved some of these 
issues. However, there were still some concerns following DIME, for example, one 




7.5.3. Exit interviews and DIME modifications  
Exit interviews did outline some areas for improvement which led to modifications of the 
DIME manual summarised in table 7.2.  For example, added content in relation to 
individualised education around medication regime and traveling with insulin on long trips. 
Other additions included exploring the importance and confidence of reducing blood 
glucose, the framing of session 3 i.e. dietary content relates to insulin which would not 
have been covered in previous diabetes education sessions, and set space for contact 
details for post-DIME queries. The final DIME manual can be found in appendix 6.2.  
 
Table 7.2- Modifications to DIME manual following exit interviews 
Exit interview quote Modification to manual 
Session 1 
“I don’t know the name of it, 
the make of it.” (01) 
Making sure everyone in group knows the name of their insulin and 
what it does (e.g. long, intermediate or short-acting) as opposed to 
talking through the types of insulin generally. 
“…with the amount of drugs, 
I’m having, the tablets, it is, 
you know to me, it is a bit 
confusing…” (01) 
 
Talking through how other medications fits in with insulin regime and 
planning how to remember to take medications (individual plans). 
Session 2  
“Keeping a record of my 
insulin and my blood sugar 
levels has led me to work out 
what it is that I'm doing 
wrong and that kind of thing.” 
(03)   
 
Explore not only importance of taking insulin but also importance in 
reducing blood glucose and confidence in reducing blood glucose. 
“Strangely enough the one I 
thought would be least useful 
and I wasn’t particular for was 
the last one which was mainly 
on food. Because I’ve had 
those sessions with various 
people before but in fact it 
was quite you know a good 
practical guide I thought.” (02) 
 
Emphasise the third DIME session on diet relates to insulin and diet, 
this content would not have necessarily been covered in other diabetes 
education groups. 
Session 3  
“…you know how do you keep 
it [insulin] and you know it’s 
ok if you are only going for a 
week or two of course but 
perhaps if you are going for 
longer [on holiday] …” (02) 
 
Content on travelling with insulin on long trips. 
“What I'd like to think that if 
something occurred to me 
that I was unsure about that 
there would be someone that I 
could phone to ask.” (03) 
 




7.5.4. Strengths and limitations  
One limitation is interviews were not returned to interviewees for comment, so 
interviewees did not have the opportunity to provide further insight. An advantage of this 
qualitative analysis over chapter 3’s analysis is diabetes treatment pre and post insulin 
initiation (and DIME attendance) could be accounted for.  
Recruitment to the pilot phase of DIME was limited due to the number of people with type 
2 diabetes referred to the secondary care diabetes teams to initiate insulin at the time of 
recruitment. The DIME intervention was designed to be flexible in group size as it was 
assessed as more important for people with type 2 diabetes to access the DIME 
intervention at the appropriate time i.e. within 1-month insulin initiation, rather than 
waiting for a larger group size (for example n>4) when people might have been prescribed 
insulin at different times (for example within 1 month versus >1 month ago).   
Interpretation of these findings is somewhat limited due to small sample size (n=3) which 
lacked diversity (all male, white ethnicity, all on similar OAD treatment before insulin 
initiation) contributing to poor information power. Lack of power and diversity in these 
results might limit the development of the next stage of the DIME intervention. However, 
owing to this only being a pilot phase, the findings are insightful towards modifying the 
manual for future feasibility randomised controlled trial. In addition, insights were 
strengthened by data analysis being conducted by two researchers with different 
backgrounds (health psychology and diabetes nurse). Future qualitative evaluation of DIME 
should adopt a larger sample size and increasing diversity by purposively sampling for age 
ethnicity, sex, and insulin treatment type; in addition to achieving information power based 
on study aim, sample specificity, quality of dialogue, and analysis strategy (Malterud et al., 
2016). This would strengthen the interpretation of results, making them more generalisable 
to the population of people with type 2 diabetes, hence providing a stronger influence in 
the development of the DIME intervention.  
Thereafter, a randomised controlled trial would be useful to determine whether the DIME 
intervention improves HbA1c, insulin adherence and persistence, and other outcomes over 
usual care. 
7.6. Chapter summary  
This initial qualitative evaluation of the pilot phase of DIME development revealed positive 
views of DIME attendees, improvements in HbA1c, and maintenance of other clinical 
outcomes. Therefore, at this stage DIME seems to an acceptable intervention for helping 
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people with type 2 diabetes start insulin. The interviewees revealed some areas of DIME 
which require improvement; hence the DIME manual has been modified considering these 
suggestions. This evaluation was useful to determine initial acceptability and to strengthen 
manual development for a future feasibility randomised controlled trial (beyond the scope 

















































8.1. Overview  
The overall aim of this thesis was to develop a group psychological intervention to optimise 
insulin initiation for people with type 2 diabetes. This new intervention was called DIME. 
This thesis covers the following MRC phases of developing and evaluating complex 
interventions: development (studies 1-3; chapters 2-4); and part of the piloting phase 






















Identifying the evidence base (studies 1-3; chapter 2-4) 
Identifying theory (study 4; chapter 6) 
Modelling processes and outcomes (study 4; chapter 5) 
Feasibility and piloting 
Testing procedures (study 4 and 5; chapter 6 and 7) 
Estimating recruitment and retention (beyond thesis) 
Determining sample size (beyond thesis) 
Implementation 
Dissemination (write up of thesis) 
Surveillance and monitoring (beyond thesis) 
Long-term follow-up (beyond thesis) 
Evaluation 
Assessing effectiveness (beyond thesis) 
Understanding change process (beyond thesis) 
Assessing cost effectiveness (beyond thesis) 
Figure 8.1-MRC phases of developing and evaluating complex interventions: DIME 
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8.2. Summary of Main findings  
 
8.2.1. Study 1: A meta-analysis to determine the effectiveness of behaviour change 
techniques in psychological interventions to improve HbA1c for people with Type 2 
diabetes mellitus. 
Study 1 of this thesis was the first meta-analysis to examine an association between HbA1c 
and behaviour change techniques extracted from psychological interventions (n=67) for 
people with type 2 diabetes. Study 1 of this thesis demonstrated that HbA1c was 
significantly lower in psychological interventions compared to the control conditions. 
Across trials, ‘social support’, ‘goals and planning’, and ‘feedback and monitoring’ were the 
most frequently used behaviour change technique categories associated with improvement 
in HbA1c.  
Although previous type 2 diabetes research has not extracted behaviour change techniques 
from psychological interventions, previous literature has extracted behaviour change 
techniques from other types of interventions including online self-management 
interventions (van Vugt, de Wit, Cleijne, & Snoek, 2013), behavioural interventions 
targeting physical activity (Avery, Flynn, Van Wersch, Sniehotta, & Trenell, 2012), 
interventions targeting both physical activity and diet (Cradock et al., 2017), and 
implementation interventions (Presseau et al., 2015). Unlike study 1 of this thesis, none of 
these previous studies performed a meta-regression between glycaemic control and 
behaviour change technique category. 
Data extraction of behaviour change techniques in study 1 of this thesis was challenging. It 
might be expected that behaviour change techniques reporting might have improved over 
time since the introduction of the behaviour change technique taxonomy (Michie et al., 
2015), however unclear reporting was evident regardless of the year of publication.  This 
was important to consider in the development of the DIME intervention which clearly 
reported all behaviour change techniques (study 4) as well as additional psychological 
techniques according to the TIDieR checklist.  
8.2.2. Study 2: Experiences of attending group education to support insulin initiation 
in type 2 diabetes- a qualitative study 
Study 2 (chapter 3), a qualitative evaluation of an existing insulin start group in south 
London, indicated the need for improved psychological skills training for nurse facilitators 
of the insulin start groups to adequately address negative insulin beliefs and manage group 
dynamics. Even though not directly related to insulin education, previous research 
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indicated nurses benefited from psychological skills training in supporting people with type 
2 diabetes (Graves, Garrett, Amiel, Ismail, & Winkley, 2016). Hence, the aim was to train 
DIME nurse facilitators in psychological skills to support the initiation and ongoing insulin 
self-management. Study 2 of this thesis specifically evaluates group insulin education, 
whereas previous research has only evaluated general type 2 diabetes education 
(Chatterjee, Davies, Stribling, Farooqi, & Khunti, 2018; Deakin, Cade, Williams, & 
Greenwood, 2006; Loveman, Frampton, & Clegg, 2008; Scain, Friedman, & Gross, 2009; 
Trento et al., 2010). 
Practical demonstrations of insulin injection technique prevent delay in initiating insulin 
(Polonsky et al., 2019), likewise in study 2 of this thesis practical insulin demonstrations 
helped address fears of ongoing uptake of insulin therapy. This technique was taken 
forward in the DIME intervention design. 
Previous qualitative work reports the positive and negative experiences of insulin initiation 
in people with type 2 diabetes (Holmes-Truscott, Browne, & Speight, 2016). Study 2 of this 
thesis sampled people with a similar duration of type 2 diabetes (around 11 years) but adds 
to the findings by exploring the impact of group insulin education and subsequent insulin 
self-management.  
8.2.3. Study 3: Prospective study of the association between psychological factors at 
type 2 diabetes diagnosis and insulin initiation- South London diabetes (SOUL-D) 
cohort 
Study 3 (chapter 4) was an 8-year primary care medical record follow-up of the SOUL-D 
cohort consisting of 1735 people with type 2 diabetes. Study 3 of this thesis study found a 
prospective association between depressive symptoms at type 2 diabetes diagnosis and 
shorter time to insulin initiation. Therefore, not only is depression more prevalent in 
people with type 2 diabetes than the general population (Ali, Stone, Peters, Davies, & 
Khunti, 2006; Anderson, Freedland, Clouse, & Lustman, 2001; Krishna, 2018; Moulton, 
Hopkins, Ismail, & Stahl, 2018), but depressive symptoms also impact ongoing treatment 
and bring forward the initiation of insulin treatment. 
Previous research on the SOUL-D cohort found an association between baseline depressive 
symptoms and increased inflammation (Laake et al., 2014) and an association between 
depressive symptoms and 2-year follow-up macrovascular symptoms (Ismail et al., 2017). 
Study 3 of this thesis adds to these findings by finding a significant association between 
insulin initiation and, baseline macrovascular complications and depressive symptoms.  
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The findings from study 3 are unique and highlight the importance of considering 
depressive symptoms from diagnosis and throughout the progression and treatment of 
type 2 diabetes. Previous work has only studied the association between depressive 
symptoms in insulin-naïve populations of people with type 2 diabetes (Iversen et al., 2015; 
Nefs, Pop, Denollet, & Pouwer, 2013), and not from type 2 diabetes diagnosis. The DIME 
intervention took this into account by utilising psychological techniques that were 
considerate of people with depressive symptoms. For example, techniques derived from 
cognitive behavioural therapy which was initially developed to treat people with 
depression that have been used in previous type 2 diabetes interventions e.g. the D-6 
(Ismail et al., 2018) and MOVE-IT (Bayley et al., 2015). 
Study 3 of this thesis was also the first study to examine the prospective longitudinal 
association between diabetes distress and negative insulin beliefs, and insulin-related 
outcomes. Previous research has found an association between diabetes distress and 
negative insulin beliefs (Makine et al., 2009). In addition, negative insulin beliefs (otherwise 
known as psychological insulin resistance) have been commonly associated with a delay in 
insulin initiation (Ng, Lai, Lee, Azmi, & Teo, 2015). However, study 3 of this thesis did not 
find a significant association between these two psychological factors at type 2 diabetes 
diagnosis and insulin-related outcomes (after controlling for baseline confounders). 
However, the variables in this analysis were only baseline predictors (i.e. measured within 6 
months of type 2 diabetes diagnosis). Negative insulin beliefs or diabetes distress 
developed later in the progression of type 2 diabetes might predict insulin-related 
outcomes. Therefore, as psychological insulin resistance is commonly reported as a barrier 
to insulin initiation elsewhere (Ng et al., 2015)  as well as negative beliefs existing in people 
with type 2 diabetes who have already started insulin (Holmes-Truscott et al., 2016), the 
DIME intervention still aimed to address psychological insulin resistance to improve insulin 
self-management behaviours and subsequent glycaemic levels.  
8.2.4. Study 4: The development of the DIME intervention  
Study 4 describes the development of the DIME intervention detailed in chapter 5 (stages 
of the behaviour change wheel) and chapter 6 (reported according to TIDieR checklist) of 
this thesis.  
There is evidence for the efficacy of general type 2 diabetes group-based education 
(Chatterjee et al., 2018; Davies et al., 2008; Khunti et al., 2012). Much evidence specifically 
exploring insulin education refers to one-to-one education sessions (Bala, Rusu, Moise, & 
Roman, 2019; Brod, Alolga, & Meneghini, 2014; Mathers et al., 2012; N Patel et al., 2015) 
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and none of these studies consider psychological aspects towards initiating as well as 
persistence or adherence to insulin treatment. The DIME intervention adds to the literature 
by developing a group-based insulin education, aiming to address psychological problems 
associated with insulin initiation and persistence/adherence to insulin.   
The behaviour change wheel is a health psychology model integrating 19 behaviour change 
frameworks. The COM-B model (capability, opportunity, and motivation- behaviour model) 
is the centre of the wheel. The first three studies of this thesis identified that all the COM-B 
components should be targeted for insulin self-management to improve. For example, 
study 1 found the most frequently reported behaviour change techniques associated with 
improvement in HbA1c were ‘social support’, ‘goals and planning’, and ‘feedback and 
monitoring’ which can be linked to opportunity (i.e. social opportunity, e.g. having more 
people around injecting insulin), motivation (i.e. reflective motivation, e.g. goal setting in 
relation to managing with insulin therapy), and capability (i.e. psychological capability, e.g. 
self-monitoring blood glucose) components of COM-B, respectively. In study 2, the 
qualitative themes generated were linked to capability (ongoing self-management success 
e.g. knowledge and skills to initiate insulin), opportunity (need for more peer support e.g. 
having peer support to self-manage with insulin), and motivation (insulin concerns post-
group e.g. confidence to inject and plans to do it) COM-B components. Study 3 indicates 
that depressive symptoms impact the initiation of insulin, therefore reducing depressive 
symptoms relates to the motivation (automatic motivation) component of the COM-B 
model. The final stages of the behaviour change wheel involve identifying specific 
behaviour change techniques (linked to COM-B components outlined) through which the 
DIME intervention was to be delivered, in addition to evaluating the appropriate mode of 
delivery.  
The outcome of the behaviour change wheel led to a draft intervention strategy of DIME. In 
brief, the DIME intervention is a group-based nurse-led psychological intervention to 
optimise insulin initiation in type 2 diabetes (within 1 month of first insulin prescription). 
DIME is 3 sessions and is delivered at a local venue (general practice, hospital, community 
venue). Printed media and phone helpline support the DIME intervention. Twenty-seven 
behaviour change techniques were identified as relevant to the DIME intervention.  The 
DIME intervention is also underpinned by psychological theory and models including the 
theory of planned behaviour (Ajzen, 1991), social cognitive theory (Bandura, 1991), 
motivational interviewing (Rollnick & Miller, 1995), cognitive behavioural therapy (Beck & 
Alford, 2009), and the transtheoretical model (Prochaska & Velicer, 1997). Combined, these 
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theories strengthen the development and delivery of the DIME intervention to optimise 
insulin initiation and self-management for people with type 2 diabetes.  
8.2.5. Study 5: An evaluation of the pilot sessions of DIME 
Study 2 of this thesis added to the literature by evaluating group-based insulin education 
which had not been previously examined, and study 5 (chapter 7) of this thesis further adds 
to the literature of evaluating group-based psychological insulin education. Study 5 of this 
thesis qualitatively (one-to-one interviews) and quantitatively (case study report) evaluated 
the DIME intervention pilot sessions. The qualitative evaluation found that DIME was 
overall acceptable to 3 people with type 2 diabetes who had attended all three DIME pilot 
sessions to initiate insulin. In addition, the case study report of the interviewees revealed 
improvements in HbA1c post DIME and maintenance of other clinical outcomes. Study 5 
allowed for modifications of the DIME materials to strengthen overall development.  
8.3. Clinical implications 
The clinical implications of the research conducted in this thesis are as follows: 
1. The behavioural change technique categories ‘social support’, ‘goals and planning’, and 
‘feedback and monitoring’ should be the initial building blocks of type 2 diabetes 
education which aim to improve glycaemic levels (study 1 of this thesis).  
2. Existing insulin start groups in south London and similar insulin group interventions 
worldwide require improvements, for example, psychological training for diabetes 
specialist nurses to help manage group dynamics and address concerns around insulin 
(study 2 of this thesis). 
3. Where possible insulin group education should be offered to people with type 2 
diabetes soon after first insulin prescription to enhance the group dynamic and shared 
experience (study 2 of this thesis). Therefore, group-based insulin education needs to 
be flexible in group size, for example, the DIME intervention is designed to admit 
people with type 2 diabetes within one month of first insulin prescription.  
4. There is a need for education that is sensitive to people with depressive symptoms and 
type 2 diabetes in initiating insulin treatment.  Depressive symptoms are prevalent 
throughout the progression of type 2 diabetes including bringing forward insulin 
initiation (study 3 of this thesis).   
5. Insulin education for people with type 2 diabetes should be group-based to address 
issue of a declining diabetes specialist nurse population (DUK, 2016), and a growing 
population of people with type 2 diabetes (NHS, 2014). Diabetes group-based 
education is also more cost-effective than individual support (Yki-Järvinen et al., 2007). 
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Initial acceptance to the DIME intervention (study 5 of this thesis) provides a rationale 
for a psychological-informed group-based insulin education.   
6. Psychologically-informed group-based insulin education could optimise insulin self-
management for people with type 2 diabetes by reducing psychological insulin 
resistance and improving glycaemic levels (study 5 of this thesis). The DIME 
intervention aims not only optimising insulin initiation but providing skills and 
knowledge for ongoing insulin self-management. The implications being that insulin is 
the best treatment in type 2 diabetes for improving HbA1c (Davies et al., 2018; Nathan 
et al., 2009), and significantly reduces the risk of developing long-term diabetes 
complications (Caballero, 2009; Turner, Cull, Frighi, Holman, & Group, 1999; UKPDS, 
1998). Not only can this be hugely beneficial to someone with type 2 diabetes in terms 
of positive physical and mental well-being (Holmes-Truscott et al., 2016; Holmes‐
Truscott, Skinner, Pouwer, & Speight, 2015), it also could significantly reduce costs to 
the NHS where a huge part of the budget is accounted for by treating diabetes 
complications (Hex, Bartlett, Wright, Taylor, & Varley, 2012).  
The strength of these clinical implications and recommendations may depend on future 
research outlined in the next sections that would assess the feasibility and effectiveness of 
psychologically-informed group-based insulin education i.e. the DIME intervention.  
 
8.4. Theoretical implications 
The theoretical implications of the research conducted in this thesis are as follows: 
1. This thesis is the first study to use the behaviour change wheel (theoretical framework) 
in the context of developing an insulin education group. Beyond this thesis, a 
randomised controlled trial involving the DIME intervention could determine whether 
the combination of behaviour change techniques underpinning DIME is effective over 
usual care in improving insulin self-management (i.e. uptake, adherence and 
persistence), reducing psychological insulin resistance, and improving glycaemic levels.  
2. Reported behaviour change techniques in the DIME intervention can be utilised in 
future fidelity assessment. The BCTTv1 could be applied to transcripts of DIME sessions 
to determine which behaviour change techniques were delivered and if all behaviour 
change techniques described in chapters 5 and 6 of this thesis were delivered as 
intended (adherence) to an adequate level (competence). Fidelity assessment of 
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control conditions could determine contamination i.e. behaviour change or 
psychological techniques delivered in control (Magill et al., 2018).  
3. Reported behaviour change techniques in the DIME intervention can also be used in a 
future process evaluation. A process evaluation would help explain how the DIME 
intervention works in improving outcomes. Following fidelity assessment of behaviour 
change techniques, an analysis could determine whether the combination of behaviour 
change techniques reported in DIME are associated with measured outcomes.   
4. Behaviour change techniques are also useful in determining cost-effectiveness. For 
example, one study examined the cost-effectiveness of health behaviour-change 
interventions (Beard et al., 2019). The BCTTv1 was applied to 338 behaviour change 
intervention descriptions and regression analyses determined the association between 
behaviour change techniques and cost-effectiveness estimates (for example, quality-
adjusted life years).  
8.5. Recommendations for future research 
Based on the findings of this thesis, the following recommendations for future research 
are: 
1. Study 3 of this thesis, the long-term SOUL-D follow-up, analysed n=1003 participants 
medical records and found a significant association between depressive symptoms and 
insulin initiation after controlling for other baseline confounders. This supports 
following up the remaining participants in the cohort, there were n=1735 recruited at 
baseline, to add power to the analysis. A multi-level methods approach could be 
applied to additionally examine general practice-level data, for example, national 
diabetes audit data such as the size of general practice and performance indicators to 
determine whether these factors are associated with insulin-related outcomes. These 
findings could influence the future development of the DIME intervention.  
2. The initial acceptability of the DIME intervention (study 5 of this thesis) provides a 
rationale for conducting a feasibility randomised controlled trial of DIME versus usual 
care (insulin start groups). A feasibility trial addresses components of the ‘feasibility 
and piloting’ MRC phase (Craig et al., 2008) which this thesis does not cover i.e. further 
testing of study procedures, estimation of recruitment and retention rates, and 
determination of sample size, figure 8.1. 
3. Future qualitative work around the DIME intervention, i.e. following a feasibility 
randomised controlled trial, should aim for a diverse sample, achieving information 
power to maximise generalisability of findings that would help optimise DIME 
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intervention development and increase acceptability to a wider population of people 
with type 2 diabetes initiating insulin.  
4. A diverse PPI group should be recruited to review DIME development so far (for 
example, the stages of the behaviour change wheel and review of the DIME manual) 
and influence future development. This would provide perspective from people with 
type 2 diabetes and strengthen the DIME development process (Staniszewska, 
Haywood, Brett, & Tutton, 2012).  
5. A multicentred randomised controlled trial would be the next step following feasibility 
testing and would address the following components of the MRC phases: assessing 
effectiveness, understanding change process (i.e. process evaluation), and assessing 
cost-effectiveness (Craig et al., 2008).  
6. A long-term follow-up of a randomised controlled trial would further aid 
implementation (dissemination, surveillance and monitoring, and long-term follow-up). 
Future long-term follow-up of the DIME intervention should consider why there are 
previously reported difficulties with long-term efficacy of general type 2 diabetes 
group-based education (Khunti et al., 2012; Norris, Lau, Smith, Schmid, & Engelgau, 
2002). For example, to prevent poor long-term outcomes, optimal contact post-
intervention should be evaluated without compromising cost-effectiveness (Khunti et 
al., 2012; Norris et al., 2002).  
7. Previous research has indicated more work is needed to support people with type 2 
diabetes in managing insulin long-term (Fulcher, Roberts, Sinha, & Proietto), hence 
future research involving the DIME intervention should aim to optimise long-term 
insulin self-management by considering plans for insulin intensification.  
8.6. Strengths and limitations 
A strength of this thesis is the reflexive research design which involved perspectives from a 
multidisciplinary team involved in different aspects of the thesis (outlined in detail in the 
‘reflexivity statement’) for example, diabetes nurses, a health psychologist, psychiatrists, 
and a statistician. This minimises bias that influences different stages of the research 
process. Another strength is the use of mixed-methods primary research to inform the 
development of DIME which increases the validity of the intervention. DIME was evidence-
based and underpinned by existing theoretical concepts. Using existing theory connects the 
research to existing evidence that guides new research, it also helps to describe an 
intervention and to explain why an intervention might be associated with an outcome of 
interest. Throughout this thesis standardised guidelines (PRISMA, COREQ, TIDieR) were 
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used to report the research which aids clarity, and transparency of reported methods and 
findings. 
Study 2 highlighted the need for culturally appropriate resources to support group insulin 
education in type 2 diabetes which supports previous research that has recommended 
culturally appropriate interventions for people of ethnic minority (Machinani, Bazargan-
Hejazi, & Hsia, 2013). However, tailoring insulin group education for people of different 
cultural backgrounds, and religious beliefs can be difficult (Rebolledo & Arellano, 2016). A 
limitation of DIME is that printed materials are still not equitable to all as only available in 
English language. This could be addressed in future research following testing of DIME in a 
randomised controlled trial.  
The pilot phase of DIME, similar to previous studies exploring insulin education 
interventions (Bala et al., 2019; Brod et al., 2014; Mathers et al., 2012; Naina Patel et al., 
2015), does not evaluate subsequent insulin uptake behaviour (adherence or persistence) 
following the intervention. Again, this could be tested in a randomised controlled trial. 
Even though DIME aims to address the psychological aspects of insulin use, it does not 
address healthcare professional clinical inertia nor systemic barriers. Therefore, future 
research should consider a broader intervention targeting insulin initiation in type 2 
diabetes.  
In south London, general practitioners in primary care were more likely to send people with 
type 2 diabetes to diabetes education who were achieving HbA1c targets than those who 
were not (Kirsty Winkley et al., 2016). This could also translate to insulin group education, 
and therefore healthcare professional barriers to sending people with type 2 diabetes 
group education need to be addressed. There are barriers for people with type 2 diabetes 
attending general group-based education (Coates, Slevin, Carey, Slater, & Davies, 2018; 
Horigan, Davies, Findlay‐White, Chaney, & Coates, 2017; Mc Sharry et al., 2019; K Winkley 
et al., 2015), in addition to healthcare professionals barriers (Mc Sharry et al., 2019; K 
Winkley et al., 2018), and system barriers (Coates et al., 2018; Murphy et al., 2018). Hence, 
this is further support for multifaceted interventions not only to support insulin initiation 
but to encourage attendance at group-based insulin education. DIME currently does not 
address all of these barriers.  
8.7. Overall conclusions  
 This thesis designed a new group psychological intervention to optimise insulin initiation 
for people with type 2 diabetes called DIME. The development of DIME was informed by 
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study 1) a meta-analysis of psychological interventions to improve HbA1c in type 2 
diabetes; study 2) a qualitative evaluation of an existing insulin start group in south 
London; and study 3) a prospective cohort of newly diagnosed people with type 2 diabetes 
to determine an association between psychological variables (depressive symptoms, 
diabetes distress, and negative insulin beliefs) and time to insulin initiation. All provided 
support for DIME to be developed as a psychological intervention. These three studies 
determined all elements of the COM-B model (of the behaviour change wheel) needed to 
change to influence improvement in insulin self-management. This thesis found that 
psychological-informed group-based insulin education, the DIME intervention, was initially 
acceptable to people with type 2 diabetes who attended the pilot sessions. This provides a 
rationale for future development and testing of the DIME intervention to evaluate the 
effectiveness of improving glycaemic control, persistence, and adherence to insulin 
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Background: The quality of evidence that psychological interventions are effective in 
improving glycaemic control for adults with type 2 diabetes (T2D) is weak.  
Purpose: We conducted a systematic review and meta-analysis of psychological 
interventions in T2D to assess whether their effectiveness in improving glycaemic levels has 
improved over the past 30 years. We applied the protocol of a systematic review and 
aggregate meta-analysis conducted to January 2003. We added network meta-analysis 
(NMA) to compare intervention and control group type against usual care. 
Data Sources: MEDLINE, CINAHL, PsycINFO, EMBASE, Cochrane Controlled Trials, Web of 
Science, and Dissertation Abstract International were searched January 2003-July 2018.  
Study Selection: Only randomized controlled trials (RCT) of psychological interventions for 
adults with T2D reported in any language were included. The primary outcome was change 
in glycaemic control (glycated haemoglobin, HbA1c (mmol/mol)). 
Data Extraction: Data were extracted from study reports and authors contacted for missing 
data.  
Data Synthesis: 94 RCTs were eligible for inclusion in the systematic review since the last 
review. In 70 RCTs (n=14,796 participants) the pooled mean difference in HbA1c in those 
randomised to psychological intervention compared with control group was -0·19 (95% C.I. 
-0·25 to -0·12) equivalent to a reduction in HbA1c of 3·7 mmol/mol with moderate 
heterogeneity across studies (I2=64·7%, p<0·001). NMA suggested probability of 
intervention effectiveness is highest for self-help material, cognitive behavioural therapy, 
and counselling, compared with usual care.  
Limitations  
There is a possibility that some studies may have been missed if diabetes did not appear in 
the title or abstract.  
Conclusion:  
The effectiveness of psychological interventions for adults with T2D have minimal clinical 
benefit for improving glycaemic control. 
Registration: International prospective register of systematic reviews (PROSPERO) 
registration, CRD42016033619.  




In type 2 diabetes (T2D), management involves adopting multiple self-care tasks which 
include consuming lower energy dense diets, increasing physical activity, self-
administration of oral and injectable therapies, self-monitoring of blood glucose levels and 
decision-making about dose of insulin, attending education and annual review 
appointments. 
Despite evidence based guidelines,(NICE, 2017) at least a third of people with T2D do not 
achieve target HbA1c levels.(NDA, 2018) This is partly attributable to psychological factors 
that adversely affect self-management. These include depressive disorders,(Anderson et 
al., 2001) anxiety disorders,(Grigsby, Anderson, Freedland, Clouse, & Lustman, 2002) and 
diabetes specific distress, such as fear of diabetes complications, hypoglycaemia,(Wild et 
al., 2007) insulin,(Brod et al., 2009) disordered eating,(Allison et al., 2007) the burden of 
living with T2D and stigma.(Polonsky, Fisher, Earles, et al., 2005) Psychological treatments, 
such as cognitive behavioural therapy (CBT) and counselling, including motivational 
interviewing, are offered with the aim of improving self-management. In 2003, we 
conducted a systematic review and meta-analysis of randomized controlled trials (RCT) 
testing the effectiveness of psychological interventions to improve glycaemic control in 
T2D. We found that there was a small but clinically significant reduction in HbA1c by 
8mmol/mol.(Ismail et al., 2004) At that time, there were only 12 studies with a pooled 
sample of 522 participants, most were published before Consolidated Reporting of Clinical 
Trials (CONSORT),(Moher, Schulz, Altman, & Group, 2001) and were of low methodological 
quality.  Since then guidance for conducting and reporting complex interventions have 
been published and widely disseminated, and there has been an explosion in the number 
of RCTs. The aim was to conduct a systematic review and meta-analysis to assess the 
effectiveness of psychological treatments as compared with control conditions in improving 
glycaemic control in adults with T2D and whether the strength for the association was 
improving over time.  
Methods 
We repeated the original protocol for the systematic review and aggregate meta-analysis 
for the primary outcome, change in glycated haemoglobin (HbA1c).(Ismail et al., 2004)  We 
added network meta-analysis (NMA) to enable us to compare all intervention arms and 
attention control groups with usual care and expanded the data extraction to include 
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further details about the intervention that allow for potential replication, the protocol is 
available at: https://www.journalslibrary.nihr.ac.uk/programmes/hta/1421310#/. 
(Hoffmann et al., 2014),(NIHR, 2019). The Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement,(Moher, Liberati, Tetzlaff, & Altman, 2009) and 
relevant extensions were followed. 
Data Sources and Searches 
MEDLINE (OVID), CINAHL, PsycINFO, EMBASE (OVID), Cochrane Controlled Trials Database, 
Web of Science, and Dissertation Abstracts International were searched from 1st January 
2003 to 1st July 2018. (Our earlier review searched literature from inception of electronic 
databases to January 2003). Conference proceedings from Diabetes UK, American Diabetes 
Association, European Association for the Study of Diabetes, and International Diabetes 
Federation were searched for the past five years (from 2012 to 2018). We checked the US 
government trial registry (clinicaltrials.gov) and searched publication status for any ongoing 
RCTs. Finally, reference lists of included studies and other reviews were searched for 
additional studies and leading experts and investigators of ongoing RCTs identified from 
clinical trials registers were contacted for additional information. Web of Science (formerly 
Web of Knowledge) launched in 2002 and clinicaltrials.gov became widely mandated from 
2004 onwards and Dissertation Abstracts International, a leading international repository 
since 2008, therefore these data sources were additional to those specified in the original 
protocol.(Ismail et al., 2004) 
We used the Cochrane collaboration’s optimum search strategy. The following terms were 
applied to search MEDLINE, ‘diabetes mellitus’, ‘psychological therapies’ and ‘mood 
disorders’, and ‘clinical trials’ and adjusted for other databases (Appendix 1, Table S1). We 
included additional keywords for some newer therapies, such as ‘Acceptance Commitment 
Therapy (ACT)’, and ‘Mindfulness’. 
Study selection  
Studies eligible for inclusion were RCTs of a psychological intervention as defined 
previously for adults (age 18 years and older) with T2D.  There was no language restriction. 
Psychological interventions were categorised as: supportive or counselling therapy, 
including motivational interviewing; CBT, including techniques commonly used in CBT such 
as relaxation, cognitive re-structuring, goal setting, problem-solving; and psychodynamic or 
interpersonal psychotherapy. We were mindful that newer therapies may have been 
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developed and may not fall into these criteria. Studies which did not explicitly describe the 
intervention or techniques, or which did not have face validity for these categories 
underwent consensus discussion by an academic liaison psychiatrist, health psychologist 
and nurse therapist trained in motivational interviewing (KI, RU, KW respectively). If 
agreement could not be reached, the study was excluded. Comparators were defined as 
usual care, waiting list, and attention control (matching the number of sessions as in the 
intervention arm) and diabetes education.  
The main outcome was change in glycaemic control using HbA1c (mmol/mol) between 
baseline and follow-up (closest to 12 months). HbA1c was an inclusion criterion for the 
review.  
All titles and abstracts of identified articles from the search were screened by two 
independent reviewers (RU and KW) to determine if they met the inclusion criteria. Full-
text articles were accessed, and inter-rater reliability conducted to determine agreement 
for inclusion. If there was a disagreement at title and abstract screening, then the study 
was included for full-text screening. Quasi RCT, N-of-1 and any design other than RCT were 
excluded. 
Data Extraction and Quality Assessment  
Data was extracted independently by both reviewers (RU and KW). The data extraction 
form was managed in Microsoft Excel, piloted independently on 5 included studies and 
compared amongst reviewers before applying to the rest of the studies. Studies written in a 
language other than English were translated and data extracted by a native speaker. If 
there were multiple publications, the main one reporting the baseline and follow-up closest 
to 12 months was included. When studies involved more than one psychological treatment, 
data from the most intensive psychological treatment was included for the aggregate meta-
analysis. Intensity was defined as number and duration of sessions (hours) and duration of 
the therapy (months). Data from all allocations (including alternative intervention, for 
example self-help material and control treatments) were extracted for the NMA. Missing 
data were requested from the authors. Any disagreements were discussed with a third 
reviewer (KI) until consensus was reached. We extracted data in a standardised format for: 
country of origin, and year. Data extracted on participant characteristics were summary 
estimates and included: age, gender, ethnicity, glycaemic control at baseline and at follow 
up, duration of T2D, type of diabetes treatment, duration of follow up. When studies 
included type 1 and type 2 diabetes, only data on T2D was extracted if the data had been 
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stratified by type. The characteristics of all interventions was coded as type, duration, 
number of sessions, mode of delivery (individual, group, family), therapist characteristics 
(profession), manualised treatment, and duration of follow up. In line with developments in 
methodology for complex interventions,(Hoffmann et al., 2014) we extracted information 
on underpinning psychological theory and data describing fidelity to the intervention and 
competency of the therapist.(NIHR, 2019) 
We changed the quality assessment from original protocol to the Cochrane Risk of Bias tool 
as this had greater validity(Higgins et al., 2011) to determine high, low or unclear 
RoB,(Higgins et al., 2011) within and across studies. RoB was conducted independently (RU 
and KW) and disagreements were resolved by a third reviewer (KI). A subgroup meta-
analysis was conducted by RoB rating, and meta-regression compared effect sizes between 
RoB groups.  
Data Synthesis and Analysis 
For the aggregate meta-analysis, the standardised mean difference (SMD), Cohen’s d, was 
calculated to determine change in HbA1c (mmol/mol) between baseline and 12-month 
follow-up or closest to that data point. SMDs were pooled in random effects meta-analysis. 
SMDs were converted to absolute HbA1c values by multiplying SMD by pooled SD of all 
studies included in the meta-analysis. Diagnostic analyses included investigations of: the 
effect of removing individual studies; Egger’s publication bias; and funnel plots(Egger et al., 
1997) and trim and fill procedure(Duval & Tweedie, 2000) to determine potential for 
missing studies.  Meta-regression was conducted if there were five or more studies with 
data that could be pooled.(M Borenstein, 2011) All meta-analyses were conducted using 
STATA 14 (StataCorp, College Station, TX, USA). 
Non-protocol analyses were performed. For example, meta-regressions for the association 
between HbA1c and, primary outcome category; HbA1c primary outcome (versus HbA1c 
secondary outcome); comorbid depression inclusion criteria (versus no comorbid 
depression criteria); suboptimal HbA1c inclusion criteria (versus no suboptimal HbA1c 
inclusion criteria). In addition, meta-regressions were performed to determine the 
interaction between depressive symptoms as an inclusion criterion and whether HbA1c 
was the study’s primary or secondary outcome; and the interaction between studies with 




To determine the potential for cohort effects we linked the data from the original meta-
analysis removing any duplicate studies.  
For the NMA we analysed direct and indirect effects of the treatment and control arms on 
the mean change in HbA1c.(Riley et al., 2017) Indirect effects compared categories of 
intervention (psychological interventions, alternative treatments) or control groups (usual 
care, attention control, waiting list, diabetes education) within and across studies. We 
constructed network plots for direct comparisons. We conducted random effects meta-
analysis allowing for heterogeneity and inconsistency between the studies.(Higgins et al., 
2012; White, Barrett, Jackson, & Higgins, 2012) Inconsistency was assessed by comparing 
direct and indirect effects of the contrast I-J and Wald tests. Hedges’ g formula was used to 
determine unbiased SMDs corrected for degrees of freedom for different categories of 
intervention with usual care as the control.(White & Thomas, 2005) Finally, we estimated 
potential ranks for each category using cumulative probability plots and surface under the 
cumulative ranking (SUCRA), the higher SUCRA (closest to one) the greater probability the 
intervention is effective. 
Role of funding source 
This research was funded by the UK’s National Institute for Health Research (NIHR) Health 
Technology Assessment (HTA) Evidence Synthesis Programme (reference: 12/213/10). The 
views expressed are those of the authors and not necessarily those of the NHS, the NIHR or 
the Department of Health and Social Care. The funders had no role in study design, data 
collection, analysis, interpretation, or writing of the report. The study is registered with 
PROSPERO, CRD42016033619.  
Results 
Study selection 
We identified 31,069 study citations from the literature search (figure 1). Once duplicates 
were removed, titles and abstracts of 23,080 citations were screened from which 547 full 
texts were selected for further extraction. There was 94·5% agreement for identifying 
abstracts for full retrieval (Cohen’s kappa=0·95). We identified 94 RCTs that met the 
inclusion criteria for the systematic review and reasons for exclusion of the other studies is 





The studies included in the systematic review are listed and the study and intervention 
characteristics are synthesised in table 1. There was a broad range of clinical settings 
and/or criteria such as sub-optimal glycaemic control (n=28), specific duration of diabetes 
(n=19), age (n=41), body mass index (n=10) and depression (n=11). The were no RCTs 
administering a psychodynamic therapy, 33 RCTs administered CBT or techniques that fall 
under its umbrella such as relaxation therapy or problem solving, 60 RCTs delivering 
counselling, and one used interpersonal psychotherapy (IPT).  In the control group, there 
were 60, 20, 10 and 4 studies, administering usual care, attention control, waiting list, and 
diabetes education respectively. Most therapists were diabetes specialists (n=37) or 
psychologists (n=31), and other (n=24) defined as research assistants (n=10), non-diabetes 
health professionals (n=11), lay people (n=3), or did not report their profession (n=2). Most 
interventions were delivered face-to-face (n=75), and mostly to individuals (n=54) and 
groups (n=37). The mean number of therapy sessions offered was 7.41 (SD 4.60); the mean 
duration of each session was 1.40 hours (SD 1.03); and mean duration of therapy was 5.44 
months (SD 6.54). Twenty-seven studies referred to an intervention manual of which 7 
provided a link to the manual, 24 studies provided a link to the study protocol. 
Risk of bias within studies  
Of those studies included in the meta-analysis, few were assessed as high RoB (n=3). The 
majority of studies were either of low RoB (n=29) or unclear RoB (n=38) (figure S1) and 
there was no association between these RoB categories, and HbA1c (p=0.23).  
Results of individual studies 
Additional information regarding the case definition of studies included in the meta-
analysis is summarized in table S2. There were 70 RCTs with data to be pooled, giving a 
total sample of n=14,796. In the random effects meta-analysis, while there was a 
statistically significant reduction in HbA1c for those randomized to a psychological 
intervention compared to the control group (SMD -0.19, 95% CI -0.25 to -0.12, p<0.001), 
this was of weak clinical significance representing an absolute reduction in HbA1c of 3.7 
mmol/mol (figure 2). Removal of individual studies had little impact on the overall effect 
size. There was moderate heterogeneity across studies (I2=64.7%, p<0.001) and evidence of 
publication bias towards positive findings via Egger’s test (p=0.002). No additional studies 
were considered missing using trim and fill method.  
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Synthesis of results 
There was no significant difference in effect size (p=0.12) between interventionist 
categories when sub-group analyses were conducted for interventions delivered by 
psychology professionals (n=23, SMD=-0.30 , 95% CI=-0.46, -0.14, p<0.001, reduction in 
HbA1c, 5 mmol/mol),  diabetes specialists (n=30, SMD=-0.18 , 95% CI=-0.25,-0.10, p<0.001, 
reduction in HbA1c 3 mmol/mol), and  ‘other’ interventionists (n=16, SMD=-0.07 , 95% CI=-
0.21, 0.06, p=0.29, reduction in HbA1c, 1 mmol/mol). Heterogeneity was high and 
significant for psychology professionals (I2=72.6%, p<0.001), and moderate for diabetes 
specialists (I2=57.7%, p<0.001), and ‘other’ interventionists (I2=58.2%, p=0.002).  For 
diabetes specialist delivered studies there was some evidence of publication bias (p= 0.01), 
but no additional studies were identified as missing using the trim and fill method. For 
psychology professional and ‘other’ interventionist delivered studies there was no evidence 
of publication bias (p=0.09, p=0.69 respectively), and no additional studies were identified 
as missing using trim and fill method.  
There was no dose response association with number of sessions (b=-0.0063 [95% C.I. : -
0.0224 to 0 .0097], p=0.43), or duration of the psychological intervention (b=-0.06 [95% 
C.I.:--0.18 to 0.07], p=0.36), or control group (b=-0.02 [95% C.I.:- -0.11 to 0.08], p=0.75).  
Additional analyses, non-protocol 
We conducted some additional non-protocol analyses. We categorised studies into 4 
groups according to their primary outcome (table S3) HbA1c (n=33), psychological (n=19 
[diabetes empowerment n=1, depressive symptoms n=11, diabetes distress n=4, self-
efficacy n=2, stress n=2]), self-management behaviours (n=13 [physical activity n=6, 
medication adherence n=5, diet adherence n=2]), or biomedical (n=5 [coronary heart 
disease risk n=1, weight n=3, BMI n=1). There was no association between type of primary 
outcome and change in HbA1c (p=0.33). A meta-regression revealed no significant 
difference in effect size in HbA1c reduction between studies where HbA1c was a primary 
outcome (n=33) compared with studies where HbA1c was a secondary outcome (n=37), 
p=0.21.    
Sixteen out of the 70 included studies had an inclusion criterion for depressive symptoms 
i.e. where participants had T2D with comorbid depressive symptoms (figure 2). A meta-
regression revealed no significant difference in effect size in HbA1c reduction between 
studies with comorbid depression inclusion criteria versus studies where there were no 
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comorbid depression inclusion criteria (p=0.80).  For 6 of the studies with comorbid 
depressive symptom inclusion criteria, HbA1c was the primary outcome (table S4). A meta-
regression was conducted for the interaction between depressive symptoms as an inclusion 
criterion and whether HbA1c was the study’s primary or secondary outcome, there was no 
significant difference between groups (p=0.63). Additionally, some of the comorbid 
depression studies included collaborative care interventions and as these could be 
considered distinct from other psychological interventions so we conducted a sensitivity 
analysis and there was no difference in overall effect size (SMD=-0.19, 95% CI= -0.26 to -
0.13).  
More information regarding inclusion/exclusion criteria of studies included in the meta-
analysis can be found in table S5. 
Eleven studies had an inclusion criterion for suboptimal glycaemic control (HbA1c 
7.5%/58mmol/mol or more), figure 2. A meta-regression revealed no significant difference 
in effect size in HbA1c reduction between studies where suboptimal HbA1c was an 
inclusion criterion versus studies where suboptimal HbA1c was not an inclusion criterion 
(p=0.62). For 8 studies with suboptimal glycaemic control as the inclusion criterion, HbA1c 
was the primary outcome (table S6). A meta-regression was conducted to determine the 
interaction between studies with suboptimal HbA1c as an inclusion criterion and whether 
HbA1c was the study primary outcome, and there was no significant difference between 
groups (p=0.51).  
Risk of bias across studies  
The RoB domain which was most difficult to assess RoB criterion across studies (i.e. coded 
as ‘unclear RoB’) was the ‘blinding of participants and personnel’ domain (figure S2). 
‘Selective reporting’ and ‘other bias’ RoB domains were mostly coded as low RoB, ‘Random 
sequence generation,’ ‘allocation concealment’ and incomplete outcome data’ showed 
high RoB across studies.  
Additional analyses: Cohort effect 
To examine whether there was a cohort effect, we pooled the HbA1c data from 12 RCTs 
included in an earlier meta-analysis (from inception to January 2003) with the current 
review (January 2003 to July 2018), totalling N=82 RCTs (N=15,306). We derived a similar 
effect size to the current review (SMD -0.20, 95% CI=-0.26 to -0.14, p<0.001, equivalent to 
264 
 
absolute change in HbA1c of -4 mmol/mol). The effect size was not significantly different 
between the two meta-analyses (b -0.13 (95% C.I. -0.38 to 0.12), p=0.31).  
Additional analyses: Network meta-analyses 
For the NMA there was data available from 70 studies, which included 5 categories of 
psychological intervention and 3 control conditions. 146 treatment arms in total were 
analysed (some studies had more than one intervention or control group) with a total 
sample size of 15,702 (table S7). A network plot for all studies demonstrated that 13 out of 
a possible 28 contrasts could be analysed (figure S3), although to reduce over-estimation of 
treatment effects we only analysed contrasts with 2 or more studies. IPT and diabetes 
education (control) were only studied once and were thus removed from the network 
meta-analyses, including the control group for IPT, resulting in a total number of studies of 
142 with a total sample size of 15,573 allowing us to study 11 out of a possible 15 
contrasts. 
Therefore, direct and indirect effects between CBT, counselling, self-help material 
(alternative intervention treatment), usual care, attention control and waiting list control 
were performed. Table S8 shows that the estimated direct and indirect effects between 
interventions did not differ significantly with only one exception (counselling versus self-
help materials). The non-significant chi2 test for inconsistency (chi(8) 8.33, p=0.402, 
I2=3.9%) supports the conclusion of model consistency.  
Table S9 shows the results of the consistency network meta-analyses comparing all 
treatments (and controls) against usual care.  Self-help material (this was an additional 
treatment arm, used in 4 studies), CBT, and, counselling showed a small to moderate 
treatment effect. Table S10 presents pairwise comparisons of all treatment effects.  
The rankogram (figure 3), indicated that self-help material had the highest probability of 
being the most successful intervention (58.1%), followed by CBT (22.4%) and counselling 
(18.8%.) while waiting list control, attention control and usual care were less likely to be 
the best treatment (all ≤0.6%). However, an assessment of mean rank and SUCRA suggests 
little differences between self-help materials, CBT and counselling (table S11). 
Conclusions  
In this study 94 RCTs were included in the systematic review, and 70 had HbA1c data which 
could be pooled and there was a statistically significant improvement in glycaemic control 
but this was of weak clinical significance. The absolute reduction in HbA1c of 3.7 
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mmols/mol is just less than the consensus minimal difference of 4 mmol/mol to reduce risk 
of microvascular and cardiovascular disease.(Baxter et al., 2016)  The NMA demonstrated 
that CBT and counselling interventions were effective compared with controls but effect 
sizes were small. Self-help was offered as an alternative treatment to CBT (n= 1,268) or 
counselling (n=6,105) in four studies and this was effective but the total sample size was 
smaller (n=792).  There was no difference in the change in glycaemic control when 
interventions were delivered by mental health or non-mental health professionals. Most 
studies were conducted in North America and Europe. 
The strengths of this systematic review were that it was protocolised, registered with 
PROSPERO, conducted according to PRISMA guidelines, and not restricted to English 
language publications. We used aggregate and network meta-analysis to optimise the 
analysis of the pooled data. As we used the same protocol, we were able to link current 
data with a previous meta-analysis to compare effects of psychological interventions over 
30 years. 
The limitations of this review are that by using an older protocol we may have missed some 
innovative studies, and clinical settings such as multi morbidity and digital interventions 
where diabetes may have not appeared in the title or abstract. We used outcome data 
closest to 12 month follow-up as the majority of the included trials were of short duration. 
We did not review the contents of the manuals as there was no systematic method to do 
so. We included collaborative care interventions under the CBT umbrella and it could be 
argued that collaborative care is a complex intervention which differs from other 
psychological interventions. However, when collaborative care studies (Chwastiak et al., 
2017; Ell et al., 2011; Williams et al., 2004) were removed from our overall aggregate meta-
analysis there was no significant change in the results.   
Our observation is that in the past 15 years there has seen an almost 10-fold increase in the 
number of RCTs testing the effectiveness of psychological interventions to improve 
glycaemic control as primary or secondary outcome, yet their effectiveness has decreased 
compared to pre-CONSORT studies. This needs discussion within the diabetes and mental 
health research and clinical community. Similar patterns of increasing research productivity 
yet decreasing effectiveness have been observed by others but has not until now been 
debated.(Ekong & Kavookjian, 2016; Pillay et al., 2015; Xie & Deng, 2017) One explanation 
is that despite guidance on the assessment for fidelity to the psychological 
intervention,(Gearing et al., 2011) there is little evidence that this is conducted. Deviations 
266 
 
in fidelity to a psychological intervention can lead to dilution of the ‘dose’ and 
underestimation of its effect. Another possible explanation is the lack of data on the level 
of proficiency or competency in the delivery of psychological treatments.(Gearing et al., 
2011) A third explanation is whether primary focus of the psychological treatment is 
targeting glycaemic control. Only a quarter of studies had links to additional materials or 
manuals that would give information on specific contents of the intervention. Only a third 
of the studies were focused on glycaemic control. A significant proportion focused on 
treating depressive symptoms or weight with the secondary outcome that this would 
improve glycaemic control. We also noticed there was no difference in the effect on 
glycaemic control by the profession of the therapist. One interpretation is that diabetes 
specialists bring diabetes knowledge which is likely to be an important prerequisite for a 
therapeutic alliance for a person with diabetes. On the other hand, the mental health 
profession brings psychotherapeutic skills which is also a prerequisite for building a 
therapeutic relationship. These skills may be more effective when combined. A fifth 
explanation is that the intervention in the control was of high standard, usual care for 
diabetes has improved and the national average HbA1c has dropped in some countries.(Ali 
et al., 2013; NDA, 2018) Last but not least, as the methodological quality has improved with 
only a handful of RCTs assessed to be of high risk of bias, another explanation is that 
collectively these types of interventions, namely CBT and counselling, are not indicated in 
T2D. The average number of sessions were seven and the average duration of the 
intervention was approximately five months. T2D is a progressive condition and if a person 
is not able to make the self-management changes alone or with standard support, it is 
possible that they are unlikely to do so with a brief relatively inexpensive psychological 
intervention. 
This review highlights a need for a balanced debate. On the one hand there is a clear policy 
agenda for integrating physical and mental health in diabetes but there needs to be 
psychological interventions that are effective in improving blood glucose, as ineffective 
interventions could do more harm and cost health systems more. National and 
international research strategy led by funding organisations need to invest in innovations in 
psychological treatments, rather than replicating existing psychological models that are 
repeatedly delivering very small effect sizes. For instance, there were no studies that used 
psychodynamic models, or addressed the high levels of disordered or addictive eating 
patterns, stigma of diabetes, or habit formation.(Gardner & Rebar, 2019) 
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In summary, brief psychological interventions in T2D have limited clinical effectiveness in 
improving glycaemic control. 
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*Sixteen studies were papers which included a type 1 & type 2 diabetes population where separate 
analysis per diabetes type could not be obtained. The remaining 8 studies which were not included in 
meta-analysis, not enough information for meta-analysis was reported in the paper and could not 
provided by author when contacted.  
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Figure 2 - Forest plot for a random-effect meta-analysis of standardised mean difference in HbA1c comparing psychological intervention 
versus with control group for adults with type 2 diabetes  
A+=depressive symptoms in inclusion criteria, A-= depressive symptoms not inclusion criteria, B+= suboptimal HbA1c in inclusion criteria (7.5%/58mmol/mol or more), B-= suboptimal HbA1c not 






Figure 3 - Rankogram for all treatments. The plot shows the surface under the cumulative 
ranking curves for all treatments for adults with type 2 diabetes. For example, usual care has 



























Intervention Description (Intervention name, facilitator, 
format, individual/group) 
Control Description (Control category, 
facilitator, format, individual/group) 
Studies included in meta-analysis and systematic review 
 
2004, USA, Whittemore 
(Whittemore et al., 2004) 
49 Counselling 6 Nurse-Coaching Intervention, Nurses, face-to-face, individual. Usual care 
2004, USA, Williams 
(Williams et al., 2004) 
293 CBT 6-8 Collaborative care (depression treatment including problem solving 
treatment); depression clinical specialist + GP; face-to-face; 
individual 
Usual care  
2006, Germany, 
Siebolds (Siebolds et al., 
2006) 




(Keeratiyutawong et al., 
2006) 
90 CBT 5 Self-management Group; Psychology researcher; face-to face; 
group 
Diabetes education; Diabetes health care team; 
face-to-face; individual 
2007, USA, Gregg 
(Gregg et al., 2007) 
81 CBT  1 Acceptance and commitment therapy (ACT), Psychologist, face-to-
face, group.   
Diabetes education, psychology masters-level 
students, face-to-face, group.   
2007, USA, West (West 
et al., 2007) 
217 Counselling  5 Motivational interviewing; clinical psychologists; face-to-face; 
individual  
Diabetes education; health educators; face-to-
face; individual  
2009, UK, Dale (Dale et 
al., 2009) 
231 Counselling 6 1) Telephone support (motivational interviewing); nurses; 
telephone; individual 
2) Telephone support (motivational interviewing); peers; 
telephone; individual 
Usual care 
2009, Iran, Davazdah 
(Davazdah Emamy et 
al., 2009) 
40 CBT 12 CBT, trained researcher, face to face, Group Waiting list; see intervention description 
2009, USA, Sacco 
(Sacco, 2009) 
62 Counselling 18 Telephone ‘‘coaching’’ intervention; Undergraduates in 
Psychology; telephone; individual 
Usual care 
2010, Australia, Evans 
(Evans, Lewin, et al., 
2010) 
60 CBT 7 CBT; face to face; group  Waiting list (usual care for 3 months then 
intervention) 
2010, USA, Wolever 
(Wolever et al., 2010) 
56 Counselling  14 Integrative health (IH) coaching; coaches (masters-level degrees 




2010, USA, Melkus 
(D'Eramo Melkus et al., 
2010) 
109 CBT 11 CBT+DSMT+CST; Nurse; face to face; group Diabetes education; Nurse; face-to-face; group 
2010, Belgium De Greef 
(De Greef et al., 2010) 
41 CBT 5 Cognitive-behavioural pedometer-based group intervention; 
coaches (degree in PE, movement sciences or clinical 
psychology); face to face; group 
Usual care 
2010, USA, Hawkins 
(Hawkins, 2010) 
66 Counselling 12 Motivational interviewing video call; nurses, telephone, individual  Attention control telephone support (no MI); 
nurses; telephone; individual   
2010, USA, Osborn 
(Osborn et al., 2010a) 
185 Counselling 1 Culturally tailored diabetes self-care intervention; bilingual medical 




Huidobro et al., 2011)  
167 Counselling  4 Family intervention, Healthcare team, face-to-face, family Usual care 
2011, Ireland, Keogh 
(Keogh et al., 2011) 
121 Counselling  3 Family-based intervention; Health psychologist; face to face; family Usual care 
2011, Belgium, De Greef 
(De Greef et al., 2011) 
67 Counselling 3 1) Group behavioural intervention; clinical psychologist; face to 
face; group 
2) individual consultation; GP, face to face, individual  
Usual care 
2011, Iran, Hamid 
(Hamid, 2011) 
46 CBT 12 CBT, trained researcher, face to face, Group Waiting list, see intervention description 
2011, USA, Piette 
(Piette et al., 2011) 
291 CBT 12 Telephone delivered CBT; Nurses; telephone; individual Enhanced usual care (usual care + copy of self-
help book based on CBT for depression) 
2011, Netherlands, 
Lamers (Lamers et al., 
2011) 
70 CBT 4 Minimal psychological 
intervention; Nurses; face to face; individual 
Usual care 
2011, USA, Welch 
(Welch et al., 2011) 
119 Counselling 4 1) MI +Computerized self-management: Diabetes educator; face 
to face; individual 
2) MI alone; Diabetes educator; face to face; individual 
1) Diabetes education alone; diabetes educator; 
face to face; individual 
2) Computer self-management alone; computer; 
individual 
 
2011, USA, Ell (Ell et al., 
2011) 
229 CBT Not reported Sociocultural adapted collaborative care (relapse prevention): 
primary care physicians/graduate social workers/ diabetes 
depression clinical 
specialists (DDCS); face to face/telephone; individual  
Enhanced usual care (usual care + prescribed 
antidepressant medication and provided 
counselling or refer to community mental health 
care.) 
2012, UK, Farmer 
(Farmer et al., 2012) 
211 Counselling 1 Consultation-based intervention, Clinical nurses, face-to-face, 
individual.  
Usual care 
2012, USA, Penckofer 
(Penckofer et al., 2012) 




Hartmann (Hartmann et 
al., 2012) 
110 Counselling 8 Mindfulness-based intervention: psychologist and a 
resident in internal medicine; face to face; group 
Usual care 
2012, Taiwan, Chen 
(Chen, Creedy, et al., 
2012) 
215 Counselling Not reported Motivational interviewing: Nurses; face to face; individual Diabetes Education; nurse/diabetes educator; 
face to face; group  
2013, Canada, Plotnikoff 
(Plotnikoff et al., 2013) 
287 Counselling 22 Telephone counselling (MI): five individuals with relevant degree 
qualifications related 
to PA promotion and/or counselling; telephone; individual 
1) Diabetes education; Educational materials 
2) Printed materials (relates to transtheoretical 
model)  
2013, Netherlands, 
Welschen (Welschen et 
al., 2013) 
154 CBT 3-6 CBT; diabetes nurse and dietician; face to face; individual Usual care; dietician/diabetes nurse; face to face; 
individual 
2013, USA, Mandel 
(Mandel et al., 2013) 
131 CBT 4 Music therapy (relaxation and imagery); Music therapy clinician; 
face to face; group  
1) Diabetes education; diabetes 
educator/dietician; face to face; group 
2) music relaxation CD 
2013, Netherlands, 
Jansink (Jansink et al., 
2013) 
521 Counselling  5-8 Motivational interviewing; Nurse; face-to-face; individual  Usual care 
2014, Denmark, Juul 
(Juul, Maindal, 
Zoffmann, Frydenberg, 
& Sandbaek, 2014b) 
3946 Counselling Variable Nurse-led diabetes consultations, GP & nurses, face-to-face, 
individual. 
Usual care 
2014, UK, Steed (Steed 
et al., 2014) 
124 Counselling 5 Self-management intervention, Diabetes specialist nurse & 
dietician, face-to-face, group.  
Usual care 
2014, USA, Safren 
(Safren et al., 2014) 
87 CBT 9-12 CBT-AD: Therapist; face to face; individual Enhanced usual care; nurse/dietician; face to 
face; individual 
2014, Portugal, Gois 





Psychotherapy (IPT), Psychiatry, face-to-face, individual. 
Medical care & sertraline 
2014, China, Li (Li et al., 
2014) 
101 Counselling  4 Motivational interviewing; therapist; face to face; individual Diabetes Education; face to face; individual 
2014, UK, Griffin (Griffin 
et al., 2014) 
478 Counselling 8 Intensive plus behavioural intervention: Life-style facilitators; face 
to face/telephone; individual 
Enhanced usual care; GP; face to face; individual 
2014, Australia, Eakin 
(Eakin et al., 2014) 
277 Counselling  27 Telephone counselling (MI): trained researchers (degree nutrition 
or dietetics); telephone; individual 
Usual care 
2014, Netherlands, van 
Son (van Son, Nyklíček, 
et al., 2014) 





2015, USA, Kim (Kim et 
al., 2015b) 
209 Counselling 6 Self-management intervention, Nurses & community health 
workers, face-to-face, group. 
Diabetes education, face-to-face, group.  
2015, USA, Chlebowy 
(Chlebowy et al., 2015) 
62 Counselling 4 Motivational interviewing: Nurses; face to face; individual Usual care 
2015, USA, Pladevall 
(Pladevall et al., 2015) 
1692 Counselling 6 Motivational interviewing and adherence information: Nurses and 
pharmacists; face to face/telephone; individual 
1) Usual care 
2) Adherence information; clinicians; face to face; 
individual 
2015, Germany, 
Hermanns (Hermanns et 
al., 2015a) 
60 CBT 5 DIAMOS: Psychologists, face to face; group Diabetes Education; diabetes educators; face to 
face; group 
2015, Croatia,  Pibernik-
Okanović (Pibernik-
Okanović, 2015) 
121 CBT 6 Psychoeducation: Psychologist; Face to face; Group Diabetes Education; diabetologist; face to face; 
group 
2015, Germany, Petrak 
(Petrak, 2015) 
53 CBT 10 CBT, Clinical psychologists, face-to-face, group Usual care and antidepressants 
2016, Taiwan, Huang 
(Huang et al., 2016) 
61 CBT 12 MET+CBT: Psychotherapist/clinical nurse; face to face; Group Usual care 
2016, China, Browning 
(Browning et al., 2016) 
682 Counselling 9 Health coaching: Clinicians (doctors, nurses and psychologists; 









Counselling 3 Motivational interviewing: Nurses; face to face; individual  Less intensive psychological intervention; nurse, 
telephone; individual  
2016, Taiwan, Chiu 
(Chiu et al., 2016) 
174 Counselling  4 Minimal Psychological Intervention: Psychology assistants; 
telephone; individual 
Usual care 
2016, China, Fan(Fan et 
al., 2016) 
276 Counselling 3 Individualized diabetes education; Nurses and clinical 
psychologists; face to face; group 
Diabetes education; nurses; face to face; group 
2016, Denmark, 
Juul(Juul et al., 2016) 
127 Counselling 6 Health 
promotion intervention; Dietician, occupational therapist; face to 
face; group 
Waiting list control 
2016, Iran, 
Shayeghian(Shayeghian 
et al., 2016) 
106 CBT 10 ACT; Clinical psychologists; face to face; group Waiting list control 
2016, USA, 
Wagner(Wagner et al., 
2016) 
107 Counselling 8 Stress 
management intervention; Community health worker; face to face; 
individual  
Diabetes education; Community health worker; 




Akturan(Akturan et al., 
2017) 
93 Counselling 3 BATHE interview technique; Physicians; face to face; individual  Usual care 
2017, Italy, 
Balducci(Balducci et al., 
2017)  




Chee(Chee et al., 2017) 
230 Counselling 1 1) Trans-cultural motivational interviewing; Dietician and 
physician; face to face; individual 




Egede(Egede et al., 
2018) 
90 CBT 8 Behaviour activation treatment; therapists; face to face; individual  Behaviour activation treatment; therapists; face to 
face; video teleconferencing 
2017, Australia, 
Furler(Furler et al., 
2017) 






160 Counselling 6 Self-management-oriented education programme; Diabetes 
educators; face to face; group 





26 Counselling Variable Motivational interviewing; Psychologist; face to face; individual Educational materials and usual care 
2017, Australia, 
Rees(Rees et al., 2017) 
40 CBT 8 Problem-solving therapy; Research assistant trained in PST 





et al., 2017) 
300 Counselling Variable Community Health Worker Intervention; Community health 
workers; telephone & face to face; individual  
Enhanced usual care (usual care +education 
materials) 
2017, Brazil, 
Gomes(Gomes et al., 
2017) 
222 Counselling 4 Family social support; families; telephone; family Education; telephone; individual  
2017, China Jiang(Jiang 
et al., 2017) 
 
52 Counselling Not reported  Problem-solving treatment, face-to-face, group Usual care plus paroxetine 
2018, Malaysia, 
Chew(Chew et al., 2018) 
124 Counselling 4 VEMOFIT (emotion focused education programme); Nurse and 
physician; face to face; group 







29 Counselling  12 Collaborative care; Nurse case manager, psychiatrist, advanced 
practice nurse; face to face; individual  
Usual care 
2018, Germany, 
Dobler(Döbler et al., 
2018) 
199 Counselling 12 Telephone support group; Counsellors; face to face; individual Usual care 
2018, UK, Ismail (Ismail 
et al., 2018) 
334 Counselling 12 D6 (MI+CBT); nurses; face to face; individual Usual care 
2018, Iran, 
Momtzi(Momtazi et al., 
2018) 
30 Counselling 4 Motivational interviewing; Psychiatrist; face to face; group Waiting list control 
2018, UK, Wroe(Wroe et 
al., 2018) 
115 CBT 6 Wellbeing Group; IAPT practitioners; face to face; group Usual care 
Studies included in systematic review only 
 
2004, UK, Clark (Clark, 







Counselling 1 Self-management intervention: Interventionist (trained in MI); face 
to face; individual 
Usual care 
2004, Norway, Karlsen 
(Karlsen, Idsoe, Dirdal, 
Rokne Hanestad, & Bru, 
2004) 
63 CBT 9 Group-based counselling; nurse; face to face; group Waiting list 
2006, USA, Hokanson 
(Hokanson, Anderson, 
Hennrikus, Lando, & 
Kendall, 2006) 
114 Counselling  4-7 Smoking cessation motivational interviewing, research staff, 
telephone, individual  
Usual care 
2010, The Netherlands, 
Heinrich (Heinrich, 
Candel, Schaper, & de 
Vries, 2010) 
537 Counselling  8 Motivational interviewing; nurses; face to face; individual Usual care 
2010, Iran, Pourisharif 






Counselling 4 1) Motivational interviewing; face to face; group 




2011, Italy, Castelnuovo 








CBT Variable TECNOB (TEChnology for OBesity): Clinical psychologist; Face to 
face/telephone/ online and text messaging; individual/ group 
Usual care 






Counselling 2 Motivational interviewing: researcher; face to face; individual Usual care 
2013, USA, Gabbay 




Counselling 8 Motivational interviewing: Nurses; face to face; individual  Usual care 
2015, USA, Inouye 





CBT 6 CBT: Research assistants; face to face; Group Diabetes education; research assistants; face to 
face; group 
2016, USA, Fitzpatrick 
(Fitzpatrick, 2016) 
182 Counselling  9 1) DECIDE Group, graduate assistant, face-to face, group 
2) DECIDE individual, graduate assistant, face-to face, individual 
1) Enhance usual care (usual care + education 
materials), face-to-face/mail, individual 
2) DECIDE self-study; mail; individual  
2016, Netherlands, 
Rondags(Rondags, de 
Wit, Twisk, & Snoek, 
2016) 






129 CBT 16 Lifestyle coaching; Peers; face to face; telephone Usual care 
2017, USA, 
Egede(Egede et al., 
2017) 
255 Counselling  12 Telephone-Delivered Behavioural Skills Intervention (knowledge, 
skills, or knowledge & skills); health educators; telephone; 
individual  
Usual care 
2017, New Zealand. 
Friis(Friis, Johnson, 
Cutfield, & Consedine, 
2016)  
17 Counselling 8 Mindful self-compassion (MSC) intervention; health psychologists; 
face-to-face; group 
Waiting list  
2017, Finland, 
Tovote(Tovote et al., 
2017) 
56 CBT 8 Mindfulness-Based Cognitive Therapy; CBT therapists; face to 
face; individual  
Waiting list 
2017, New Zealand, 
Whitehead(Whitehead et 
al., 2017) 
97 CBT 1 Education + ACT; clinical psychologist & nurses; face to face; 
group 
1) Diabetes education; nurses; face to face; group 




Berk(Berk et al., 2018) 
158 CBT 14 Group cognitive behavioural therapy; trained 
psychologist/psychotherapist, with experience in diabetes care; 
face to face; group 
Usual care 
2018, Iran, Kian(Armani 
Kian et al., 2018) 
59 Counselling 8 Mindfulness-Based Stress Reduction; Mindfulness instructor; face 
to face; group 
Usual care 
2018, USA, 
Pyatak(Pyatak et al., 
2018) 
19 Counselling  Variable Occupational therapy; occupational therapists; face to face; 
individual  
Attention control follow-up phone calls 
2014, USA, Lin (Lin et 
al., 2014) 
Not reported Counselling  Variable Collaborative care; Primary care physician & nurse & psychiatrist 
& psychologist; face to face; individual 
Usual care 
2011, Denmark, Minet 
(Minet, Wagner, Lonvig, 
Hjelmborg, & Henriksen, 
2011) 
349 Counselling 5 Motivational interviewing; HCPs (nurse, dietician, physiotherapist 
or psychologist); face to face; individual  
Usual care 
2015, USA, Safford 
(Safford et al., 2015) 
Not reported Counselling Variable  Motivational interviewing; peers, telephone; individual  Diabetes education; face to face; individual 
2015, Netherlands, 
Schroevers (Schroevers 
et al., 2015) 
24 CBT 8 Mindfulness-based cognitive therapy (MBCT); clinical 
psychologist; face to face; individual  
Waiting list 
2011, USA, Weinger 
(Weinger et al., 2011) 
222 CBT 5 Structured behavioural group; diabetes educators; face to face, 
group 
1) Group attention control; diabetes educators; 
face to face, group 












Appendix 2.1.1. Supplementary material: Psychological interventions to improve glycaemic 
control in type 2 diabetes: a systematic review and meta-analysis. 
 
Table S1 – Search strategy for the systematic review of psychological interventions for people 
with Type 2 diabetes 
1. exp Diabetes Mellitus/ 
2. diabet$.ab,ti. 
3. (DKA or IDDM).mp. or DMI.ab,ti. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
4. (MODY or DM2 or NIDDM).mp. or IIDM.ti,ab. [mp=title, original title, abstract, 
name of substance word, subject heading word] 
5. insulin$ secret$ dysfunc$.ti,ab. 
6. insulin$ resist$.ti,ab. 
7. ((impaired glucose tolerance or glucose intoleran$ or insulin$ resist$) and (DM or 
DM2)).ti,ab. 
8. insulin$ depend$.mp. or insulin?depend$.ti,ab. [mp=title, original title, abstract, 
name of substance word, subject heading word] 
9. (non insulin$ depend$ or nonisulin$ depend$ or nonisulin?depend).mp. or non 
insulin?depend$.ti,ab. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
10. (("typ$ 1" or typ$ I) adj6 DM).ti,ab. 
11. (("typ$ 2" or typ$ II) adj6 DM).ti,ab. 
12. ((juvenil$ or child$ or keto$ or labil$ or brittl$ or earl$ onset) adj6 (DM or 
DM1)).ti,ab. 
13. ((keto$ prone or autoimmun$ or auto immun$ or sudden onset) adj6 (DM or 
DM1)).ti,ab. 
14. ((keto$ resist$ or nonketo$ or non keto$ or adult$ onset or matur$ onset or late$ 
onset or slow onset or stabl$) adj6 (DM or DM2)).ti,ab. 
15. exp Insulin Resistance/ 
16. (insulin$ defic$ adj6 (absolut$ or relativ$)).ti,ab. 
17. metabolic$ syndrom$.ti,ab. 
18. (syndrom$ X not (fragil$ X or X linked)).ti,ab. 
19. (plurimetabolic$ syndrom$ or pluri metabolic$ syndrom$).ti,ab. 
20. or/1-19 
21. exp Psychotherapy/ 
22. exp Counseling/ 
23. exp Mood disorders/ 





29. (interpersonal adj5 therap$).mp 
30. art therap$.mp 
31. aversion therap$.mp 
32. balint.mp 
33. behavio?r adj5 (intervention or therap* or modific*)  
34. cognitive adj5 (therap* or intervention or program* or train* or theory)  
35. (family adj3 (intervention or treatment or counsel* or therap*) 
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36. colo?r therap$.mp. 
37. crisis intervention.mp 
38. dance therap$.mp 
39. gestalt therap$.mp 
40. music therap$.mp 
41. milieu therap$.mp 
42. (assert$ adj5 training).mp 
43. Narrative therap$.mp. 
44. nondirective therap$.mp 
45. (problem solving adj5 therap$).mp 
46. (self control adj5 therap$).mp 
47. person cent$.mp 
48. client cent$.mp 
49. psychodrama$.mp 
50. paradoxical technique$.mp 
51. play therap$.mp 
52. rational emotive.mp 
53. reality therap$.mp 
54. role play$.mp 
55. (relax$ adj5 training).mp 
56. sociotherap$.mp 
57. socioenvironmental.mp 
58. supportive therap$.mp 
59. transactional.mp 
60. acceptance adj2 (commitment therap*) 
61. coping skills training.mp. 
62. exp Mindfulness/ 
63. motivation* adj2 (interview* or therap*) 
64. multisystemic therapy 
65. or/21-64 
66. Randomized Controlled Trials as Topic/ 
67. randomized controlled trial/ 
68. Random Allocation/ 
69. Double Blind Method/ 
70. Single Blind Method/ 
71. clinical trial/ 
72. clinical trial, phase i.pt 
73. clinical trial, phase ii.pt 
74. clinical trial, phase iii.pt 
75. clinical trial, phase iv.pt 
76. controlled clinical trial.pt 
77. randomized controlled trial.pt 
78. multicenter study.pt 
79. clinical trial.pt 
80. exp Clinical Trials as topic/ 
81. (clinical adj25 trial$).tw 
82. ((singl$ or doubl$ or treb$ or tripl$) adj25 (blind$3 or mask$3)).tw 
83. PLACEBOS/ 
84. placebo$.tw 
85. randomly allocated.tw 




88. case report.tw 
89. letter/ 
90. historical article/ 
91. Or/ 88-90 
92. 87 NOT 91 
93. 20 AND 65 AND 92 






Table S2 – Case definition of included meta-analysed studies 









































2004, USA, Whittemore 









7% or more 
2004, USA, Williams 
(Williams et al., 2004) 





2006, Germany, Siebolds 
(Siebolds et al., 2006) 
58∙7 (7∙6) 
  









(Keeratiyutawong et al., 2006) 







2007, USA, Gregg (Gregg et 
al., 2007) 









52.0 (10.0) 5∙8 (6∙5) 
 







2009, UK, Dale (Dale et al., 
2009) 
NR NR NR  NR 1) 8.9% (1.5) 
2) 8.4% (1.1) 












2009, Iran, Davazdah 
(Davazdah Emamy et al., 
2009) 






2009, USA, Sacco (Sacco, 
2009) 





2010, Australia, Evans 










2010, USA, Wolever 
(Wolever et al., 2010) 
53∙1 (8∙29) 52∙8(7∙64) 11∙8 (8∙5) 
 







2010, USA, Melkus (D'Eramo 
Melkus et al., 2010) 
47.0 (9.0) 
 





2010, Belgium De Greef (De 
Greef et al., 2010) 
NR NR NR NR 7.5% (1.1) 
 

















7% or more 
2010, USA, Osborn (Osborn 
et al., 2010a) 
56∙9 (11∙3) 
 
58∙4 (10∙1) 13∙2 (12) 
 





2011, Chile, Garcia-Huidobro 
(Garcia-Huidobro et al., 2011)  
53∙4 (8∙1) 
 






7% or more 
 
2011, Ireland, Keogh (Keogh 




57∙29 (11∙34) 9∙17(7∙1) 
 










8% or more 
 
2011, Belgium, De Greef (De 
Greef et al., 2011) 
I1: 70 (6∙3) 
I2: 66∙6 
(9∙5)  











2011, Iran, Hamid (Hamid, 
2011) 





2011, USA, Piette (Piette et 
al., 2011) 





2011, Netherlands, Lamers 
(Lamers et al., 2011) 
70∙7 (6∙6) 
 
69∙7 (6∙6) 8∙2 (8∙8) 
  


















I1: 9∙8 (8) 
I2: 9 (7∙3) 
 
C1: 7 (6∙5) 
C2: 7∙1 (5∙8) 
I1: 9.1 (1.5) 
I2: 8.8 (1.0) 
C1: 8.8 (1.3) 








7.5% or more 
 
2011, USA, Ell (Ell et al., 
2011) 





2012, UK, Farmer (Farmer et 
al., 2012) 
62∙5 (11.0) 64∙1 (10∙3) 6∙7 (4∙8) 
 










2012, USA, Penckofer 
(Penckofer et al., 2012) 
54∙8 (8∙8) 
 





2012, Germany, Hartmann 
(Hartmann et al., 2012) 
58∙7 (7∙4) 
 
59∙3 (7∙8) 11.0 (7∙5) 
 





2012, Taiwan, Chen (Chen, 
Creedy, et al., 2012) 
59∙19 
(10∙24)  
58∙67 (10∙23) 7∙98 (7∙57) 
 







2013, Canada, Plotnikoff 









C1: 11∙7 (9∙9) 
C2: 10∙7 (9∙9) 















2013, Netherlands, Welschen 
(Welschen et al., 2013) 
60∙5 (9∙4) 
  
61∙2 (8∙8) 7∙6 (5) 
 






7% or more 
 
2013, USA, Mandel (Mandel 









C1: 2∙32 (6∙1) 
C2: 3∙78 
(7∙06) 















2013, Netherlands, Jansink 
(Jansink et al., 2013) 
64∙1 (8∙9) 
 
63∙9 (9∙8) 7∙5 (6∙0) 
 






7% or more 
 




60∙7 (8∙6) 8 (4-14) 
 









60∙3 (8∙6) 10∙7 (7∙5) 
  





2014, USA, Safren (Safren et 
al., 2014) 






7% or more 
 

















59∙2 (5∙2) 1∙3 (0∙5) 
 



















2014, Australia, Eakin (Eakin 
et al., 2014) 
57∙7 (8∙1) 
  
58∙3 (9∙0) NR NR Median: 
7.6% (6.3, 8.5) 
Median: 






2014, Netherlands, van Son 





























7% or more 
 
2015, USA, Chlebowy 
(Chlebowy et al., 2015) 
55∙8 (2∙1) 
  





2015, USA, Pladevall 







NR  NR 8.0% (1.3) C1: 8.2% (1.4) 









7% or more 
 
2015, Germany, Hermanns 
















58∙2 (5∙6) 11∙4 (9∙1) 
 











47∙9 (12∙8) 15∙7 (10∙4) 
 








7.5% or more 
2016, Taiwan, Huang (Huang 




















2016, China, Browning 
(Browning et al., 2016) 
63∙7 (7∙6) 
 
64.0 (9.0) 10.0 (6∙5) 
  









65∙6 (9∙4) 7.0 (2∙8-16) 
 









2016, Taiwan, Chiu (Chiu et 
al., 2016) 
64∙78 (0∙3) 64∙59 (0∙4) 10.0 (0∙6) 
 












64∙89 (10∙14) 11∙4 (4∙8) 
 







2016, Denmark, Juul(Juul et 
al., 2016) 
Median: 
58 (50, 63) 
Median: 
60 (51, 64) 
NR NR 40.7 mmol/mol 
(3.5) 














55∙70 (8∙98) 4∙9 (1∙40) 
 




2016, USA, Wagner(Wagner 
et al., 2016) 
60.0 (11∙2) 
 






7% or more 
 
2017, Turkey, 
Akturan(Akturan et al., 2017) 
57∙51 (7.0) 
 





2017, Italy, Balducci(Balducci 
et al., 2017)  









NR NR NR I1: 7.7% (1.1) 
I2: 7.7% (1.4) 















2017, Australia, Furler(Furler 
et al., 2017) 
61∙7 (9∙7) 
  





7.5% or more 
 
2017, Germany, 
Hermanns(Hermanns et al., 
2017) 























58∙6 (8∙8) 17∙5 (10) 
 





2017, USA, Carrasquillo 55∙3 (7∙1) 
 
55∙2 (6∙1) 11∙7 (8∙2) 
 










2017, Brazil, Gomes(Gomes 
et al., 2017) 










57∙1 (5∙5) 1∙24 (0∙38) 
  







2018, Malaysia, Chew(Chew 
et al., 2018) 
55∙6 (10∙8) 
  






8% or more 
 
2018, USA, 
Chwastiak(Chwastiak et al., 
2017) 






8% or more 
 
2018, Germany, 
Dobler(Döbler et al., 2018) 
51∙6 (5∙7) 
 
52∙2 (5∙4) 8∙7 (6∙6) 
  









58∙9 (11∙4) 10.0 (7-13) 
 








8% or more 
 
2018, Iran, Momtzi(Momtazi 
et al., 2018) 






7% or more 
 






















Table S3 – Primary outcome of included meta-analysed studies 
Reference  Primary outcome category Primary outcome description  
Whittemore et al. 2004  Self-management  Diet self-management  
Williams et al. 2004 HbA1c HbA1c 
Keeratiyutawong et al. 2006 HbA1c HbA1c 
Gregg et al. 2007 HbA1c HbA1c 
West et al. 2007 Biomedical Weight  
Dale et al. 2009 Psychological Self-efficacy 
Davazdah et al. 2009 HbA1c HbA1c 
Sacco et al. 2009 Self-management Medication adherence 
De Greef et al. 2010 Self-management Physical activity 
Osborn et al. 2010 Self-management Diet adherence 
Evans et al. 2010 Psychological Depression 
Hawkins et al. 2010 HbA1c HbA1c 
Wolever et al. 2010  Self-management  Medication adherence  
Melkus et al. 2010 HbA1c HbA1c 
Keogh et al. 2011 HbA1c HbA1c 
Welch et al. 2011 HbA1c HbA1c 
Piette et al. 2011 HbA1c HbA1c 
Garcia-Huidobro et al. 2011 HbA1c HbA1c 
Lamers et al. 2011  Psychological  Depressive symptoms  
Ell et al. 2011  
Psychological 
  
Depressive symptom treatment 
  
De Greef et al. 2011 Self-management Physical activity  
Hamid et al. 2011 HbA1c HbA1c 
Farmer et al. 2012 Self-management Medication adherence 
Hartnamnn et al. 2012 Psychological Depressive symptoms 
Penckofer et al. 2012 Psychological Depression 
Chen et al. 2012 HbA1c HbA1c 
Welschen et al. 2013 Biomedical Coronary heart disease risk 
Jansink et al 2013 HbA1c HbA1c 
Mandel et al. 2013 HbA1c HbA1c 
Plotnikoff et al. 2013 HbA1c HbA1c 
Gois et al. 2014 Psychological Depressive symptoms 
Steed et al. 2014 Psychological Self-efficacy 
Siebolds et al. 2006 HbA1c Hba1c 
Juul et al. 2014 HbA1c HbA1c 
Eakin et al. 2014 Biomedical Weight loss 
Safren et al. 2014 Self-management Medication adherence 
Van Son et al. 2014 Psychological Stress 
Griffin et al. 2014 Self-management Physical activity 
Li et al. 2014 HbA1c HbA1c 
289 
 
Chlebowy et al. 2015 Self-management Medication adherence 
Petrak et al. 2015 HbA1c HbA1c 
Hermanns et al. 2015 Psychological Depressive symptoms  
Pladevall et al. 2015 HbA1c HbA1c 
Pibernik-Okanović  et al. 2015 Psychological Depressive symptoms 
Kim et al. 2015 HbA1c HbA1c 
Browning et al. 2016 HbA1c HbA1c 
Fan et al. 2016 Biomedical BMI 
Wagner et al. 2016 Psychological Depressive symptoms 
Huang et al. 2016 HbA1c HbA1c 
Shayeghian et al. 2016 HbA1c Hba1c 
Kasteleyn et al. 2016 Psychological Diabetes distress 
Chiu et al 2016 Psychological Diabetes distress 
Juul et al. 2016 Biomedical Weight loss 
Jiang et al. 2017 HbA1c HbA1c 
Chee et al. 2017 HbA1c HbA1c 
Balducci et al. 2017 Self-management Physical Activity 
Hermanns et al. 2017 HbA1c HbA1c 
Rees et al. 2017 Psychological Diabetes distress  
Akturan et al. 2017 Psychological Diabetes Empowerment 
Furler et al. 2017 HbA1c HbA1c 
Carrasquillo et al. 2017 HbA1c HbA1c 
Gomes et al. 2017 HbA1c HbA1c 
Egede et al. 2017 Psychological Depressive symptoms 
Munoz-Florez et al. 2017 Self-management Physical activity  
Dobler et al. 2018 Self-management Physical activity  
Momtazi et al. 2018 HbA1c HbA1c 
Ismail et al. 2018 HbA1c HbA1c 
Wroe et al. 2018 Psychological Depressive symptoms 
Chew et al. 2018 Psychological Diabetes Distress 














Table S4- Frequency of studies with co-morbid depressive symptoms inclusion criteria and 
HbA1c as a primary outcome 






Yes No Total 
Yes 6 10 16 
No 27 27 54 





Table S5 – Additional inclusion/exclusion criteria information 
Reference Inclusion/exclusion based on mental health 
or cognitive impairment  
Other inclusion criteria  Other exclusion criteria 
Whittemore et 
al. 2004 
 Female, able to exercise, no advanced diabetes 
complications, fluent in English, previously 
participated in diabetes education. 
 
Williams et al. 
2004 
Included if systematic depression screening 
with a 2-item depression screener adapted 




et al. 2006 
 Only oral diabetes meds, fasting blood glucose 
>130mg for 2 times or more, read Thai.   
Excluded if on insulin therapy, presence of 
other serious illness or complications relating 
to diabetes. 
Gregg et al. 
2007 
 English-speaking, receiving medical care at 
low-income community health centre, and 
referred to diabetes education. 
 
West et al. 2007  Treated with OADs not insulin, BMI 27-50, 
able to walk for exercise.  
Excluded if pregnant, recent significant 
weight loss (>10 lbs), or a severe debilitating 
disease that might interfere with study 
participation. 
Dale et al. 2009 Exclude if severe accompanying disorders 
(e.g. mentally ill). 
Not on insulin, Speak English; no severe 
accompanying disorders (e.g. mentally ill, 
severe learning difficulties, severe hearing 
difficulties). 
 
Davazdah et al. 
2009 
Included if presence of depressive symptoms 
according to DASS scale. 
  
Sacco et al. 2009 Excluded if evidenced major mental disorder 
(e.g. schizophrenia) that would potentially 
interfere with implementation of intervention. 
Able to speak and read English, at least one of 
the following cardiovascular risk factors (low-
density lipoprotein =100 mg/dl; high-density 




women; triglycerides =150; cholesterol/high-
density lipoprotein ratio =5/1).  
De Greef et al. 
2010 
 No physical activity limitations.  
Osborn et al. 
2010 
 Puerto Rican ethnicity.  
Evans et al. 2010 Borderline personality disorder   
Hawkins et al. 
2010 
  Excluded if unable to pass the Short Portable 
Mental Status Questionnaire (SPMSQ) 
Wolever et al. 
2010 
Excluded if presence of dementia, Alzheimer, 
schizophrenia, cognitive impairment. 
Have taken OADs for at least 1 year, not on 
insulin.  
 
Melkus et al. 
2010 
Excluded if presence of serious psychiatric 
disorder. 
Black women, not on insulin, BMI<37, not 
pregnant.  
Excluded if diagnosed with a serious medical 
condition (cancer, AIDS), diabetes related 
complications.  
Keogh et al. 
2011 
   
Welch et al. 
2011 
Excluded if presence of severe psychiatric 
disorders or mental retardation, or visual, 
literacy, or comprehension barriers that would 
prevent completion of study questionnaires. 
Able to speak or write in English.  Excluded if diagnosed with major diabetes 
complications, or pregnant. 
Piette et al. 2011 Included if presence of depressive symptoms 
according to PHQ (score of 11 or more). 
Excluded if diagnosed with bipolar disorder or 
schizophrenia. 
Prescribed antihyperglycemic medication.  Excluded if not using antihyperglycemic 
medication, had been diagnosed with or were 
in active treatment for another serious illness 
such as severe heart failure, severe chronic 
obstructive pulmonary disease, or end-stage 
renal disease. 
Garcia-Huidobro 
et al. 2011 
Excluded if diagnosed with cognitive disorder 
which limits participation. 
Live in household with a significant family 
member >15yrs.  
Excluded if hospitalised during 3m prior 
HbA1c measurement. 
Lamers et al. 
2011 
Included if presence of depressive symptoms 
according to MINI (Mild to moderate major 
depression). Excluded if treatment with 
 Excluded if on waiting list for nursing home, 
bedridden, loss of spouse in last 3 months 
and not being fluent in Dutch. 
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antidepressants for depression or present , 
major psychiatric problems (bipolar 
depression, schizophrenia, alcohol or 
substance abuse), current 
psychosocial/psychiatric treatment, serious 
cognitive problems. 
Ell et al. 2011 Included if presence of depressive symptoms 
according to PhQ-9 (one of the two cardinal 
depression symptoms more than half the days 
to nearly every day over the last 2 weeks and 
scored ≥10 on the) PhQ-9. Excluded if present 
acute suicidal ideation, alcohol abuse, self-
reported recent lithium/antipsychotic 
medication use. 
  
De Greef et al. 
2011 
 BMI 25-35; pharmaceutically treated for type 2 
diabetes; no physical limitations; Speak Dutch. 
 
Hamid et al. 
2011 
Included if presence of depressive symptoms 
according to DASS scale. 
  
Farmer et al. 
2012 
 Taking OADs (not excluded if taking insulin).  
Hartnamnn et al. 
2012 
Excluded if presence of psychiatric disorders.  Excluded if presence of albuminuria, non-
diabetic kidney disease, alcohol or drug 
abuse, malignant tumours, heart failure, 
acute coronary syndrome. 
Penckofer et al. 
2012 
Included if presence of depressive symptoms 
according to CES-D score (16 more more). 
Excluded if a history of bipolar depression, or 
any other psychotic disorder. 
 Excluded if current alcohol or substance 
abuse disorders, a diabetes knowledge score 
<70 % on the Brief Diabetes Knowledge Test 
(since the program emphasis was not 
diabetes education); and severe 
complications of diabetes (blindness, renal 
failure, or amputation). 
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Chen et al. 2012 Excluded if presence of psychiatric illness. Speak Chinese. Excluded if too ill due to terminal illness or 
haemodialysis. 
Welschen et al. 
2013 
 Able to understand Dutch language, high risk 
of developing CVD and diabetes complications 
(HbA1c = 52 mmol/mol (7.0 %) and/or body-
mass index = 27.0 kg/m2 and/or smoking). 
 
Jansink et al 
2013 
 BMI>25.  Exclusion if presence of complex 
comorbidity and receiving treatment in 
hospital. 
Mandel et al. 
2013 
  Excluded if diagnosed with gestational 
diabetes, dementia, severe hearing loss. 
Plotnikoff et al. 
2013 
 Access to telephone, no English language 
barrier 
 
Gois et al. 2014 Included if presence of depressive symptoms 
according to HADs score (7 or more on 
depression sub-scale), MADRS (score of 17 or 
more points), and major depression diagnosis 
using MINI and DSM-IV. Excluded if history 
of psychotic disorder or have regular 
psychoactive medications, active suicidal 
ideation.  
 Excluded if presence of severe complications 
that interfere with self-care activities, other 
chronic physical disease, alcohol or drug 
abuse.  
Steed et al. 2014  Presence of microalbuminuria as indicated by 
two or more urinary albumin to creatinine 
ratios >3.0 mg/mmol or a urinary albumin 
excretion >30 mg/24h, fluency in spoken 
English 
 
Siebolds et al. 
2006 
   
Juul et al. 2014    
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Eakin et al. 2014  Physically inactive, BMI 25 or more, not using 
weight loss medications, without previous or 
planned bariatric surgery 
 
Safren et al. 
2014 
Included if presence of depressive symptoms 
according to DSM-IV. Excluded if severely 
depressed (requiring intensive treatment such 
as hospitalisation). Excluded if untreated 
major mental illness (e.g., untreated 
psychosis), bipolar disorder, eating disorder, 
mental retardation, dementia, or active 
suicidality or were undergoing current CBT 
for depression were excluded. 
 Excluded if unable or unwilling to provide 
informed consent. 
Van Son et al. 
2014 
Included if Poor emotional well-being (<13 
score on WHO-5). Excluded if a recent history 
of severe psychopathology (i.e., psychosis, 
risk of suicide attempts), or were already in an 
(extensive) psychological treatment which 
started within a period of 6 week before the 
start of the training. 
 Excluded if alcohol/drugs abuse; have a 
severe physical co-morbidity (i.e., severe 
forms of cancer or heart failure); when they 
have insufficient reading and comprehension 
skills of the Dutch language. 
Griffin et al. 
2014 
Excluded if had a psychotic illness.  Excluded if had an illness with a likely 
prognosis of <1 year; women pregnant. 
Li et al. 2014  Education level of at least 6 years.  Excluded if disturbance of consciousness, 
cognitive disorders or defects in language 
communication; presence of a severe acute 
disease or chronic disease (e.g. severe heart 
failure, lung function failure, tumors). 
Chlebowy et al. 
2015 
Excluded if receiving treatment form a mental 
health provider. 
African American ethnicity; treated by OADs 
or insulin; English speaking; able to engage in 
moderate physical activity. 
 
Petrak et al. 
2015 
Included if presence of major depression 
according to DSM-IV. Excluded if suicidal 
ideations, psychotic symptoms, bipolar 
Insulin treated.  Excluded if liver enzyme elevations to 
exclude severe liver dysfunction. 
296 
 
disorder, substance abuse or dependence in the 
past 6 months, psychotherapy in the preceding 
3 months, current use of mood stabilizers 
neuroleptics, antidepressants, or 
benzodiazepines. 
Hermanns et al. 
2015 
Included if presence of depressive symptoms 
CES-D (score of 16 or more). Excluded if 
presence of major depression, current 
schizophrenia/psychotic disorder, eating 
disorder, bipolar disorder, addictive disorder, 
or personality disorder; current use of 
antidepressant medication or ongoing 
psychotherapy. 
Sufficient German language skills.  Excluded if bedridden; and under 
guardianship. 
Pladevall et al. 
2015 
 1 or more HbA1c 7% or more ≥1 LDL-C 
measurement with the last value ≥100 mg/dL, 
and ≥1 prescription for both an oral diabetes 
medication and a lipid-lowering medication. 
 
Pibernik-
Okanović et al. 
2015 
Included if presence of depressive symptoms 
according to PhQ-2 (1 depressive symptom 
over past month & need for professional help). 
Excluded if presence of major depression, or 
dysthymia, as determined by phone-
administered Structured Clinical Interview of 
DSM-IV, current psychiatric treatment. 
 Excluded if diagnosed with advanced 
diabetes complications, medical 
contraindications for physical exercise. 
Kim et al. 2015  Korean American immigrant.  
Browning et al. 
2016 
 Lived in Fengtai district, had health record at 
participating health services. 
 
Fan et al. 2016 Excluded if any known psychological or 
psychiatric disorders, such as major 
depression or generalize anxiety disorders. 
 Excluded if severe co-morbidities such as 
renal failure, hepatic dysfunction, cancer or 




Wagner et al. 
2016 
Excluded for bipolar disorder or thought 
disorder; or suicide attempt or psychiatric 
hospitalization in the past 2 years. 
Latino or Hispanic, Spanish-speaking.  Excluded for medical instability or intensive 
medical treatment.  
Huang et al. 
2016 
Included if presence of depressive symptoms 
according to CES-D (score of 16 or more). 
Exclusion= alcohol or drug abuse or 
dependence, clinically diagnosed neurological 
illness such as dementia, medical illness, and 
physical impairments severely influencing the 
individual’s cognitive dysfunction. 
 
Shayeghian et al. 
2016 
 No change in diabetes medication for 3 months 
before entering study.  
Excluded if hospitalised or diagnosed with 
diabetes complications. 
Kasteleyn et al. 
2016 
 Speak Dutch, no serious illness to prevent 
participation. 
 
Chiu et al 2016 Included if occasional distress or minor 
depressive symptoms. Excluded if on anti-
depressant medication, receiving ongoing 
psychological/psychiatric treatment, 
diagnosed with psychosis, severe cognitive 
problem. 
 Excluded if hearing impairment, lost partner 
within the past three months. 
Juul et al. 2016  Impaired fasting glucose.  
Jiang et al. 2017 Excluded if presence of psychological 
disorders. 
BMI>30. Excluded if diagnosed with diabetes 
complications, severe visceral organ disease. 
Chee et al. 2017  BMI>23; not treated with insulin, diabetes 
treatment not changed in last 3 months; nor 
pregnant; no history of serious diabetes 
complications 
 
Balducci et al. 
2017 
 BMI 27-40; physical inactivity; sedentary 
lifestyle for at least 6m; able to walk 1.6km 
without assistance 
 
Hermanns et al. 
2017 
Excluded if presence of psychiatric disorders, 
dementia, severe cognitive impairment. 
Treated with OADs or 2 years or more, non-
intensified insulin treatment, BMI 20-40, read 
and understand German.  




Rees et al. 2017 Included if presence of diabetes distress 
according to the DDS (score of 2 or more. 
Excluded if insufficient cognitive ability to 
engage in study. 
Diagnosis of diabetic retinopathy. Excluded if insufficient English language.  
Akturan et al. 
2017 
Excluded if diagnosed or treated for 
depression. 
  
Furler et al. 2017 Excluded if presence of severe mental illness. Max OAD treatment (2 OADs at max dose). Excluded if complex debilitating medical 
condition, such as end stage cancer, or 
unstable cardiovascular disease. 
Carrasquillo et 
al. 2017 
 Latino.  
Gomes et al. 
2017 
 Lack of advanced complications, other serious 
diseases that can prevent participation. 
 
Egede et al. 
2017 
Included if presence of depressive symptoms 
according to DSM-IV criteria for major 
depressive disorder. Excluded if diagnosis 
with active psychosis, dementia, suicidal 





 Ability to exercise (low to moderate activity 
every week). 
 
Dobler et al. 
2018 
 Speak German; no acute substance-related 
disorder. 
 
Momtazi et al. 
2018 
 At least high school diploma, taking oral 
diabetes medications. 
 
Ismail et al. 
2018 
Excluded if presence of severe mental 
disorders (PhQ-9 >20 if psychotic depression 
or active suicidal ideation) or receiving 
psychological treatment elsewhere. 
 Excluded if diagnosed with a terminal illness 




Wroe et al. 2018 presenting with symptoms consistent with 
depression or anxiety, or both, as indicated by 
either PHQ-9 score of 10 or above, or GAD-7 
score of 8 or above, and a clinical assessment 
that indicated a presentation of depression or 
anxiety. 
 Excluded if their goals for therapy were not 
related to an improvement in depression or 
anxiety. 
Chew et al. 2018 Included if presence of diabetes distress 
according to DDS (score of 3 or more). 
Excluded if any known 
psychiatric/psychological disorders that could 
impair judgement and memory. 
Read or understand English or Malay; BP 
140/90 mmHG or more; LDL level 2.6 or 
more. 
 
Chwastiak et al. 
2018 
Excluded if presence of cognitive impairment, 
current suicidality, homicidally. 
BP>140/90; read English.  Excluded if grave disability that requires 
hospitalisation, cardiovascular event in last 




Table S6- Frequency of studies with suboptimal glycaemic control as an inclusion criteria and 
HbA1c as a primary outcome 
 






Yes No Total 
Yes 8 3 11 
No 25 34 59 






Table S7- Number of studies and arms included in the network meta-analyses for adults with 
type 2 diabetes.  
Arm N %   
Sample 
size 
CBT 24 16·44 T 1268 
Counselling 46 31·51 T 6105 
Usual care 46 31·51 C 5954 
Attention 
control 18 12·33 C 1297 
Self-help 
materials 4 2·74 C 792 
IPT 1 0·68 T 11 
Diabetes 
education 1 0·68 C 46 
Waiting list 
control 6 4·11 C 229 
      
Total 146 100   15702 










Table S8- Direct and indirect treatment effects (where indirect treatment effects were available) and the difference between them for adults with type 2 diabetes, 











Table S9- Summary of treatment effects compared with usual care assuming common heterogeneity estimate for all treatment design comparisons for adults with 
type 2 diabetes. 
Treatment b 95% C.I. SE z p 
Usual care 0 
    
CBT -0·194 -0·33 to -0·057 0·069 -2·79 0·005 
Counselling -0·196 -0·292 to -0·099 0·049 -3·97 <0·001 
Attention control -0·031 -0·185 to 0·124 0·079 -0·39 0·698 
Self-help material -0·257 -0·499 to -0·015 0·123 -2·08 0·037 











SMD SE SMD SE SMD SE p 
Usual care Attention control -0·02 0·281 -0·032 0·083 0·012 0·293 0·966 
Usual care  Self-help materials -0·091 0·176 -0·412 0·171 0·321 0·246 0·192 
CBT Usual care 0·231 0·081 0·088 0·136 0·144 0·158 0·364 
CBT Attention control 0·035 0·126 0·275 0·118 -0·241 0·173 0·164 
CBT  Self-help materials -0·117 0·288 -0·048 0·153 -0·068 0·326 0·834 
CBT  Waiting list control 0·352 0·209 0·266 0·207 0·086 0·295 0·770 
Counselling Usual care 0·188 0·053 0·259 0·151 -0·071 0·16 0·659 
Counselling Attention control 0·231 0·079 -0·044 0·141 0·274 0·162 0·091 
Counselling  Self-help materials -0·192 0·151 0·174 0·201 -0·366 0·252 0·146 
Counselling  Waiting list control 0·274 0·191 0·36 0·224 -0·086 0·295 0·770 
Attention control  Self-help materials 0·102 0·285 -0·317 0·15 0·419 0·322 0·193 
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Table S10- Summary of pairwise comparisons of all treatment assuming common heterogeneity 
estimate for all treatment design comparisons for adults with T2DM. SMD=SMD:  





Table S11- Probability to be the best treatment, mean rank and surface under the cumulative 










Best 0 22.4 18.8 0.1 58.1 0.6 
MEAN 
RANK 
4.9 2.2 2.2 4.5 1.8 5.5 







Treatment comparison SMD (95% C.I>) SE z p 
Usual care CBT -0.264 (-0.41 to -0.117) 0.075 -3.520 <0.001 
Usual care Counselling -0.222 (-0.313 to -0.13) 0.047 -4.740 <0.001 
Usual care Attention control -0.038 (-0.192 to 0.117) 0.079 -0.480 0.635 
Usual care Self-help materials -0.243 (-0.479 to -0.007) 0.120 -2.020 0.044 
Usual care IPT 0.059 (-0.222 to 0.341) 0.144 0.410 0.679 
Usual care Structured diabetes -0.160 (-0.475 to 0.154) 0.160 -1.000 0.318 
Counselling CBT 0.042 (-0.123 to 0.208) 0.084 0.500 0.616 
Attention control CBT 0.226 (0.034 to 0.418) 0.098 2.310 0.021 
Self-help materials CBT 0.021 (-0.251 to 0.293) 0.139 0.150 0.880 
IPT CBT 0.323 (0.009 to 0.638) 0.160 2.010 0.044 
Structured diabetes CBT 0.104 (-0.239 to 0.447) 0.175 0.590 0.553 
Attention control Counselling 0.184 (0.044 to 0.324) 0.071 2.580 0.010 
Self-help materials Counselling -0.021 (-0.252 to 0.21) 0.118 -0.180 0.857 
IPT Counselling 0.281 (-0.01 to 0.572) 0.149 1.890 0.059 
Structured diabetes Counselling 0.061 (-0.239 to 0.362) 0.153 0.400 0.689 
Self-help material Attention control -0.205 (-0.459 to 0.049) 0.129 -1.590 0.113 
IPT Attention control 0.097 (-0.207 to 0.401) 0.155 0.620 0.532 
Structured diabetes Attention control -0.123 (-0.454 to 0.209) 0.169 -0.730 0.468 
IPT Self-help material 0.302 (-0.061 to 0.665) 0.185 1.630 0.103 
Structured diabetes Self-help material 0.083 (-0.296 to 0.461) 0.193 0.430 0.669 



































Figure S1- Risk of bias within RCTs of psychological interventions 




Figure S2- Risk of bias domain assessment across psychological intervention RCTs for adults 
with Type 2 diabetes. 
 
 
Figure S3- Network plots for reduce number of studies (N=143). Network plots of direct 




The width of the lines is proportional to the number of trials comparing each pair of treatments and 
the size of each node is proportional to the number of studies testing the specific treatment. It shows 
roughly how much information is available for each treatment and for each treatment comparison. 











Appendix 2.2: PRISMA checklist for study 1 
Section/topic  # Checklist item  
Section 
reported in 
this thesis  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Chapter 2 
heading 
ABSTRACT    
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
Appendix 
2.1 
INTRODUCTION    
Rationale  3 Describe the rationale for the review in the context of what is already known.  2.2 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
2.2 
METHODS    
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
2.3.1 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
2.3.2 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
2.3.3 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  2.3.4 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 




Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
2.3.6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
2.3.7 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
2.3.8 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  2.3.9 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
2.3.9 
 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
2.3.10 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
2.3.11 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
2.4.1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
2.4.2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  2.4.3 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest plot.  
2.4.4 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  2.4.4 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  2.4.5 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  2.4.6 
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DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
2.5.1 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
2.5.2 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  2.5.3 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 




From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 









Appendix 2.3: MEDLINE search strategy  
1. exp Diabetes Mellitus/ 
2. diabet$.ab,ti. 
3. (DKA or IDDM).mp. or DMI.ab,ti. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
4. (MODY or DM2 or NIDDM).mp. or IIDM.ti,ab. [mp=title, original title, abstract, 
name of substance word, subject heading word] 
5. insulin$ secret$ dysfunc$.ti,ab. 
6. insulin$ resist$.ti,ab. 
7. ((impaired glucose tolerance or glucose intoleran$ or insulin$ resist$) and (DM or 
DM2)).ti,ab. 
8. insulin$ depend$.mp. or insulin?depend$.ti,ab. [mp=title, original title, abstract, 
name of substance word, subject heading word] 
9. (non insulin$ depend$ or nonisulin$ depend$ or nonisulin?depend).mp. or non 
insulin?depend$.ti,ab. [mp=title, original title, abstract, name of substance word, 
subject heading word] 
10. (("typ$ 1" or typ$ I) adj6 DM).ti,ab. 
11. (("typ$ 2" or typ$ II) adj6 DM).ti,ab. 
12. ((juvenil$ or child$ or keto$ or labil$ or brittl$ or earl$ onset) adj6 (DM or 
DM1)).ti,ab. 
13. ((keto$ prone or autoimmun$ or auto immun$ or sudden onset) adj6 (DM or 
DM1)).ti,ab. 
14. ((keto$ resist$ or nonketo$ or non keto$ or adult$ onset or matur$ onset or late$ 
onset or slow onset or stabl$) adj6 (DM or DM2)).ti,ab. 
15. exp Insulin Resistance/ 
16. (insulin$ defic$ adj6 (absolut$ or relativ$)).ti,ab. 
17. metabolic$ syndrom$.ti,ab. 
18. (syndrom$ X not (fragil$ X or X linked)).ti,ab. 
19. (plurimetabolic$ syndrom$ or pluri metabolic$ syndrom$).ti,ab. 
20. or/1-19 
21. exp Psychotherapy/ 
22. exp Counseling/ 
23. exp Mood disorders/ 





29. (interpersonal adj5 therap$).mp 
30. art therap$.mp 
31. aversion therap$.mp 
32. balint.mp 
33. behavio?r adj5 (intervention or therap* or modific*)  
34. cognitive adj5 (therap* or intervention or program* or train* or theory)  
35. (family adj3 (intervention or treatment or counsel* or therap*) 
36. colo?r therap$.mp. 
37. crisis intervention.mp 
38. dance therap$.mp 
39. gestalt therap$.mp 
40. music therap$.mp 
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41. milieu therap$.mp 
42. (assert$ adj5 training).mp 
43. Narrative therap$.mp. 
44. nondirective therap$.mp 
45. (problem solving adj5 therap$).mp 
46. (self control adj5 therap$).mp 
47. person cent$.mp 
48. client cent$.mp 
49. psychodrama$.mp 
50. paradoxical technique$.mp 
51. play therap$.mp 
52. rational emotive.mp 
53. reality therap$.mp 
54. role play$.mp 
55. (relax$ adj5 training).mp 
56. sociotherap$.mp 
57. socioenvironmental.mp 
58. supportive therap$.mp 
59. transactional.mp 
60. acceptance adj2 (commitment therap*) 
61. coping skills training.mp. 
62. exp Mindfulness/ 
63. motivation* adj2 (interview* or therap*) 
64. multisystemic therapy 
65. or/21-64 
66. Randomized Controlled Trials as Topic/ 
67. randomized controlled trial/ 
68. Random Allocation/ 
69. Double Blind Method/ 
70. Single Blind Method/ 
71. clinical trial/ 
72. clinical trial, phase i.pt 
73. clinical trial, phase ii.pt 
74. clinical trial, phase iii.pt 
75. clinical trial, phase iv.pt 
76. controlled clinical trial.pt 
77. randomized controlled trial.pt 
78. multicenter study.pt 
79. clinical trial.pt 
80. exp Clinical Trials as topic/ 
81. (clinical adj25 trial$).tw 
82. ((singl$ or doubl$ or treb$ or tripl$) adj25 (blind$3 or mask$3)).tw 
83. PLACEBOS/ 
84. placebo$.tw 
85. randomly allocated.tw 
86. (allocated adj2 random$).tw 
87. Or/66-86 
88. case report.tw 
89. letter/ 
90. historical article/ 
91. Or/ 88-90 
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92. 87 NOT 91 
93. 20 AND 65 AND 92 
































Appendix 3.1: COREQ Checklist for study 2 
COREQ (COnsolidated criteria for REporting Qualitative research) Checklist  
A checklist of items that should be included in reports of qualitative research. You must report the 
page number in your manuscript where you consider each of the items listed in this checklist. If you 
have not included this information, either revise your manuscript accordingly before submitting or 




Item No.  
  
Guide Questions/Description  Reported in 
section of 
this thesis  
Domain 1: Research team 
and reflexivity   
      
Personal characteristics         
Interviewer/facilitator  1  Which author/s conducted the interview or focus group?   3.3.3 
Credentials  2  What were the researcher’s credentials? E.g. PhD, MD   3.3.3 and 
reflexivity 
statement  
Occupation  3  What was their occupation at the time of the study?   3.3.3 and 
reflexivity 
statement 
Gender  4  Was the researcher male or female?   3.3.3 
Experience and training  5  What experience or training did the researcher have?   3.3.3 
Relationship with 
participants   
     
Relationship established  6  Was a relationship established prior to study 
commencement?   
3.3.3 
Participant knowledge of 
the interviewer   
7  What did the participants know about the researcher? e.g. 
personal goals, reasons for doing the research   
3.3.3 
Interviewer characteristics  8  What characteristics were reported about the inter 
viewer/facilitator? e.g. Bias, assumptions, reasons and 
interests in the research topic   
Reflexivity 
statement 
Domain 2: Study design        
Theoretical framework        
Methodological orientation 
and Theory   
9  What methodological orientation was stated to underpin 
the study? e.g.  
grounded theory, discourse analysis, ethnography, 
phenomenology, content analysis   
3.3.4 
Participant selection        
Sampling  10  How were participants selected? e.g. purposive, 
convenience, consecutive, snowball   
3.3.1 
Method of approach  11  How were participants approached? e.g. face-to-face, 
telephone, mail, email   
3.3.3 
Sample size  12  How many participants were in the study?   3.4 
Non-participation  13  How many people refused to participate or dropped out? 
Reasons?   
3.4 
Setting       
Setting of data collection  14  Where was the data collected? e.g. home, clinic, 
workplace   
3.3.3 
Presence of nonparticipants  15  Was anyone else present besides the participants and 
researchers?   
3.3.3 
Description of sample  16  What are the important characteristics of the sample? e.g. 




Item No.  
  
Guide Questions/Description  Reported on 
Page No.  
Data collection         
Interview guide  17  Were questions, prompts, guides provided by the authors? 




Repeat interviews  18  Were repeat inter views carried out? If yes, how many?   3.3.3 
Audio/visual recording  19  Did the research use audio or visual recording to collect 
the data?   
3.3.4 
Field notes  20  Were field notes made during and/or after the interview 
or focus group?  
3.3.4 
Duration  21  What was the duration of the inter views or focus group?   3.4 
Data saturation  22  Was data saturation discussed?   3.3.3 
(information 
power) 
Transcripts returned  23  Were transcripts returned to participants for comment 
and/or correction? 
3.5.4 
Domain 3: analysis and 
findings   
     
Data analysis        
Number of data coders  24  How many data coders coded the data?   3.3.4 
Description of the coding 
tree  
25  Did authors provide a description of the coding tree?   3.4 (figure 1) 
Derivation of themes  26  Were themes identified in advance or derived from the 
data?   
3.3.4 
Software  27  What software, if applicable, was used to manage the 
data?   
3.3.4 
Participant checking  28  Did participants provide feedback on the findings?   3.5.4 
Reporting        
Quotations presented  29  Were participant quotations presented to illustrate the 
themes/findings?  
Was each quotation identified? e.g. participant number   
3.4 
Data and findings consistent  30  Was there consistency between the data presented and 
the findings?   
3.5.4 
Clarity of major themes  31  Were major themes clearly presented in the findings?   3.4 
Clarity of minor themes  32  Is there a description of diverse cases or discussion of 
minor themes?        
3.4 
  
Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 
(COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in 















Appendix 3.2: Information sheet for study 2 
 
Patient information sheet 
Title of project: Patient views and experiences of starting insulin therapy. 
 
You are being invited to participate in a study which involves interviewing type 2 
diabetic patients who have started or are due to start on insulin. This study is funded 
by the National Institute for Health Research (NIHR).  Before you decide whether to 
take part in this study it is important that you understand why the research is being 
conducted and what is involved. Please take time to read the following information 
and feel free to ask if there is anything that is not clear or if you would like more 
information. 
1. What is the purpose of this study? 
This study is part of a research project in the department of Psychological Medicine 
at King’s College London. The purpose of this study is to determine patient views on 
the barriers to insulin self-management, views on diabetes education courses (if you 
have attended any) and suggestions for additional support to aid self-management 
in Type 2 diabetes. This will be used to develop a new group intervention to help 
people start insulin with Type 2 diabetes.  
2.  Do I have to take part? 
No. It is entirely your decision as to whether you take part in this study. If you decide 
to take part,  you will be asked to complete a consent form. However, you are still 
free to withdraw at any time during the study period without giving a reason.  
3. What will happen to me if I take part? 
If you decide to take part in the study, please fill out the consent form (attached). 
You will then be invited to an interview which will take place at your local diabetes 
clinic or GP surgery in Lambeth, at an agreed time/date of your convenience. The 
duration of the interview will be around 30 minutes. The interviewer will be a 
diabetes nurse or researcher. The interviewer will ask your views on barriers to 
insulin self-management, current diabetes education courses and suggestions for 
additional support to aid self-management in Type 2 diabetes. Interviews will be 
recorded.  
4. What are the possible disadvantages or risks of taking part? 
We do not foresee any disadvantages of participating in this study.  You do not have 
to answer any questions if you do not wish to.  
 
5. What are the possible advantages of taking part?  
You will have opportunity to share your thoughts of diabetes and insulin initiation in 
depth. The results from these interviews will help in the development of an 
intervention to improve health outcomes following insulin initiation. 
6. Will my taking part in the study be kept confidential? 
314 
 
Yes. We will follow ethical and legal practise and all information about you will be 
handled in confidence. We will also take measures to anonymise the data you give 
us. You will be given this information sheet and a signed consent form to keep, if 
you wish.  
Contact details (email, telephone numbers, and/or addresses) of participants will be 
kept in a file, in a locked filing cabinet in a locked office at a King’s College London 
University campus. Audiotapes of interviews will be also kept in a locked filing 
cabinet. Typed transcripts of interview recordings will be stored on a University 
password-protected computer in a locked office at the University. Password-
protected laptops may be used to transcribe interviews, these will be kept in the 
locked office when not in use. Only the research team, chief investigator and PhD 
student, will have access to password protected computers/laptops which contain 
data for this research, in addition to locked filing cabinets. The clinical team of the 
patient will have access to NHS computers with patient medical data, the research 
team will only have access to this information with consent of the patient. 
King's College London policy advises that data which is funded and is published can 
be retained for 7 years to cover contractual liability. After this, data will be disposed 
securely. For paper records, they will be shredded within the King's College London 
office or disposed via the College confidential waste service. For disposal of 
electronic records, information held on local databases (i.e. participant contact 
details) will be deleted once it ceases to be relevant (i.e. once the project is 
completed, or sooner if the information has no further use). Once retention period 
has expired, research data in electronic form will be erased from the computer hard 
drive. 
 
7. Who has reviewed the study? 
The research proposal has been reviewed by staff in the Academic Department of 
Diabetes at King’s College London and by the local Research Ethics Committee at 
King’s College Hospital NHS Foundation Trust. 
 
Further information and contact details  
If you have any further questions or wish to know more information please do not 
hesitate to contact the researchers on: 
kirsty.1.winkley@kcl.ac.uk, 02078485664 (Chief Investigator) 
rebecca.j.upsher@kcl.ac.uk, 02078485666 (PhD student) 
 
If you would like to seek assistance if you have any concerns about any aspect of 
the study, please contact the Patient Advice and Liaison Service (PALS): 
Telephone: 020 3299 3625 or 020 3299 360, 




If you have any questions concerning your rights as a study participant you may 
wish to read the following leaflet: Getting Involved in Research: A guide for 
consumers, available at: http://www.invo.org.uk/pdfs/guide_for_consumers.pdf or 
contact the Consumers in NHS Research Support Unit, Tel: 01962 872247. 































Appendix 3.3: Consent form for study 2 
KING’S COLLEGE LONDON PARTICIPANT CONSENT FORM 
Title of Project: Patient views and experiences of starting insulin therapy 
Name of Researcher: 
Please check the box if you agree with the statements: 
1. I confirm that I have read the information sheet for the above study. I have had the  
opportunity to consider the information, ask questions and have had these answered 
satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that the information collected about me will be used to support 
other research in the future, and may be shared anonymously with other researchers. 
 
4. I am willing and able to attend an interview at my local diabetes clinic/GP surgery.   
 
5. I am willing for my interview to be recorded 
 
6. I agree to take part in the above study. 
 
7. I agree to my General Practitioner being informed of my participation in the study. 
 
            
Name of Participant  Date    Signature 
            

















Appendix 4.1: General Data Protection Regulation Health Research Authority 
information letter for SOUL-D follow-up study  
 
The South London Diabetes (SOUL-D) study long-term follow-up study (IRAS ID 223971) 
 
You may remember participating in the South London Diabetes (SOUL-D) study about 6-8 
years ago. Thank you for your participation in this study. You consented to your medical 
records to be accessed by the research team for a period of up to 20 years. Here is some 
information on how we will be using your personal data, and what rights are under the law. 
Please contact us on with details below if you have any questions regarding this 
information. 
 
King’s College Hospital is the sponsor for this study based in United Kingdom. We will be 
using information from you and/or your medical records in order to undertake this study 
and will act as the data controller for this study. This means that we are responsible for 
looking after your information and using it properly. King’s College Hospital will keep 
identifiable information about you for 10 years after the study has finished. 
Your rights to access, change or move your information are limited, as we need to manage 
your information in specific ways in order for the research to be reliable and accurate. If 
you withdraw from the study, we will keep the information about you that we have already 
obtained. To safeguard your rights, we will use the minimum personally-identifiable 
information possible. 
You can find out more about how we use your information by contacting Lisa Kuriakose 
(lisa.kuriakose@kcl.ac.uk).  
King’s College London will use your name, NHS number and contact details to contact you 
about the research study, and make sure that relevant information about the study is 
recorded for your care, and to oversee the quality of the study. Individuals from King’s 
College Hospital and regulatory organisations may look at your medical and research 
records to check the accuracy of the research study. Your GP surgery will pass these details 
to King’s College London along with the information collected from you and/or your 
medical records. The only people in King’s College London who will have access to 
information that identifies you will be people who need to contact you about future 
opportunities to participate in research or audit the data collection process. The people 
who analyse the information will not be able to identify you and will not be able to find out 
your name, NHS number or contact details. 
King’s College London will keep identifiable information about you from this study for 10 
years after the study has finished. 
King’s College London will collect information about you for this SOUL-D research study 
from medical records. This information will include your name/ NHS number/ contact 
details/ add other identifiers and health information, which is regarded as a special 
category of information. We will use this information to determine whether your 
information obtained at the time of your type 2 diabetes diagnosis is associated with 




Your information could be used for research in any aspect of health or care, and could be 
combined with information about you from other sources held by researchers, the NHS or 
government.  
Where this information could identify you, the information will be held securely with strict 
arrangements about who can access the information. The information will only be used for 
the purpose of health and care research, or to contact you about future opportunities to 
participate in research. It will not be used to make decisions about future services available 
to you, such as insurance. 
Where there is a risk that you can be identified your data will only be used in research that 
has been independently reviewed by an ethics committee. 
Further information and contact details 
If you would like further information about this study please contact: 
Lisa Kuriakose                      
Research Assistant           
Tel.: 020 7848 5759 
Email: lisa.kuriakose@kcl.ac.uk  
If you have any questions or complaints at any stage, you can contact the Patient Advice and 
Liaison Service at King’s College Hospital on 020 3299 3601. 
Kind regards, 
Professor Khalida Ismail 















Appendix 5.1: Definition of intervention functions 
The following definitions can be found in the Behaviour Change Wheel guide (Michie et al., 
2014). Examples are in relation to improving insulin self-management.  
Met APEASE criteria for DIME: 
• Training: Communicating skills e.g. training in insulin injection technique.  
• Education: Providing information to increase knowledge e.g. providing information 
to promote insulin therapy for type 2 diabetes.  
• Environmental restructuring: Altering the physical or the social environment e.g. 
ensuring insulin education location is accessible to attendees.  
• Enablement: Increase capability (not by education or training) or opportunity (not 
via environmental restructuring) by increasing means or reducing barriers e.g. 
behavioural support for initiating insulin.  
• Modelling: A demonstration of a behaviour for people to copy e.g. diabetes nurse 
demonstrates injecting insulin.  
• Persuasion: Changing attitudes or behaviour by communicating information which 
stimulates positive or negative feelings e.g. Using imagery of fatty liver to motivate 
weight loss.  
Did not meet APEASE criteria for DIME: 
• Incentivisation: Providing potential prize by engaging in a behaviour e.g. prize draw  
• Coercion: Suggestion of potential punishment e.g. increase cost of cigarettes  
• Restriction: Reduce opportunity to participate in a behaviour by using rules e.g. 
prohibit sales of energy drinks to under 16s 
Appendix 5.2: Definition of policy categories 
The following definitions can be found in the Behaviour Change Wheel (Michie et al., 2014).  
Met APEASE criteria for DIME: 
• Communication/marketing: E.g. leaflets, electronic media, telephone marketing or 
broadcast.  
• Service provision: Service delivery e.g. support services  
• Environmental/social planning:  Design or control of the physical or social 
environment e.g. town planning  
Did not meet APEASE criteria for DIME: 
• Guidelines: Recommendations for practice e.g. treatment protocol 
• Fiscal measures: Use tax to increase or reduce cost e.g. sugar tax 
• Regulation: Rules for practice e.g. agreements on advertisements  







Appendix 5.3: Definition of APEASE criteria  
The following definitions can be found in the Behaviour Change Wheel guide (Michie et al., 
2014).  
Below are the definitions of the APEASE criterion: 
• Affordability: The intervention can be delivered within an acceptable budget and 
can be financially accessed by people it is relevant to. 
• Practicability: The intervention can be delivered as intended in the context it was 
created for e.g. in practice not just in research where staff are specially trained.  
• Effectiveness and cost-effectiveness: Effectiveness relates to effect size of the 
intervention when delivered in a controlled trial (intervention vs control group). 
Cost-effectiveness relates to the ratio of effect to the cost.   
• Acceptability: The judgement of the intervention according to stakeholders e.g. 
patients, healthcare professionals etc.  
• Side-effects/safety: Intervention design needs to consider safety aspects and any 
potentially harmful side effects.  
• Equity: A consideration of whether the intervention reduces or increases the 














Appendix 6.1: TIDieR checklist for study 4 
The TIDieR (Template for Intervention Description and Replication) Checklist*: 
Item 
number 
Item  Where located ** 





1. Provide the name or a phrase that describes the intervention. 6.2 
 WHY  
2. Describe any rationale, theory, or goal of the elements essential to the intervention. 6.3 
 WHAT  
3. Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or 
used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed 
(e.g. online appendix, URL). 
6.4.1 
4. Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or 
support activities. 
6.4.2 
 WHO PROVIDED  
5. For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, background and any 
specific training given. 
6.5 
 HOW  
6. Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of the intervention 
and whether it was provided individually or in a group. 
6.6 
 WHERE  




WHEN and HOW MUCH 
 
8. Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their 
schedule, and their duration, intensity or dose. 
6.8 
 TAILORING  
9. If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how. 6.9 
 MODIFICATIONS  
10.ǂ If the intervention was modified during the course of the study, describe the changes (what, why, when, and how). 6.9 
 HOW WELL  
11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to 















Appendix 6.2: DIME facilitator notes 
 
 
Appendix redacted. Please contact rebecca.j.upsher@kcl.ac.uk for more information.  
 
Appendix 6.3: DIME workbooks 
 
Appendix redacted. Please contact rebecca.j.upsher@kcl.ac.uk for more information.  
 
 
Appendix 6.4: DIME printed materials 
 





















Appendix 6.5: Information sheet for study 4 
Patient information sheet 
Title of project: Testing of a newly developed group intervention to help people 
with type 2 diabetes start insulin. 
 
You are being invited to participate in a  study which will involve testing a new 
intervention to help type 2 diabetic patients start insulin. This study is funded by the 
National Institute for Health Research (NIHR). Before you decide whether to take 
part in this study it is important that you understand why the research is being 
conducted and what is involved. Please take time to read the following information 
and feel free to ask if there is anything that is not clear or if you would like more 
information. 
1. What is the purpose of this study? 
This study is part of a research project in the department of Psychological Medicine 
at King’s College London. The purpose of this study is to test a newly developed 
group intervention to help people with type 2 diabetes start insulin.  
2.  Do I have to take part? 
No. It is entirely your decision as to whether you take part in this study. If you do 
decide to take part, you will be asked to complete a consent form. However, you are 
still free to withdraw at any time during the study period without giving a reason.  
3. What will happen to me if I take part? 
If you decide to take part in the study, please fill out the consent form (attached). 
You will then be invited to a group (6-10 people) intervention with others who have 
just started insulin, this will last around 1.5 hours at a community venue in Lambeth. 
Following the group session  you will be asked to provide feedback via interview on 
the intervention, for example, views on content, appropriateness for patients starting 
insulin as well as suggestions for future development. Interviews will be recorded. 
The interview will take place at your local GP surgery.  
4. What are the possible disadvantages or risks of taking part? 
We do not foresee any disadvantages of participating in this study.  You do not have 
to answer any questions you do not desire.  
5. What are the possible advantages of taking part?  
You will receive a newly developed, evidenced-based group intervention which is 
not currently available. This could result in improved outcomes following insulin 
initiation such as reduced hyperglycaemia. 
6. Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practise and all information about you will be 
handled in confidence. We will also take measures to anonymise the data you give 
us. You will be given this information sheet and a signed consent form to keep, if 
you wish.  
Contact details (email, telephone numbers, and/or addresses) of participants will be 
kept in a file, in a locked filing cabinet in a locked office at a King’s College London 
University campus. Audiotapes of interviews will be also kept in a locked filing 
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cabinet. Typed transcripts of interview recordings will be stored on a University 
password-protected computer in a locked office at the University. Password-
protected laptops may be used to transcribe interviews, these will be kept in the 
locked office when not in use. Only the research team, chief investigator and PhD 
student, will have access to password protected computers/laptops which contain 
data for this research, in addition to locked filing cabinets. The clinical team of the 
patient will have access to NHS computers with patient medical data, the research 
team will only have access to this information with consent of the patient. 
King's College London policy advises that data which is funded and is published can 
be retained for 7 years to cover contractual liability. After this, data will be disposed 
securely. For paper records, they will be shredded within the King's College London 
office or disposed via the College confidential waste service. For disposal of 
electronic records, information held on local databases (i.e. participant contact 
details) will be deleted once it ceases to be relevant (i.e. once the project is 
completed, or sooner if the information has no further use). Once retention period 
has expired, research data in electronic form will be erased from the computer hard 
drive. 
 
7. Who has reviewed the study? 
The research proposal has been reviewed by staff in the Academic Department of 
Diabetes at King’s College London and by the local Research Ethics Committee at 
King’s College Hospital NHS Foundation Trust. 
 
Further information and contact details  
If you have any further questions or wish to know more information please do not 
hesitate to contact the researchers on: 
kirsty.1.winkley@kcl.ac.uk, 02078485664 (Chief Investigator) 
rebecca.j.upsher@kcl.ac.uk, 02078485666 (PhD student) 
 
If you would like to seek assistance if you have any concerns about any aspect of 
the study, please contact the Patient Advice and Liaison Service (PALS): 
Telephone: 020 3299 3625 or 020 3299 360, 
or write to PALS, King’s College Hospital, Denmark Hill, London SE5 9RS 
 
If you have any questions concerning your rights as a study participant you may 
wish to read the following leaflet: Getting Involved in Research: A guide for 
consumers, available at: http://www.invo.org.uk/pdfs/guide_for_consumers.pdf or 
contact the Consumers in NHS Research Support Unit, Tel: 01962 872247. 




Appendix 6.6: Consent form for study 4 
 
KING’S COLLEGE LONDON PARTICIPANT CONSENT FORM 
Title of Project: Testing of a newly developed group intervention to help people with type 2 
diabetes start insulin.  
Name of Researcher: 
Please check the box if you agree with the statements: 
1. I confirm that I have read the information sheet for the above study. I have had the  
opportunity to consider the information, ask questions and have had these answered 
satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that the information collected about me will be used to support 
other research in the future, and may be shared anonymously with other researchers. 
 
4. I am willing and able to attend an interview at my local diabetes clinic/GP surgery.   
 
5. I am willing to have my interview recorded 
 
6. I agree to take part in the above study. 
 
7. I agree to my General Practitioner being informed of my participation in the study.  
 
            
Name of Participant  Date    Signature 
            

















Appendix 7.1: COREQ Checklist for study 5 
COREQ (COnsolidated criteria for REporting Qualitative research) Checklist  
A checklist of items that should be included in reports of qualitative research. You must report the 
page number in your manuscript where you consider each of the items listed in this checklist. If you 
have not included this information, either revise your manuscript accordingly before submitting or 







Guide Questions/Description  Reported in 
section of 
this thesis  
Domain 1: Research 
team and reflexivity   
      
Personal characteristics         
Interviewer/facilitator  1  Which author/s conducted the interview or focus 
group?   
7.3.2 
Credentials  2  What were the researcher’s credentials? E.g. PhD, 
MD   
7.3.2 
Occupation  3  What was their occupation at the time of the study?   7.3.2 
Gender  4  Was the researcher male or female?   7.3.2 
Experience and training  5  What experience or training did the researcher 
have?   
7.3.2 
Relationship with 
participants   
     
Relationship established  6  Was a relationship established prior to study 
commencement?   
7.2 
Participant knowledge of 
the interviewer   
7  What did the participants know about the 
researcher? e.g. personal goals, reasons for doing 




8  What characteristics were reported about the inter 
viewer/facilitator? e.g. Bias, assumptions, reasons 
and interests in the research topic   
7.3.2 
Domain 2: Study design        
Theoretical framework        
Methodological 
orientation and Theory   
9  What methodological orientation was stated to 
underpin the study? e.g.  
grounded theory, discourse analysis, ethnography, 
phenomenology, content analysis   
7.3.3 
Participant selection        
Sampling  10  How were participants selected? e.g. purposive, 
convenience, consecutive, snowball   
7.3.1 
Method of approach  11  How were participants approached? e.g. face-to-
face, telephone, mail, email   
7.3.2 
Sample size  12  How many participants were in the study?   7.4.1 
Non-participation  13  How many people refused to participate or dropped 
out? Reasons?   
7.2 
Setting       
Setting of data collection  14  Where was the data collected? e.g. home, clinic, 




15  Was anyone else present besides the participants 
and researchers?   
7.3.2 
Description of sample  16  What are the important characteristics of the 









Guide Questions/Description  Reported on 
Page No.  
Data collection         
Interview guide  17  Were questions, prompts, guides provided by the 
authors? Was it pilot tested?   
7.3.2; 
appendix 7.2 
Repeat interviews  18  Were repeat inter views carried out? If yes, how 
many?   
7.3.2 
Audio/visual recording  19  Did the research use audio or visual recording to 
collect the data?   
7.3.2 
Field notes  20  Were field notes made during and/or after the inter 
view or focus group?  
7.3.2 
Duration  21  What was the duration of the inter views or focus 
group?   
7.4.2 
Data saturation  22  Was data saturation discussed?   7.5.2 
Transcripts returned  23  Were transcripts returned to participants for 
comment and/or correction? 
7.5.2 
Domain 3: analysis and 
findings   
     
Data analysis        
Number of data coders  24  How many data coders coded the data?   7.3.3 
Description of the coding 
tree  
25  Did authors provide a description of the coding tree?   7.4.2; figure 
7.1 
Derivation of themes  26  Were themes identified in advance or derived from 
the data?   
7.3.3 
Software  27  What software, if applicable, was used to manage 
the data?   
7.3.3 
Participant checking  28  Did participants provide feedback on the findings?   7.5.2 
Reporting        
Quotations presented  29  Were participant quotations presented to illustrate 
the themes/findings?  
Was each quotation identified? e.g. participant 
number   
7.4.2 
Data and findings 
consistent  
30  Was there consistency between the data presented 
and the findings?   
7.4.2 
Clarity of major themes  31  Were major themes clearly presented in the 
findings?   
7.4.2 
Clarity of minor themes  32  Is there a description of diverse cases or discussion 
of minor themes?        
7.4.2 
  
Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 
(COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in 









Appendix 7.2: Interview schedule for DIME pilot exit interviews for study 5 
Warm up question 
Tell me a little about the insulin you are taking….  
Main questions 
1. Why did you choose to attend the insulin education group?   
o Prompts:  
▪ What did you hope to achieve by attending the group? 
▪ Was there anything that worried you about attending the 
group sessions? 
2. In what ways did the insulin education groups meet your 
expectations/needs? 
o Prompts:  
▪ Did the course cover all the things you wanted to learn 
about? 
▪ What did you think about having group sessions? 
3. In what ways did the insulin education group fail to meet your 
expectations/needs?  
o Prompts:  
▪ Was there anything else you wanted the course to cover? 
▪ What else would you have liked?  
4. In what ways do you think the knowledge you have gained from the group 
has benefited you? 
o Prompts: 
▪ Has your management of diabetes changed following the 
group sessions? How so? 
▪ Can you tell me about any changes in the way you feel about 
your diabetes as a result of attending these sessions? 
▪ What are the most important benefits that have resulted 
from the group? 
▪ What helped you learn?  
5. How do you feel about the resources which were given to you to take 
home? 
o Prompts: 
▪ Did you read any of it after the session? 
▪ What would be the most useful in terms of materials to take 
home with you?  
6. How did you feel about the activities in the group sessions? 
o Prompts: 
▪ Which ones did you enjoy/ not enjoy? 
▪ How could the activities be improved? 
7. How would you rate the overall success of the insulin education group from 




▪ What would help improve this rating?  
8. What are your views about the number of sessions you had for the insulin 
group? 
o Prompts: 
▪ Too little/too many? 
▪ Preferred a whole day session instead or longer 2 sessions? 
▪ What are your views about the length of sessions? 
9. Were there any barriers to you attending the sessions? 
o Prompts: 
▪ What would have made it easier to attend? 
10. What do you think about the way the sessions were structured? 
o Prompts: 
▪ Was the content understandable/easy to follow? 
▪ What do you think about the way the nurse talked to you 
during the appoints/style of talking? 
▪ Were the topics ordered in a way that made sense to you?  
11. Can you think of anything the insulin groups could differently to support 
ongoing self-management of insulin for people with type 2 diabetes?   
o Prompts: 
▪ Any recommendations for future groups? 
Final comments  
12. Is there anything else at all you would like to say that we haven’t covered 
already? 
 
 
 
